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 i 
Abstract 
Carbohydrates are one of the most abundant classes of biomolecules on earth. In the initial stages 
of research on carbohydrates much effort was focused on investigation and determination of the 
structural aspects and complex nature of individual monosaccharides. Later on, development of 
protective group strategies and methods for oligosaccharide synthesis became the main topics of 
research. Today, the methodologies developed early on are being utilized in the production of 
carbohydrates for biological screening events. This multidisciplinary approach has generated the 
new discipline of glycobiology which focuses on research related to the appearance and 
biological significance of carbohydrates. In more detail, studies in glycobiology have revealed 
the essential roles of carbohydrates in cell-cell interactions, biological recognition events, protein 
folding, cell growth
 
and tumor cell metastasis. As a result of these studies, carbohydrate derived 
diagnostic and therapeutic agents are likely to be of growing interest in the future. 
 
In this doctoral thesis, a journey through the fundamentals of carbohydrate synthesis is presented. 
The research conducted on this journey was neither limited to the study of any particular 
phenomena nor to the addressing of a single synthetic challenge. Instead, the focus was 
deliberately shifted from time to time in order to broaden the scope of the thesis, to continue the 
learning process and to explore new areas of carbohydrate research. Throughout the work, several 
previously reported synthetic protocols, especially procedures related to glycosylation reactions 
and protective group manipulations, were evaluated, modified and utilized or rejected. The 
synthetic molecules targeted within this thesis were either required for biological evaluations or 
utilized to study phenomena occuring in larger molecules. In addition, much effort was invested 
in the complete structural characterization of the synthesized compounds by a combination of 
NMR spectroscopic techniques and spectral simulations with the PERCH-software.  
 
This thesis provides the basics of working with carbohydrate chemistry. In more detail, synthetic 
strategies and experimental procedures for many different reactions and guidelines for the NMR-
spectroscopic characterization of oligosaccharides and glycoconjugates are provided. Therefore, 
the thesis should prove valuable to researchers starting their own journeys in the ever expanding 
field of carbohydrate chemistry. 
 
 ii 
Abstrakt 
Kolhydrater tillhör en av de största grupperna av naturligt förekommande biomolekyler. Den 
tidiga forskningen inom kolhydratkemi fokuserades på bestämning av enskilda kolhydraters 
strukturer och undersökning av den komplexa naturen hos monosackarider. Senare blev 
utvecklingen av skyddsgruppsstrategier och metoder för oligosackaridsyntes de viktigaste 
forskningsgrenarna inom området. I dagens läge används de tidigare utvecklade metoderna vid 
framställning av kolhydrater för biologiska studier. Denna tvärvetenskapliga forskning har gett 
upphov till en ny forskningsgren som bär namnet glykobiologi. Forskningen inom glykobiologi 
är fokuserad på kolhydraters förekomst och biologiska funktioner. Studier i glykobiologi har 
bland annat avslöjat att kolhydrater spelar viktiga roller i cell-cell interaktioner, biologiska 
igenkänningsfenomen, proteininveckning, cellväxt och cancermetastas. På grund av dessa studier 
kommer sannolikt kolhydratbaserade diagnostiska och terapeutiska föreningar att vara av 
växande intresse i framtiden. 
 
I denna doktorsavhandling kommer en utflykt genom den fundamentala kolhydratkemin att 
presenteras. Forskningen som utfördes under denna resa var inte begränsad till undersökning av 
specifika fenomen eller syntetiska utmaningar. Istället skiftades vikten för studierna från tid till 
tid för att utvidga avhandlingens omfattning, fortsätta inlärningsprocessen och undersöka nya 
områden inom kolhydratkemi. Under hela arbetet evaluerades, modifierades och användes en stor 
mängd tidigare rapporterade syntetiska protokoll, speciellt procedurer relaterade till 
glykosyleringsreaktioner och skyddsgruppsmanipuleringar. De syntetiska målmolekylerna inom 
arbetet var av två slag: molekyler för undersökning av fundamentala processer och molekyler för 
evaluering av deras biologiska tillämpningar. Dessutom lades mycket arbete ner på strukturell 
karakterisering av de syntetiska substanserna med hjälp av både NMR spektroskopiska tekniker 
och spektrala simuleringar med programmet PERCH. 
 
Denna avhandling innehåller de fundamentala elementen för arbete inom kolhydratkemi eftersom 
syntetisk planering, experimentella procedurer och riktlinjer för NMR spektroskopisk analys av 
kolhydrater finns beskrivna. Därför torde avhandlingen vara av värde för forskare som startar 
egna resor inom det expanderande ämnesområdet kolhydratkemi.  
 iii 
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 1 
Introduction 
1 Biological Applications of Carbohydrates 
Carbohydrates, nucleotides, lipids and peptides constitute the major classes of biomolecules 
found in living organisms.
1
 The division of molecules into these categories is not as 
straightforward as the categories may imply since many of the biomolecules exist in nature in 
mixed forms, e.g., glycoproteins, glycolipids etc., containing structural elements from multiple 
categories. Research on carbohydrates has always received considerable attention as these 
molecules are present in large quantities in nature, display diverse structural variations and have 
many biological functions.  
 
 
Figure 1. The chemical structure of chitin (repeating β-1,4-linked N-acetylglucosamine units). 
 
Early on, already before the 1960s, carbohydrates were considered to be important structural 
molecules in biological membranes and surfaces as often exemplified by chitin,
2
 a polysaccharide 
consisting of β-1,4-linked N-acetylglucosamine residues (Figure 1). Chitin is the main constituent 
of fungal cell walls and the exoskeleton of arthropods. In addition, carbohydrates were 
recognized as energy storage molecules, e.g., glucose can be stored in the form of glycogen in 
animals and as starch in plants. In humans, glucose is released from glycogen during glycolysis 
thus providing ATP and pyruvate as substrates for the Krebs cycle.
3
 While these features remain 
important today, many new and exciting applications for carbohydrates have emerged in recent 
years, simultaneously expanding the borders of glycoscience and generating the discipline of 
glycobiology.
4
 Studies in glycobiology have revealed the vital roles of carbohydrates in cell-cell 
interactions,
5
 biological recognition events,
6
 protein folding,
7
 cell growth
8 
and tumor cell 
metastasis.
9
 Since all these interactions are mediated at least partially by carbohydrates (often 
specific glycans or glycoconjugates), the potential utilization of carbohydrates as biomarkers for 
celltypes, disease and developmental states is a highly promising area of research.
10
 In the next 
section, the general concept of carbohydrate biomarkers and their potential applications will be 
addressed and discussed. These areas are, according to the personal view of this author, among 
 2 
the most important research topics in modern glycobiology and accordingly relevant background 
information for glycoscience as a whole. Large numbers of carbohydrate derived compounds and 
materials are also utilized extensively in food technology
11
 and the pharmaceutical industry.
12
  
 
1.1 Carbohydrate Biomarkers 
A carbohydrate biomarker is by definition a carbohydrate utilizable as an indicator for a 
biological state.
10
 The most well documented example of carbohydrate biomarkers stems from 
the identification of the bloodtype determinants which are utilized in the ABO blood-system. In 
more detail, Watkins and James established the carbohydrate composition of these biomarkers in 
the 1950s (Figure 2) by studying the cell surface of red blood cells.
13
 This knowledge together 
with information on the serological relationships of the bloodtype determinants has enabled the 
safe blood transfusion processes which save many lives each year.
14 
This is but one example of 
the beneficial and health promoting effects that research on carbohydrates can provide for 
society. From the structures in Figure 2, it can be noticed that even small differences in the 
structure of biomarkers (one sugar residue or a single functional group) can have significant 
impact on their biological properties (blood clotting if blood from an incompatible bloodtype is 
utilized during blood transfusions). 
 
 
Figure 2. The carbohydrate biomarkers of the ABO blood-system.  
 
While carbohydrates bear great potential as biomarkers for biological states, the identification of 
specific biomarkers was for a long time considered challenging due to the presence of thick 
layers of heterogenous mixtures of complex carbohydrates (in many glycoforms) on cell surfaces 
and in the extracellular matrix. In recent years, however, advancements in analytical tools 
(nuclear magnetic resonance spectroscopy, mass spectrometry and gene sequencing) and 
multidisciplinary approaches of large collaborative networks between scientists in different fields 
 3 
(chemistry, biochemistry, cellbiology, molecular biology etc.) have enabled the isolation and 
identification of carbohydrate biomarkers on an acceptable timescale. Once a biomarker has been 
identified, a large number of possibilities are generated towards deepening the understanding of 
biological events, monitoring changes in biological systems, and developing new and improved 
therapeutic and diagnostic agents.
10,15
 Monitoring changes in carbohydrate (biomarker) 
composition and expression patterns at a cellular level is often done indirectly with selective 
carbohydrate binders, such as lectins (carbohydrate binding proteins), which recognize specific 
sugar residues.
16
 In order to further underline and exemplify the importance of carbohydrate 
biomarkers, their use in the identification and monitoring of cancer onset and progression is 
provided below.    
 
 
Figure 3. Chemical structures of two common carbohydrate associated cancer antigens. 
 
Cancer is the general term for a large group of diseases where celldivision is accelerated and 
uncontrolled thereby resulting in the formation and spreading of malignant tumors.
17
 
Transformation of a normal cell into a diseased cancer cell is often accompanied by alterations of 
genes which results in changes in biosynthetic pathways, protein functions etc.
17,18
 Although 
many changes occur in cancerous cells, the discussion will herein be limited to the fate of 
glycans. Changes in the composition of glycans and their expression patterns, during the 
transformation of healthy cells to cancer cells, has been thoroughly studied over the years.
4a
 As a 
result, several carbohydrates are currently considered as cancer associated antigens (CAAs).
19 
CAAs present on the cell surface of cancerous cells can be either glycolipid- or glycoprotein 
based. Globo H, depicted in Figure 3, is a common CAA belonging to the glycolipid category and 
is often expressed on the cell surface of breast cancer cells.
20
 The Tn antigen (Figure 3) on the 
other hand is a member of the glycoprotein category and overexpressed in malignant cells due to 
defects in the glycan biosynthetic pathway.
21
 In fact, the occurrence of elevated amounts of the 
 4 
Tn antigen has been identified in more than 90 % of all solid tumors.
10b
 Consequently, the Tn 
antigen is an excellent biomarker for carcinomas and has found further use in the generation of 
anticancer vaccines.
22
 Another common trend in the altered glycan expression of malignant cells 
is an increased amount of sialylated carbohydrates.
4a
 Increased capping of N-glycans by α-
(2→6)-linked sialyl acid residues23 and overexpression of sialyl lewisx (Figure 4)24 are closely 
associated with carcinomas. The increase in sialylated oligosaccharides and glycans in cancerous 
cells is according to current understanding, a way for the cancer to escape/delay deadly 
encounters with the immunesystem.
4a 
While many other changes in glycan compositions occur in 
malignant cells, such as the increased length and branching patterns of N-glycans and the aberrant 
glycosylation patterns of mucins,
 4a
 a more thorough discussion on these alterations is outside the 
scope of this thesis.    
 
 
Figure 4. Chemical structure of sialyl lewis
x
.  
 
The utilization of carbohydrates as biomarkers for biological states has large potential which is 
also apparent from the limited examples provided above. In the first example on the ABO blood-
system, carbohydrates on the cell surface of red blood cells were shown to be biomarkers for 
bloodtype. Furthermore, a minimal deviation in one functional group in these biomarkers was 
sufficient to alter the bloodtype of an individual. This is a clear indication on how sensitive 
biomarkers are in biological systems. In the second example, a change in the biological state of a 
cell (from normal to cancerous) was accompanied by several changes in carbohydrate expression 
patterns.  This example provided undeniable evidence of the potential of carbohydrate biomarkers 
in the determination and monitoring of biological properties and states. Carbohydrate biomarkers 
are not limited to these examples as they are also widely utilized in studies on signal transduction 
pathways,
25
 stem cell differentiation processes,
26
 and invasion processes of infectious diseases.
27
  
This far, the focus has been purely on the appearance of carbohydrates and their use as 
biomarkers in the monitoring of biological states. As also mentioned earlier, the identification of 
 5 
carbohydrate biomarkers provides several other opportunities related to the understanding of 
biological events and development of new and improved therapeutic agents.
12c,28
 In the next 
section, the utilization of carbohydrate biomarkers in immunology and vaccine development will 
be briefly discussed. 
 
1.2 Immunological Applications of Carbohydrates 
In modern medicine, diseases and infections are commonly treated with pharmaceuticals. While 
much progress has undoubtedly been achieved by the use of pharmaceuticals, infectious diseases 
caused by microorganisms (viruses, bacteria, fungi and parasites) still represent a major global 
health concern due to the emergence of multidrug resistant strains and mutated forms of such 
species.
28a 
The use of long-term protective therapies, such as vaccines, might offer a solution to 
these concerns and is generally considered by the World Health Organization (WHO) as the most 
cost-effective strategy for controlling infectious diseases.  
 
 
Figure 5. The cell surface glycocalyx of an endothelial cell;  bar = 200 nm. Reprinted with 
permission from Wolters Kluwer Health.
29
 
 
As mentioned on page 2, cells are coated with thick layers of heterogenous complex 
carbohydrates (Figure 5).
4a
 These carbohydrates play essential roles in many molecular 
recognition events such as adhesion and invasion processes of microorganisms.
27
 Such processes 
are often mediated by unique glycan structures found on the cell surfaces of pathogens (absent in 
the host). As a consequence, these structures are also utilizable as biomarkers for specific 
pathogens. While the term biomarker has been frequently used, such molecules will here be 
 6 
referred to as antigens. Antigens are molecules which are recognized as foreign or potentially 
dangerous by the immune system of the host. The host immune system responds to antigens by 
the production of antibodies which recognize them and mark them for disposal. The long-term 
protection of vaccines is in part due to the immunological memory which allows the immune 
system to respond rapidly to previously encountered antigens.
30
Alongside these principals, two 
general strategies for protective therapies against infectious diseases have arisen.
31
 
The first strategy is based on generation of protective antibodies against the corresponding 
antigen(s). This information will be stored in the immunological memory in case of future 
encounters with the particular antigen(s).
30
 The generation of antibodies can be achieved by a few 
deviating routes. The most common way of generating antibodies against a particular pathogen is 
to administer complete cells of heat killed or attenuated microorganims into humans.
31
 This is a 
good way of generating antibodies for different cell surface structures present in the pathogen. 
The main drawback of this approach is the challenges/problems associated with the cultivation 
and storage of large quantities of potentially dangerous pathogens. In addition, the number of 
antigens present at cell surfaces of entire pathogens is overwhelming and can therefore result in 
allergic side reactions in humans.  
The second approach is based on utilization of pure carbohydrate antigens or conjugates 
thereof.
32
 These can be isolated from cell walls or synthesized by chemical means.
28a
 Here, the 
focus will be on fully synthetic compounds. A synthetic approach offers several advantages over 
utilization of weakened or heat killed pathogens. First, synthetic carbohydrates are homogeneous 
compounds, devoid of biological contaminations, and can, in principle, be manufactured on large 
scale without any batch to batch variation. Second, the number of different antigens are by these 
routes limited to the synthetic compound and, therefore, allergic sidereactions can be avoided. 
There are, however, several challenges associated with the production of synthetic vaccines. The 
carbohydrate antigens have to be selected without risking cross-reactivity with carbohydrate 
fractions present in healthy cells in individuals. In addition, identification of the correct antigenic 
epitope in pathogens is a time consuming process with many stages and possibilities to fail. 
Nevertheless, solving these challenges is highly motivated as the final products are safer 
alternatives to the general vaccines with capabilities of saving millions of lives.  
These are the two basic pathways available for raising antibodies against pathogens in order to 
achieve long-term protection from infectious diseases. As mentioned above, another strategy for 
 7 
dealing with pathogens exists and the basic principles of this strategy will be briefly addressed 
next. 
Adhesion and invasion processes of microorganisms are often mediated by carbohydrates present 
at the cell surfaces of such species.
27
 Instead of generating antibodies against pathogens, it is 
possible to design and produce specific carbohydrate binding molecules with high affinity for 
unique oligosaccharides present on the cell surfaces of microorganisms (absent in the host).
10a,16a
 
In recent years, much success has been achieved by the utilization of artificial lectins 
(carbohydrate binding proteins). These lectins can be divided into two main categories: boronic 
acid based and non-boronic acid based.
33 
While natural lectins are selective in their recognition 
events, they cannot be applied in these applications due to cross-reactivity issues with healthy 
cells. The main concept of this approach relies on the high binding affinity between artificial 
binders and the unique glycan structures present on the cell surface of pathogens. Once binding is 
achieved, the functionalized binder can transport the pathogen away from the infection site or 
mark it for disposal by the immune system.  
The carbohydrate based approaches briefly addressed above are frequently applied in the 
development of modern protective therapies for infectious diseases.
28 
In order to convey the 
health promoting potential of these approaches, one additional example on the development of a 
synthetic carbohydrate vaccine against Haemophilus influenza will be provided next. 
Haemophilus influenza (Hib) was the leading cause for bacterial meningititis in children in the 
USA before the 1990s.
28a
 As a result, much effort was devoted to finding and producing a 
vaccine against Haemophilus influenza. After fourteen years of experimentation and 
optimization, a Hib vaccine with a success rate of 99.7 % in children was developed by Verez-
Bencomo and Roy.
34
 This vaccine is the first and only commercially available synthetic 
carbohydrate vaccine on the market and it is also a member of the Cuban vaccination program 
since 2004. The vaccine, the chemical structure of which is shown in Figure 6, is based upon a 
conjugated form of the repeating carbohydrate unit found in the cell wall of Haemophilus 
influenza.
35
 Although not discussed previously, conjugation of carbohydrate antigens to carrier 
proteins is usually required in carbohydrate based vaccines. This is mainly because the generation 
of long-term immunological memory is difficult to achieve with oligosaccharides as such.
36
 
While the vaccine is available in developed countries, WHO estimates that Hib causes more than 
three million serious infections and over 350000 deaths in children in third world countries each 
 8 
year. The large number of infections and deaths still observed today is due to the high cost and 
low availability of the vaccine in developing countries.  
 
 
 
Figure 6. Chemical structure of the Hib vaccine developed by Verez-Bencomo and Roy. 
 
This introduction on biological applications of carbohydrates is not intended as a thorough survey 
of all the possible applications of carbohydrates found in the literature as this would be redundant 
and space consuming to write. Instead, a focused and brief description of a few important areas 
were highlighted in order to provide an overall picture of the potential benefits studies on 
carbohydrates can provide for the general public and society. As mentioned previously, the 
identification of carbohydrate biomarkers is the cornerstone of biological studies on their nature 
and roles. While the initial identification of carbohydrate biomarkers can be performed by 
extracting material from cell surfaces and carefully analyzing the samples by mass spectrometry 
and NMR spectroscopy,
37
 the small amounts obtainable by these routes are seldom sufficient to 
launch a deeper investigation on the biological profiles of single components. In addition, 
obtaining pure samples devoid of biological contaminations by fragmentation of cell walls and 
isolation processes may be challenging. As a consequence, chemical (and/or enzymatic) synthesis 
is usually relied on for production of larger amounts of single components for more demanding 
biological screening events.
28a,38
 Chemical synthesis of carbohydrates is also the main topic of 
this thesis and, therefore, a brief introduction to carbohydrate chemistry will be provided next. 
 
2 Carbohydrate Chemistry 
The role of carbohydrates in biological applications is mostly studied by the use of pure synthetic 
oligosaccharides as these are devoid of biological contaminations and can be produced on large 
scale without any batch to batch variation. The synthesis of oligosaccharides is a laborious 
 9 
process as there are no universal reaction conditions or general applicable methodologies 
available for their construction. Instead, each oligosaccharide synthesis is an independent 
challenge which requires systematic research of trained synthetic chemists to solve.
39
 Ole 
Hindsgaul has estimated that a trained carbohydrate chemist will spend on average seven weeks 
for each monosaccharide residue while synthesizing oligosaccharides.
40
 The biological target 
molecules are seldom smaller than trisaccharides and, therefore, it will take on average more than 
five months for a carbohydrate chemist to prepare, by the traditional routes, one sample for 
biological screening events. In the next section, the main approaches used in the synthesis of 
carbohydrates will be briefly addressed. As in any synthesis, the starting materials and their 
structural features play an important role in the design of synthetic pathways and, hence, a short 
introduction to the structural properties of carbohydrates is provided first.  
 
2.1 Structural Properties of Carbohydrates 
 
 
Figure 7. Fischer projections of the acyclic forms of some selected aldoses and ketoses. 
 
Carbohydrates are generally divided into three separate categories (mono-, oligo- and 
polysaccharides) depending on the number of sugar residues present in the molecule. 
Monosaccharides are the simplest form of carbohydrates and this category contains molecules 
such as the aldoses and ketoses with three to nine carbon atoms. Even though these molecules are 
relatively small, a large number of structural variations are nevertheless possible due to the 
presence of multiple stereocenters (R or S) and the existence of two distinct enantiomers of each 
respective sugar (the D- and L-sugars).
41
 The pioneering work on structural identification of 
monosaccharides was conducted by Emil Hermann Fischer starting from the early 1880s. The 
excellent work of Fischer, for which he was later awarded the Nobel Prize, provided the 
structural basis for carbohydrate chemistry in the form of accurate chemical structures of the D-
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aldoses.
42
 Inversion of the stereochemistry of D-aldoses, according to the method of Rosanoff, 
generates the corresponding enantiomeric L-aldoses.
43
 As mentioned previously, some 
monosaccharides appear in nature as ketoses. Ketoses are generated upon extension of dihydroxy 
acetone while aldoses are generated upon extension of glyceraldehyde.
41
 Some selected examples 
of sugars from these two categories are depicted in Figure 7.  
 
 
Scheme 1. Formation of hemiacetals and the effects of mutarotation displayed for D-glucose in 
water: Pathway (a) shows formation of pyranoses and pathway (b) the formation of furanoses. 
 
While Fischer assumed that monosaccharides were acyclic, it is today known that they exist 
mostly in their ring-closed forms as either pyranoses or furanoses. This is due to the 
intramolecular attack of the hydroxyl groups at either C-4 or C-5 on the carbonyl carbon. 
Furthermore, the hemiacetals or hemiketals that result from this attack may possess either α- or β-
anomeric configuration depending on which face of the carbonyl is attacked. The hemiacetals and 
hemiketals open spontaneously and equilibrate between the different ring-closed products and the 
acyclic forms due to mutarotation as shown in Scheme 1 for D-glucose in water.
44
 The ratio 
between the different forms of a sugar present in solution is governed by the electronic and steric 
properties of the individual sugar and the nature of the solvent used.
45
 In general, however, cyclic 
forms are favored over acyclic ones and pyranoses over furanoses due to the lower amount of 
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ring strain in a six-membered ring. The complex structural features of monosaccharides are not 
limited to the occurrence of the forms shown in Scheme 1 as carbohydrates can adopt several 
different three dimensional shapes even within the individual cyclic forms. These structural 
arrangements are also termed conformations and the different conformations of carbohydrate 
pyranosides and furanosides will be briefly addressed below.
46  
 
 
Figure 8. Representative conformations of pyranoses (top row) and furanoses (bottom row). 
 
In pyranoses, four main ring shapes and a large number of variations of these are possible. To 
distinguish between pyranose conformations the following notation system is applied; C for 
chair, B for boat, S for skew and H for half-chair.
46a,47
 The ring atoms that are above the plane of 
the sugar ring are given as superscripts before the notation and the ring atoms that are below the 
plane are given as subscripts after the notation. The pyranose ring can adopt a total of two chair, 
six boat, twelve half-chair and six skew conformations. Furanoses on the other hand, can adopt 
two main ring shapes which are designated as E for envelope and T for twist.
47,48
 A total of ten 
envelope conformations and ten twist conformations are possible for furanoses. A few examples 
of different pyranose and furanose conformations are provided in Figure 8. While pyranoses 
mainly prefer the 
4
C1 or 
1
C4 conformations and furanoses the 
2
E, E2, 
3
E or E3 conformations, the 
high energy conformations of such structures may be important in biological interactions and 
recognition events.
49
 The ring shapes adopted by free sugars in solution are governed by steric 
and electronic factors. Naturally, similar factors also contribute to the preferred conformation. 
The discussion on steric and electronic interactions and their effect on the conformation adopted 
by sugars will here be limited to a few examples on pyranosides.  
Generally, substituents at different positions in pyranoses will tend to be placed in equatorial 
positions in order to reduce the amount of steric ring strain. If this is not possible for all of the 
individual substituents, then, large substituents will be placed equatorially in preference to small 
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substituents. This is one of the main reasons for the common occurrence of the 
4
C1 conformer in 
D-sugars and 
1
C4 conformer in L-sugars as the largest substituent, the hydroxymethyl substituent 
at C-5, can obtain the favorable equatorial position in both cases.
50
 These main steric factors are 
summarized in Scheme 2.  
 
 
Scheme 2. The equilibrium between chair conformations in β-D-glucopyranose (left, arrows 
indicate unfavorable steric interactions), and the stable 
1
C4 chair conformation of β-L-
glucopyranose (right). 
 
Another conformational feature of monosaccharides, especially aldohexoses existing in the 
pyranose ring, is the rotation around the C-5–C-6 bond which gives rise to three distinct low-
energy conformations termed gg (gauche-gauche), gt (gauche-trans) and tg (trans-gauge). These 
conformers are determined by the O-5–C-5–C-6–O-6 torsion angle (–60 for gg, +60 for gt, 
180 for tg) and the population equilibrium between them is heavily influenced by steric 
constraints.
51
 For example, different conformers are favored for D-glucopyranose and D-
galactopyranose due to the stereochemistry of the hydroxyl group at C-4. If the hydroxyl group is 
equatorial, as in D-glucopyranose, the gg and gt conformational states will be populated and if the 
hydroxyl group is axial, as in D-galactopyranose, the gt and tg conformational states will be 
populated (Figure 9).  
 
 
Figure 9. Possible low-energy conformations of the C-5–C-6 bond in pyranosides.   
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With the main steric interactions and their effects on the conformation of monosaccharides 
considered, the electronic interactions will be addressed below. The electronic interactions 
present in monosaccharides existing in the pyranose form are mainly limited to the anomeric 
effect. The anomeric effect, first described in the mid 20
th
 century by Edwards and Lemieux,
52
 is 
a partial delocalization of the lone pair electrons of the ring oxygen to the antibonding orbital at 
the anomeric centre. Alternatively, the anomeric effect can be described as a more favorable 
dipole-dipole interaction. Generally, the anomeric effect tends to place anomeric substituents in 
an axial position and has therefore the opposite effect as the steric interactions discussed earlier. 
The anomeric effect stabilizes the molecule and lowers its energy and the effect is greater when 
more electron withdrawing substituents are present at the anomeric position. One example of the 
net result of the anomeric effect is the existence of 2,3,4-tri-O-acetyl-β-D-xylopyranosyl bromide  
in the 
1
C4 conformation although this places large steric constraints on the molecule as all 
substituents occupy axial positions (Scheme 3).
14 
 
 
Scheme 3. The partial delocalization of the lone pair electrons of the ring oxygen into the 
antibonding orbital at the anomeric center (left) and the conformational equilibrium of 2,3,4-tri-
O-acetyl-β-D-xylopyranosyl bromide (right). 
 
Controlling the ring shape, anomeric configuration and conformation of monosaccharides is 
essential when synthesizing carbohydrates for biological purposes as small variations in the 
structure of individual sugars can have severe consequences on the biological activity. This brief 
introduction on the structural properties of monosaccharides was given in order to provide a 
background to the challenges that may arise during the synthesis of oligosaccharides.  
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2.2 Synthesis of Carbohydrates 
As mentioned in the introductory section, appropriate starting materials are the corner stone of all 
synthetic routes. Fortunately, carbohydrates are present in large quantities in nature. As a 
consequence, many monosaccharides, such as D-mannose, D-glucose and D-galactose, and some 
disaccharides, such as lactose, are available in large amounts at low cost. Nevertheless, it would 
be naive to think that all sugars would be cheap and readily available. For example, the price for 
ten grams of the common monosaccharide D-galactose is around 18 euro while the price for the 
rare enantiomer L-galactose is around 9000 euro for a similar amount.
53
 In addition, some rare 
sugars cannot be purchased at all and need to be synthesized from other starting materials.
54
  
 
 
Figure 10. The different hydroxyl functionalities in pyranoses and furanoses, illustrated with β-
D-glucopyranose (left) and β-D-glucofuranose (right). 
 
As depicted in Figure 10, three types of functionalities are generally found in carbohydrates [can 
also be more (e.g. aminosugars) or less (e.g. deoxysugars) depending on the structure]. These 
functionalities consist of the hemiacetal at the anomeric center, the secondary hydroxyl groups 
and the primary hydroxyl group. The reactivity of the anomeric center is different from the other 
hydroxyl groups and can therefore be selectively manipulated under acidic conditions. While the 
manipulation is selective, it can still give rise to two different anomers if reaction conditions are 
not appropriately optimized. Under basic conditions on the other hand, the primary hydroxyl 
group, being the least hindered one, is most reactive followed by the anomeric hydroxyl group 
and the secondary ones. While equatorial hydroxyl groups are, in general, more reactive than 
axial ones,
55
 the reactivity pattern can easily be modified by other functionalities present in the 
molecule and the conformation adopted. Furthermore, at elevated temperatures the ring may flip, 
simultaneously inverting all its stereocenters. Therefore, the reactivities of the secondary 
 15 
hydroxyl groups are usually modified and distinguished by the use of protective groups. The 
protective group strategies for selective protection of individual hydroxyl groups and the basis for 
carbohydrate synthesis were developed in the 1970s.
56
 With the basics of both the structural 
features and reactivity patterns of individual monosaccharides explained, the introduction will be 
finalized by addressing issues related to the synthesis of oligosaccharides. 
 
 
Scheme 4. An example of a glycosylation of unprotected sugars under acidic conditions (not all 
of the possible compounds formed are shown). 
 
Oligosaccharides are carbohydrates consisting of several sugar residues. As mentioned on page 9, 
biologically active carbohydrates usually contain at least three sugar units. The synthesis of such 
structures is important for the production of compounds for biological evaluations. There are 
many factors that require consideration when constructing oligosaccharides.
14,57
 First, the 
glycosidic linkages should exist between specific positions and the anomeric configuration 
should be well defined. If two unprotected sugars were utilized as such in a glycosylation 
attempt, the end result would be detrimental. Not only would there be no control of anomeric 
configuration and regioselectivity, but the individual sugars could cross-react with each other and 
react more than once. This would lead to a complex mixture of many compounds with a fairly 
low chance for isolation of a single component for further screening events. One hypothetical 
example of such a reaction is shown in Scheme 4. From this example, the major challenges 
associated with synthesis of oligosaccharides are evident. In the coupling of two sugar units 
together, the regioselectivity, stereoselectivity (anomeric configuration) and the number of 
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glycosylation reactions should be carefully controlled. This can be done by two major pathways 
involving either the use of enzymes or organic chemistry or both.
57,58
 
The enzymatic pathway, which employs glycosyltranferases (carbohydrate synthesizing 
enzymes) is appealing as naturally occurring unprotected monosaccharides can be utilized as 
donors and acceptors in glycosylation reactions. This approach circumvents the need for 
protective groups and minimizes the number of synthetic steps required to reach 
oligosaccharides. Enzymes are, however, simultaneously rather limited to specific substrates (and 
linkages) and can therefore not be considered as a general strategy for synthesis of carbohydrates. 
In addition, commercial enzymes for construction of challenging linkages, such as the β-(1→2)-
mannosidic linkage, are not necessary available on the market. As in most areas of science, the 
methodologies used in enzymatic synthesis of carbohydrates are constantly evolving and 
enzymatic synthesis certainly has large potential in future applications related to this area.  
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Scheme 5. A typical glycosylation reaction. Activation of a glycosyl donor followed by 
nucleophilic displacement of the leaving group (X) by the incoming glycosyl acceptor, PG = 
protective group. 
 
Chemical synthesis on the other hand, requires very different considerations than enzymatic 
synthesis. To accomplish the challenges related to control of stereoselectivity, regioselectivity 
and amount of glycosylation possibilities a number of chemical tools are available. The main 
strategy relies on the use of a fully protected glycosyl donor, containing an anomeric leaving 
group, and a selectively protected glycosyl acceptor, containing one free hydroxyl group.
57
 In a 
typical glycosylation reaction, the leaving group in the glycosyl donor is first activated followed 
by a displacement reaction by the incoming nucleophile (glycosyl acceptor) as depicted in 
Scheme 5.
59
 This approach solves the challenges related to regioselectivity and excludes the 
possibility of uncontrolled glycosylation events (which would lead to mixtures of compounds 
with different chain length). The anomeric configuration in the newly formed glycoside can be 
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controlled by the use of participating protective groups or by careful control of reaction 
conditions. 
Participating protective groups have been utilized extensively in carbohydrate chemistry to 
influence the stereoselective outcome of glycosylation reactions and in exploration of reaction 
mechanisms.
60
 The most common example is the use of ester protective groups at C-2 to generate 
1,2-trans glycosides (the reaction mechanism is shown in Scheme 6). This is the main reason 
why 1,2-trans glycosides are easy to synthesize and 1,2-cis glycosides more challenging. 
 
 
Scheme 6. Neighbouring group participation exemplified by the 1,2-trans glycosylation of a 2-O-
Ac-D-mannoside, R = protective group, X = leaving group, Nu = nucleophile. 
 
Stereoselective 1,2-cis glycosylations on the other hand, are more difficult to perform. The first 
requirement in 1,2-cis glycosylations is the use of nonparticipating protective groups in key 
positions in the molecule (usually ether protective groups at C-2). In several cases, utilization of 
appropriate solvent mixtures has been applied to inflict high cis selectivities in glycosylation 
reactions.
61
 Further possibilities include conformational control of the glycosyl donor by the use 
of protective groups. Such procedures have been utilized in 1,2-cis glycosylation reactions with 
good results.
62
 In addition, indirect approaches based on intermolecular aglycon delivery 
(molecular tethering prior to glycosylation reactions)
63
 and isomerization reactions of 1,2-trans 
glycosides have been found to be effective strategies for generating 1,2-cis linkages.
64
  
This introduction to carbohydrate chemistry was not intended to cover all the progress which has 
been made in the field as this information is available in any textbook on the subject.
12c,14,15b
 
Instead, a brief introduction to structural features and synthetic aspects of carbohydrate chemistry 
was given. It is important to understand the structural features of carbohydrates when planning 
synthetic routes and, especially, when searching for biologically active compounds. In the section 
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on structural properties of carbohydrates, their existence in several different forms (cyclic vs. 
acyclic) and conformations (
1
C4, 
4
C1, 
3
E, gg, gt etc.) were shown in order to highlight the 
complex nature of monosaccharides and sugars in general. Furthermore, the steric and electronic 
interactions which determine the preferred structure of an individual sugar were briefly 
addressed. In the second part of the introduction to carbohydrate chemistry, the functional groups 
and the reactivity patterns of unprotected sugars were discussed. In addition, a coarse view on the 
general approaches and considerations of oligosaccharide synthesis was provided. A more 
detailed discussion on glycosyl donors and acceptors, activation protocols and protective groups 
and their manipulations (especially, orthogonal protection strategies) was not provided as these 
issues will hopefully become clear throughout the episodes presented in this thesis.  
 
3 Outline of the Thesis  
This thesis is based on the personal explorations and adventures of the author in the field of 
carbohydrate chemistry during the years 2008–2011. The topics of the individual episodes 
summarized in this thesis are not related to each other and represent three larger entities where 
special interest was invested during the years.  
In Episode 1, synthesis of β-(1→2)-linked mannosides and structurally related compounds 
resembeling cell wall structures of Candida albicans will be addressed.
65
 The synthesis of these 
structures was conducted in order to produce compounds for immunological screening of their 
potential applications in the treatment of atopic allergies. In addition, structural features of such 
molecules were investigated by the use of NMR spectroscopic methods and molecular modelling 
in order to obtain valuable information on their three dimensional properties. 
In Episode 2, the synthesis of a repeating trisaccharide unit and a less abundant tetrasaccharide 
fragment found in the galactoglucomannan-polysaccharide isolated from Picea abies is 
addressed. These molecules were synthesized in order to provide reference samples for analyzing 
the effect of individual fragments in similar applications as the polymer is used. In addition, 
acetyl-group migration phenomena reported in the polysaccharide were investigated and some 
comparative NMR spectroscopic studies were conducted by the use of small molecular model 
substrates. 
In Episode 3, methods for the glycosylation of different aglycones are investigated and the 
synthesis of a limited amount of glycoconjugates with biological potential is described.
66
 Most of 
 19 
the molecules have not yet been submitted for biological screening. Several of them are, 
however, close mimics of compounds with known biological activity (e.g., anticancer activity of 
anthracyclines).  
While not discussed in the Introduction, reliable synthesis of new molecules requires reliable 
analytical data on the prepared substrates. The author of this thesis has never been pleased with 
the low standard of NMR spectroscopic assignments often found acceptable in synthetic reports 
and, as a consequence, overwhelming in the literature. Therefore, throughout this work, special 
attention was focused on the NMR spectroscopic characterization (and spectral simulations) of 
the synthesized molecules and a short section on the spectral analysis of each class of compounds 
will be given at the end of each Episode.  
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Episode 1: Synthesis of -(1→2)-Linked Mannosides 
 
 
 
-(1→2)-Linked oligomannosides found in the cell wall of Candida albicans are promising 
structures for the development of C. albicans vaccines. Furthermore, these structures have been 
shown to possess interesting immunostimulating properties applicable to the treatment of atopic 
disorders such as allergic inflammation. Due to the biological applications of -(1→2)-linked 
oligomannosides, considerable effort has in recent years been devoted to the synthesis of these 
compounds. In this chapter, synthetic challenges related to the synthesis of -(1→2)-linked 
oligomannosides will be discussed and methods for overcoming these difficulties addressed. In 
addition, synthesis of divalent mannosides and structural details related to the three-dimensional 
nature of -(1→2)-linked mannosides will be presented. 
                                                                      
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
This chapter is based on the previously published papers: F. S. Ekholm, M. Poláková, A. J. 
Pawłowicz, R. Leino, “Synthesis of Divalent 2,2-Linked Mannose Derivatives by 
Homodimerization”, Synthesis 2009, 4, 567–576; M. Poláková, M. U. Roslund, F. S. Ekholm, 
T. Saloranta, R. Leino, “Synthesis of -Linked Oligomannosides”, Eur. J. Org. Chem. 2009, 
870–888; F. S. Ekholm, J. Sinkkonen, R. Leino, “Fully Deprotected -(1→2)-Linked 
Mannotetraose Forms a Contorted -Helix in Solution: Convergent Synthesis and 
Conformational Characterization by NMR and DFT”, New. J. Chem. 2010, 34, 667–675. 
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1 Introduction 
The yeast Candida albicans, an opportunistic pathogen found in the mucous membrane of the 
gut, skin, gastrointestinal tract and mouth, is considered to be part of the normal human flora. In 
immunocompromised persons C. albicans can grow out of control, a condition termed 
candidiasis, thereby resulting in severe infections.
1
 Through studies on the composition of C. 
albicans’ cell wall, an epitope consisting of -(1→2)-linked mannan isolated from the acid labile 
fraction of the phosphopeptidomannan has been identified as important for the inhibition of such 
infections (see Figure 1).
1c,2
 To date, several biological studies have confirmed the protective role 
of -(1→2)-linked mannans and furthermore implicated their involvement in the stimulation of 
TNF- production from macrophages.1c,3 Although the interest in C. albicans vaccines has been 
the main motivator behind most of the biological work conducted with these oligosaccharides, 
the interest in these molecules is here connected to their applications in the treatment of atopic 
allergies.
4
 Atopic allergies are a growing health concern in the western world due to the 
decreased exposure to microbe loads in developed countries. The decreased exposure to microbes 
has altered the immune response of some humans to favor a Th2-pathway which is one of the 
characteristics of atopic allergies.
5
 While a detailed description of the biology of atopic allergies 
is beyond the scope of this introduction and thesis, an optimal synthetic molecule would favor a 
Th1-pathway and thereby induce the production of Th1- and Treg-cytokines (such as IFN-, IL-
12 and IL-18) and suppress the production of Th2-cytokines (IL-4, IL-5 and IL-13).
6 
In general, 
biological studies of this type require large amounts of homogenous pure compound. The option 
of isolating material from natural sources can often be ruled out due to: 1) The heterogeneous 
nature of cell wall oligosaccharides; and, 2) The low quantities of compound available for 
extraction and purification. As a result, chemical methods must be sought for the production of 
analytically pure compounds in sufficient quantities. 
There are several synthetic challenges associated with the construction of -(1→2)-linked 
mannosides.
7
 First, both thermodynamic and kinetic conditions favor the formation of the α-
anomer. In addition, neighboring group participation (NGP) from ester protective groups at C-2 
will lead to formation of the α-mannoside. Despite these challenges, several successful 
methodologies have been developed to overcome the obstacles.
7a,8 
Eventhough the development 
of selective methodologies for the synthesis of complex carbohydrates is important, the full 
spectroscopic analysis of such compounds is of equal importance. 
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The cell wall composition of C. albicans has been the subject of several structural studies.
2 
Special attention has been drawn to -(1→2)-linked mannans not only due to the 
immunochemical activity shown by portions of these polymers but also because such structures 
have been predicted to display interesting conformational properties.
9 
Delicate conformational 
studies by Bundle and coworkers on propyl-capped glycosides have revealed that these 
carbohydrates form contorted α-helical-like structures in solution.9b Studies on fully deprotected 
oligomannosides have, however, not been reported earlier.  
In light of the extensive and elegant work previously conducted in this field, this chapter is 
devoted to the synthesis and NMR spectroscopic characterization of -(1→2)-linked 
oligomannosides,
10
 culminating in the synthesis and conformational study of a -(1→2)-linked 
mannotetraose.
10c
  
 
   
Figure 1. The cell wall of C. albicans (left) and the schematic structure of the 
phosphopeptidomannan (right). Reproduced with permission from the American Society for 
Microbiology.
1c
 
 
2 Results and Discussion 
2.1 Synthesis of -(1→2)-Linked Oligomannosides 
Considerable effort has been devoted to solving the challenges related to the chemical synthesis 
of -(1→2)-linked oligomannosides due to their biological potential. As also mentioned in the 
introductory paragraph, synthesis of -linked mannosides is challenging for various reasons. The 
greatest challenges are the thermodynamic and kinetic preference for formation of the α-anomer.7 
To date, three main pathways (and variations thereof) for constructing the -mannosidic linkage 
have emerged.  
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The first method published by Hindsgaul in 1994 features molecular tethering of the acceptor and 
donor prior to the glycosylation reaction via intramolecular aglycon delivery.
8a
 Although the -
selectivity was excellent as a result of the direct attack from the -face of the ring, a significant 
drawback of the methodology was its low efficiency in the construction of -(1→2)-mannosidic 
linkages,
11
 which in turn was the linkage of interest in our studies. 
The second approach, developed initially by Lichtenthaler and later modified by Bundle and 
coworkers
12
 features the utilization of a glucopyranosyl trichloroacetimidate donor (ulosyl donor 
by Lichtenthaler). In this approach, the -glucosidic linkage is constructed first, followed by 
epimerization at C-2 by an oxidation-reduction sequence to generate the -linked mannoside. 
While this methodology is appealing, both the glycosylation and the epimerization yields have 
been shown to decline when moving towards larger oligosaccharides.
8b
 
The third and final pathway to -linked mannosides, developed by Crich and coworkers,8e 
features a highly selective direct coupling of two appropriately protected mannopyranoside 
building blocks. This protocol is based on the triflate activation of a 4,6-O-benzylidene protected 
mannopyranosyl sulfoxide donor in the presence of TTBP at –60 C, followed by an SN2-like 
reaction with a glycosyl acceptor. Crich and coworkers have shown the robustness of this 
methodology both in their synthesis of a cyclohexyl capped -(1→2)-linked 
mannooctasaccharide and several oligomannosides in the  -(1→3)- and -(1→4)-series.8e,9a,13 
The Crich protocol was utilized here as a starting point for the synthesis of -(1→2)-linked 
oligomannosides due to its robustness and high efficiency. Synthesis of the building blocks, 
following previously reported procedures,
10a,13b,14
 commenced by the route shown in Scheme 1. 
In short, peracetylated mannose was subjected to BF3OEt2 promoted glycosylation with various 
acceptors and the corresponding glycosides were easily deacetylated under Zemplén conditions
15
 
thereby providing compounds 3–6. When the glycosylation was tested with cyclohexanol the 
yield was only around 5 %. Therefore, the more reactive imidate donor 2
16
 was utilized in the 
glycosylation with cyclohexanol, thus providing cyclohexyl 2,3,4,6-tetra-O-acetyl-α-D-
mannopyranoside in 69 % yield. The deprotected molecules 3–6 were converted into the 4,6-O-
benzylidene protected substrates 7–10 with benzaldehyde dimethylacetal under acidic 
conditions.
17
 The moderate yields of this reaction are due to the cis relationship of the 2- and 3-
hydroxyl groups which decreases the yield of the desired product by formation of a dibenzylidene 
protected mannoside.
18 
Substrates 7–10 were converted to acceptors 11–14 by selectively 
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benzylating the equatorial 3-OH-group through alkylation of a 2,3-dibutylstannylene acetal 
intermediate with benzyl bromide.
19
 The thio acceptors were converted into two different donors, 
bearing either a 2-O-benzyl or 2-O-propargyl protective group, for screening the effects of the 
protective group at C-2 on the -selectivity of the glycosylation reaction. Furthermore, the allyl 
glycoside 13 and the compounds bearing a 2-O-allyl protective group (15, 16, 19) could 
potentially be applied in a cross coupling metathesis pathway for generation of divalent 
carbohydrates.
10a,20
 With the building blocks synthesized, the attention was turned towards the 
preparation of oligosaccharides. 
 
 
Scheme 1. i) 1. Hydrazine acetate, DMF, 55 C, 2 h, 95 %; 2. DBU, CCl3CN, CH2Cl2, r.t., 1.5 h, 
72 %; ii) 1. BF3OEt2, corresponding alcohol (BnOH, CyOH, AllOH, SHPh), CH2Cl2, r.t., 24 h; 
2. NaOMe, MeOH, rt, 3–24 h, 3 (75 %), 4 (63 %), 5 (73 %), 6 (90 %); iii) PTSA, 
C6H5OCH(OMe)2, DMF, 60 C, 200 mbar, 2 h, 7 (56 %), 8 (57 %), 9 (51 %), 10 (53 %); iv) 1. 
Bu2SnO, toluene, 120 C, 3 h; 2. TBAB, CsF, BnBr, 120 C, 3 h, 11 (75 %), 12 (84 %), 13 (80 
%), 14 (85 %); v) NaH, corresponding bromide, DMF, r.t., 1–3 h, 15 (96 %), 16 (95 %), 17 (96 
%), 18 (94 %), 19 (95 %). 
 
In the -mannosylation protocol originally reported by Crich and utilized here for the current 
synthesis, the thioglycoside is activated with Tf2O in the presence of TTBP and BSP in CH2Cl2 at 
–60 C to yield an -mannopyranosyl triflate.8e To the activated donor species is then added the 
corresponding acceptor at –78 C. After 1.5 hours the reaction is essentially completed and the 
disaccharide isolated by conventional work-up procedures.
21
 Mechanistic studies by Crich have 
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revealed that the selectivity of the reactions most probably stems from a dissociative mechanism 
involving a transient contact ion pair intermediate which is in equilibrium with the -
mannopyranosyl triflate as depicted in Scheme 2.
22
  
 
 
Scheme 2. The proposed -mannosylation mechanism.  
 
The initial glycosylation reaction was performed with donor 17 and acceptor 14 in order to 
produce a disaccharide donor for the tetrasaccharide synthesis. The reaction proceeded with a 
:-selectivity of 10:1 and disaccharide 20 could be isolated in up to 76 % yield. A similar 
selectivity (: 10:1) was observed when donor 17 was coupled with acceptor 13 thereby 
showing a clear connection between selectivity and the 2-OBn protective group. Next, donor 18, 
bearing a 2-O-propargyl group, was evaluated in the glycosylation of acceptors 11 and 12. Both 
glycosylations were found to proceed smoothly thus providing disaccharides 22 and 23 in high 
yields and excellent selectivities (: 20:1). Similar results were reported already in 2005 by 
Crich and coworkers. In their work, the effect was suggested to be a combination of the minimal 
steric bulk and disarming nature of the propargyl group.
13a 
The propargyl group was next cleaved, 
in yields ranging from 80–85 %, by isomerization of the triple bond with tBuOK to give an 
allenyl ether followed by oxidative cleavage utilizing NMO/OsO4 in acetone/water.
13b,23 
The 
cyclohexyl disaccharide 25 was deprotected by hydrogenolysis (2.8 bar H2-pressure) to give the 
cyclohexyl capped trisaccharide mimic 26 in 94 % yield.  
After experimenting on the synthesis of disaccharides and smaller building blocks, a route for the 
synthesis of a fully deprotected -(1→2)-linked mannotetraose was developed.  
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Scheme 3. i) 1. Donor 17 or 18, TTBP, BSP, Tf2O, CH2Cl2, –60 C, 0.5 h; 2. corresponding 
acceptor –78 C, 3 h, 20 (78 %), 21 (72 %), 22 (74 %), 23 (72 %); ii) 1. tBuOK, THF, r.t., 5 h; 2. 
OsO4, NMO, acetone/H2O (4:1), rt, 3 h, 24 (83 %), 25 (85 %); iii) H2, Pd/C, MeOH:EtOAc 
(10:1), 2.8 bar, r.t., 19 h, 98 %; iv) 1. 20, TTBP, BSP, Tf2O, CH2Cl2,–60 C, 0.5 h; 2. 24 –78 C, 
3 h, 55 %; v) H2, Pd/C, MeOH, 2.8 bar, r.t., 19 h, 75 %. 
 
The synthesis of larger oligosaccharides can in general be considered as the ultimate proving 
ground for any glycosylation methodology. In the linear glycosylation protocol utilized by the 
research group of Crich, the selectivity of the individual glycosylation reactions was found to 
decline rapidly when progressing towards the tetrasaccharide stage (from : 9.9:1 for the 
trisaccharide to 3.9:1 for the tetrasaccharide).
8e 
Despite the decrease in selectivity, a high 
efficiency was maintained throughout the entire synthetic pathway. Bundle and coworkers, on the 
other hand, noted in their linear synthesis of a hexasaccharide in the -(1→2)-series that the 
efficiency was significantly reduced from 65 % at the trisaccharide stage to 48 % at the 
tetrasaccharide stage when utilizing glucose-based imidate donors.
8b
 Based on these two 
approaches it seemed obvious that the linear approach may not be the best alternative for 
constructing larger oligosaccharides. In general, the convergent approach has several advantages 
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over the linear one, the most important being a shorter synthetic route.
24
 One previous study on 
convergent synthesis, featuring a disaccharide/disaccharide coupling reaction for the construction 
of a -(1→2)-linked mannotetrasaccharide, has been reported by Mallet and coworkers.8d In their 
work, however, neither the selectivity in the crucial glycosylation reaction nor the NMR 
spectroscopic data of the compounds were reported. In addition, three different types of 
protective groups were utilized leading to a three step deprotection sequence in order to obtain 
the target tetrasaccharide. In the present work, a convergent strategy featuring disaccharide donor 
20 and disaccharide acceptor 24, containing only one type of protective groups, was utilized. The 
reaction between the two disaccharide building blocks proceeded smoothly following the 
standard activation protocol and tetrasaccharide 27 could, after work-up, be isolated in 55 % 
yield (: 10:1).10c In comparison with the earlier reported linear approach,8e the selectivity in the 
crucial glycosylation was more than two times higher when the convergent protocol was applied. 
The yield was only slightly lower than those reported earlier by Crich and coworkers
8e
 (53 % 
yield, starting from the disaccharide acceptor and monosaccharide donor) but slightly higher than 
the yield reported by Bundle et al.
8b
 (31 % yield, starting from the disaccharide acceptor and 
monosaccharide donor). In contrast to the convergent approach of Mallet,
8d
 the deprotection of 
the β-(1→2)-linked mannotetrasaccharide was here achieved in one step by hydrogenolysis 
instead of the three step deprotection sequence required in their approach. The hydrogenolysis of 
27 under 2.8 bar H2–pressure in methanol proceeded smoothly to provide 28. The yield was 
highly dependent on the deprotection conditions. When 2.5 weight equiv. of Pd/C (10 % Pd) was 
utilized with a substrate concentration of 10 mg/ml (in MeOH), a reduced tetrasaccharide 
containing mannitol at the reducing end was obtained in 40 % yield. The formation of this 
byproduct was verified by both HRMS (m/z 691.2281 [M + Na]
+
) and NMR spectroscopy 
showing three anomeric signals in the 
1
H-NMR spectrum at 4.89, 4.82 and 4.81 ppm and in the 
13
C-NMR spectrum at 101.1, 100.5 and 99.7 ppm. Formation of this undesired side-product was 
strongly suppressed when two weight equiv. Pd/C was used and the concentration of 28 was 20 
mg/ml (in MeOH), thereby increasing the yield of the desired product to 75 % (for purification 
details, see the experimental section).  
With the tetrasaccharide fragment synthesized, the attention was next turned towards the 
synthesis of divalent carbohydrates.
10a
 Multivalent carbohydrate structures are in general 
considered to be important due to their ability to target multiple receptors simultaneously which 
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in many cases leads to an increase in the biological response.
25
 Divalent molecules are the 
simplest form of multivalent compounds and, therefore, ideal systems to start the exploration of 
the effects of multivalency on the biological activity. In this work, cross-coupling metathesis 
(CCM)
26 
featuring Grubbs 1
st
 generation catalyst was utilized as a tool for the creation of divalent 
mannose derivatives. This is also apparent since many of the building blocks in Scheme 1 and 3 
contain a terminal alkene.
10a 
It should be noted that the applications of “Click” chemistry, 
especially the coupling between an alkyne and an azide,
27
 were rather limited in the field of 
carbohydrates at the outset of these investigations. Later on, “Click” chemistry has been shown to 
be a simple, efficient and robust method for the preparation of multivalent carbohydrate 
assemblies.
28 
The main limitations for the use of CCM in the construction of divalent 
carbohydrates have previously been the poor diastereoselectivities sometimes observed and the 
fact that, in contrast to ring-closing olefin metathesis, the CCM reaction is not driven by an 
increase in entropy.
29  
 
 
Scheme 4. i) Grubbs 1
st
 generation catalyst, CH2Cl2, 40 C, 6 h, 29 (95 %), 30 (75 %), 31 (74 %); 
ii) H2, Pd/C, MeOH:EtOAc (9:1), 1.4 bar, r.t., 18 h, 32 (70 %), 33 (70 %).  
 
In order to evaluate cross coupling metathesis as a methodology for the preparation of divalent 
carbohydrates, the monosaccharide building blocks 15, 16 and 19 bearing a terminal alkene 
moiety were screened in the reaction following experimental procedures reported previously by 
Roy and coworkers.
30 
Homodimerizations of compounds 15, 16 and 19 proceeded with excellent 
diastereoselectivites (E/Z ratios up to 20:1) to give the divalent compounds 29–31 in good to 
excellent yields after purification.
10a
 In previous examples, E/Z ratios ranging from 1:1 to 6:1 
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have been observed in homodimerization reactions.
29a,31 
Higher selectivities have been witnessed 
previously also when the two starting moieties were tethered together prior to the CCM 
reaction.
32 
The high diastereoselectivites observed here may be due to the protective groups 
present in compounds 15, 16 and 19. Furthermore, electron rich substituents at the anomeric 
position influence the diastereoselective outcome of the reaction as the benzyl and thiophenyl 
mannosides gave higher selectivities than the cyclohexyl mannoside. The selectivity of the CCM 
reaction was not important in this study since the newly formed alkene functionality is 
hydrogenated in the hydrogenolyses reaction. For future modifications and development of CCM 
reactions, however, it may turn out to be useful information. Compounds 29 and 30 were 
deprotected by hydrogenolyses to give the divalent 2,2-linked mannosides 32 and 33 in 70 % 
yield.  
 
 
Scheme 5. i) 1. TTBP, BSP, Tf2O, –60 C, 0.5 h; 2. 11 –78 C, 3 h, 70 %; ii) H2, Pd/C, 
MeOH:EtOAc (9:1), 1.4 bar, r.t., 18 h, 50 %. 
 
With the divalent monosaccharides prepared, the study on -linked mannosides was extended and 
finalized by the synthesis of divalent disaccharides. For this purpose, divalent donor 31 and allyl 
glycoside 21 were utilized. The divalent donor 31 was activated as previously described
8e
 and 
coupled with acceptor 11 to give the divalent disaccharide 34, after work-up, in 70 % yield as a 
single -anomer. To our knowledge, this was the first time when several leaving groups were 
activated simultaneously in the synthesis of -linked mannosides. Due to the high efficiency in 
the double glycosylation reaction, similar strategies might be applied also to the synthesis of 
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other structures containing interconnected carbohydrates attached at multiple locations in the 
aglycone. Compound 35 could after hydrogenolyses be isolated in 50 % yield as a mixture 
containing an 8:2:1 ratio of ::-anomers.10a  
 
 
Scheme 6. i) Grubbs 1
st
 generation catalyst, CH2Cl2, 40 C, 6 h, 65 %; ii) H2, Pd/C, 
MeOH:EtOAc (9:1), 1.2 bar, r.t., 18 h, 95 %. 
 
Synthesis of the divalent 1,1-linked disaccharide 37 commenced by the route shown in Scheme 
6. The homodimerization of 21 gave a slightly lower yield than the monosaccharides, most 
probably due to the significant size difference which adds a factor of steric constrain. Also the 
E/Z value of 5:1 in the reaction was poor compared to the E/Z values in the homodimerization of 
monosaccharides 15, 16 and 19. Hydrogenolyses of 36 proceeded smoothly to afford 37 as a 
colorless oil in 95 % yield.  
Overall, a variety of -linked mannosides including a trisaccharide mimic, a fully deprotected 
mannotetraose and divalent mono- and disaccharides were prepared and subjected for biological 
screening of their immunostimulatory effects. While the biological data is not addressed here in 
more detail, it should be mentioned that some deviances from earlier reported TNF- values were 
found in the cytokine stimulation assay.
1a–c
 When synthesizing oligosaccharides of this type, it is 
important to ensure the integrity of the synthesized compounds. This is usually achieved with a 
number of different methods including NMR spectroscopy, HRMS and optical rotation. The 
NMR spectroscopic characterization of oligosaccharides can sometimes be complicated due to 
overlapping signals in the 
1
H-NMR spectra. The -linked mannopyranosides add a few more 
challenges than the average oligosaccharides and, therefore, the next section will be devoted to 
the NMR spectroscopic characterization of these substrates.  
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2.2 NMR Spectroscopic Characterization 
It would be redundant to discuss the NMR spectroscopic characterization of all synthesized 
compounds here and, therefore, the NMR spectroscopic characterization will be exemplified by 
the complete characterization of compounds 27 and 28 (Figure 2). All other molecules were 
assigned by the use of similar NMR spectroscopic techniques.  
 
 
Figure 2. The chemical structures of compounds 27 and 28. 
 
During the convergent synthesis of 27 it was important to verify the linkages in the 
tetrasaccharide formed. In general, the H-1–H-2 coupling constants are utilized in determination 
of :-ratios of carbohydrates. In the case of mannopyranosides, however, these values differ 
insignificantly (difference ~ 1 Hz) and cannot be used as a reliable measure.  In the literature, the 
chemical shifts of H-3 and H-5 protons in -linked mannopyranosides have been reported to 
appear at a considerably lower frequency than in the corresponding -linked 
mannopyranosides.
8e,10b,33
 Furthermore, the C-5 carbons have been suggested to appear at a 
slightly higher frequency in the case of -linked mannopyranosides as compared to -linked 
mannopyranosides. In the 
1
H-NMR spectrum of 27 (Figure 3), chemical shifts for the three H-5β 
protons were observed at low frequencies (3.42 ppm for H-5, 3.31 ppm for H-5 and 3.30 ppm 
for H-5) in comparison to the chemical shift of H-5 (3.86 ppm for H-5) thereby suggesting that 
the β-anomer had indeed been formed in the disaccharide/disaccharide coupling reaction. A 
similar difference was witnessed in the 
13
C-NMR spectrum (Figure 4) where the three C-5β 
carbons (67.9 ppm for C-5, 67.8 ppm for C-5, 67.5 ppm for C-5) appear at slightly higher 
frequency than the C-5 (64.2 ppm for C-5). 
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Figure 3. The region between 8.00–3.00 ppm in the 1H-NMR spectrum of 27.  
 
 
Figure 4. The region between 145.0–60.0 ppm in the 13C-NMR spectrum of 27. 
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Furthermore, an up-field shift of the three H-3β protons (3.64 ppm for H-3, 3.53 ppm for H-3 
and H-3) was observed further indicating a different linkage than the one existing in the first 
residue (4.01 ppm for H-3). As mentioned earlier, these results are in accordance with the general 
view on the chemical shifts of - and β-mannopyranosides.8e,10b,33 In general, the full spectral 
characterization of complex oligosaccharides is one of the most demanding tasks in carbohydrate 
chemistry.
34
 For this purpose, 1D-TOCSY (1D-TOtal Correlation SpectroscopY) proved to be a 
valuable tool.
35 
Well separated signals corresponding to the different ring units were targeted by 
selective excitation with a spinlock time of 500 ms being suitable for assuring magnetization 
spreading to the entire ring-system. The 1D-TOCSY spectra of the different residues of 27 are 
shown in Figure 5. 
 
H-1
H-2
H-3
H-5H-6a
H-6b
H-4
H-1
H-2 H-3
H-5H-6a
H-6bH-4
H-1
H-2 H-3
H-5
H-6b
H-6a
H-4
H-1
H-2
H-3
H-5
H-6b
H-6a
H-4
 
Figure 5. 1D-TOCSY spectra of the different residues and the entire 
1
H-NMR spectrum of the 
carbohydrate region of 27.  
 
As also seen from Figure 5, the use of 1D-TOCSY reduces the spectral complexity to a 
monosaccharide level. The individual 1D-TOCSY spectra are easier to interpret as the amount of 
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overlapping signals is reduced. In order to obtain accurate coupling constants, the spectral 
simulation software PERCH (Peak ResearCH) was utilized.
36
 The coupling constants obtained 
(although not reliable as such) by simulation of the 
1
H-NMR spectrum clearly indicated a 
difference between the H-1–H-2 coupling constants for the -linked residue (J1,2 = 1.6 Hz for H-
1) and the β-linked ones (J1,2 = 0.3 Hz for H-1, J1,2 = 0.8 Hz for H-1 and J1,2 = 0.7 Hz for 
H-1). Ultimately, the linkages were proven by the use of coupled HSQC showing large 
differences in the JC,H coupling contants (JC-1,H-1 = 158.3 Hz for C-1, JC-1,H-1 = 158.6 Hz for 
C-1, JC-1,H-1 = 156.0 Hz for C-1 and JC-1,H-1 = 167.8 Hz for C-1).
37
 The order of the residues 
and positions of protecting groups were determined by HMBC correlations by conventional 
methods.  
In order to fully assign the 
1
H-NMR spectrum of 28, a similar set of NMR spectroscopic methods 
was applied. The NMR spectrum of a tetrasaccharide alone is in many cases problematic to solve. 
Here, due to mutarotation, an : ratio of 7:2 for 28 was observed thereby further complicating 
the assignment. Again, 1D-TOCSY proved to be a powerful tool and was utilized to overcome 
the complications.
35
 Compound 28 gives rise to well separated signals corresponding to the H-1 
and H-2 protons on the different residues of both anomers. These signals were also targeted using 
1D-TOCSY. The separation was found to be highly influenced by the NMR-solvent used (MeOD 
vs. D2O). In MeOD, an enhanced separation of the crucial signals was observed. From the 
biological standpoint, however, D2O is of more interest and, accordingly, NMR spectroscopic 
data was recorded in both solvents. The importance of an improved signal separation is 
significant and thus the following discussion is based on the NMR spectra recorded in MeOD. By 
narrowing the excitation range in 1D-TOCSY, even signals separated by only 6 Hz could be 
selectively excitated to give the 
1
H-NMR spectrum of a single residue. With the eight individual 
1D-TOCSY spectra recorded, one for each of the eight residues present in the 
1
H-NMR spectrum, 
the attention was turned towards determination of the order of residues. For this purpose, the 
13
C 
chemical shifts of the reducing end anomers were chosen as a starting point. These signals appear 
at a considerably lower frequency (94.1 ppm for C-1 and 95.5 for C-1) when compared with 
the other anomeric carbons (between 103.3–101.1 ppm). In HMBC, the long range coupling 
between H-2-C-1 was clearly visible. The inverse coupling between H-1-C-2 was also observed. 
By iteration of this approach, the different monomers were determined in order starting from the 
reducing end residue. H-5 was shown to give a signal at a higher frequency in both anomers 
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(3.36 ppm for H-5 and 3.39 for H-5) than the remaining of the H-5 protons (between 
3.25–3.20 ppm). This also indicates that the residues were assigned correctly. In D2O this effect 
does not occur and therefore all the H-5 protons appear at a similar chemical shift. Furthermore, 
the 2D-NOESY spectrum showed correlations between H-1
n+
 and H-2
n
 (where n= 0, , ) which 
were in agreement with the assignment based on the HMBC spectrum. Determination of the order 
of residues of the -anomer of 28 by 2D-NOESY is depicted with red arrows in Figure 6.  
 
H-1
H-2
H-1
H-2
H-1
H-2
H-1
 
Figure 6. Determination of the order of residues in the -anomer of 28 with 2D-NOESY. 
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Figure 7. Spectral simulation of the 
1
H-NMR spectrum of 28 in MeOD (5.2–3.1 ppm region) 
with Perch NMR software: simulated spectrum (above), observed spectrum (below). 
 
The information gained by 2D-NOESY will be further discussed below when assessing the 
conformation of this molecule. With the information received from these standard NMR 
spectroscopic techniques (
1
H, 
13
C, DQF-COSY, HSQC, HMBC, 1D-TOCSY and 2D-NOESY), 
the 
1
H-NMR spectrum was simulated with PERCH.
10c
 In order to simplify the matter, the 
individual 1D-TOCSY spectra were first simulated followed by simulation of the complete 
spectrum containing both anomers. The result of the simulation is shown in Figure 7. With the 
NMR spectroscopic characterization completed, several NOESY correlations between non-
contiguous residues were observed in the 2D-NOESY spectrum of 28. Intrigued by these findings 
a more detailed conformational analysis of the fully deprotected -(1→2)-linked mannotetraose 
was performed. 
 
2.3 Conformational Analysis 
The -(1→2)-linked oligomannosides were predicted to form interesting three dimensional 
structures more than 30 years ago.
9c
 The earlier work by Bundle and coworkers on a -(1→2)-
linked mannopentasaccharide revealed these assumptions to be correct.
9b
 NOE-contacts between 
non-contiguous residues were witnessed suggesting that a contorted -helical-like structure is 
formed. These studies were conducted with propyl-capped glycosides. Further evidence of their 
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contorted nature was reported by Crich
9a
 based on a crystal structure of a fully protected 
tetrasaccharide. In the present study, the conformational analysis was performed with the 
unprotected tetrasaccharide 28. In contrast to the previous studies where -linked glycosides have 
been used, the discussion below is based on the information of the dominating -anomer of the 
hemiacetal. 
 
 
Figure 8. 2D-NOESY spectrum of 28 in MeOD displaying the correlations between protons 
close in space. The most important correlations are highlighted by a red circle. 
 
In the 
1
H-NMR spectrum of 28 recorded in MeOD, the key signal for this conformational study 
was well separated (H-4, dd at 3.63 ppm). This was not the case in D2O. From the 2D-NOESY 
spectrum the correlations also witnessed by Bundle and coworkers were confirmed.
9b
 The most 
important correlations between the non-contiguous residues are H-4–H-2, H-4–H-1 and H-4–
H-1 (Figures 8 and 9). The H-4–H-2 correlation was stronger than the H-4–H-1 and H-4–H-
1 correlations as also seen in Figure 8. This information confirms the contorted structure 
predicted several years ago and witnessed by Bundle
9b
 and Crich.
9a 
A correlation between H-1–
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H-1 and H-1–H-2 was observed here for the first time. The lack of this correlation in the study 
of Bundle and coworkers may have been partly due to the use of propyl-capped -linked 
mannoglycosides. As mentioned earlier, 2D-NOESY correlations between H-1
n+
 and H-2
n
 
(where n= 0, , ) were witnessed thereby suggesting steric interactions to place the residues in a 
particular order. In addition, correlations between H-1–H-2, H-1–H-3 and H-1–H-5 of the -
linked residues along with the accurate coupling constants obtained by PERCH suggest the 
different residues to exist in the 
4
C1 chair conformation. To further investigate and verify the 
conformation suggested by NMR, computational methods were utilized to model the preferred 
structure. 
 
Figure 9. The B3LYP/6-31G(d,p) optimized structure of the -anomer showing the most 
important NOESY correlations on the left and the -helical nature of 28 on the right. 
 
The initial structure was first sketched by rapid modeling using molecular mechanics with 
Chem3D Pro 11.0 software. The geometry of the obtained structure was further optimized by 
DFT method B3LYP using 6-31G(d,p) as a basis set. This method has been found to give good 
results in a reasonable time for fairly large molecules.
38
 Since the potential energy surface for 
relatively flexible molecules may consist of several minima, the initial optimization did not find 
the structure corresponding to all of the NMR spectroscopic (especially NOE) results. Therefore, 
the torsion angles were modified in order to obtain a starting structure in agreement with the 
witnessed NOE correlations. When this structure was optimized, a stationary point was found 
which was in full agreement with the experimental results. Frequency calculation was performed 
in order to prove that the stationary point found was a minimum energy point. The optimized 
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structure is presented in Figure 9. In the optimized structure, the distances between the protons 
for the key NOE connectivities were found to be 3.19 Å (H-4-H-2), 4.13 Å (H-4-H-1) and 3.65 
Å (H-4-H-1). These values were in good agreement with the cross-peak intensities in the 
NOESY spectrum. All mannose moieties were found to exist in the 
4
C1 conformation as 
expected. The optimized results also show the contorted α-helical nature of the molecule, 
although, a tetrasaccharide does not seem to be sufficient in length for forming a complete helix 
(Figure 9).  
As seen from the models shown in Figure 9, the glycosidic linkages appear to be hidden in the 
middle of the contorted -helical-like structure creating a hydrophobic interior. The hydroxyl 
groups are oriented outwards further creating a hydrophilic exterior. A similar pattern was also 
suggested in the previous studies.
9b
 The nature of these molecules are but one example of the 
large diversity of three dimensional structures often found in naturally occurring carbohydrates. 
The creation of models by molecular modeling together with the complete NMR spectroscopic 
characterization of these compounds provide important reference material for others working 
with similar substrates and contribute to the overall understanding of the biological nature of such 
molecules.  
 
3 Conclusions 
A variety of β-(1→2)-inspired mannopyranoside derivatives were prepared by chemical 
synthesis. Based on the presented findings, a convergent route to larger oligomannosides may be 
a suitable alternative to the earlier reported linear approaches. In addition, several divalent 
molecules were prepared by utilization of highly diastereoselective CCM reactions. The 
synthesized molecules were prepared for biological purposes in order to evaluate their potential 
as C. albicans vaccines and as agents for the treatment of atopic allergies. The results from the 
immunostimulatory studies show slight deviation from the previously published literature and 
will be reported in detail elsewhere.  
Furthermore, much effort was invested in the complete NMR spectroscopic characterization of 
these compounds and as a result the first fully assigned 
1
H- and 
13
C-NMR spectra of the fully 
deprotected β-(1→2)-linked mannotetraose could be reported. This information should prove 
valuable not only to chemists synthesizing compounds but also to scientists working with the 
isolation of oligosaccharides from cell walls. From the 2D-NOESY spectra of 28, interesting 
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cross-peaks were found revealing the three dimensional -helical nature of these 
oligomannosides. It should, however, be noted that a tetrasaccharide is not sufficient in length to 
complete a helix-like structure. Overall, a complete study encompassing chemical synthesis, 
NMR spectroscopic characterization and conformational analysis of -(1→2)-inspired 
mannopyranosides was accomplished and presented in this Episode. 
 
4 Experimental Section 
Reaction solvents were dried and distilled prior to use when necessary. All reactions containing 
moisture- or air-sensitive reagents were carried out under argon atmosphere. All chemicals were 
purchased from commercial sources, mainly the chemical vendors Acros and Aldrich.  
The NMR spectra were recorded with Bruker Avance NMR spectrometers operating at 500.13 
MHz (
1
H: 500.13 MHz, 
13
C: 125.77 MHz) or 600.13 MHz (
1
H: 600.13 MHz, 
13
C: 150.90 MHz). 
The probe temperature during the experiments was kept at 25 C unless indicated otherwise. All 
products were fully characterized by utilization of 
1
H, 
13
C and TOCSY 1D-NMR techniques and  
DQF-COSY, NOESY, HSQC (both coupled and decoupled) and HMBC 2D-NMR techniques by 
using pulse sequences provided by the manufacturer. For more details on the pulse sequences 
utilized during the conformational analysis see reference [10c]. Chemical shifts are expressed on 
the  scale (in ppm) using TMS (tetramethylsilane), residual chloroform, acetone, H2O or 
methanol as internal standards. Coupling constants are given in Hz and provided only once when 
first encountered. Coupling patterns are given as s (singlet), d (doublet), t (triplet) etc. When 
signals appeared at similar chemical shifts in structures 27 and 28 additional decimals were used 
to determine the order of the signals. The computational analysis of the 
1
H-NMR spectra of all 
compounds, except 35, was achieved by utilization of the PERCH NMR software with starting 
values and spectral parameters obtained from the various NMR techniques used.
36
  
HRMS were recorded using Bruker Micro Q-TOF with ESI (electrospray ionization) or a Fison 
ZabSpecOaTOF with EI (electron impact) operated in positive mode. Optical rotations were 
measured at 23 C with a Perkin Elmer polarimeter equipped with a Na-lamp (589 nm). TLC was 
performed on aluminium sheets precoated with silica gel 60 F254 (Merck). Preparative TLC was 
performed on aluminium sheets precoated with silica gel 60 F254 (0.5 cm, Merck). Flash 
chromatography was carried out on silica gel 60 (0.040–0.060 mm, Merck). Spots were 
visualized by UV followed by charring with 1:10 H2SO4/MeOH and heating. Compound 28 was 
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purified by High-pH anion exchange chromatography (HPAEC) with a Dionex DX600 system 
equipped with an amperometric detector. Compounds 32, 33 and 35 were purified by HPLC 
utilizing an Agilent 1100 series liquid chromatographic system. 
The initial structure for modeling was drawn with ChemBioDraw Ultra 11.0 and modelled by 
Chem3D Pro 11.0 using a MM2 molecular mechanic method. All higher quality calculations 
were done by Gaussian 03 software using density functional method B3LYP as a hybrid 
functional and 6-31G(d,p) as basis set.
39
 The results were examined by GaussView 4.1.2 
program. 
 
4.1 General Experimental Procedures 
 
General procedure for glycosylation of 1,2,3,4,6-penta-O-acetyl-D-mannopyranose. To a 
solution containing 1,2,3,4,6-penta-O-acetyl-D-mannopyranose (1 equiv.) and 4 Å MS in CH2Cl2 
(3 ml/1 mmol) was added the corresponding alcohol (1.5–4 equiv.) and the resulting mixture was 
stirred for 0.5 h. The mixture was then cooled with an ice bath and BF3OEt2 (5–8 equiv.) was 
added dropwise. The resulting mixture was stirred for 0.5 h, brought to r.t. and stirring was 
continued for 20 h. The reaction mixture was diluted with CH2Cl2 (8 ml/1 mmol starting 
material) and poured into ice-cold H2O (16 ml/1 mmol starting material) with stirring. The 
organic phase was separated and washed with sat. NaHCO3 (8 ml/1 mmol starting material), H2O 
(8 ml/1 mmol starting material) and brine (8 ml/1 mmol starting material). The organic phase was 
dried over anhydrous MgSO4 or Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography (hexane:EtOAc 4:1) to give the corresponding glycoside.  
 
General procedure for synthesis of acetylated imidate donors. To a solution containing 
peracetylated mannose (1 equiv.) in dry DMF (15 ml/1 g of starting material) was added 
hydrazine acetat (1.1 equiv.). The resulting mixture was stirred for 2 h at 55 C, cooled to r.t., 
diluted with EtOAc (30 ml/1 g), washed with sat. NaHCO3 (20 ml/1 g), filtered through celite 
whereafter the organic phase was separated. The organic phase was then washed with H2O (2  
20 ml/ 1 g), brine (20 ml/1 g), dried over anhydrous MgSO4, filtered and concentrated to give the 
free hemiacetal. The hemiacetal was then dissolved in dry CH2Cl2 (13 ml/1 g) and DBU (12 
mol%) and trichloroacetonitrile (1.2 equiv.) were added at 0 C. The reaction mixture was stirred 
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for 1.5 h, brought to r.t., diluted with CH2Cl2 (13 ml/1 g) and washed with brine (20 ml/1 g). The 
organic phase was dried over Na2SO4, filtered and concentrated to give the crude product. The 
crude product was purified through a plug of silica (hexane:EtOAc:Et3N 2:1:0.01) to give the 
corresponding imidate donor. 
 
General procedure for deacetylation. To a solution containing the acetylated glycoside (1 
equiv.) in dry MeOH or dry MeOH:THF mixture (2:1) (1 ml/100 mg substrate) was added 
NaOMe (2 equiv.) and the resulting mixture was stirred for 3–20 h at r.t., neutralized with 
DOWEX 50 H
+
-form, filtered and concentrated. The crude product was purified by column 
chromatography (CH2Cl2→CH2Cl2:MeOH, 5:1) to give the corresponding deacetylated 
glycoside. 
 
General procedure for synthesis of 4,6-O-benzylidene--D-mannopyranosides. To a solution 
of the corresponding deacetylated glycoside (1 equiv.) in DMF (1 ml/40 mg starting material) 
was added PTSA (10 mol%) and benzaldehyde dimethyl acetal (1 equiv.). The resulting mixture 
was stirred at 60 C and 200 mbar for 2 h and concentrated. To the concentrated residue was 
added H2O (10 ml/500 mg) and formation of a white solid was received. The solid was filtered 
off and washed with H2O (10 ml/ 500 mg) and Et2O (3 ml/1 g) to obtain the crude product. The 
crude product was either used as such or in some cases further purified by column 
chromatography (CH2Cl2→CH2Cl2:MeOH, 5:1) to give the corresponding 4,6-O-benzylidene--
D-mannopyranosides. 
 
General procedure for the selective benzylation of the equatorial 3-OH group. To a solution 
of the corresponding 4,6-O-benzylidene--D-mannopyranoside (1 equiv.) in toluene (4 ml/100 
mg starting material) was added Bu2SnO (1 equiv.) and the resulting mixture was refluxed for 3 h 
at 120 C. The reaction mixture was then cooled to r.t. and TBAB (1.05 equiv.), CsF (1.02 
equiv.) and BnBr (1.04 equiv.) were added and the mixture was again refluxed for 3 h, cooled to 
r.t., diluted with EtOAc (4 ml/100 mg) and sat. NaHCO3 (3 ml/100 mg) and filtered through 
celite. The organic phase was separated and the aqueous phase was extracted with EtOAc (3  3 
ml/ 100 mg). The combined organic phase was washed with H2O (4 ml/100 mg) and brine (3 
ml/100 mg), dried over anhydrous Na2SO4, filtered and concentrated. The crude product was 
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purified by column chromatography (hexane:EtOAc 4:1) to give the corresponding 3-O-benzyl 
derivatives.  
 
General procedure for alkylation of the 2-OH group. To a solution containing the 
corresponding 3-O-benzyl derivative (1 equiv.) in DMF (2 ml/100 mg starting material) was 
added NaH (1.5–1.9 equiv.) at 0 C. The reaction mixture was stirred for 15 min, then brought to 
r.t., stirred for 10 min then the corresponding bromide (1.5 equiv.) was added. The resulting 
mixture was stirred for 1–3 h, quenched with MeOH (0.4 ml/1 mmol starting material), diluted 
with CH2Cl2 (4 ml/100 mg) and washed with sat. NaHCO3 (3 ml/100 mg). The organic phase was 
separated and the aqueous phase was washed with CH2Cl2 (3  3 ml/100 mg). The combined 
organic phase was washed with brine (3 ml/100 mg), dried over Na2SO4, filtered and 
concentrated. The crude product was purified by column chromatography (hexane:EtOAc 8:1) to 
give the fully protected substrates 15–19.  
 
General procedure for -mannosylation. To a solution containing the corresponding donor (1 
equiv.) in dry CH2Cl2 (4 ml/ 0.5 mmol of donor) was added at – 60 C (acetone + dry ice) BSP 
(1.2 equiv.), TTBP (1.5 equiv.) and Tf2O (1.3 equiv.). The resulting mixture was stirred for 0.5 h 
followed by cooling to –78 C and addition of the corresponding acceptor (1.15 equiv.), 
dissolved in CH2Cl2 (3 ml/0.5 mmol of acceptor), over a timeperiod of 15 min. The reaction 
mixture was stirred for 2 h and quenched by addition of triethyl phosphite (3 equiv.). The 
reaction mixture was stirred for 1 h at –78 C, brought to r.t., diluted with CH2Cl2 (3 ml/100 mg) 
and washed with sat. NaHCO3-solution (3 ml/100 mg). The water phase was separated and 
extracted with CH2Cl2 (3  3 ml/100 mg). The combined organic phase was washed with brine (3 
ml/100 mg), dried over Na2SO4, filtered and concentrated. The crude product was purified by 
column chromatography (hexane:EtOAc 6:1→4:1→3:2) to give the glycosylated product.  
 
General procedure for propargyl group deprotection. To a solution of the corresponding 2-O-
propargylated compound (1 equiv.) in dry THF (2 ml/100 mg of starting material) was added 
t
BuOK (1.2 equiv.). The resulting mixture was stirred at r.t. for 5 h, diluted with CH2Cl2 (3 ml/ 
100 mg) and washed with H2O (2 ml/100 mg). The organic phase was dried and concentrated and 
the crude product was utilized as such in the following reaction. Successful isomerization was 
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confirmed by NMR spectroscopy at this stage. The isomerized 2-O-allenyl sugar (1 equiv.) was 
dissolved in acetone/water (4:1) and treated with a catalytic amount of OsO4 followed by NMO 
(2 equiv.). The reaction mixture was stirred for 3 h, diluted with (3 ml/100 mg) and washed with 
H2O (2 ml/100 mg). The water phase was extracted with CH2Cl2 (2  3 ml/100 mg) and the 
combined organic phases were dried over Na2SO4, filtered and concentrated. The crude product 
was purified by column chromatography (hexane:EtOAc 4:1→3:2) to give the depropargylated 
product. 
 
General procedure for hydrogenolysis. To a solution of the corresponding protected mannoside 
(1 equiv.) in MeOH or MeOH:EtOAc (10:1, 1 ml/10 mg of starting material) was added Pd/C (10 
% Pd, 2.5 equiv. by mass). The reaction mixture was stirred in an autoclave under H2 (1.4–2.8 
bar) overnight, filtered through celite and concentrated to give the deprotected substrates. 
 
General procedure for homodimerization reactions. To a solution containing the terminal 
olefin (1 equiv.) in CH2Cl2 (1 ml/100 mg starting material) was added Grubbs 1
st
 generation 
catalyst (10 mol%). The reaction mixture was refluxed for 6 h, cooled to r.t. and concentrated. 
The crude product was purified by column chromatography (hexane:EtOAc 8:1→1:2) to give 
brownish oils. The resulting oils were diluted with CH2Cl2 (5 ml/100 mg) and stirred for 19 h 
with activated carbon (0.1 equiv. by mass), filtered through celite and finally through a plug of 
silica to give the corresponding divalent molecules.  
 
4.2 Analytical Data on Selected Substrates
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2,3,4,6-tetra-O-acetyl--D-mannopyranose trichloroacetimidat (2). Synthesized from 1 (1.67 
g, 4.78 mmol) according to the general procedure for synthesis of acetylated imidate donors to 
give the title compound as a yellowish oil (2.00 g, 72 %). TLC: Rf= 0.58  (hexane:EtOAc 1:1). 
1
H 
NMR (600.13 MHz, CDCl3, 25 °C):  8.79 (s, 1 H, NH), 6.29 (d, 1 H, J1,2 = 2.0 Hz, H-1), 5.48 
(dd, 1 H, J2,3 = 3.2 Hz, H-2), 5.41 (dd, 1 H, J3,4 = 10.1 Hz, H-3), 5.40 (dd, 1 H, J4,5 = 10.0 Hz, H-
4), 4.28 (dd, 1 H, J6b,5 = 5.0, J6b,6a = –12.4 Hz, H-6b), 4.19 (ddd, 1 H, J5,6a = 2.4 Hz, H-5), 4.17 
(dd, 1 H, H-6a), 2.20, 2.10, 2.07, 2.01 (each s, each 3 H, OCOCH3). 
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13
C NMR (150.90 MHz, CDCl3, 25 °C):  170.6, 169.8, 169.7, 169.6 (OCOCH3), 159.8 (CCl3), 
94.5 (C-1), 71.2 (C-5), 68.8 (C-3), 67.8 (C-2), 65.4 (C-4), 62.0 (C-6), 20.8, 20.7, 20.7, 20.6 
(OCOCH3).  
HRMS: m/z calcd. for C16H20Cl3NO10Na [M+Na]
+
 514.0045; found 514.0029. 
 
Benzyl -D-mannopyranosid (3). Synthesized from 1 (4.7 g, 12.7 mmol) according to the 
general procedure for glycosylation of 1,2,3,4,6-penta-O-Ac-D-mannopyranose to give the 
acetylated benzyl glycoside as a colorless oil (4.4 g, 79 %). This product (0.7 g, 1.6 mmol) was 
deprotected according to the general procedure for deacetylation to give the title compound as a 
white solid (0.4 g, 91 %). TLC: Rf = 0.44 (CH2Cl2:MeOH 4:1). []D
23
 +85.9° (c 1.0, MeOH); 
1
H 
NMR (600.13 MHz, CD3OD, 25 °C):  7.29–7.14 (m, 5 H, arom. H), 4.83 (d, 1 H, J1,2 = 1.7 Hz, 
H-1), 4.75 and 4.51 (each d, each 1 H, J = –11.8 Hz, 1-CH2Ph), 3.84 (dd, 1 H, J6a,5 = 2.2, J6a6b = –
11.8 Hz, H-6a), 3.82 (dd, 1 H, J2,3 = 3.4 Hz, H-2), 3.72 (dd, 1 H, J3,4 = 9.3 Hz, H-3), 3.71 (dd, 1 
H, J6b,5 = 6.0 Hz, H-6b), 3.62 (dd, 1 H, J4,5 = 9.9 Hz, H-4), 3.59 (ddd, 1 H, H-5). 
13
C NMR (150.90 MHz, CD3OD, 25 °C):  139.1, 129.4, 129.2, 128.8 (arom. C), 100.7 (C-1), 
75.0 (C-5), 72.7 (C-3), 72.3 (C-2), 69.9 (1-CH2Ph), 68.7 (C-4), 63.0 (C-6). 
HRMS: m/z calcd. for C13H18O6Na [M+Na]
+
 293.0996; found 293.0999.  
 
Cyclohexyl -D-mannopyranoside (4). Synthesized from 2 (0.84 g, 1.7 mmol) according to the 
general procedure for glycosylation of 1,2,3,4,6-penta-O-Ac-D-mannopyranose to give the 
acetylated cyclohexyl glycoside as a colorless oil (0.5 g, 69 %). This product (0.41 g, 0.96 mmol) 
was deprotected according to the general procedure for deacetylation to give the title compound 
as a white foam (0.23 g, 91 %). TLC: Rf = 0.42 (CH2Cl2:MeOH 4:1). []D
23
 + 93.5° (c 1.0, 
MeOH). 
1
H NMR (600.13 MHz, CD3OD, 25 °C):  4.89 (d, 1 H, J1,2 = 1.8 Hz, H-1), 3.80 (dd, 1 
H, J6a,5 = 2.2, J6a,6b = –11.8 Hz, H-6a), 3.73 (dd, 1 H, J2,3 = 3.4 Hz, H-2),  3.70 (dd, 1 H, J6b,5 = 5.6 
Hz, H-6b), 3.70 (dd, 1 H, J3,4 = 9.2 Hz, H-3), 3.70 – 3.62 (m, 1 H, OCHC5H10), 3.60 (ddd, 1 H, 
J5,4 = 9.3 Hz, H-5), 3.60 (dd, 1 H, H-4), 1.93 – 1.70 (m, 4 H, OCHC5H10), 1.58 – 1.2 (m, 6 H, 
OCHC5H10). 
 
13
C NMR (150.90 MHz, CD3OD, 25 °C):  99.4 (C-1), 75.8 (OCHC5H10), 74.7 (C-5), 72.8 (C-
2), 72.7 (C-3), 68.8 (C-4), 63.0 (C-6), 34.5, 32.4, 26.9, 25.1, 24.9 (OCHC5H10). 
HRMS: m/z calcd. for C12H22O6Na [M+Na]
+
 285.1314; found 285.1321. 
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Allyl -D-mannopyranoside (5). Synthesized from 1 (1.0 g, 2.6 mmol) according to the general 
procedure for glycosylation of 1,2,3,4,6-penta-O-Ac-D-mannopyranose to give the acetylated 
allyl glycoside as a colorless oil (0.6 g, 69 %). This product (3.4 g, 8.7 mmol) was deprotected 
according to the general procedure for deacetylation to give the title compound as a colorless oil 
(1.9 g, quant.). TLC: Rf = 0.25 (CH2Cl2:MeOH 5:1). []D
23
 +73.6° (c 1.0, MeOH). 
1
H NMR 
(600.13 MHz, CD3OD, 25 °C):  5.93 (dddd, 1 H, JCHCH2,CH2a = 5.1, JCHCH2,CH2b = 6.0, 
JCHCH2,CHCH2cis = 10.5, JCHCH2,CHCH2trans = 17.2 Hz, 1-OCH2CH=CH2), 5.29 (dddd, 1 H, 
JCH2trans,CH2b = –1.6, JCH2trans,CH2a = –1.8, JCH2trans,CH2cis = –1.9 Hz, 1-OCH2CH=CH2trans), 5.16 
(dddd, 1 H, JCH2cis,CH2b = –1.3, JCH2cis,CH2a = –1.4 Hz, 1-OCH2CH=CHcis), 4.79 (d, 1 H, J1,2 = 1.7 
Hz, H-1), 4.21 (dddd, 1 H, JCH2a,CH2b = –13.1 Hz, 1-OCH2aCH=CH2), 4.00 (dddd, 1 H, 1-
OCH2bCH=CH2), 3.83 (dd, 1 H, J6a,5 = 2.3, J6a,6b = –11.8 Hz, H-6a), 3.80 (dd, 1 H, J2,3 = 3.4 Hz, 
H-2), 3.70 (dd, 1 H, J6b,5 = 6.0 Hz, H-6b), 3.70 (dd, 1 H, J3,4 = 9.5 Hz, H-3), 3.60 (dd, 1 H, J4,5 = 
9.9 Hz, H-4), 3.53 (ddd, 1 H, H-5). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  135.5 (1-OCH2CH=CH2), 117.3 (1-OCH2CH=CH2), 
100.8 (C-1), 74.8 (C-5), 72.7 (C-3), 72.2 (C-2), 68.9 (1-OCH2CH=CH2), 68.7 (C-4), 63.0 (C-6). 
HRMS: m/z calcd. for C9H16O6Na [M+Na]
+
 243.0839; found 243.0836.  
 
Phenyl 1-thio-α-D-mannopyranoside (6). Synthesized from 1 (11.17 g, 28.6 mmol) according to 
the general procedure for glycosylation of 1,2,3,4,6-penta-O-acetyl-D-mannopyranose to give the 
thio glycoside as a yellowish oil (11.9 g, 95 %). This product (11.9 g, 27.1 mmol) was 
deprotected according to the general procedure for deacetylation to give the title compound as a 
colorless oil (7.1 g, 96 %). TLC: Rf = 0.29 (CH2Cl2:MeOH 5:1). 
1
H NMR (600.13 MHz, CD3OD, 
25 °C):  7.53–7.25 (m, 5 H, arom. H), 5.42 (dd, 1 H, J1,2 = 1.6 Hz, H-1), 4.08 (dd, 1 H, J2,3 = 3.3 
Hz, H-2), 4.03 (ddd, 1 H, J5,6a = 2.4, J5,6b = 5.6, J5,4 =  9.8 Hz, H-5), 3.81 (dd, 1 H, J6a,6b = –12.0 
Hz, H-6a), 3.76 (dd, 1 H, H-6b), 3.72 (dd, 1 H, J4,3 = 9.5 Hz, H-4), 3.68 (dd, 1 H, H-3). 
13
C NMR (150.90 MHz, CD3OD, 25 °C):  136.0, 133.0, 130.1, 128.6 (arom. C), 90.6 (C-1), 75.7 
(C-5), 73.8 (C-2), 73.2 (C-3), 68.8 (C-4), 62.7 (C-6). 
HRMS: m/z calcd. for C12H16O5SNa [M+Na]
+
 295.0611; found 295.0603; m/z calcd. for 
C12H16O9SK [M+K]
+
 311.0350; found 311.0348. 
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Benzyl 4,6-O-benzylidene--D-mannopyranoside (7). Synthesized from 3 (0.4 g, 1.4 mmol) 
according to the general procedure for synthesis of 4,6-O-benzylidene--D-mannopyranosides to 
give the title compound as a white solid (0.3 g, 56 %). TLC: Rf = 0.06 (CHCl3). 
1
H NMR (600.13 
MHz, CDCl3, 25 °C):  7.50–7.32 (m, 10 H, arom. H), 5.58 (s, 1 H, CHPh), 4.98 (d, 1 H, J1,2 = 
1.5 Hz, H-1), 4.75 and 4.54 (each d, each 1 H, J = –11.9 Hz, 1-CH2Ph), 4.27 (dd, 1 H, J6a,5 = 5.0, 
J6a,6b = –10.4 Hz, H-6a), 4.15 (ddd, 1 H, J3,3-OH = 0.4, J3,2 = 3.5, J3,4 = 9.6 Hz, H-3), 4.11 (ddd, 1 
H, J2,2-OH = 1.2 Hz, H-2), 3.95 (dd, 1 H, J4,5 = 9.5 Hz, H-4), 3.90 (ddd, 1 H, J5,6b = 10.3 Hz, H-5), 
3.84 (dd, 1 H, H-6b), 2.59 (d, 1 H, 3-OH), 2.56 (d, 1 H, 2-OH). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  137.2, 136.9, 129.3, 128.6, 128.4, 128.0, 126.2 (arom. 
C), 102.3 (CHPh), 99.3 (C-1), 78.9 (C-4), 71.0 (C-2), 69.5 (1-CH2Ph), 68.8 (C-6), 68.7 (C-3), 
63.2 (C-5). 
HRMS: m/z calcd. for C20H22O6Na [M+Na]
+
 381.1309; found 381.1316. 
 
Cyclohexyl 4,6-O-benzylidene--D-mannopyranoside (8). Synthesized from 4 (70 mg, 0.3 
mmol) according to the general procedure for synthesis of 4,6-O-benzylidene--D-
mannopyranosides to give the title compound as a colorless oil (57 mg, 57 %). TLC: Rf = 0.06 
(CHCl3). []D
23
 + 70.5° (c 1.0, CH2Cl2). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.51–7.36 (m, 
5 H, arom. H), 5.58 (s, 1 H, CHPh), 5.03 (d, 1 H, J1,2 = 1.5 Hz, H-1), 4.27 (dd, 1 H, J6a,5 = 4.8, 
J6a,6b = –10.4 Hz, H-6a), 4.13 (ddd, 1 H, J3,3-OH = 3.4, J3,2 = 3.5, J3,4 = 9.5 Hz, H-3), 4.02 (ddd, 1 
H, J2,2-OH = 2.4 Hz, H-2), 3.93 (dd, 1 H, J4,5 = 8.9 Hz, H-4), 3.92 (ddd, 1 H, J5,6b = 10.1 Hz, H-5), 
3.82 (dd, 1 H, H-6b), 3.67–3.58 (m, 1 H, OCHC5H10), 2.57 (d, 1 H, 2-OH), 2.54 (d, 1 H, 3-OH), 
1.95–1.80 (m, 2 H, OCHC5H10), 1.78–1.68 (m, 2 H, OCHC5H10), 1.56–1.18 (m, 6 H, 
OCHC5H10). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  137.3, 129.3, 128.4, 126.2 (arom. C), 102.2 (CHPh), 
98.0 (C-1), 79.2 (C-4), 75.3 (OCHC5H10), 71.6 (C-2), 68.9 (C-6), 68.8 (C-3), 63.0 (C-5), 33.4, 
31.3, 25.6, 24.0, 23.8 (OCHC5H10). 
HRMS: m/z calcd. for C19H26O6Na [M+Na]
+
 373.1622; found 373.1632. 
 
Allyl 4,6-O-benzylidene--D-mannopyranoside (39). Synthesized from 5 (0.4 g, 1.8 mmol) 
according to the general procedure for synthesis of 4,6-O-benzylidene--D-mannopyranosides to 
give the title compound as a white solid (0.4 g, 70 %). TLC: Rf = 0.04 (CHCl3). []D
23 
+71.4° (c 
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1.0, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.50–7.37 (m, 5 H, arom. H), 5.91 (dddd, 
1 H, JCHCH2,CH2a = 5.1, JCHCH2,CH2b = 6.1, JCHCH2,CHCH2cis = 10.5, JCHCH2,CHCH2trans = 17.2 Hz, 1-
OCH2CH=CH2), 5.58 (s, 1 H, CHPh), 5.31 (dddd, 1 H, JCH2trans,CH2b = –1.5, JCH2trans,CH2cis = –1.6, 
JCH2trans,CH2a = –1.7 Hz, 1-OCH2CH=CH2trans), 5.23 (dddd, 1 H, JCH2cis,CH2b = –1.2, JCH2cis,CH2a = –
1.3 Hz, 1-OCH2CH=CH2cis), 4.93 (d, 1 H, J1,2 = 1.5 Hz, H-1), 4.28 (dd, 1 H, J6a,5 = 5.0, J6a,6b = –
10.3 Hz, H-6a), 4.21 (dddd, 1 H, JCH2a,CH2b = –12.9 Hz, 1-OCH2aCH=CH2), 4.12 (dd, 1 H, J3,2 = 
3.5, J3,4 = 9.7 Hz, H-3), 4.08 (dd, 1 H, H-2), 4.02 (dddd, 1 H, 1-OCH2bCH=CH2), 3.94 (dd, 1 H, 
J4,5 = 9.4 Hz, H-4), 3.87 (ddd, 1 H, J5,6b = 10.3 Hz, H-5), 3.83 (dd, 1 H, H-6b).  
13
C NMR (150.90 MHz, CDCl3, 25 °C):  137.2 (arom. C), 133.4 (1-OCH2CH=CH2), 129.3, 
128.4, 126.2 (arom. C), 117.8 (1-OCH2CH=CH2), 102.3 (CHPh), 99.3 (C-1), 78.9 (C-4), 71.0 (C-
2), 68.8 (C-6), 68.7 (C-3), 68.3 (1-OCH2CH=CH2), 63.1 (C-5).  
HRMS: m/z calcd. for C16H20O6Na [M+Na]
+
 331.1152; found 331.1164. 
 
Benzyl 3-O-benzyl-4,6-O-benzylidene--D-mannopyranoside (11). Synthesized from 7 (0.64 
g, 1.8 mmol) according to the general procedure for selective benzylation of the equatorial 3-OH 
group to give the title compound as a colorless oil (0.65 g, 75 %). TLC: Rf = 0.55 (hexane:EtOAc 
1:1). []D
23
 +55.9° (c 1.0, CH2Cl2). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.32–7.28 (m, 15 
H, arom. H), 5.63 (s, 1 H, CHPh), 4.97 (d, 1 H, J1,2 = 1.5 Hz, H-1),  4.86 and 4.72 (each d, each 1 
H, J = –11.8 Hz, CH2Pha), 4.71 and 4.52 (each d, each 1 H, J = –11.8 Hz, CH2Phb), 4.27 (dd, 1 H, 
J6a,5 = 4.9, J6a,6b = –10.3 Hz, H-6a), 4.12 (dd, 1 H, J4,5 = 9.5, J4,3 = 9.6 Hz, H-4), 4.11 (ddd, 1 H, 
J2,2-OH = 1.4, J2,3 = 3.5 Hz, H-2), 3.98 (dd, 1 H, H-3), 3.91 (ddd, 1 H, J5,6b = 10.5 Hz, H-5), 3.87 
(dd, 1 H, H-6b), 2.65 (d, 1 H, 2-OH).  
13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.0, 137.5, 136.9, 128.9, 128.5, 128.2, 128.1, 127.9, 
127.8, 126.0 (arom. C), 101.6 (CHPh), 99.2 (C-1), 78.9 (C-4), 75.7 (C-3), 73.1 (CH2Pha), 70.1 
(C-2), 69.4 (CH2Phb), 68.9 (C-6), 63.5 (C-5). 
HRMS: m/z calcd. for C27H28O6Na [M+Na]
+
 471.1778; found 471.1765. 
 
Cyclohexyl 3-O-benzyl-4,6-O-benzylidene--D-mannopyranoside (12). Synthesized from 8 
(0.13 g, 0.4 mmol) according to the general procedure for selective benzylation of the equatorial 
3-OH group to give the title compound as a colorless oil (0.14 g, 84 %). TLC: Rf = 0.64 i  
hexane:EtOAc 1:1. []D
23
 +49.5° (c 1.0, CH2Cl2). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  
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7.52–7.30 (m, 10 H, arom. H), 5.62 (s, 1 H, CHPh), 5.03 (d, 1 H, J1,2 = 1.5 Hz, H-1), 4.88 and 
4.73 (each d, each 1 H, J = –11.7 Hz, 3-CH2Ph), 4.27 (dd, 1 H, J6a,5 = 4.9, J6a,6b = –10.4 Hz, H-
6a), 4.10 (dd, 1 H, J4,3 = 9.6, J4,5 = 9.7 Hz, H-4), 4.04 (ddd, 1 H, J2,2-OH = 1.4, J2,3 = 3.4 Hz, H-2), 
3.97 (dd, 1 H, H-3), 3.93 (ddd, 1 H, J5,6b = 10.4 Hz, H-5), 3.85 (dd, 1 H, H-6b), 3.65–3.55 (m, 1 
H, OCHC5H10), 2.63 (d, 1 H, 2-OH), 1.86–1.71 (m, 4 H, OCHC5H10), 1.58–1.23 (m, 6 H, 
OCHC5H10). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.1, 137.6, 128.9, 128.5, 128.2, 127.9, 127.8, 126.0 
(arom. C), 101.5 (CHPh), 97.8 (C-1), 79.1 (C-4), 75.8 (C-3), 75.2 (OCHC5H10), 73.1 (3-CH2Ph), 
70.6 (C-2), 68.9 (C-6), 63.3 (C-5), 33.4, 31.3, 25.6, 24.1, 23.8 (OCHC5H10). 
HRMS: m/z calcd. for C26H32O6 [M]
+
 440.2198; found 440.2199. 
 
Allyl 3-O-benzyl-4,6-O-benzylidene--D-mannopyranoside (13). Synthesized from 9 (0.15 g, 
0.5 mmol) according to the general procedure for selective benzylation of the equatorial 3-OH 
group to give the title compound as a colorless oil (0.15 g, 80 %). TLC: Rf = 0.65 (hexane:EtOAc 
1:1). []D
23
 +52.8° (c 1.0, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.51 – 7.29 (m, 10 
H, Ph), 5.90 (dddd, 1 H, JCHCH2,CH2a = 5.1, JCHCH2,CH2b = 6.2, JCHCH2,CHCH2cis = 10.4, 
JCHCH2,CHCH2trans = 17.3 Hz, 1-OCH2CH=CH2), 5.62 (s, 1 H, CHPh), 5.31 (dddd, 1 H, JCH2trans,CH2b 
= –1.0, JCH2trans,CH2a = –1.3, JCH2trans,CH2cis = –1.6 Hz, 1-OCH2CH=CH2trans), 5.22 (dddd, 1 H, 
JCH2cis,CH2b = –1.0, JCH2cis,CH2a = –1.5 Hz, 1-OCH2CH=CH2cis), 4.93 (d, 1 H, J1,2 = 1.4 Hz, H-1), 
4.87 and 4.73 (each d, each 1 H, J = –11.8 Hz, 3-CH2Ph), 4.27 (dd, 1 H, J6a,5 = 5.1, J6a,6b = –10.5 
Hz, H-6a), 4.19 (dddd, 1 H, JCH2a,CH2b = –12.9 Hz, 1-OCH2aCH=CH2), 4.11 (dd, 1 H, J4,5 = 9.4, 
J4,3 = 9.6 Hz, H-4), 4.09 (ddd, 1 H, J2,2-OH = 1.4, J2,3 = 3.5 Hz, H-2), 4.00 (dddd, 1 H, 1-
OCH2bCH=CH2), 3.96 (dd, 1 H, H-3), 3.87 (ddd, 1 H, J5,6b = 10.3 Hz, H-5), 3.86 (dd, 1 H, H-6b), 
2.64 (d, 1 H, 2-OH). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.0, 137.5 (arom. C), 133.5 (1-OCH2CH=CH2), 
128.9, 128.5, 128.2, 127.9, 127.8, 126.1 (arom. C), 117.9 (1-OCH2CH=CH2), 101.6 (CHPh), 99.1 
(C-1), 78.9 (C-4), 75.7 (C-3), 73.1 (3-CH2Ph), 70.0 (C-2), 68.9 (C-6), 68.2 (1-OCH2CH=CH2), 
63.4 (C-5).   
HRMS: m/z calcd. for C23H26O6 [M]
+
 398.1729; found 398.1733. 
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Phenyl 3-O-benzyl-4,6-O-benzylidene-1-thio--D-mannopyranoside (14). Synthesized from 
10 (2.6 g, 7.2 mmol) according to the general procedure for selective benzylation of the 
equatorial 3-OH group to give the title compound as a colorless oil (2.9 g, 85 %). TLC: Rf = 0.65 
(hexane:EtOAc 1:1). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.52–7.28 (m, 15 H, arom. H), 
5.63 (s, 1 H, CHPh), 5.60 (d, 1 H, J1,2 = 1.2 Hz, H-1), 4.90 and 4.75 (each d, each 1 H, J = –11.8 
Hz, 3-CH2Ph), 4.34 (ddd, 1 H, J5,6a = 4.9, J5,4 = 9.6, J5,6b = 10.2 Hz, H-5), 4.29 (ddd, 1 H, J2,2-OH 
= 1.4, J2,3 = 3.4 Hz, H-2), 4.21 (dd, 1 H, J6a,6b = –10.4 Hz, H-6a), 4.18 (dd, 1 H, J4,3 = 9.6 Hz, H-
4), 3.97 (dd, 1 H, H-3), 3.86 (dd, 1 H, H-6b), 2.82 (d, 1 H, 2-OH). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  137.7, 137.4, 133.3, 131.8, 129.2, 129.0, 128.6, 128.3, 
128.1, 127.9, 127.7, 126.1 (arom. C), 101.6 (CHPh), 87.8 (C-1), 79.0 (C-4), 75.7 (C-3), 73.2 (3-
CH2Ph), 71.4 (C-2), 68.5 (C-6), 64.6 (C-5). 
HRMS: m/z calcd. for C26H26O5SNa [M+Na]
+
 473.1393; found 473.1403. 
 
Benzyl 2-O-allyl-3-O-benzyl-4,6-O-benzylidene--D-mannopyranoside (15). Synthesized 
from 11 (0.18 g, 0.4 mmol) according to the general procedure for alkylation of the 2-OH group 
to give the title compound as a white solid (0.21 g, quant.). TLC: Rf = 0.84 (hexane:EtOAc 1:1). 
[]D
23
 +66.6º (c 1.0, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.50–7.27 (m, 15 H, 
arom. H), 5.90 (dddd, 1 H, JCHCH2,CH2a = 6.0, JCHCH2,CH2b = 6.2, JCHCH2,CHCH2cis = 10.3, 
JCHCH2,CHCH2trans = 17.2 Hz, 2-OCH2CH=CH2), 5.63 (s, 1 H, CHPh), 5.26 (dddd, 1 H, JCH2trans,CH2b 
= –1.5, JCH2trans,CH2a = –1.5, JCH2trans,CH2cis = –1.7 Hz, 1-OCH2CH=CH2trans), 5.17 (dddd, 1 H, 
JCH2cis,CH2b = –1.1, JCH2cis,CH2a = –1.2 Hz, 1-OCH2CH=CH2cis), 4.90 (d, 1 H, J1,2 = 1.7 Hz, H-1), 
4.87 and 4.70 (each d, each 1 H, J = –12.1 Hz, CH2Pha), 4.72 and 4.49 (each d, each 1 H, J = – 
11.9 Hz, CH2Phb), 4.25 (dddd, 1 H, JCH2a,CH2b = –12.9 Hz, 1-OCH2aCH=CH2), 4.24 (dd, 1 H, J6a,5 
= 4.7, J6a,6b = –10.2 Hz, H-6a), 4.21 (dd, 1 H, J4,5 = 9.2, J4,3 = 10.0 Hz, H-4), 4.15 (dddd, 1 H, 1-
OCH2bCH=CH2), 4.01 (dd, 1 H, J3,2 = 3.2 Hz, H-3), 3.88 (dd, 1 H, J6b,5 = 10.4 Hz, H-6b),  3.85 
(ddd, 1 H, H-5), 3.82 (dd, 1 H, H-2). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.7, 137.7, 137.0 (arom. C), 134.8 (2-
OCH2CH=CH2), 128.8, 128.5, 128.3, 128.2, 128.0, 127.9, 127.5, 126.0 (arom. C), 117.8 (2-
OCH2CH=CH2), 101.4 (CHPh), 98.9 (C-1), 79.2 (C-4), 76.6 (C-2), 76.3 (C-3), 73.3 (CH2Pha), 
73.1 (2-OCH2CH=CH2), 69.3 (CH2Phb), 68.8 (C-6), 64.4 (C-5). 
HRMS: m/z calcd. for C30H32O6Na [M+Na]
+
 511.2091; found 511.2103. 
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Cyclohexyl 2-O-allyl-3-O-benzyl-4,6-O-benzylidene--D-mannopyranoside (16). Synthesized 
from 12 (20 mg, 0.4 mmol) according to the general procedure for alkylation of the 2-OH group 
to give the title compound as a colorless oil (22 mg, quant.). TLC: Rf = 0.82 (hexane:EtOAc 1:1). 
[]D
23
 +48.3° (c 0.1, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.51–7.27 (m, 10 H, 
arom. H), 5.94 (dddd, 1 H, JCHCH2,CH2a = 5.5, JCHCH2,CH2b = 6.3, JCHCH2,CHCH2cis = 10.3, 
JCHCH2,CHCH2trans = 17.2 Hz, 2-OCH2CH=CH2), 5.63 (s, 1 H, CHPh), 5.29 (dddd, 1 H, JCH2trans,CH2b 
= –1.6, JCH2trans,CH2a = –1.6, JCH2trans,CH2cis = –1.7 Hz, 2-OCH2CH=CH2trans), 5.20 (dddd, 1 H, 
JCH2cis,CH2b = –1.1, JCH2cis,CH2a = –1.3 Hz, 2-OCH2CH=CH2cis), 4.95 (d, 1 H, J1,2 = 1.7 Hz, H-1), 
4.88 and 4.71 (each d, each 1 H, J = –12.1 Hz, 3-CH2Ph), 4.30 (dddd, 1 H, JCH2a,CH2b = –13.0 Hz, 
2-OCH2aCH=CH2), 4.24 (dd, 1 H, J6a,5 = 4.8, J6a,6b = –10.2 Hz, H-6a), 4.18 (dd, 1 H, J4,5 = 9.2, 
J4,3 = 10.0 Hz, H-4), 4.17 (dddd, 1 H, 2-OCH2bCH=CH2), 3.99 (dd, 1 H, J3,2 = 3.2 Hz, H-3), 3.87 
(ddd, 1 H, J5,6b = 10.5 Hz, H-5), 3.85 (dd, 1 H, H-6b), 3.74 (dd, 1 H, H-2), 3.61–3.53 (m, 1 H, 
OCHC5H10), 1.89–1.65 (m, 4 H, OCHC5H10), 1.58–1.20 (m, 6 H, OCHC5H10). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.8, 137.7 (arom. C), 135.0 (2-OCH2CH=CH2), 
128.8, 128.3, 128.2, 127.5, 127.4, 126.0 (arom. C), 117.6 (2-OCH2CH=CH2), 101.3 (CHPh), 97.5 
(C-1), 79.4 (C-4), 78.2 (C-2), 76.5 (C-3), 75.1 (OCHC5H10), 73.2 (3-CH2Ph), 73.1 (2-
OCH2CH=CH2), 68.9 (C-6), 64.2 (C-5), 33.3, 31.3, 25.6, 24.0, 23.8 (OCHC5H10). 
HRMS: m/z calcd. for C29H38O6 [M+H]
+
 481.2585; found 481.2574; m/z calcd. for C29H37O6Na 
[M+Na]
+
 503.2404; found 503.2386; m/z calcd. for C29H37O6K [M+K]
+
 519.2143; found 
519.2120. 
 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-O-propargyl-1-thio--D-mannopyranoside (18). 
Synthesized from 14 (55 mg, 0.1 mmol) according to the general procedure for alkylation of the 
2-OH group to give the title compound as a colorless oil (60 mg, 98 %). TLC: Rf = 0.86 
(hexane:EtOAc 1:1). []D
23
  +143.9° (c 1.0, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  
7.52–7.28 (m, 15 H, arom. H), 5.63 (s, 1 H, CHPh), 5.62 (d, 1 H, J1,2 = 1.5 Hz, H-1), 4.88 and 
4.76 (each d, each 1 H, J = –12.1 Hz, 3-CH2Ph), 4.43 (dd, 1 H, JCH2a,CH = 2.3, JCH2a,CH2b = –16.2 
Hz, 2-OCH2aCCH), 4.41 (dd, 1 H, JCH2b,CH = 2.4 Hz, 2-OCH2bCCH),4.29 (ddd, 1 H, J5,6a = 4.8, 
J5,4 = 9.4, J5,6b = 10.2 Hz, H-5), 4.27 (dd, 1 H, J2,3 = 3.2 Hz, H-2), 4.23 (dd, 1 H, J4,3 = 10.0 Hz, 
H-4), 4.22 (dd, 1 H, J6a,6b = –10.3 Hz, H-6a), 4.00 (dd, 1 H, H-3), 3.87 (dd, 1 H, H-6b), 2.44 (dd, 
1 H, 2-OCH2CCH). 
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13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.2, 137.5, 131.6, 129.2, 128.4, 128.2, 127.7, 126.1 
(arom. C), 101.5 (CHPh), 87.4 (C-1), 79.5 (2-OCH2CCH), 79.2 (C-4), 77.7 (C-2), 76.1 (C-3), 
75.2 (2-OCH2CCH), 73.3 (3-CH2Ph), 68.5 (C-6), 65.3 (C-5), 58.8 (2-OCH2CCH). 
HRMS: m/z calcd. for C29H28O5SNa [M+Na]
+
 511.1550; found 511.1562. 
 
Phenyl 2-O-allyl-3-O-benzyl-4,6-O-benzylidene-1-thio--D-mannopyranoside (19). 
Synthesized from 14 (0.16 g, 0.35 mmol) according to the general procedure for alkylation of the 
2-OH group to give the title compound as a colorless oil (0.18 g, quant.). TLC: Rf = 0.93 
(hexane:EtOAc 1:1). []D
23
 +145.2° (c 1.0, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  
7.52–7.27 (m, 15 H, arom. H), 5.92 (dddd, 1 H, JCHCH2,CH2a = 5.8, JCHCH2,CH2b = 5.9, 
JCHCH2,CHCH2cis = 10.3, JCHCH2,CHCH2trans = 17.2 Hz, 2-OCH2CH=CH2), 5.64 (s, 1 H, CHPh), 5.53 
(d, 1 H, J1,2 = 1.5 Hz, H-1), 5.29 (dddd, 1 H, JCH2trans,CH2b = –1.5, JCH2trans,CH2a = –1.5, 
JCH2trans,CH2cis = –1.7 Hz, 2-OCH2CH=CH2trans), 5.20 (dddd, 1 H, JCH2cis,CH2b = –1.2, JCH2cis,CH2a = –
1.2 Hz, 2-OCH2CH=CH2cis), 4.88 and 4.73 (each d, each 1 H, J = –12.2 Hz, 3-CH2Ph), 4.29 (ddd, 
1 H, J5,6a = 4.8, J5,4 = 9.5, J5,6b = 10.0 Hz, H-5), 4.26 (dd, 1 H, J4,3 = 9.9 Hz, H-4), 4.22 (dd, 1 H, 
J6a,6b = –10.3 Hz, H-6a), 4.20 (dddd, 1 H, JCH2a,CH2b = –12.2 Hz, 2-OCH2aCH=CH2), 4.18 (dddd, 1 
H, 2-OCH2bCH=CH2), 3.99 (dd, 1 H, J2,3 = 3.2 Hz, H-2), 3.96 (dd, 1 H, H-3), 3.88 (dd, 1 H, H-
6b).  
13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.4, 137.6 (arom. C), 134.5 (2-OCH2CH=CH2), 
131.5, 129.1, 128.9, 128.4, 128.2, 127.7, 127.6, 126.1 (arom. C), 118.0 (2-OCH2CH=CH2), 101.5 
(CHPh), 87.3 (C-1), 79.1 (C-4), 78.1 (C-2), 76.1 (C-3), 73.2 (3-CH2Ph), 72.6 (2-OCH2CH=CH2), 
68.5 (C-6), 65.4 (C-5). 
HRMS: m/z calcd. for C29H30O5SNa [M+Na]
+
 513.1706; found 513.1740; m/z calcd. for 
C29H30O5SK [M+K]
+
 529.1446; found 529.1478. 
 
Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-β-D-mannopyranosyl-(1→2)-3-O-benzyl-4,6-O-
benzylidene-1-thio-α-D-mannopyranoside (20). Synthesized from 17 (40 mg, 0.07 mmol) and 
14 (1.15 equiv.) according to the general procedure for β-mannosylation to give the title 
compound as a white foam (47 mg, 76 %). [α]D
23
 = –3.5 (c 0.2, CH2Cl2). 
1
H NMR (600.13 MHz, 
CDCl3, 25 °C): δ = 7.51–7.25 (m, 30 H, arom. H), 5.60 (s, 1 H, CHPh), 5.51 (s, 1 H, CHPh), 
5.49 (d, 1 H, J1,2 = 1.5 Hz, H-1), 5.04 and 4.96 (each d, each 1 H, J = –12.3 Hz, 3-CH2Ph), 4.80 
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and 4.76 (each d, each 1 H, J = –12.1 Hz, 3-CH2Ph), 4.69 and 4.61 (each d, each 1 H, J = –12.5 
Hz, 2-CH2Ph), 4.62 (d, 1 H, J1,2 = 0.9 Hz, H-1), 4.51 (dd, 1 H, J2,3 = 3.2 Hz, H-2), 4.33 (ddd, 1 
H, J5,6a = 4.8, J5,4 = 9.5, J5,6b = 10.2 Hz, H-5), 4.25 (dd, 1 H, J4,5 = 9.3, J4,3 = 9.9 Hz, H-4), 4.25 
(dd, 1 H, J6a,5 = 4.8, J6a,6b = –10.4 Hz, H-6a), 4.23 (dd, 1 H, J6a,6b = –10.2 Hz, H-6a), 4.17 (dd, 1 
H, J4,3 = 10.0 Hz, H-4), 3.98 (dd, 1 H, H-3), 3.97 (dd, 1 H, J2,3 = 3.2 Hz, 2-H), 3.87 (dd, 1 H, 
J6b,5 = 10.1 Hz, H-6b), 3.79 (dd, 1 H, H-6b), 3.59 (dd, 1 H, H-3), 3.31 (ddd, 1 H, H-5) ppm.  
13
C NMR (150.90 MHz, CDCl3, 25 °C): δ = 138.5–126 (arom. C), 101.7 (CHPh), 101.4 (CHPh), 
99.8 (C-1), 86.4 (C-1), 78.7 (C-4), 78.4 (C-4), 77.5 (C-3), 76.2 (C-2), 76.0 (C-2), 74.6 (3-
CH2Ph), 74.3 (C-3), 72.3 (2-CH2Ph), 71.5 (3-CH2Ph), 68.6 (C-6), 68.5 (C-6), 67.8 (C-5), 65.4 
(C-5) ppm. 
HRMS: m/z calcd. for C55H51O10S [M–H]
–
 903.3203; found 903.3810. 
 
Benzyl 3-O-benzyl-4,6-O-benzylidene-2-O-propargyl-β-D-mannopyranosyl-(1→2)-3-O-
benzyl-4,6-O-benzylidene-α-D-mannopyranoside (22). Synthesized from 18 (0.32 g, 0.66 
mmol) and 11 (1.15 equiv.) according to the general procedure for β-mannosylation to give the 
title compound as a white foam (0.44 g, 82 %). [α]D
23
 = –37.0 (c 1.0, CH2Cl2). 
1
H NMR (600.13 
MHz, CDCl3, 25 °C): δ = 7.51–7.28 (m, 25 H, arom. H), 5.60 (s, 1 H, CHPh), 5.57 (s, 1 H, 
CHPh), 4.96 (d, 1 H, J1,2 = 1.6 Hz, H-1), 4.80 (s, 2 H, 3-CH2Ph), 4.73 and 4.50 (each d, each 1 
H, J = –11.9 Hz, 1-CH2Ph), 4.72 (s, 2 H, 3-CH2Ph), 4.70 (dd, 1 H, JCH2a,CH = 2.4, JCH2a,CH2b = –
16.1 Hz, 2-OCH2aCCH), 4.63 (d, 1 H, J1,2 = 0.8 Hz, H-1), 4.61 (dd, JCH2b,CH = 2.4 Hz, 2-
OCH2bCCH), 4.27 (dd, 1 H, J2,3 = 3.4 Hz, H-2), 4.24 (dd, 1 H, J6a,5 = 4.8, J6a,6b = –10.4 Hz, H-
6a), 4.24 (dd, 1 H, J2,3 = 3.1 Hz, H-2), 4.23 (dd, 1 H, J6a,5 = 4.9, J6a,6b = –10.2 Hz, H-6a), 4.16 
(dd, 1 H, J4,5 = 9.4, J4,3 = 9.9 Hz, H-4), 4.12 (dd, 1 H, J4,5 = 9.5, J4,3 = 10.0 Hz, H-4), 4.02 (dd, 
1 H, H-3), 3.87 (ddd, 1 H, J5,6b = 10.4 Hz, H-5), 3.84 (dd, 1 H, J6b,5 = 10.1 Hz, H-6b), 3.82 (dd, 
1 H, 6b-H), 3.60 (dd, 1 H, H-3), 3.26 (ddd, 1 H, H-5), 2.44 (dd, 1 H, 2-OCH2CCH) ppm.  
13
C NMR (150.90 MHz, CDCl3, 25 °C): δ = 138.7–126.0 (arom. C), 101.6 (CHPh), 101.4 (C 
HPh), 100.2 (C-1), 97.3 (C-1), 80.4 (2-OCH2CCH), 78.6 (C-4), 78.3 (C-4), 76.9 (C-3) , 75.0 
(2-OCH2CC), 74.5 (C-2), 74.4 (C-2), 74.4 (C-3), 72.2 (3-CH2Ph), 71.7 (3-CH2Ph), 69.4 (1-
CH2Ph), 68.9 (C-6), 68.5 (C-6), 67.8 (C-5), 64.4 (C-5), 59.8 (2-OCH2CCH) ppm.  
HRMS: m/z calcd. for C50H50O11 [M]
+
 826.3353; found 826.3325. 
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Cyclohexyl 3-O-benzyl-4,6-O-benzylidene-2-O-(3-O-benzyl-4,6-O-benzylidene-2-O-
propargyl--D-mannopyranosyl)--D-mannopyranoside (23). Synthesized from 18 (87 mg, 
0.18 mmol) and 12 (1.15 equiv.) according to the genereal procedure for β-mannosylation to give 
the title compound as white foam (0.1 g, 72 %). TLC: Rf = 0.82 (hexane:EtOAc 1:1). []D
23
 –
39.0°  (c 1.0, CH2Cl2). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.50–7.25 (m, 20 H, arom. H), 
5.60 (s, 1 H, CHPh), 5.58 (s, 1 H, CHPh), 5.00 (d, 1 H, J1,2 = 1.7 Hz, H-1), 4.82 (s, 2 H, 3-
CH2Ph), 4.73 (s, 2 H, 3-CH2Ph), 4.72 (dd, 1 H, JCH2a,CH = 2.3, JCH2a,CH2b = –16.1 Hz, 2-
OCH2aCCH), 4.68 (d, 1 H, J1,2 = 0.7 Hz, H-1), 4.62 (dd, 1 H, JCH2b,CH = 2.4 Hz, 2-
OCH2bCCH), 4.27 (dd, 1 H, J6a,5= 4.8, J6a,6b= –10.4 Hz, H-6a), 4.26 (dd, 1 H, J2,3 = 3.1 Hz, 
H-2), 4.24 (dd, 1 H, J6a,5 = 4.7, J6a,6b = –10.2 Hz, H-6a), 4.18 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 4.17 
(dd, 1 H, J4,5 = 9.3, J4,3 = 9.9 Hz, H-4), 4.10 (dd, 1 H, J4,5 = 9.5, J4,3 = 10.0 Hz, H-4), 3.99 (dd, 
1 H, H-3), 3.89 (ddd, 1 H, J5,6b = 10.4 Hz, H-5), 3.86 (dd, 1 H, J6b,5 = 10.0 Hz, H-6b), 3.80 (dd, 
1 H, H-6b), 3.63 (dd, 1 H, H-3), 3.61–3.54 (m, 1 H, OCHC5H10), 3.32 (ddd, 1 H, H-5), 2.50 (dd, 
1 H, 2-OCH2CCH), 1.86–1.18 (m, 10 H, OCHC5H10).  
13
C NMR (150.90 MHz, CDCl3, 25 °C):  138.9, 138.2, 137.6, 137.5, 129.1, 129.0, 128.5, 128.3, 
128.2, 127.8, 127.5, 127.6, 126.0, 125.9 (arom. C), 101.4 (CHPh, CHPh), 100.4 (C-1), 96.1 (C-
1), 81.0 (2-OCH2CCH), 79.0 (C-4), 78.2 (C-2), 76.9 (C-3), 75.7 (OCHC5H10), 75.4 (C-2), 
75.0 (2-OCH2CCH), 74.8 (C-4), 74.5 (C-3), 72.2 (3-CH2Ph), 71.6 (3-CH2Ph), 69.0 (C-6), 
68.7 (C-6), 67.8 (C-5), 64.3 (C-5), 59.8 (2-OCH2CCH), 33.3, 31.3, 25.6, 23.8, 23.5 
(OCHC5H10).  
HRMS: m/z calcd. for C49H54O11 [M]
+
 818.3666; found 818.3730. 
 
Benzyl 3-O-benzyl-4,6-O-benzylidene-β-D-mannopyranosyl-(1→2)-3-O-benzyl-4,6-O-
benzylidene-α-D-mannopyranoside (24). Synthesized from 22 (0.4 g, 0.5 mmol) according to 
the general procedure for propargyl group deprotection to give the title compound as a colorless 
oil (0.3 g, 80 %). [α]D
23
 = –15.0 (c 1.0, CH2Cl2). 
1
H NMR (600.13 MHz, CDCl3, 25 °C): δ = 
7.49–7.25 (m, 25 H, arom. H), 5.56 (s, 1 H, CHPh), 5.47 (s, 1 H, CHPh), 4.90 (d, 1 H, J1,2 = 1.6 
Hz, H-1), 4.82 and 4.75 (each d, each 1 H, J = –12.3 Hz, 3-CH2Ph), 4.80 and 4.75 (each d, each 1 
H, J = –11.8 Hz, 3-CH2Ph), 4.71 and 4.49 (each d, each 1 H, J = –11.9 Hz, 1-CH2Ph), 4.67 (d, 1 
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H, J1,2 = 1.3 Hz, H-1), 4.43 (dd, 1 H, J2,3 = 3.5 Hz, H-2), 4.24 (dd, 1 H, J4,3 = 9.1, J4,5 =  9.6 
Hz, H-4), 4.21 (dd, 1 H, J6a,5 = 4.8, J6a,6b = –10.3 Hz, H-6a), 4.21 (dd, 1 H, J6a,5 = 4.9, J6a,6b = –
10.4 Hz, H-6a), 4.14 (dd, 1 H, J4,5 = 9.4, J4,3 = 9.9 Hz, H-4), 4.14 (dd, 1 H, J2,3 = 3.7 Hz, H-2), 
4.04 (dd, 1 H, H-3), 3.85 (ddd, 1 H, J5,6b = 10.4 Hz, H-5), 3.78 (dd, 1 H, H-6b), 3.73 (dd, 1 H, 
J6b,5 = 10.0 Hz, H-6b), 3.64 (dd, 1 H, H-3), 3.34 (ddd, 1 H, H-5), 3.22 (s, 1 H, 2-OH) ppm.  
13
C NMR (150.90 MHz, CDCl3, 25 °C): δ = 138.7–126.0 (arom. C), 101.4 (CHPh), 101.3 
(CHPh), 98.2 (C-1), 97.9 (C-1), 78.8 (C-4), 78.4 (C-4), 76.0 (C-3), 74.2 (C-3), 72.8 (C-2), 72.6 
(3-CH2Ph), 72.4 (3-CH2Ph), 69.4 (C-2), 69.1 (1-CH2Ph), 68.4, (C-6), 68.3 (C-6), 66.8 (C-5), 
63.9 (C-5) ppm.  
HRMS: m/z calcd. for C47H48O11 [M]
+
 788.3197; found 788.3211. 
 
Cyclohexyl 3-O-benzyl-4,6-O-benzylidene-2-O-(3-O-benzyl-4,6-O-benzylidene--D-
mannopyranosyl)--D-mannopyranoside (25). Synthesized from 23 (90 mg, 0.1 mmol) 
according to the general procedure for propargyl group deprotection to give the title compound as 
a white foam (75 mg, 85 %). TLC: Rf = 0.63 (hexane:EtOAc 1:1). []D
23
 –15.1°  (c 0.1, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 °C):  7.50–7.28 (m, 20 H, arom. H), 5.55 (s, 1 H, CHPh), 
5.48 (s, 1 H, CHPh), 4.95 (d, 1 H, J1,2 =1.7 Hz, H-1), 4.83 and 4.76 (each d, each 1 H, J = –12.3 
Hz, 3-CH2Ph), 4.81 and 4.76 (each d, each 1 H, J = –11.7 Hz, 3-CH2Ph), 4.74 (d, 1 H, J1,2 = 1.3 
Hz, H-1), 4.34 (dd, 1 H, J2,3 = 3.4 Hz, H-2), 4.27 (dd, 1 H, J4,3 = 9.0, J4,5 = 9.5 Hz, H-4), 4.26 
(dd, 1 H, J6a,5 = 4.9, J6a,6b = –10.3 Hz, H-6a), 4.21 (dd, 1 H, J6a,5 = 4.8, J6a,6b = –10.3 Hz, H-6a), 
4.16 (ddd, 1 H, J2,2-OH = 3.1, J2,3 = 3.8 Hz, H-2), 4.11 (dd, 1 H, J4,5 = 9.2, J4,3 = 9.9 Hz, H-4), 
4.02 (dd, 1 H, H-3), 3.87 (ddd, 1 H, J5,6b = 10.4 Hz, H-5), 3.76 (dd, 1 H, H-6b), 3.76 (dd, 1 H, 
J6b,5 = 10.0 Hz, H-6b), 3.67 (dd, 1 H, H-3), 3.60–3.54 (m, 1 H, OCHC5H10), 3.40 (ddd, 1 H, H-
5), 3.22 (d, 1 H, 2-OH), 1.80–1.65 (m, 4 H, OCHC5H10), 1.55–1.15 (m, 6 H, OCHC5H10). 
13
C NMR (150.90 MHz, CDCl3, 25 °C):  139.4, 138.4, 137.6, 137.3, 128.9, 128.8, 128.4, 128.3, 
128.2, 127.9, 127.8, 127.6, 126.0 (arom. C), 101.4 (CHPh, CHPh), 98.3 (C-1), 96.7 (C-1), 79.0 
(C-4), 78.5 (C-4), 76.3 (C-3), 75.5 (OCHC5H10), 74.8 (C-3), 73.9 (C-2), 72.6 (3-CH2Ph, 3-
CH2Ph), 68.8 (C-2), 68.7 (C-6, C-6), 66.9 (C-5), 64.0 (C-5), 33.3, 31.3, 25.5, 24.0 (OCHC5H10). 
HRMS: m/z calcd. for C46H52O11Na [M+Na]
+
 803.3402; found 803.3380; m/z calcd. for 
C46H52O11K [M+K]
+
 819.3141; found 819.3105. 
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Cyclohexyl 2-O-(-D-mannopyranosyl)--D-mannopyranoside (26). Synthesized from 25 (22 
mg, 0.03 mmol) according to the general procedure for hydrogenolyses to give the title 
compound as a white solid (12 mg, quant.). []D
23
 +0.5°  (c 1.0, MeOH). 
1
H NMR (600.13 MHz, 
CD3OD, 25 °C):  5.04 (d, 1 H, J1,2 = 1.8 Hz, H-1), 4.66 (d, 1 H, J1,2 = 1.0 Hz, H-1), 3.98 (dd, 1 
H, J2,3 = 3.4 Hz, H-2), 3.90 (dd, 1 H, J2,3 = 3.2 Hz, H-2), 3.87 (dd, 1 H, J6a,5 = 2.3, J6a,6b = –
12.0 Hz, H-6a), 3.80 (dd, 1 H, J6a,5 = 2.4, J6a,6b = –11.8 Hz, H-6a), 3.73 (dd, 1 H, J3,4 = 9.6 Hz, 
H-3), 3.70 (dd, 1 H, J6b,5 = 5.8 Hz, H-6b), 3.68 (dd, 1 H, J6b,5 = 6.4 Hz, H-6b), 3.70–3.65 (m, 1 
H, OCHC5H10), 3.63 (dd, 1 H, J4,5 = 9.8 Hz, H-4), 3.60 (ddd, 1 H, H-5), 3.54 (dd, 1 H, J4,3 = 9.4, 
J4,5 = 9.7 Hz, H-4), 3.47 (dd, 1 H, H-3), 3.24 (ddd, 1 H, H-5), 1.98–1.82 (m, 2 H, OCHC5H10), 
1.80–1.70 (m, 2 H, OCHC5H10), 1.55–1.20 (m, 6 H, OCHC5H10).  
13
C NMR (150.90 MHz, CD3OD, 25 °C):  100.0 (C-1), 97.1 (C-1), 79.2 (C-2), 78.6 (C-5), 76.4 
(OCHC5H10), 75.1 (C-3), 74.8 (C-5), 72.6 (C-2), 72.1 (C-3), 69.1 (C-4), 68.5 (C-4), 62.9 (C-6), 
62.7 (C-6), 34.5, 32.6, 26.8, 25.2, 25.0 (OCHC5H10).  
HRMS: m/z calcd. for C18H32O11Na [M+Na]
+
 447.1837; found 447.1843. 
 
Benzyl 2,3-di-O-benzyl-4,6-O-benzylidene--D-mannopyranosyl-(1→2)-3-O-benzyl-4,6-O-
benzylidene--D-mannopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylidene--D-
mannopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylidene--D-mannopyranoside (27). The 
synthesis commenced by following the general procedure for -mannosylation starting from 
donor 20 (76 mg, 0.09 mmol) and acceptor 24 (78 mg, 0.1 mmol). The purification of 27 was 
accomplished by preparative TLC (hexane:EtOAc 3:2). The spots containing the product were 
scraped off the plate and dissolved in EtOAc (50 ml). After 2 h of stirring the mixture was 
filtered and concentrated to give the title compound as a colorless oil (73 mg, : 10:1, 55 %). 
TLC: Rf = 0.40 (hexane:EtOAc 3:2). []D = –25.4 (c 0.5, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 
25 C):  = 7.48–7.07 (m, 50 H, arom. H), 5.57 (s, 1 H, CHPh), 5.52 (s, 1 H, CHPh), 5.43 (s, 1 
H, CHPh), 5.41 (s, 1 H, CHPh), 5.24 (d, 1 H, J1,2 = 0.3 Hz, H-1), 5.05 (d, 1 H, J1,2 = 0.8 
Hz, H-1), 5.00 and 4.83 (each d, each 1 H, J = –12.5 Hz, 2-CH2Ph), 4.89 (d, 1 H, J1,2 = 1.6 
Hz, H-1), 4.72 and 4.495 (each d, each 1 H, J = –11.9 Hz, 1-CH2Ph), 4.71 and 4.68 (each d, each 
1 H, J = –12.4 Hz, 3-CH2Ph), 4.69 and 4.62 (each d, each 1 H, J = –12.3 Hz, 3-CH2Ph), 4.63 and 
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4.45 (each d, each 1 H,  J = –12.0 Hz, 3-CH2Ph), 4.496 and 4.39 (each d, each 1 H, J = –11.8 
Hz, 3-CH2Ph), 4.61 (d, 1 H, J1,2 = 0.7 Hz, H-1), 4.53 (dd, 1 H, J2,3 = 3.1 Hz, H-2), 4.45 (dd, 
1 H, J2,3 = 3.2 Hz, H-2), 4.41 (dd, 1 H, J2,3 =  3.2 Hz, H-2), 4.34 (dd, 1 H, J6a, 5 = 4.7, 
J6a,6b = –10.2 Hz, H-6a), 4.29 (dd, 1 H, J2,3 = 3.5 Hz, H-2), 4.29 (dd, 1 H, J6a,5 = 4.7, J6a,6b = –
10.3 Hz, H-6a), 4.22 (dd, 1 H, J6a,5 = 4.8, J6a,6b = –10.3 Hz, H-6a), 4.182 (dd, 1 H, J4,5 = 9.3, 
J4,3 = 9.8 Hz, H-4),  4.177 (dd, 1 H, J6a,5 = 4.7, J6a,6b =  –10.3 Hz, H-6a), 4.06 (dd, 1 H, 
J4,5 =  9.5,  J4,3 = 9.6 Hz, H-4), 4.01 (dd, 1 H, J3,4 = 10.0 Hz, H-3), 3.92 (dd, 1 H, J4,5 = 9.5 
Hz, H-4), 3.91 (dd, 1 H, J4,5 = 9.4, J4,3 = 9.9 Hz, H-4), 3.864 (ddd, 1 H, J5,6b = 10.3 Hz, H-5), 
3.862 (dd, 1 H, J6b,5 = 10.3 Hz, H-6b), 3.78 (dd, 1 H, J6b,5 = 10.0 Hz, H-6b), 3.75 (dd, 1 H, 
J6b,5 = 10.1 Hz, H-6b), 3.69 (dd, 1 H, H-6b), 3.64 (dd, 1 H, H-3), 3.53 (dd, 1 H, H-3), 3.53 
(dd, 1 H, H-3), 3.42 (ddd, 1 H, H-5), 3.31 (ddd, 1 H, H-5), 3.30 (ddd, 1 H, H-5) ppm. 
13
C NMR (150.90 MHz, CDCl3, 25 C):  = 139.4–126.1 (arom. C), 103.5 (C-1, JC-1,H-1 = 
158.3 Hz), 101.91 (CHPh), 101.88 (CHPh), 101.87 (C-1, JC-1,H-1 = 158.6 Hz), 101.5 (CHPh), 
101.2 (CHPh), 100.2 (C-1, JC-1,H-1 = 156.0 Hz), 96.9 (C-1, JC-1,H-1 = 167.8 Hz), 79.0 (C-3, C-
4), 78.5 (C-4), 78.3 (C-4), 78.2 (C-4), 76.9 (C-3), 76.34 (C-3), 76.27 (C-2), 75.9 (C-2), 
74.8 (C-2), 74.63 (2-CH2Ph), 74.60 (C-3), 74.2 (C-2), 72.2 (3-CH2Ph), 72.1 (3-CH2Ph), 71.2 
(3-CH2Ph), 70.8 (3-CH2Ph), 69.5 (1-CH2Ph), 68.87 (C-6), 68.85 (C-6), 68.72 (C-6), 68.66 
(C-6), 67.9 (C-5), 67.8 (C-5), 67.5 (C-5), 64.2 (C-5) ppm. 
HRMS: m/z calcd. for C94H95O21Na [M + Na]
+
 1582.6264; found 1582.6207; m/z calcd. for 
C94H95O21K [M + K]
+
 1598.6003; found 1598.5932. 
 
-D-Mannopyranosyl-(1→2)--D-mannopyranosyl-(1→2)--D-mannopyranosyl-(1→2)-D-
mannopyranose (28). The synthesis of 28 commenced by the general procedure for 
hydrogenolysis (H2-pressure 2.8 bar, 2 weight equiv. Pd/C) starting from 27 (0.1 g, 0.064 mmol). 
The crude product received after the work-up, was purified by HPAEC (CarboPac PA 1 column; 
9  250 mm) with the gradient elution, 50 mM NaOH over 0-10 min, followed by a linear 
gradient from 50 to 150 mM NaOH  over 10-30 min, and finally a linear gradient from 0 to 200 
mM NaAc in 150 mM NaOH over 30-60 min. The product was collected and the fractions were 
neutralized by addition of 1 M aqueous acetic acid. The sample was desalted using a column of 
successive cation and anion exchange resins (Bio-Rad AG 50W-8X Resin 200-400 mesh, 
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hydrogen form and Bio-Rad AG 1-X8 Resin 200-400 mesh, acetate form) and concentrated to 
give the title compound (32 mg, : 7:2, 75 %). Data for the -anomer. 1H NMR (600.13 MHz, 
CD3OD, 25 C):  = 5.17 (d, 1 H, J1,2 = 1.8 Hz, H-1), 4.93 (d, 1 H, J1,2 = 0.9 Hz, H-1), 4.84 
(d, 1 H, J1,2 = 0.8 Hz, H-1), 4.71 (d, 1 H, J1,2 = 0.7 Hz, H-1), 4.42 (dd, 1 H, J2,3 = 3.1 Hz, H-
2), 4.08 (dd, 1 H, J2,3 = 2.8 Hz, H-2), 4.04 (dd, 1 H, J2,3 = 3.1 Hz, H-2), 3.98 (dd, 1 H, J2,3 
= 3.1 Hz, H-2), 3.91 (dd, 1 H, J6a ,5 = 2.2, J6a,6b = –12.2 Hz, H-6a), 3.89 (dd, 1 H, J6a,5 = 
2.3, J6a,6b = –12.0 Hz, H-6a),  3.85 (dd, 1 H, J6a,5 = 2.5, J6a,6b = –11.7 Hz, H-6a), 3.82 (dd, 1 
H, J3,4 = 9.6 Hz, H-3), 3.78 (dd, 1 H, J6a,5 = 4.1, J6a,6b = –12.0 Hz, H-6a), 3.76 (dd, 1 H, J6b,5 = 2.2 
Hz, H-6b), 3.71 (dd, 1 H, J6b,5 = 5.8 Hz, H-6b), 3.70 (ddd, 1 H, J5,4 = 9.7 Hz, H-5), 3.69 (dd, 1 
H, J6b,5 = 5.8 Hz, H-6b), 3.65 (dd, 1 H, J6b,5 = 7.3 Hz, H-6b), 3.63 (dd, 1 H, H-4), 3.53 (dd, 1 
H, J4,3 = 9.5, J4,5 = 9.7 Hz, H-4), 3.52 (dd, 1 H, H-3), 3.51 (dd, 1 H, J3,4 = 9.7 Hz, H-3), 
3.50 (dd, 1 H, J3,4 = 9.5 Hz, H-3), 3.46 (dd, 1 H, J4,5 = 9.2 Hz, H-4), 3.45 (dd, 1 H, J4,5 = 
9.3 Hz, H-4), 3.37 (ddd, 1 H, H-5), 3.25 (ddd, 1 H, H-5), 3.21 (ddd, 1 H, H-5) ppm. 
13
C NMR (150.90 MHz, CD3OD, 25 C):  = 103.3 (C-1), 102.3 (C-1), 101.1 (C-1), 94.1 (C-
1), 81.8 (C-2), 81.5 (C-2), 79.1 (C-2), 78.3 (C-5, C-5), 78.1 (C-5), 75.2 (C-3), 74.3 (C-
3), 74.2 (C-5), 74.1 (C-3), 72.1 (C-2), 71.2 (C-3), 69.1 (C-4, C-4), 69.0 (C-4), 68.6 (C-4), 
63.5 (C-6), 62.5 (C-6, C-6), 62.3 (C-6) ppm. 
Data for the -anomer. 1H NMR (600.13 MHz, CD3OD, 25 C):  = 4.98 (d, 1 H, J1,2 = 0.8 Hz, 
H-1), 4.94 (d, 1 H, J1,2 = 1.0 Hz, H-1), 4.84 (d, 1 H, J1,2 = 0.8 Hz, H-1), 4.76 (d, 1 H, J1,2 = 
0.7 Hz, H-1), 4.40 (dd, 1 H, J2,3 = 2.3 Hz, H-2), 4.24 (d, 1 H, J2,3 = 3.2 Hz, H-2), 4.04 (dd, 1 
H, J2,3 = 2.6 Hz, H-2), 4.02 (dd, 1 H, J2,3 = 2.4 Hz, H-2), 3.91 (dd, 1 H, J6a,5 = 2.4, J6a,6b = 
–12.3 Hz, H-6a), 3.89 (dd, 1 H, J6a,5 = 2.3, J6a,6b = –11.8 Hz, H-6a), 3.86 (dd, 1 H, J6a,5 = 2.5, 
J6a,6b = –11.9 Hz, H-6a), 3.83 (dd, 1 H, J6a,5 = 2.1, J6a,6b = –12.1 Hz, H-6a), 3.73 (dd, 1 H, J6b,5 = 
5.3 Hz, H-6b),  3.72 (dd, 1 H, J6b,5 = 5.9 Hz, H-6b), 3.68 (dd, 1 H, J6b,5 = 6.2 Hz, H-6b), 3.65 
(dd, 1 H, J6b,5 = 7.4 Hz, H-6b), 3.54 (dd, 1 H, J3,4 = 9.5 Hz, H-3), 3.53 (dd, 1 H, J4,5 = 9.5 
Hz, H-4), 3.52 (dd, 1 H, J4,3 = 9.7, J4,5 = 9.7 Hz, H-4), 3.50 (dd, 1 H, H-3), 3.50 (dd, 1 H, J3,4 = 
9.0 Hz, H-3), 3.48 (dd, 1 H, J3,4 = 9.7 Hz, H-3), 3.45 (dd, 1 H, J4,5 = 9.7 Hz, H-4), 3.44 (dd, 1 
H, J4,5 = 8.9 Hz, H-4), 3.39 (ddd, 1 H, H-5), 3.24 (ddd, 1 H, H-5), 3.23 (ddd, 1 H, H-5), 
3.20 (ddd, 1 H, H-5) ppm. 
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13
C NMR (150.90 MHz, CD3OD, 25 C):  = 103.3 (C-1), 103.0 (C-1), 102.3 (C-1), 95.5 (C-
1), 82.3 (C-2), 81.5 (C-2), 79.1 (C-2), 78.4 and 78.3 (C-5, C-5, C-5), 78.0 (C-5), 75.2 (C-
3), 74.3 (C-3, C-3), 74.2 (C-3), 72.1 (C-2), 69.1 (C-4, C-4), 68.8 (C-4), 68.6 (C-4), 63.6 
(C-6), 62.6 (C-6, C-6, C-6) ppm. 
HRMS: m/z calcd. for C24H24O21Na [M + Na]
+
 689.2111; found 689.2131. 
 
1,4-Bis(benzyl 3-O-benzyl-4,6-O-benzylidene-2-O-α-D-mannopyranosyl)but-2-ene (29). 
Synthesized from 15 (0.13 g, 0.26 mmol) according to the general procedure for 
homodimerization reactions to give the title compound as a white foam (0.12 g, 95 %, E/Z 20:1). 
TLC: Rf = 0.81 (hexane:EtOAc 1:1). 
1
H NMR of the E-isomer (600 MHz, CDCl3, 25 C):  = 
7.50–7.23 (m, 30 H, arom. H), 5.79–5.78 (m, 2 H, OCH2CH=CHCH2O), 5.61 (s, 2 H, CHPh), 
4.89 (d, 2 H, J1,2 = 1.7 Hz, H-1), 4.85 and 4.68 (each d, each 2 H, J = –12.1 Hz, CH2Pha), 4.70 
and 4.47 (each d, each 2 H, J = –11.9 Hz, CH2Phb), 4.26–4.24 (m, 2 H, OCH2aCH=CHCH2aO), 
4.22 (dd, 2 H, J6a,5 = 4.8, J6a,6b = –10.2 Hz, H-6a), 4.19 (dd, 2 H, J4,5 = 9.3, J4,3 = 10.0 Hz, H-4), 
4.13–4.10 (m, 2 H, OCH2bCH=CHCH2bO), 4.00 (dd, 2 H, J3,2 = 3.2 Hz, H-3), 3.86 (dd, 2 H, J6b,5 
= 10.5 Hz, H-6b), 3.84 (ddd, 2 H, H-5), 3.78 (dd, 2 H, H-2). 
13
C NMR of the E-isomer (150.90 MHz, CDCl3, 25 C):  = 138.5–126.1 (arom. C), 129.8 
(OCH2CH=CHCH2O), 101.7 (CHPh), 99.1 (C-1), 79.5 (C-4), 77.0 (C-2), 76.5 (C-3), 73.6 
(CH2Pha), 72.5 (OCH2CH=CHCH2O), 69.5 (CH2Phb), 69.0 (C-6), 64.7 (C-5). 
HRMS: m/z calcd. for C58H60O12Na [M + Na]
+
 971.3977; found 971.3988; m/z calcd. for 
C58H60O12K [M + K]
+
 987.3716; found 987.3726. 
 
1,4-Bis(cyclohexyl 3-O-benzyl-4,6-O-benzylidene-2-O-α-D-mannopyranosyl)but-2-ene (30). 
Synthesized from 16 (20 mg, 0.04 mmol) according to the general procedure for 
homodimerization reactions to give the title compound as a white foam (15 mg, 75 %, E/Z 10:1). 
TLC: Rf = 0.35 (hexane:EtOAc 1:1). 
1
H NMR of the E-isomer (600 MHz, CDCl3, 25 C):  = 
7.50–7.23 (m, 20 H, arom. H), 5.86–5.84 (m, 2 H, OCH2CH=CHCH2O), 5.62 (s, 2 H, CHPh), 
4.94 (d, 2 H, J1,2 = 1.7 Hz, H-1), 4.87 and 4.70 (each d, each 2 H, J = –12.2 Hz, 3-CH2Ph), 4.33–
4.30 (m, 2 H, OCH2aCH=CHCH2aO), 4.23 (dd, 2 H, J6a,5 = 4.8, J6a,6b = –10.1 Hz, H-6a), 4.17 (dd, 
2 H, J4,5 = 9.3, J4,3 = 10.0 Hz, H-4), 4.18–4.15 (m, 2 H, OCH2bCH=CHCH2bO), 3.98 (dd, 2 H, J3,2 
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= 3.2 Hz, H-3), 3.87 (ddd, 2 H, J5,6b = 10.4 Hz, H-5), 3.84 (dd, 2 H, H-6b), 3.72 (dd, 2 H, H-2) 
3.60–3.54 (m, 2 H, OCHC5H10), 1.85–1.19 (m, 20 H, OCHC5H10).  
13
C NMR of the E-isomer (150.90 MHz, CDCl3, 25 C):  = 138.8–126.0 (arom. C), 129.9 
(OCH2CH=CHCH2O), 101.3 (CHPh), 97.5 (C-1), 79.4 (C-4), 77.7 (C-2), 76.6 (C-3), 75.2 
(OCHC5H10), 73.3 (3-CH2Ph), 72.2 (OCH2CH=CHCH2O), 68.9 (C-6), 64.2 (C-5), 33.3, 31.4, 
31.0, 24.1, 23.8 (OCHC5H10). 
HRMS: m/z calcd. for C56H68O12Na [M + Na]
+
 955.4603; found 955.4607; m/z calcd. for 
C56H68O12K [M + K]
+
 971.4342; found 971.4340. 
 
1,4-Bis(phenyl 3-O-benzyl-4,6-O-benzylidene-1-thio-2-O-α-D-mannopyranosyl)but-2-ene 
(31). Synthesized from 19 (0.13 g, 0.28 mmol) according to the general procedure for 
homodimerization reactions to give the title compound as a white foam (0.10 g, 75 %, E/Z 20:1). 
TLC: Rf = 0.89 (hexane:EtOAc 1:1). 
1
H NMR of the E-isomer (600 MHz, CDCl3, 25 C):  = 
7.51–7.27 (m, 30 H, arom. H), 5.83–5.82 (m, 2 H, OCH2CH=CHCH2O), 5.61 (s, 2 H, CHPh), 
5.51 (d, 2 H, J1,2 = 1.3 Hz, H-1), 4.87 and 4.70 (each d, each 2 H, J = –12.1 Hz, 3-CH2Ph), 4.28 
(ddd, 2 H, J5,6a = 5.1, J5,4 = 9.4, J5,6b = 10.2 Hz, H-5), 4.24 (dd, 2 H, J4,3 = 9.7 Hz, H-4), 4.20 (dd, 
2 H, J6a,6b = –10.4 Hz, H-6a), 4.20–4.12 (m, 4 H, OCH2CH=CHCH2O), 3.95 (dd, 2 H, J2,3 = 3.1 
Hz, H-2), 3.94 (dd, 2 H, H-3), 3.86 (dd, 2 H, H-6b). 
13
C NMR of the E-isomer (150.90 MHz, CDCl3, 25 C):  = 137.6–126.1 (arom. C), 129.6 
(OCH2CH=CHCH2O), 101.5 (CHPh), 87.3 (C-1), 79.1 (C-4), 78.7 (C-2), 76.2 (C-3), 73.2 (3-
CH2Ph), 71.6 (OCH2CH=CHCH2O), 68.5 (C-6), 65.3 (C-5). 
HRMS: m/z calcd. for C56H56O12Na [M + Na]
+
 975.3207; found 975.3219; m/z calcd. for 
C56H56O12K [M + K]
+
 991.2946; found 991.2943. 
 
1,4-Bis(2-O-D-mannopyranose)butane (32). Synthesized from 29 (16 mg, 0.023 mmol) 
according ot the general procedure for hydrogenolyses to give the title compound as a colorless 
oil (7 mg, 70 %, αα:αβ:ββ 5:1:1). 1H NMR of the αα-anomer (600 MHz, CD3OD, 25 C):  = 
5.18 (d, 2 H, J1,2 = 1.7 Hz, H-1), 3.81 (dd, 2 H, J6a,5 = 2.4, J6a,6b = –11.7 Hz, H-6a), 3.79 (dd, 2 H, 
J3,2 = 3.5, J3,4 = 9.6 Hz, H-3), 3.70 (ddd, 2 H, J5,6b = 5.9, J5,4 = 9.7 Hz, H-5), 3.68 (dd, 2 H, H-6b), 
3.64–3.59 (m, 4 H, OCH2CH2CH2CH2O), 3.58 (dd, 2 H, H-4), 3.50 (dd, 2 H, H-2), 1.70–1.66 (m, 
4 H, OCH2CH2CH2CH2O). 
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13
C NMR of the αα-anomer (150.90 MHz, CD3OD, 25 C):  = 93.2 (C-1), 81.3 (C-2), 74.2 (C-
5), 72.4 (OCH2CH2CH2CH2O, C-3), 69.3 (C-4), 63.2 (C-6), 27.7 (OCH2CH2CH2CH2O). 
HRMS: m/z calcd. for C16H30O12Na [M + Na]
+
 437.1629; found 437.1608. 
 
1,4-Bis(cyclohexyl 2-O-D-mannopyranosyl)butane (32). Synthesized from 30 (38 mg, 0.04 
mmol) according ot the general procedure for hydrogenolyses to give the title compound as a 
colorless oil (17 mg, 70 %). 
1
H NMR (600 MHz, CD3OD, 25 C):  = 5.01 (d, 2 H, J1,2 = 1.7 Hz, 
H-1), 3.81 (dd, 2 H, J6a,5 = 2.3, J6a,6b = –11.7 Hz, H-6a), 3.74 (dd, 2 H, J3,2 = 3.5, J3,4 = 9.4 Hz, H-
3), 3.70–3.65 (m, 2 H, OCHC5H10), 3.66 (dd, 2 H, J6b,5 = 5.9 Hz, H-6b), 3.64–3.58 (m, 4 H, 
OCH2CH2CH2CH2O), 3.57 (ddd, 2 H, J5,4 = 9.6 Hz, H-5), 3.56 (dd, 2 H, H-4), 3.46 (dd, 2 H, H-
2), 1.95–1.70 (m, 8 H, OCHC5H10), 1.70–1.60 (m, 4 H, OCH2CH2CH2CH2O), 1.56–1.00 (m, 12 
H, OCHC5H10).  
13
C NMR (150.90 MHz, CD3OD, 25 C):  = 96.9 (C-1), 81.1 (C-2), 76.1 (OCHC5H10), 74.9 (C-
5), 72.6 (C-3), 72.3 (OCH2CH2CH2CH2O), 69.3 (C-4), 63.2 (C-6), 34.5, 32.6 (OCHC5H10), 27.6 
(OCH2CH2CH2CH2O), 26.9, 25.2, 25.0 (OCHC5H10). 
HRMS: m/z calcd. for C28H50O12Na [M + Na]
+
 601.3194; found 601.3194. 
 
1,4-Bis[benzyl 3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranosyl-(2→1)-3-O-benzyl-4,6-
O-benzylidene-2-O-β-D-mannopyranosyl]but-2-ene (34). Synthesized from 19 (74 mg, 0.8 
mmol) and 11 (2.3 equiv.) according to the general procedure for β-mannosylation to give the 
title compound as a colorless oil (88 mg, 70 %, β:α 10:1). TLC: Rf = 0.10 (hexane-EtOAc 1:1). 
1
H NMR of the E-isomer (600 MHz, CDCl3, 25 C):  = 7.50–7.21 (m, 50 H, arom. H), 6.02–
5.96 (m, 2 H, OCH2CH=CHCH2O), 5.57 (s, 2 H, CHPha), 5.50 (s, 2 H, CHPhb), 4.89 (d, 2 H, J1,2 
= 1.6 Hz, H-1), 4.76 and 4.71 (each d, each 2 H, J = –10.5 Hz, CH2Pha), 4.72 (s, 4 H, CH2Phb), 
4.68 and 4.46 (each d, each 2 H, J = –12.0 Hz, CH2Phc), 4.53–4.49 (m, 2 H, 
OCH2aCH=CHCH2aO), 4.25 (d, 2 H, J1,2 = 0.7 Hz, H-1), 4.34–4.30 (m, 2 H, 
OCH2bCH=CHCH2bO), 4.20 (dd, 2 H, J2,3 = 3.3 Hz, H-2), 4.19 (dd, 2 H, J6a,5 = 4.8, J6a,6b = –10.1 
Hz, H-6a), 4.18 (dd, 2 H, J6a,5 = 4.9, J6a,6b = –10.2 Hz, H-6a), 4.15 (dd, 2 H, J4,5 = 9.3, J4,3 = 
9.9 Hz, H-4), 4.12 (dd, 2 H, J4,5 = 9.3, J4,3 = 10.0 Hz, H-4), 3.99 (dd, 2 H, H-3), 3.86 (dd, 2 H, 
J2,3 = 3.2 Hz, H-2), 3.84 (ddd, 2 H, J5,6b = 10.3 Hz, H-5), 3.79 (dd, 2 H, H-6b), 3.78 (ddd, 2 H, 
J6b,5 = 10.1 Hz, H-6b), 3.53 (dd, 2 H, H-3), 3.21 (ddd, 2 H, H-5).  
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13
C NMR of the E-isomer (150.90 MHz, CDCl3, 25 C):  = 138.8–126.0 (arom. C), 130.2 
(OCH2CH=CHCH2O), 101.5 (CHPha), 101.3 (CHPhb), 100.7 (C-1, 
1
JC,H = 155.2 Hz), 97.7 (C-1, 
1
JC,H = 168.5 Hz), 78.6 (C-4), 78.4 (C-4), 77.2 (C-3), 77.1 (C-2), 75.2 (C-2), 74.3 (C-3), 73.6 
(OCH2CH=CHCH2O), 72.2 (CH2Pha), 71.6 (CH2Phb), 69.3 (CH2Phc), 68.8 (C-6, C-6), 68.5 (C-
5), 67.6 (C-5). 
HRMS: m/z calcd. for C98H100O22Na [M + Na]
+
 1651.6598; found 1651.6665. 
 
1,4-Bis[2-O-β-D-mannopyranosyl-(1→2)-D-mannopyranose]butane (35). Synthesized from 34 
(20 mg, 0.01 mmol) according to the general procedure for hydrogenolyses to give the title 
compound as a colorless oil (5 mg, 50 %, αα:αβ:ββ 8:2:1). 1H NMR of the αα-anomer (600 MHz, 
CD3OD, 25 C):  = 5.18 (d, 2 H, J1,2 = 1.8 Hz, H-1), 4.64 (d, 2 H, J1,2 = 0.8 Hz, H-1), 3.94 (dd, 
2 H, J2,3 = 3.2 Hz, H-2), 3.91–3.86 (m, 2 H, OCH2aCH2CH2CH2aO), 3.87 (dd, 2 H, J6a,5 = 2.3, 
J6a,6b = –12.0 Hz, H-6a), 3.82–3.80 (m, 2 H, H-6a), 3.78 (dd, 2 H, J3,4 = 9.6 Hz, H-3), 3.77–3.73 
(m, 2 H, OCH2bCH2CH2CH2bO), 3.73–3.67 (m, 8 H, H-2, H-3, H-6b, H-6b), 3.65 (dd, 2 H, J4,5 
= 9.5 Hz, H-4), 3.53 (dd, 2 H, J45 = 8.8, J4,3 = 9.5 Hz, H-4), 3.50–3.45 (m, 2 H, H-5), 3.21 
(ddd, 2 H, J5,6b = 5.8 Hz, H-5), 1.80–1.60 (m, 4 H, OCH2CH2CH2CH2O).  
13
C NMR of the αα-anomer (150.90 MHz, CD3OD, 25 C):  = 101.4 (C-1), 93.7 (C-1), 81.0 (C-
2), 80.6 (C-2), 78.8 (C-5), 75.3 (C-5), 75.1 (OCH2CH2CH2CH2O), 74.3 (C-3), 71.6 (C-3), 69.5 
(C-4), 68.8 (C-4), 62.9 (C-6, C-6), 27.6 (OCH2CH2CH2CH2O). 
HRMS: m/z calcd. for C28H59O22Na [M + Na]
+
 761.2686; found 761.2688. 
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Episode 2: Synthesis of Galactoglucomannan Core Tri/Tetrasaccharides 
                                                                      
 
 
 
 
Galactoglucomannan (GGM), a heteropolymer consisting of mainly mannose, glucose and 
galactose, is the most abundant hemicellulose in Norway spruce (Picea abies). Apart from the 
large amounts present in P. abies, GGM has also been found in the cell wall of flax seed, tobacco 
plants and kiwifruit. Although many applications of the GGM polymer have been developed, for 
example in pulp and paper manufacturing, no attempts to synthesize and study the individual 
fragments of this oligosaccharide have been made previously. In this chapter, the synthesis of one 
of the core trisaccharides and a less abundant tetrasaccharide fragment of GGM is discussed. In 
addition, some preliminary comparative NMR spectroscopic studies on the individual fragments 
and the GGM polymer will be presented along with other studies related to this polymer. 
 
 
 
 
 
 
This chapter is based on unpublished results: F. S. Ekholm, A. Ardá, P. Eklund, S. André, H.-J. 
Gabius, J. Jiménez-Barbero, R. Leino, “Studies on Norway Spruce Galactoglucomannans: 
Chemical Synthesis, Conformational Analysis, NMR Spectroscopic Characterization and 
Molecular Recognition of Model Compounds”, manuscript submitted. 
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1 Introduction 
Galactoglucomannan (GGM) is the most abundant hemicellulose in Norway spruce (Picea 
abies).
1
 GGM has also been found in several other plants and fruits including clubmosses, 
horsetails, whisk fern, kiwifruit and tobacco plants.
2
 The utilization of water soluble 
polysaccharides, in particular GGM, in mechanical pulping and papermaking has traditionally 
been of great importance.
3
 Recently, methods for the large scale isolation of AcGGM from Picea 
abies were developed simultaneously sparking new interest in these molecules. By use of these 
methods, polysaccharide material can today be isolated on kg-scale thus providing sufficient 
amounts of material for screening and extension of the applications of these compounds.
1a,4
 As a 
result, a deeper understanding of the roles of GGM in pulp and paper manufacturing has been 
achieved along with new applications of GGM in immunology.
5
 GGM has also been shown to be 
a good substitute to the widely utilized gum arabic (arabinogalactan) as an emulsifier of 
hydrophobic beverages.
1a
  
 
 
Figure 1. The proposed chemical structure of AcGGM from Picea abies. 
 
Structural elucidation of water soluble AcGGM from P. abies has been the focus of several 
studies.
6
 It has been suggested that the main chain consists of randomly distributed -(1→4)-
linked mannopyranosyl and -(1→4)-linked glucopyranosyl units. Furthermore, the existence of 
-(1→6)-linked galactopyranosyl residues has been confirmed in several studies.6a,7 In all 
studies, the galactopyranosyl units were found to be connected to mannopyranoside residues in 
the linear backbone of GGM. These monosaccharides have been suggested to appear in a 
Man:Glc:Gal ratio of  4:1:0.1. This ratio is highly influenced by the isolation conditions.
8
 In 
addition, the acetyl group pattern of P. abies AcGGM, bearing an acetylation degree of 0.3, has 
been analyzed and it is today widely accepted that acetyl groups are mainly present at the O-2 
and O-3 of the mannopyranosyl units.
1a,6a 
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While AcGGM can be isolated on large scale, several ambiguities concerning the structure and 
acetylation pattern of AcGGM remain. Furthermore, determination of the structure and size has 
been extremely difficult due to the heterogenous nature of the native material. This is also 
reflected in the wide range of molar masses (between 20–78 kDa) suggested for these 
polysaccharides.
1a,4
 In addition, acetyl group migration has been proposed to occur even from the 
O-2 and O-3 to the O-6 position in the mannopyranosyl residues.
1a
 Investigation of such 
phenomena is difficult to perform on the heterogenous polysaccharide samples available. 
Therefore, it was decided to synthesize and utilize small molecular models instead. In this 
Episode, the synthesis of one of the trisaccharide repeating units of AcGGM, a tetrasaccharide 
fragment containing an -(1→6)-linked galactopyranosyl residue and some model substrates for 
the acetyl group migration study are presented. In addition, some comparative NMR 
spectroscopic data on the native polysaccharide and the synthetic model substrates will be 
discussed. 
 
2 Results and Discussion 
2.1 Synthesis of AcGGM Tri- and Tetrasaccharide Units  
As mentioned in the introduction, the applications of AcGGM have in recent years rapidly 
expanded from the traditional roles in pulp and papermaking processes to applications in the food 
and medicinal industries.
1a,3,5 
From a biochemical standpoint, the roles of the individual 
fragments of the GGM-polysaccharide would be interesting to study as such especially in 
immunological applications. This has not been possible previously due to the heterogenous nature 
of the native samples. In the present work, the synthesis of fragments found in AcGGM was 
planned in order to provide material for such studies (Figure 2).  
 
 
Figure 2. The synthetic targets representing one of the trisaccharide repeating units of GGM (1) 
(left), and a less abundant tetrasaccharide fragment (2) (right). 
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Scheme 1. Retrosynthetic analysis of trisaccharide 1. 
 
In the case of AcGGM, the individual fragments contain challenging glycosidic linkages, such as 
the -mannopyranosyl and -galactopyranosyl linkages, which for a long time were considered 
difficult to construct by chemical methods. The synthetic study towards these fragments is 
currently ongoing and, therefore, at the time of the writing, synthesis of the acetylated 
trisaccharide fragment representing the second repeating unit (Figure 1) has not yet been 
completed. For the initial attempt on the synthesis of trisaccharide 1, a linear strategy was 
deviced starting from the three monosaccharide building blocks 3, 4 and 5 (Scheme 1).  
 
 
Scheme 2. Synthesis of acceptor 4: i) PTSA, C6H5OCH(OMe)2, 2 h, 60 C, 200 mbar, 60 %; ii) 
BnBr, NaH, DMF, 3 h, r.t., 88 %; iii) TFA, Et3SiH, CH2Cl2, 2 h, r.t., 50 %. 
 
The synthesis of donor 3 was discussed in the previous Episode and a similar preparative route 
was also used in the present synthesis.
9
 Acceptor 4 was prepared by the route shown in Scheme 2.  
The commercially available methyl mannopyranoside 6 was converted into 7 utilizing one 
equivalent of benzaldehyde dimethylacetal under slightly acidic conditions according to the 
procedures described by McGowan in 1982.
10
 The remaining hydroxyl groups were benzylated 
by the standard protocol using NaH and BnBr. Next, the benzylidene acetal was partially cleaved 
by the reductive methodology of Fraser-Reid, DeNinno and coworkers to give the 4-OH/6-OBn 
containing acceptor 4 in moderate yield.
11
 A similar efficiency was also witnessed previously in 
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cases where benzylidene protected mannopyranosides were partially cleaved under these 
conditions.
12
 With building blocks 3 and 4 at hand, the attention was turned towards preparation 
of building block 5. 
 
 
Scheme 3. Synthesis of donor 5: i) 1. SHPh, BF3OEt2, CH2Cl2, 24 h, r.t., 96 %; 2. NaOMe, 
MeOH:THF 3:1, 24 h, r.t., 95 %; ii) PTSA, C6H5OCH(OMe)2, DMF, 60 C, 200 mbar, 88 %; iii) 
BzCl, pyridine, 5 h, r.t., 90 %.  
 
Donor 5 was synthesized according to the synthetic route shown in Scheme 3. Peracetylated D-
glucopyranose was subjected to a BF3OEt2 promoted glycosylation followed by deacetylation 
under Zemplén conditions.
13
 The benzylidene protected thioglycoside 11 was synthesized 
according to earlier described procedures.
10
 As expected, the yields were significantly higher in 
the benzylidene formation with the glucopyranoside in comparison to those of the 
mannopyranosides. This is mainly due to the trans-relationship of the 2- and 3-hydroxyl groups 
in the glucose moiety which significantly reduces the formation of the dibenzylidene side product 
formed with mannopyranosides. The remaining hydroxyl groups were next benzoylated by 
standard methods using BzCl in pyridine. With the building blocks prepared the focus was shifted 
towards assembly of the trisaccharide 1.   
 
 
Scheme 4. Synthesis of disaccharide 12: i) NIS (1.2 eq.), TMSOTf (0.12 eq.), CH2Cl2, 1.5 h, – 25 
C, 47 %; ii) NIS (1.2 eq.), TMSOTf (0.06 eq.), CH2Cl2, 1.5 h, – 25 C, 76 %; iii) TFA, Et3SiH, 
CH2Cl2, r.t., 1–5 h, <15 %. 
 
Following a linear pathway, donor 5 was first coupled with acceptor 4 by the conventional 
promoter/activator system featuring NIS and TMSOTf (Scheme 4).
14
 Several difficulties were 
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encountered already during the first attempts of this glycosylation. In our initial attempt, 
following the standard activation protocol featuring 0.12 equivalents of TMSOTf, a moderate 
yield of 47 % was obtained due to formation of several side products. When the amount of 
TMSOTf was lowered to 0.06 equivalents, the yield of the desired disaccharide 12 increased. The 
main difficulty encountered during the synthesis was the highly crystalline nature of the 
benzoylated glucose donor 5 and disaccharide 12. This resulted in extremely difficult purification 
procedures since the products crystallized in the column while performing column 
chromatography, despite being highly soluble in the solvent system as such. In addition, 
crystallization of disaccharide 12 in the presence of donor 5 was found to be impossible due to 
the small scale of the synthesis. Furthermore, the partial reductive cleavage following the 
protocol described by Fraser-Reid and coworkers resulted in a poor yield of the desired 
disaccharide 13.
11
 As a result of these trials, the synthetic strategy required revision. Since the 
selective ring-opening of the benzylidene acetal in disaccharide 12 turned out to be difficult, it 
was decided to change the synthetic route from linear to convergent. The convergent route would 
add two potential benefits to the synthetic pathway. The -mannopyranosyl linkage could be 
constructed first followed by convergent coupling of a disaccharide to acceptor 4. In addition, the 
selective ring-opening of the benzylidene acetal could now be performed on the glucose building 
block instead of the disaccharide. In order to avoid the problematic crystalline nature displayed 
by dibenzoylated glucoside, the benzoyl groups were simultaneously replaced by acetyl groups. 
The synthesis of trisaccharide 1 is shown in Scheme 5. The synthesis of donor 3 was described in 
Episode 1 and was available on large scale for the present synthetic route. Acceptor 14 was 
synthesized from 11 by acetylation of the free hydroxyl group followed by selective ring opening 
of the benzylidene acetal by use of the methods described previously. This time, the reaction 
yield was excellent.
11
 The large variation in the efficiency of the methodology described by 
Fraser-Reid et al. was found to be highly dependent on the stereochemistry of the individual 
sugars. Similar results have been reported in the literature previously.
12
 Next, donor 3 was 
activated according to the -mannosylation protocol described by Crich and coworkers and 
coupled with acceptor 14.
15
 The glycosylation reaction proceeded with moderate efficiency and 
high selectivity (: 10:1). The yield of this individual glycosylation reaction could probably 
have been increased by addition of 1-octene to the reaction mixture following the activation of 
donor 3.
 
1-Octene has been shown to be a mild reagent which traps the thioadducts formed as 
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side products during the activation and conversion of donor 3 to the activated glycosyl triflate.
16
 
This useful information was, however, not known to the author of this thesis at the time when the 
synthesis was conducted. With donor 15 synthesized, it was coupled with acceptor 4 under the 
optimized reaction conditions (0.06 equivalents of TMSOTf) from our previous synthetic attempt 
displayed in Scheme 4. The convergent glycosylation proceeded smoothly to give the protected 
trisaccharide 16 in 77 % isolated yield. A two step deprotection sequence featuring 
deacetylation
13b
 followed by hydrogenolyses gave the trisaccharide 1 in 84 % overall yield. 
 
 
Scheme 5. Synthesis of GGM core trisaccharide 1: i) 1. Ac2O, pyridine, r.t., 5 h, 95 %; 2. Et3SiH, 
TFA, 0 C→r.t., 3 h, 85 %; ii) 1. BSP, TTBP, Tf2O, CH2Cl2, –60 C, 0.5 h: 2. 14, –78 C, 2 h, 55 
%; iii) 4, NIS, TMSOTf, CH2Cl2, –40 C, 1.5 h, 77 %; iv) 1. NaOMe, MeOH:THF 1:1, r.t., 19 h, 
84 %; 2. Pd/C, H2 (2.8bar), MeOH, r.t, 19 h, quant. 
 
With the trisaccharide repeating unit synthesized, the focus was shifted towards assembly of the 
less abundant tetrasaccharide fragment 2. Trisaccharide 16 was chosen as a suitable starting 
material for the synthesis of tetrasaccharide 2. Once again, selective ring-opening of the 
benzylidene acetal was required as a key transformation in preparation of the trisaccharide 
acceptor. This time, however, the 6-OH/4-OBn substrate was targeted as the galactopyranosyl 
residue in 2 is -(1→6)-linked to the sugar backbone. For this purpose, several procedures have 
been described in the literature. Some of the utilized procedures feature reagents including 
PhBCl2/Et3SiH,
17
 LiAlH4/AlCl3,
18
 TMSOTf/BH3THF
19
 and Cu(OTf)2/BH3THF.
20
 Instead of 
evaluating these procedures on trisaccharide 16, the appropriately protected monosaccharide 8 
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was utilized in the initial screening of reaction conditions. The results of this initial screening of 
methodologies are summarized in Scheme 6. In our hands, several of the previously reported 
procedures did not work with the efficiencies reported in the literature.
17–19
 In our initial trials, 
both the PhBCl2/Et3SiH
17
 and LiAlH4/AlCl3
18
 protocols were quickly ruled out from further use 
due to poor efficiencies. Considering the moderate efficiency displayed by the 
TMSOTf/BH3THF protocol,
19
 a continued investigation into borane based protocols was started. 
The selectivity in the partial cleavage of benzylidene acetals is generally a combination of steric 
and electronic factors. It has been suggested that 6-OBn derivatives are formed when borane is 
activated by Lewis acid thereby coordinating to the more nucelophilic 6-OH group. If borane is 
not activated under the reaction conditions, the Lewis acid is the most electrophilic species in the 
mixture and coordinates to the 6-OH group of the sugar thus providing the 4-OBn derivative as a 
product.
21
 Consequently, in the present study, it was important to investigate different Lewis 
acids under similar conditions. Recently Shie published a procedure using Cu(OTf)2 as a Lewis 
acid in the selective ring-opening of benzylidene acetals.
20
 Initial attempts utilizing this protocol 
resulted in complete cleavage of the benzylidene acetal. The solvent was identified as the major 
obstacle in this reaction and after switching from THF to CH2Cl2, monosaccharide 18 could be 
isolated in high yield. While this procedure appeared to be functioning well in the case of 
monosaccharides, only a few reports on the applications of similar protocols to oligosaccharides 
have been described previously.  
 
 
Scheme 6. Screening of methodologies for the selective ring-opening of benzylidene acetals: i) 
PhBCl2, Et3SiH, –78 C, CH2Cl2, 2–4 h, 35 %; ii) LiAlH4, AlCl3, CH2Cl2: Et2O 4:1, r.t. →50 C, 
1 h, 35 %; iii) TMSOTf, BH3THF, CH2Cl2, r.t., o.n., 50 %; iv) Cu(OTf)2, BH3THF, CH2Cl2, r.t., 
o.n., 82 %.  
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Scheme 7. Synthesis of the trisaccharide acceptor 18: i) Cu(OTf)2, BH3THF, CH2Cl2, r.t., o.n., 
85 %.  
 
Fortunately, applying similar conditions to the protected trisaccharide 16 gave the trisaccharide 
acceptor 18 in excellent yield. This was, to our knowledge, one of the first times where a similar 
procedure has been applied to an oligosaccharide. The high efficiency and selectivity observed 
under these conditions are encouraging for future applications of this methodology.  
 
 
Scheme 8. Synthesis of donors 19 and 20: i) 1. Ac2O, NaOAc, reflux, 2 h, 50 % (pure ); 2. 
SHEt, BF3OEt2, CH2Cl2, 0 C, 4 h, 95 %; 3. NaOMe, MeOH:THF 4:3, r.t., o.n., quant.; 4. BnBr, 
NaH, DMF, r.t., 20 h, 80 %; ii) 1. Ac2O, NaOAc, reflux, 2 h, 50 % (pure ); 2. SHPh, BF3OEt2, 
CH2Cl2, 0 C, 4 h, 95 %; 3. NaOMe, MeOH:THF 1:1, r.t., o.n., quant; 4. a) Di-TBS(OTf)2, 
pyridine, r.t., 3 h; b) BzCl, r.t., 2 h, 57 %.  
 
With the trisaccharide acceptor prepared, the challenge concerning the -galactosylation 
remained. For this purpose, donors 19 and 20 were prepared according to literature procedures by 
the routes shown in Scheme 8.
22 
Both of these donors have in recent years been applied in -
galactosylation of various acceptors and were therefore also screened in the present study. Donor 
19 has previously been shown to give high -selectivities and efficiencies in ethereal solvents 
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such as Et2O.
23
 As a result, these conditions were first screened in the -galactosylation of 
acceptor 18 featuring the NIS/TMSOTf promoter system.
14
 Unfortunately, moderate to low 
selectivity (: 4:1) was achieved under these conditions and separation of the two diastereomers 
by column chromatography turned out to be challenging. While several variations in solvent 
proportions (Et2O:CH2Cl2) and activation/promoter systems were tried, no improvements on the 
selectivity of the glycosylation could be achieved. Therefore, another methodology, featuring 
CuBr2, TBAB, AgOTf in dichloroethane and DMF, reported previously by Mukherjee and 
coworkers was screened.
24
 This methodology was successfully applied to the -galactosylation of 
a tetrasaccharide acceptor in their work. In the present study the protocol failed to yield the 
desired product.  
 
Scheme 9. Synthesis of tetrasaccharide 2: i) 20, NIS, TfOH (or TMSOTf), CH2Cl2, 0 C, 1.5 h, 
68 %; ii) HF-pyridine, THF, 0 C → r.t., 6 h, 68 %; iii) 1. NaOMe, MeOH:THF 1:1, r.t., o.n., 96 
%; 2. Pd/C, H2 (2.8 bar), MeOH, r.t., o.n., 96 %. 
 
As a result, our hope was placed on donor 20. This donor has previously been applied to the -
selective galactosylation of several oligosaccharides and various aglycones by Ando and 
coworkers.
22b-c,25 
In the present study, the methodology was applied to the -selective 
galactosylation of 18 providing tetrasaccharide 21 in good yield as shown in Scheme 9. While the 
yield was good and the selectivity excellent, the formation of a second tetrasaccharide was also 
observed. Since the tetrasaccharide byproduct appeared to be -linked (based on JH-1,H-2),
26
 it was 
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most probably an orthoester of the product. With the efficiency already in the desired range, 
further attempts to optimize the experimental conditions were not made. The reason for the high 
-selectivity in the glycosylation reaction is puzzling since ester protective groups are present at 
both the O-2 and O-3 in donor 20. The only possible explanation for the high -selectivity may, 
at least in part, be due to the steric and electronic properties caused by the 4,6-silylene acetal. For 
synthesis of the deprotected tetrasaccharide 2, the protective groups present in 21 had to be 
removed. Since silicon has great affinity for fluorine, the silylene acetal was first removed with 
HF-pyridine complex in 68 % yield.
27
 The ester protective groups were next cleaved under 
Zemplén conditions with NaOMe in a MeOH:THF solvent mixture, followed by hydrogenolyses 
of the benzyl groups in 92 % overall yield over two steps.  
With one of the core trisaccharide repeating units (1) and a less abundant tetrasaccharide unit (2) 
synthesized, the attention was turned to the investigation of other phenomena occurring during 
the isolation of GGM.  
 
2.2 Acetyl Group Migration in Mannopyranosyl Units of GGM 
As mentioned in the introduction, the acetylation degree of GGM is ~0.3 slightly varying 
depending on the methods utilized in the isolation process.
1a,6
 The acetyl groups are mainly 
located at the O-2 and O-3 positions of the mannopyranosyl residues. It has been proposed that 
acetyl groups can migrate either directly from O-2 to O-6 or from O-3 to O-6 in the 
mannopyranosyl units.
1a
 Migration between O-2 and O-3 is known to take place in substrates 
containing acetyl protective groups and will not be discussed in more detail in this context. The 
migration from O-2 and O-3 to O-6 is unique as it would require the acetyl group to “leap” across 
the molecule in space. This phenomenon is difficult to study on the native polysaccharide due to 
severe overlap of signals in the NMR spectra. As a consequence, small molecular models were 
synthesized in order to study these phenomena in more detail. It is known that mannopyranosides 
mainly exist in the energetically favoured 
4
C1-conformation. Based on this assumption a few 
different acetylated mannopyranosides were synthesized (Scheme 10). The synthesis of these 
compounds followed standard protecting group manipulations and will not be addressed in more 
detail here. In our initial study, the acetyl group migration possibilities from O-2 to O-6 in 
4
C1-
mannopyranosides were evaluated. Compound 23 was chosen as a suitable model substrate for 
studying acetyl group migration from O-2 to O-6 as it is locked in the 
4
C1-conformation by the 
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diacetal protective group between positions 3 and 4. No migration was observed when this 
substrate was subjected to the conditions utilized during the isolation of GGM (75 C, 
D2O:DMSO 1:1). One possible reason for this result could be the low degree of flexibility in this 
molecule and hence mannoside 24 was synthesized. While 24 has a much higher degree of 
flexibility, migration did not take place in this substrate either. 
 
 
Scheme 10. Synthesis of model substrates 23 and 24: i) 1. Butanedione, trimethyl orthoformate, 
CSA (camphorsulfonic acid), MeOH, reflux, 24 h, 79 %; 2. TBDMSCl, imidazole, DMF, 0 C → 
r.t., 24 h, 90 %; 3. Ac2O, pyridine, DCM, 48 h, 92 %; 4. 70 % HF-pyridine, THF, 0 C → r.t., 24 
h, 93 %; ii) 1. PTSA, C6H5OCH(OMe)2, DMF, 60 C, 200 mbar, 2 h, 53 %; 2. a) Bu2SnO, 
toluene, 120 C, 3 h; b) TBAB, CsF, BnBr, 120 C, 3 h, 85 %; 3. Ac2O, pyridine, r.t., 3 h, 93 %; 
4. 80 % AcOH, 70 C, 1.5 h, 87 %. 
 
Based on these results, it seems highly unlikely that migration would occur in the GGM-
polysaccharide from O-2 to O-6 as has been suggested previously.
1a
 More model substrates are 
needed in order to investigate the acetyl group migration from O-3 to O-6. In order to investigate 
the overall possibility of acetyl group migration, appropriately protected high energy 
conformations, such as those depicted in Figure 4, should be synthesized and studied under 
similar conditions. Such an approach should further be combined with molecular modeling in 
order to create appropriate models for investigating these phenomena in detail. The synthesis of 
appropriately protected mannosides for further studies on the acetyl migration behavior of GGM 
is currently under planning. The acetylated trisaccharide fragment (in preparation) representing 
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the second repeating unit in the GGM backbone might prove to be an additional substrate 
utilizable in the study on acetyl group migration/cleavage patterns of GGM. 
 
 
Figure 4. High energy conformations of mannopyranosides where acetyl group migration could 
be possible; from the left to right 
1
C4, B1,4, 
5
H4. 
 
2.3 NMR Spectroscopic Comparison of the Synthetic Model Substrates vs. Native GGM 
 
 
Figure 5. The synthetic targets representing one of the trisaccharide repeating units of GGM 
(left) and a less abundant tetrasaccharide fragment (right). 
 
In order to compare the NMR data of the synthetic structures and native GGM, the complete 
spectral characterization of both 
13
C- and 
1
H-NMR spectra of 1 and 2 was desirable. In the 
previous chapter the complete characterization of a -(1→2)-linked mannotetraose was described 
and a similar set of NMR experiments was utilized also for the current spectral characterization. 
The NMR spectra were recorded at 308 K (in D2O) in order to shift the water peak, as it was 
otherwise overlapping with anomeric protons, and in order to increase the solubility of the 
polysaccharide sample. The spectral characterization of oligosaccharides was discussed in detail 
in the previous chapter and the discussion will be less thorough here. In short, the 
1
H-NMR 
spectrum of 1 gives rise to three well separated anomeric protons at 4.76 (d, H-1), 4.74  (d, H-1) 
and 4.52 (d, H-1) ppm. These signals were also targeted by selective excitation utilizing the 1D-
TOCSY experiment
28
 and a spinlock time of 300 ms. The results of these experiment are 
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visualized in Figure 6. With the help of COSY, HSQC (coupled and decoupled) and HMBC both 
the 
1
H- and 
13
C-NMR spectra could be completely solved.
29
  
 
H-1 H-2
H-6a
H-5
H-6b
H-3
H-4
H-1
H-2
H-6a
H-5H-6b
H-3
H-4
H-1
H-2
H-3 H-5H-4
H-6a
H-6b
 
Figure 6. 1D-TOCSY spectra of the different residues in 1: from the top, Manp, Glcp, Manp 
and the entire 
1
H-NMR spectrum of 1.  
 
Characterization of 2 followed a similar strategy. Well separated signals from each of the sugar 
residues in the 
1
H-NMR spectrum were targeted by selective excitation using the 1D-TOCSY 
experiment (Figure 7).
28 
Utilization of standard NMR experiments [COSY, HSQC (both coupled 
and decoupled) and HMBC] allowed the complete assignment of both the 
1
H- and 
13
C-NMR 
spectra of 2. The 
1
H-NMR spectra of 1 and 2 were simulated with the PERCH software in order 
to obtain reliable coupling constants for the individual protons. With the NMR spectra of model 
substrates 1 and 2 solved, the attention was focused on comparing the chemical shifts with those 
of native GGM. The proton and carbon chemical shifts of 1, 2 and literature values of the 
chemical shifts of GGM
6a,8a,30
 are summarized in Table 1. The coupling constants and patterns 
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observed in the 
1
H-NMR spectrum and the JC,H coupling constants for the anomeric centers are 
provided in the experimental section for 1 and 2. 
 
H-1
H-2
H-6a H-5
H-6b
H-3
H-4
H-1
H-2
H-6a H-5H-6b
H-3
H-4
H-1 H-2
H-3
H-5
H-4H-6a H-6b
H-1
H-2
H-3
H-4
H-5
H-6a
H-6b
 
Figure 7. 1D-TOCSY spectra of the different residues in 2: from the top, Galp, Manp, Glcp, 
Manp and the entire 
1
H-NMR spectrum of 2.  
 
As seen from Table 1, many of the chemical shifts for the individual signals in 1 and 2 correlate 
relatively well with the values reported in the literature for native GGM.
6a,8a,30
 There are certain 
signals where significant chemical shift differences have been reported in the literature. One of 
the main signals where large deviations have been reported is the H-2 of the -(1→4)-linked 
mannopyranoside residue. This signal has been reported to appear in native GGM at 3.08 or 4.08 
ppm.
6a,8a,30
 In both model substrates 1 and 2 the chemical shift for H-2 was found to be close to 
4.08 ppm simultaneously indicating these literature values to be correct. In fact, all other signals 
in this residue are located at similar frequencies in both the model substrates and native GGM 
thus suggesting an error or typo in the literature value given by Hannuksela and coworkers for the 
chemical shift of H-2 in native GGM.
6a
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Table 1. The chemical shifts of native GGM and model substrates 1 and 2 are expressed on the -scale (in ppm) utilizing CD3OD/D2O 
as internal standards. The chemical shifts for the GGM polysaccharide are literature values.
6a,8a,30
 
Sugar H-1  
C-1 
H-2 
C-2 
H-3 
C-3 
H-4 
C-4 
H-5 
C-5 
H-6a, b 
C-6 
Native GGM 
-Manp-(1→ 
 
 
→4)--Glcp-(1→ 
 
 
-Galp-(1→ 
 
 
→6)--Manp-(1→ 
 
4.75 
101.2 
 
4.53 
103.6 
 
5.038 
99.84 
 
4.79 
- 
 
 
4.08 (or 3.08)
6a
 
71.12 
 
3.364 
73.87 
 
3.83 
69.46 
 
- 
 
3.66 
72.50 
 
3.702 
74.98 
 
3.958 
70.31 
 
- 
 
3.58 
77.63 
 
3.63 
79.519 
 
4.01 
70.26 
 
- 
 
3.45 
76.1 
 
3.78 
77.5 
 
3.92 
72.3 
 
3.70 
- 
 
3.95, 3.735 
61.9 
 
- 
 
 
3.77 
62.29 
 
4.03–3.94,  
3.84–3.79 
- 
Model substrate 1 
-Manp-(1→ 
 
 
→4)--Glcp-(1→ 
 
 
→4)--Manp 
 
4.73 
100.6 
 
4.52 
103.0 
 
4.76 
101.2 
 
4.05 
71.1 
 
3.35 
73.5 
 
3.99 
70.1 
 
3.65 
73.4 
 
3.69 
74.6 
 
3.86 
69.8 
 
3.58 
67.3 
 
3.68 
79.2 
 
3.86 
77.2 
 
3.41 
77.0 
 
3.61 
75.3 
 
3.73 
71.8 
 
3.93, 3.73 
61.5 
 
3.90, 3.73 
60.8 
 
3.95, 3.84 
60.9 
Model substrate 2 
→6)--Manp-(1→ 
 
 
→4)--Glcp-(1→ 
 
 
→4)--Manp 
 
 
-Galp-(1→ 
 
 
4.75 
100.8 
 
4.53 
103.0 
 
4.76 
101.2 
 
5.00 
98.9 
 
4.07 
71.1 
 
3.35 
73.5 
 
3.98 
70.1 
 
3.81 
69.1 
 
3.65 
73.5 
 
3.69 
74.7 
 
3.86 
69.9 
 
3.95 
71.6 
 
3.68 
67.2 
 
3.67 
79.6 
 
3.85 
77.3 
 
3.99 
69.9 
 
3.61 
75.1 
 
3.62 
75.1 
 
3.73 
71.8 
 
3.95 
70.0 
 
3.96, 3.78 
66.8 
 
3.89, 3.73 
60.8 
 
3.95, 3.84 
60.9 
 
3.74, 3.74 
61.8 
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The chemical shifts for the H-6a, H-6b and C-6 of the -(1→4)-linked glucopyranoside residues 
have not been reported in the literature for native GGM but were found to differ less than 0.2 
ppm in both model substrates and could, therefore, be assumed to be similar in the polysaccharide 
structure. The H-5 and C-5 chemical shifts in the -(1→4)-linked glucopyranoside residues of 
native GGM appeared at higher frequency than in model substrates 1 and 2. As the values are 
almost exactly similar for all other signals in this residue, there might be some uncertainties in the 
chemical shifts reported for GGM in the literature. Suprisingly, there was little data available on 
the -(1→4)-linked mannopyranoside residue bearing an -(1→6)-linked galactopyranosyl unit. 
These chemical shifts were easily identified in our model substrates and will complement the data 
available in the literature. Interestingly, the H-5 proton is shifted towards higher frequency and 
C-5 carbon towards lower frequency when the -(1→4)-linked mannopyranosyl unit is 
substituted by an -(1→6)-linked galactopyranosyl residue. A further notable difference in 
chemical shifts of the -(1→6)-galactosylated mannopyranosyl unit is the large difference for the 
C-6 carbon which is located at 66.8 ppm in the substituted mannopyranosyl residue vs. 61.5 ppm 
in the unsubstituted one. This will provide a good reference point for future determinations of the 
amount of 6-substituted -(1→4)-linked mannopyranosyl units in the GGM backbone.  
While slight deviations were found in the NMR spectroscopic characterization of GGM as 
compared to our model substrates, most signals were found to be in good agreement with the 
previously suggested spectral data. These results suggest that it is indeed possible to study the 
composition of polysaccharides by utilization of small molecular models of limited size. To 
further evaluate and continue the study on the GGM polymer, several other small molecular 
fragments will need to be synthesized and analyzed. Most important among these fragments will 
be the synthesis and characterization of the second repeating unit bearing acetyl groups along 
with a complete conformational study on all of the fragments.  
 
3 Conclusions 
In this chapter, recent studies related to the nature of GGM found in P. abies were described. In 
the first part of the chapter the synthesis of some model compounds of the GGM backbone were 
discussed. One of the trisaccharide repeating units of GGM was synthesized along with a less 
abundant tetrasaccharide fragment. The synthesis of the tetrasaccharide required a thorough 
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investigation of methodologies for selective ring-opening of benzylidene acetals
11,12,17,18,19,20
 as 
well as methodologies for -selective galactosylation23,24 of oligosaccharides. 
In the second part of the chapter, a brief investigation of the previously suggested acetyl group 
migration patterns of GGM were analyzed by utilization of synthetic monosaccharide models. No 
migration was found to occur between the O-2 and O-6 in the mannopyranoside unit when 
unflexible and flexible models existing in the 
4
C1-conformation were utilized. Since the 
mannosides generally exist in this low energy conformation also in polysaccharides, the acetyl 
group migration seems highly unlikely to occur in the polysaccharide material. A continued study 
on these phenoma would require the synthesis of partially acetylated (O-2, O-3) 
mannopyranosides existing in high energy conformations. In these substrates the O-6 of the 
mannopyranoside is closer to the O-2 and O-3 and, therefore, the acetyl group transfer might be 
more favoured.  
In the third part of the chapter, NMR spectroscopic characterization of the synthetic structures 
were described along with a short comparison of chemical shifts between the model substrates 
and those reported in the literature for native GGM.
6a,8a,30
 Although many of the chemical shifts 
were found to be in good agreement, several of the uncertainties found in the literature values of 
GGM could be pointed out with the help of the fragments synthesized. Further information 
gained with small molecular models involved the significant downfield shift (6 ppm) of the C-6 
in the -(1→4)-linked mannopyranoside residue when bearing an -(1→6)-galactopyranosyl unit 
vs. the -(1→4)-linked mannopyranoside without any substituents. In addition, several chemical 
shifts not present in the literature were found such as those for the (→6)--Manp-(1→)-fragment. 
Based on the results reported here, it appears possible to study the fine chemical structure of large 
polysaccharides by use of small molecular model substrates. Encouraged by these findings, we 
aim to synthesize the remaining repeating unit of GGM, the partially acetylated mannotriose, and 
continue the NMR spectroscopic comparison of model substrates vs. native GGM. The individual 
fragments will also be submitted for evaluation of their immunological properties. 
 
4 Experimental Section 
Reaction solvents were dried and distilled prior to use when necessary. All reactions containing 
moisture- or air-sensitive reagents were carried out under argon atmosphere. The NMR spectra 
were recorded with Bruker Avance NMR spectrometer operating at 600.13 MHz (
1
H: 600.13 
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MHz, 
13
C: 150.90 MHz). The probe temperature during the experiments was kept at 25 C unless 
indicated otherwise. All products were fully characterized by utilization of the following 1D-
techniques: 
1
H, 
13
C and TOCSY and the following 2D-techniques; DQF-COSY, NOESY, HSQC 
and HMBC by using pulse sequences provided by the manufacturer. Chemical shifts are 
expressed on the  scale (in ppm) using TMS (tetramethylsilane), residual chloroform or 
methanol as internal standards. Coupling constants are given in Hz and provided only once, when 
first encountered. Coupling patterns are given as s (singlet), d (doublet), t (triplet) etc. The 
computational analysis of the 
1
H-NMR of all compounds was achieved by utilization of the 
PERCH NMR software with starting values and spectral parameters obtained from the various 
NMR techniques used.
29
 HRMS were recorded using Bruker Micro Q-TOF with ESI 
(electrospray ionization) operated in positive mode. Optical rotations were measured at 23 C, 
unless otherwise stated, with a Perkin Elmer polarimeter equipped with a Na-lamp (589 nm). 
TLC was performed on aluminium sheets precoated with silica gel 60 F254 (Merck). Flash 
chromatography was carried out on silica gel 60 (0.040-0.060 mm, Merck). Spots were visualized 
by UV followed by charring with 1:4 H2SO4/MeOH and heating. 
 
4.1 General Experimental Procedures 
 
General procedure for glycosylation of peracetylated sugars. To a solution containing 
peracetylated sugar (1 equiv.) and 4 Å MS in CH2Cl2 (3 ml/1 mmol) was added the 
corresponding alcohol (1.5–4 equiv.) and the resulting mixture was stirred for 0.5 h. The mixture 
was then cooled with an ice bath and BF3OEt2 (5–8 equiv.) was added dropwise. The resulting 
mixture was stirred for 0.5 h, brought to r.t. and stirring was continued for 20 h. The reaction 
mixture was diluted with CH2Cl2 (8 ml/ 1 mmol starting material) and poured into ice-cold H2O 
(16 ml/1 mmol starting material) with stirring. The organic phase was separated and washed with 
sat. NaHCO3 (8 ml/1 mmol starting material), H2O (8 ml/1 mmol starting material) and brine (8 
ml/1 mmol starting material). The organic phase was dried over anhydrous MgSO4 or Na2SO4, 
filtered and concentrated. The crude product was purified by column chromatography 
(hexane:EtOAc 4:1) to give the corresponding glycoside.  
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General procedure for deacetylation. To a solution containing the acetylated glycoside (1 
equiv.) in dry MeOH or dry MeOH:THF mixture (2:1) (1 ml/100 mg substrate) was added 
NaOMe (2 equiv.) and the resulting mixture was stirred for 3–20 h at r.t., neutralized with 
DOWEX 50 H
+
-form, filtered and concentrated. The crude product was purified by column 
chromatography (CH2Cl2→CH2Cl2:MeOH, 5:1) to give the corresponding deacetylated 
glycoside. 
 
General procedure for synthesis of 4,6-O-benzylidene acetals. To a solution of the 
corresponding deacetylated glycoside (1 equiv.) in DMF (1 ml/40 mg starting material) was 
added PTSA (10 mol%) and benzaldehyde dimethyl acetal (1 equiv.). The resulting mixture was 
stirred at 60 C and 200 mbar for 2 h and concentrated. To the concentrated residue was added 
H2O (10 ml/500 mg) and formation of a white solid was received. The solid was filtered off and 
washed with H2O (10 ml/500 mg) and Et2O (3 ml/1 g) to obtain the crude product. The crude 
product was either used as such or in some cases further purified by column chromatography 
(CH2Cl2→CH2Cl2:MeOH, 5:1) to give the corresponding 4,6-O-benzylidene-protected-
glycosides. 
 
General procedure for the selective benzylation of the equatorial 3-OH-group. To a solution 
of the corresponding 4,6-O-benzylidene--D-mannopyranoside (1 equiv.) in toluene (4 ml/100 
mg starting material) was added Bu2SnO (1 equiv.) and the resulting mixture was refluxed at 120 
C for 3 h. The reaction mixture was the cooled to r.t. and TBAB (1.05 equiv.), CsF (1.02 equiv.) 
and BnBr (1.04 equiv.) were added and the mixture was again refluxed for 3 h, cooled to r.t., 
diluted with EtOAc (4 ml/100 mg) and sat. NaHCO3 (3 ml/100 mg) and filtered through celite. 
The organic phase was separated and the aqueous phase was extracted with EtOAc (3  3 ml/100 
mg). The combined organic phase was washed with H2O (4 ml/100 mg) and brine (3 ml/100 mg), 
dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by 
column chromatography (hexane:EtOAc 4:1) to give the corresponding 3-O-benzyl derivatives.  
 
General procedure for alkylation of free hydroxyl groups. To a solution containing the 
partially protected glycoside (1 equiv.) in DMF (2 ml/100 mg starting material) was added NaH 
(1.5–1.9 equiv./free OH-group) at 0 C. The reaction mixture was stirred for 15 min, then brought 
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to r.t., stirred for 10 min then the corresponding bromide (1.5 equiv./free OH-group) was added. 
The resulting mixture was stirred for 1–20 h, quenched with MeOH (0.4 ml/ mmol starting 
material), diluted with CH2Cl2 (4 ml/100 mg) and washed with sat. NaHCO3 (3 ml/100 mg). The 
organic phase was separated and the aqueous phase was washed with CH2Cl2 (3  3 ml/100 mg). 
The combined organic phase was washed with brine (3 ml/100 mg), dried over Na2SO4, filtered 
and concentrated. The crude product was purified by column chromatography (hexane:EtOAc 
8:1).  
 
General procedure for silylation of 6-OH group. To a solution containing the corresponding 
glycoside (1 equiv.) in DMF (30 ml/1 g of starting material) was added imidazole (2 equiv.) and 
the reaction mixture was cooled to 0 C. TBDMSiCl (1.1 equiv.) was added and the reaction was 
brought to r.t. and stirring was continued for 24 h. The solution was concentrated, diluted with 
EtOAc (100 ml/3 g) and washed with H2O (80 ml/3 g). The water phase was then extracted with 
EtOAc (3  50 ml/3 g) and the combined organic phase was dried over Na2SO4, filtered and 
concentrated. The crude product was purified by flash chromatography (hexane:EtOAc 3:1) to 
give the protected glycoside. 
 
General procedure for ring-opening of benzylidene acetal to give the 4-OH/6-OBn 
substrate. To a solution containing the corresponding 4,6-O-benzylidene acetal (1 equiv.) in 
CH2Cl2 (6 ml/0.5 g of starting material) was added Et3SiH (5 equiv.), followed by dropwise 
addition of TFA (5 equiv.) at 0  C. The resulting mixture was brought to r.t., stirred for 2 h, 
diluted with EtOAc (20 ml/0.5 g), washed with sat. NaHCO3 (20 ml/0.5 g) and brine (20 ml/0.5 
g), dried over Na2SO4, filtered and concentrated. The crude product was purified by column 
chromatography (hexane:EtOAc 3:2) to give the corresponding acceptor. 
 
General procedure for ring-opening of benzylidene acetal to give the 4-OBn/6-OH 
substrate. To a solution containing the corresponding 4,6-O-benzylidene acetal (1 equiv.) in dry 
DCM (3 ml/0.3 g of starting material) was added pre activated 4 Å molecular sieves and 
borane/tetrahydrofuran complex in THF (5 equiv.). The resulting mixture was stirred for 10 
minutes and Cu(OTf)2 (0.07 equiv.) was added and stirring was continued for 3 hours. The 
reaction mixture was then cooled to 0 C and the reaction was quenched by the addition of Et3N 
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and MeOH. The resulting mixture was concenctrated to give the crude product which was 
purified by column chromatography (hexane:EtOAc 3:21:1) to give the corresponding 
acceptor. 
 
General procedure for insertion of 3,4-O-(2,3-dimethoxybutane-2,3-diyl) protective 
group. To a solution of methyl -D-mannopyranoside (1 equiv.) and CSA (10 mol%) in MeOH 
(10 ml/1 g) was added trimethylorthoformate (4.2 equiv.) and butane-2,3-dione (1.6 equiv.). The 
resulting mixture was refluxed for 19 h and cooled to r.t. The reaction was quenched with Et3N 
and concentrated to give the crude product which was purified by column chromatography (Et2O) 
to give the protected substrate.  
 
General procedure for esterification of/insertion of 4,6-O-di-tertbutyl silylene protective 
group. To a solution containing the partially protected glycoside in pyridine (3 ml/1 g of starting 
material) was added either Ac2O (3 ml/1 g of starting material), BzCl (1.6 ml/1 g of starting 
material) or DTBS(OTf)2 (0.4 ml/0.2 g glycoside). The resulting mixture was stirred for 1–5 h, 
cooled to 0 C, quenched with MeOH (3 ml/1 g of starting material), brought to r.t., diluted with 
CH2Cl2 (50 ml/2 g) and washed with sat. NaHCO3 (50 ml/2 g). In the case of DTBS(OTf)2, the 
remaining hydroxyl groups were simultaneously converted to esters by the addition of BzCl 
according to the procedures above and the work up was conducted accordingly. The organic 
phase was separated and washed with H2O (3  50 ml/3 g), dried over Na2SO4, filtered and 
concentrated. The crude product was purified by flash chromatography chromatography 
(hexane:EtOAc 6:1).  
 
General procedure for -mannosylation. To a solution containing the corresponding donor (1 
equiv.) in dry DCM (4 ml/0.5 mmol of donor) was added at – 60 C (acetone + dry ice) BSP (1.2 
equiv.), TTBP (1.5 equiv.) and Tf2O (1.3 equiv.). The resulting mixture was stirred for 0.5 h 
followed by cooling to –78 C and addition of the corresponding acceptor (1.15 equiv.), 
dissolved in DCM (3 ml/0.5 mmol of acceptor), over a timeperiod of 15 min. The reaction 
mixture was stirred for 2 h and quenched by addition of triethylphosphite (3 equiv.). The reaction 
mixture was stirred for 1 h at –78 C, brought to r.t., diluted with CH2Cl2 (3 ml/100 mg) and 
washed with sat. NaHCO3-solution (3 ml/100 mg). The water phase was separated and extracted 
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with CH2Cl2 (3  3 ml/100 mg). The combined organic phase was washed with brine (3 ml/100 
mg), dried over Na2SO4, filtered and concentrated. The crude product was purified by column 
chromatography (hexane:EtOAc 6:1→4:1→3:2) to give the glycosylated product.  
 
General procedure for glycosylation utilizing NIS/TMSOTf. To a solution containing the 
corresponding donor (1.2 equiv.) and the corresponding acceptor (1 equiv.) in dry DCM (2.5 
ml/100 mg of starting material) was added pre-activated 4 Å molecular sieves and the reaction 
mixture was cooled to –40 C. To the solution was added NIS (1.2 equiv.) and TMSOTf (0.06 
equiv.) and the resulting mixture was stirred for 1.5 hours. The reaction was quenched by the 
addition of sat. NaHCO3-solution, brought to rt, diluted with CH2Cl2 (30 ml/400 mg of substrate) 
and washed with sat. NaHCO3-solution (20 ml/400 mg of substrate). The organic phase was 
separated, dried over Na2SO4, filtered and concentrated. The crude product was purified by 
column chromatography (hexane:EtOAc 3:2) to give the corresponding glycoside. 
 
General procedure for removal of silyl protective groups. To a solution containing the silyl-
protected glycoside (1 equiv.) in dry THF (3 ml/0.2 g starting material) at 0 C was added HF-
pyridine complex (18 l/0.03 mmol of starting material) and the resulting mixture was brought to 
r.t. and stirred for 19 h. The reaction mixture was diluted with CH2Cl2 (30 ml/0.5 g) and 
quenched by addition of sat. NaHCO3-solution. The organic phase was washed with brine (20 
ml/0.5 g), dried over Na2SO4, filtered and concentrated. The crude product was purified by 
column chromatography (hexane:EtOAc 1:1) to give the deprotected glycoside. 
 
General procedure for hydrogenolysis. To a solution of the corresponding protected mannoside 
(1 equiv.) in MeOH or MeOH-EtOAc (10:1, 1 ml/10 mg of starting material) was added Pd/C (10 
% Pd, 2.5 equiv. by mass). The reaction mixture was stirred in an autoclave under H2 (1.4–2.8 
bar) overnight, filtered through celite and concentrated to give the deprotected substrates. 
 
4.2 Analytical Data on Selected Substrates 
The analytical data will here be limited to the substrates prepared while synthesizing the GGM 
model oligosaccharides.
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Thiophenyl 2,3-di-O-benzyl-4,6-O-benzylidene--D-mannopyranosyl-(1→4)-2,3-di-O-acetyl-
6-O-benzyl--D-glucopyranoside (15).  Synthesized from donor 3 (116 mg, 0.24 mmol) and 14 
(110 mg, 0.25 mmol, 1.15 equiv.) according to the general procedure for β-mannosylation to give 
the title compound as a white foam (100 mg, 53 %). TLC: Rf = 0.54 (hexane:EtOAc 3:2). []D = –
46.2 (c 0.2, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  7.51–7.24 (m, 25 H, arom. H), 5.55 (s, 1 
H, CHPh), 5.23 (dd, 1 H, J3,2 = 9.3, J3,4 = 9.4 Hz, H-3), 4.92 (dd, 1 H, J2,1 = 10.1 Hz, H-2), 4.78 
and 4.67 (each d, each 1 H, J = –12.1 Hz, 2-CH2Ph), 4.71 and 4.57 (each d, each 1 H, J = –12.4 
Hz, 3-CH2Ph), 4.68 (d, 1 H, H-1), 4.57 and 4.38 (each d, each 1 H, J = –11.9 Hz, 6-CH2Ph), 4.38 
(d, 1 H, J1,2 = 1.0 Hz, H-1), 4.26 (dd, 1 H, J6a,5 = 4.8, J6a,6b = –10.2 Hz, H-6a), 4.07 (dd, 1 H, 
J4,5 = 9.3, J4,3 = 9.8  Hz, H-4), 3.89 (dd, 1 H, J4,5 = 9.9 Hz, H-4), 3.78 (dd, 1 H, J6b,5 = 10.0 Hz, 
H-6b), 3.68 (dd, 1 H, J6a,5 = 1.9, J6a,6b = –11.2 Hz, H-6a), 3.65 (dd, 1 H, J2,3 = 3.1  Hz, H-2), 
3.52 (dd, 1 H, J6b,5 = 3.5 Hz, H-6b), 3.46 (ddd, 1 H, H-5), 3.40 (dd, 1 H, H-3), 3.13 (ddd, 1 H, H-
5), 2.08 (s, 3 H, 2-OCOCH3), 2.08 (s, 3 H, 3-OCOCH3).  
13
C NMR (150.9 MHz, CDCl3):  170.0 (3-OCOCH3), 169.5 (2-OCOCH3), 138.6–126.0 (arom. 
C), 101.9 (C-1, 1JC-1,H-1 = 157.4 Hz), 101.4 (CHPh), 85.6 (C-1, 
1
JC-1,H-1 = 157.1 Hz), 78.9 (C-5), 
78.6 (C-4), 78.0 (C-3), 76.4 (C-2), 75.3 (C-4), 74.6 (2-CH2Ph), 74.2 (C-3), 73.6 (6-CH2Ph), 
72.4 (3-CH2Ph), 70.2 (C-2), 68.6 (C-6), 68.3 (C-6), 67.4 (C-5), 20.9 (3-OCOCH3), 20.8 (2-
OCOCH3). 
HRMS: m/z calcd. for C50H52O12SNa [M + Na]
+
 899.3077; found 899.3080.  
 
Methyl 2,3-di-O-benzyl-4,6-O-benzylidene--D-mannopyranosyl-(1→4)-2,3-di-O-acetyl-6-O-
benzyl--D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl--D-mannopyranoside (16). 
Synthesized from donor 15 (81 mg, 0.09 mmol, 1.2 equiv.) and acceptor 4 (36 mg, 0.08 mmol) 
according to the general procedure for glycosylation utilizing NIS/TMSOTf to give the title 
compound as a white foam (73 mg, 77 %). TLC: Rf = 0.39 (hexane:EtOAc 3:2). []D = –11.0 (c 
0.1, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  7.47–7.13 (m, 35 H, arom. H), 5.54 (s, 1 H, 
CHPh), 5.06 (dd, 1 H, J3,4 = 9.3, J3,2 = 9.7 Hz, H-3), 4.86 (dd, 1 H, J2,1 = 8.1 Hz, H-2), 4.77 
and 4.63 (each d, each 1 H, J = –12.1 Hz, 2-CH2Ph), 4.77 and 4.51 (each d, each 1 H, J = –11.9 
Hz, 6-CH2Ph), 4.76 and 4.57 (each d, each 1 H, J = –12.5 Hz, 3-CH2Ph), 4.73 (d, 1 H, J1,2 = 1.9 
Hz, H-1), 4.72 and 4.67 (each d, each 1 H, J = –12.4 Hz, 2-CH2Ph), 4.65 and 4.51 (each d, each 1 
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H, J = –12.4 Hz, 3-CH2Ph), 4.65 (d, 1 H, H-1), 4.41 and 4.20 (each d, each 1 H, J = –12.0 Hz, 
6-CH2Ph), 4.33 (s, 1 H, H-1), 4.25 (dd, 1 H, J6a,5 = 4.9, J6a,6b = –10.3 Hz, H-6a), 4.24 (dd, 1 
H, J4,3 = 9.0, J4,5 = 9.7 Hz, H-4), 4.05 (dd, 1 H, J4,5 = 9.3, J4,3 = 9.8 Hz, H-4), 3.87 (dd,1 H, 
J4,5 = 9.8 Hz, H-4), 3.83 (dd, 1 H, J3,2 = 3.2 Hz, H-3), 3.79 (dd, 1 H, J6a,5 = 4.6, J6a,6b = –11.0 
Hz, H-6a), 3.77 (dd, 1 H, J6b,5 = 10.0 Hz, H-6b), 3.74 (dd, 1 H, H-2), 3.69 (dd, 1 H, J6b,5 = 1.9 
Hz, H-6b), 3.66 (ddd, 1 H, H-5), 3.59 (d, 1 H, J2,3 = 3.1 Hz, H-2), 3.40 (dd, 1 H, J6a,5 = 2.1, 
J6a,6b = –11.3 Hz, H-6a), 3.33 (dd, 1 H, H-3), 3.31 (s, 3 H, OCH3), 3.28 (dd, 1 H, J6b,5 = 3.2 
Hz, H-6b), 3.11 (ddd, 1 H, H-5), 3.09 (dd, 1 H, H-5), 1.99 (s, 3 H, 3-OCOCH3), 1.93 (s, 3 H, 
2-OCOCH3).  
13
C NMR (150.9 MHz, CDCl3):  170.0 (3-OCOCH3), 169.7 (2-OCOCH3), 139.3–126.0 (arom. 
C), 102.1 (C-1), 101.3 (CHPh), 100.6 (C-1), 99.2 (C-1), 78.5 (C-4), 78.4 (C-3), 77.9 (C-3), 
76.3 (C-2), 75.8 (C-4), 75.3 (C-4), 75.2 (C-2), 74.6 (2-CH2Ph), 74.4 (C-5), 73.6 (6-CH2Ph), 
73.4 (6-CH2Ph), 73.4 (C-3), 73.0 (2-CH2Ph), 72.5 (C-2), 72.3 (3-CH2Ph, 3-CH2Ph), 71.4 (C-
5), 68.6 (C-6, C-6), 68.0 (C-6), 67.4 (C-5), 54.8 (OCH3), 21.0 (3-OCOCH3), 20.7 (2-
OCOCH3).  
HRMS: m/z calcd. for C72H78O18Na [M + Na]
+
 1253.5086; found 1253.5080.   
 
Methyl 2,3-di-O-benzyl-4,6-O-benzylidene--D-mannopyranosyl-(1→4)-6-O-benzyl--D-
glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl--D-mannopyranoside. Synthesized from 16 (33 
according to the general procedure for deacetylation (column purification solvent: hexane:EtOAc 
1:1) to give the title compound as a white foam (26 mg, 84 %). TLC: Rf = 0.40 (hexane:EtOAc 
1:1). []D = +6.8 (c 1.0, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  7.48–7.12 (m, 35 H, arom. 
H), 5.58 (s, 1 H, CHPh), 4.76 and 4.56 (each d, each 1 H, J = –12.2 Hz, 3-CH2Ph), 4.75 and 
4.70 (each d, each 1 H, J = –12.2 Hz, 2-CH2Ph),  4.75 and 4.61 (each d, each 1 H, J = –12.3 Hz, 
3-CH2Ph), 4.73 and 4.63 (each d, each 1 H, J = –12.3 Hz, 6-CH2Ph), 4.72 (d, 1 H, J1,2 = 1.9 Hz, 
H-1), 4.71 and 4.65 (each d, each 1 H, J = –12.4 Hz, 2-CH2Ph), 4.59 (d, 1 H, J1,2 = 7.9 Hz, H-
1), 4.44 and 4.09  (each d, each 1 H, J = –12.1 Hz, 6-CH2Ph), 4.36 (dd, 1 H, J4,3 = 9.2, J4,5 = 9.6 
Hz, H-4), 4.28 (dd, 1 H, J6a,5 = 5.0, J6a,6b = –10.4 Hz, H-6a), 4.26 (s, 1 H, H-1), 4.15 (dd, 
1H, J4,5 = 9.0, J4,3 = 9.9 Hz, H-4), 3.96 (dd, 1 H, J6a,5 = 4.2, J6a,6b = –11.5 Hz, H-6a), 3.90 
(dd, 1 H,  J3,2 = 3.1 Hz, H-3), 3.88 (dd, 1H, J6b,5 = 10.1 Hz, H-6b), 3.78 (dd, 1 H, J6b,5 = 2.5 
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Hz, H-6b), 3.77 (ddd, 1 H, H-5), 3.73 (dd, 1 H, H-2), 3.54 (dd, 1 H, J4,3 = 8.7, J4,5 = 9.6 Hz, H-
4), 3.52 (dd, 1 H, J3,2 = 9.3 Hz, H-3), 3.48 (d, 1 H, J2,3 = 3.0 Hz, H-2), 3.39 (dd, 1 H, H-3), 
3.38 (dd, 1 H, H-2), 3.29 (s, 3 H, OCH3), 3.29 (ddd, 1 H, H-5), 3.19 (dd, 1 H, J6a,5 = 2.0, J6a,6b 
= –10.8 Hz, H-6a), 3.11 (dd, 1 H, J6b,5 = 3.4 Hz, H-6b), 3.11 (dd, 1 H, H-5).  
13
C NMR (150.9 MHz, CDCl3):  139.0–126.0 (arom. C), 103.4 (C-1), 102.7 (C-1), 101.4 
(CHPh), 99.1 (C-1), 81.3 (C-4), 79.1 C-3), 78.4 (C-4), 78.3 (C-3), 75.7 (C-2), 75.4 (C-4), 
74.9 (C-2), 74.8 (2-OCH2Ph), 74.4 (C-3), 74.1 (C-2), 73.8 (C-5), 73.4 (6-OCH2Ph), 73.3 (6-
OCH2Ph), 73.0 (3-OCH2Ph),  72.8(2-OCH2Ph), 71.9 (3-OCH2Ph), 70.9 (C-5), 69.2 (C-6), 68.0 
(C-6), 67.9 (C-6), 67.4 (C-5), 54.8 (OCH3). 
HRMS: m/z calcd. for C68H74O16Na [M + Na]
+
 1169.4875; found 1169.4862.  
 
Methyl -D-mannopyranosyl-(1→4)--D-glucopyranosyl-(1→4)--D-mannopyranoside (1). 
Synthesized from Methyl 2,3-di-O-benzyl-4,6-O-benzylidene--D-mannopyranosyl-(1→4)-6-O-
benzyl--D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl--D-mannopyranoside (26 mg, 0.02 
mmol) according to the general procedure for hydrogenolysis thereby providing 1 as a colorless 
oil (11 mg, quant.). []D = +11.1 (c 1.0, MeOH). 
1
H NMR (600.13 MHz, D2O, 35 C):  4.76 (d,1 
H, J1,2 = 1.8 Hz, H-1),  4.74 (d 1 H, J1,2 = 1.9 Hz, H-1), 4.52 (d, 1H, J1,2 = 8.0 Hz, H-1), 4.05 
(dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.99 (dd, 1H, J2,3 = 3.3 Hz, H-2), 3.95 (dd, 1 H, J6a,5 = 2.3, J6a,6b 
= –12.3 Hz, H-6a), 3.93 (dd, 1 H, J6a,5 = 2.3, J6a,6b = –12.3 Hz, H-6a), ), 3.90 (dd, 1 H, J6a,5 = 
2.2, J6a,6b = –12.4 Hz, H-6a), 3.86 (dd, 1 H, J3,4 = 9.2 Hz, H-3), 3.85 (dd, 1 H, J4,5 = 9.7 Hz, H-
4), 3.85 (dd, 1 H, J6b,5 = 5.5 Hz, H-6b), 3.73 (dd, 1 H, J6b,5 = 5.2 Hz, H-6b), 3.73 (dd, 1 H, J6b,5 
= 6.4 Hz, H-6b), 3.73 (ddd, 1 H, H-5), 3.69 (dd, 1 H, J3,4 = 8.8, J3,2 = 9.7 Hz, H-3), 3.68 (dd, 1 
H, J4,5 = 9.7 Hz, H-4), 3.64 (dd, 1 H, J3,4 = 9.7 Hz, H-3), 3.61 (ddd, 1 H, H-5), 3.58 (dd, 1 H, 
J4,5 = 9.8 Hz, H-4), 3.41 (ddd, 1 H, H-5), 3.40 (s, 3 H, OCH3), 3.35 (dd, 1 H, H-2). 
13
C NMR (150.9 MHz, D2O, 35 C):  103.0 (C-1, 
1
JC-1,H-1 = 163.5 Hz), 101.2 (C-1, 
1
JC-1,H-1 = 
173.4 Hz), 100.6 (C-1, 1JC-1,H-1 = 160.8 Hz), 79.2 (C-4), 77.2 (C-4), 77.0 (C-5), 75.3 (C-5), 
74.6 (C-3), 73.5 (C-2), 73.4 (C-3), 71.8 (C-5), 71.1 (C-2), 70.1 (C-2), 69.8 (C-3), 67.3 (C-4), 
61.5 (C-6), 60.9 (C-6), 60.8 (C-6), 55.4 (OCH3).  
HRMS: m/z calcd. for C19H34O16Na [M + Na]
+
 541.1745; found 541.1744.  
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Methyl 2,3,4-tri-O-benzyl--D-mannopyranosyl-(1→4)-2,3-di-O-acetyl-6-O-benzyl--D-
glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl--D-mannopyranoside (18). Synthesized from 16 
(70 mg, 0.06 mmol) according to the general procedure for ring-opening of benzylidene acetal to 
give the 4-OBn/6-OH substrate thereby providing the title compound as a colorless oil (60 mg, 85 
%). TLC: Rf = 0.52 (hexane:EtOAc 1:1). []D = –11.5 (c 0.1, CHCl3). 
1
H NMR (600.13 MHz, 
CDCl3):  7.37–7.15 (m, 35 H, arom. H), 5.08 (dd, 1 H, J3,4 = 9.3, J3,2 = 9.7 Hz, H-3), 4.88 (dd, 
1 H, J2,1 = 8.0 Hz, H-2), 4.88 and 4.57 (each d, each 1 H, J = –11.6 Hz, 3-CH2Ph), 4.77 and 4.51 
(each d, each 1 H, J = –11.9 Hz, 6-CH2Ph), 4.76 and 4.62 (each d, each 1 H, J = –12.5 Hz, 2-
CH2Ph), 4.76 and 4.56 (each d, each 1 H, J = –11.1 Hz, 4-CH2Ph), 4.72 (d, 1 H, J1,2 = 1.9 Hz, 
H-1), 4.70 and 4.66 (each d, each 1 H, J = –12.4 Hz, 2-CH2Ph), 4.64 (d, 1 H, H-1), 4.42 and 4.38 
(each d, each 1 H, J = –11.8 Hz, 3-CH2Ph), 4.40 and 4.29 (each d, each 1 H, J = –12.1 Hz, 6-
CH2Ph), 4.38 (s, 1 H, H-1), 4.24 (dd, 1 H, J4,5 = 9.0, J4,3 = 10.0 Hz, H-4), 3.86 (dd, 1 H, J4,5 = 
9.8 Hz, H-4), 3.82 (dd, 1 H, J6a,5 = 4.3, J6a,6b = –11.0 Hz, H-6a), 3.82 (dd, 1 H, J6a,5 = 2.9, 
J6a,6b = –9.9 Hz, H-6a), 3.79 (dd, 1 H, J3,2 = 3.6 Hz, H-3), 3.74 (dd, 1 H, J4,3 = 9.3, J4,5 = 9.5 
Hz, H-4), 3.72 (dd, 1 H, H-2), 3.68 (dd, 1 H, J6b,5 = 1.8 Hz, H-6b), 3.66 (ddd, 1 H, H-5), 3.64 
(dd, 1 H, J6b,5 = 5.8 Hz, H-6b), 3.61 (d, 1 H, J2,3 = 2.9 Hz, H-2), 3.51 (dd, 1 H, J6a,5 = 2.1, 
J6a,6b = –11.4 Hz, H-6a), 3.34 (dd, 1 H, J6b,5 = 3.5 Hz, H-6b), 3.31 (s, 3 H, OCH3), 3.31 (dd, 1 
H, H-3), 3.23 (ddd, 1 H, H-5), 3.19 (ddd, 1 H, H-5), 2.00 (s, 3 H, 3-OCOCH3), 1.93 (s, 3 H, 
2-OCOCH3).  
13
C NMR (150.9 MHz, CDCl3):  170.4 (3-OCOCH3), 169.7 (2-OCOCH3), 139.3–127.1 (arom. 
C), 100.8 (C-1), 100.7 (C-1), 99.4 (C-1), 82.3 (C-3), 78.5 (C-3), 76.0 (C-5), 75.4 (C-4, C-2), 
75.3 (3-OCH2Ph), 75.2 (C-4), 74.9 (C-4), 74.8 (C-5), 74.4 (C-2), 74.0 (2-OCH2Ph), 73.8 (6-
OCH2Ph), 73.6 (6-OCH2Ph), 73.5 (C-3), 72.9 (2-OCH2Ph), 72.6 (C-2, 4-OCH2Ph), 71.6 (C-5), 
71.5 (3-OCH2Ph),  68.7 (C-6), 68.5 (C-6), 62.8 (C-6), 55.0 (OCH3), 21.0 (3-OCOCH3), 20.9 
(2-OCOCH3).  
HRMS: m/z calcd. for C72H80O18Na [M + Na]
+
 1255.5242; found 1255.5249.  
 
Methyl 2,3-di-O-benzoyl-4,6-O-di-tertbutylsilylene--D-galactopyranosyl-(1→6)-2,3,4-tri-O-
benzyl--D-mannopyranosyl-(1→4)-2,3-di-O-acetyl-6-O-benzyl--D-glucopyranosyl-(1→4)-
2,3,6-tri-O-benzyl--D-mannopyranoside (21). Synthesized from acceptor 18 (21 mg, 0.017 
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mmol) and donor 20 (13 mg, 0.020 mmol, 1.2 equiv.) according to the general procedure for 
glycosylation with NIS/TMSOTf thus providing the title compound as a colorless oil (20 mg, 69 
%). TLC: Rf = 0.52 (hexane:EtOAc 3:2). []D = +24.9 (c 1.0, CHCl3). 
1
H NMR (600.13 MHz, 
CDCl3):  8.00–7.10 (m, 45 H, arom. H), 5.73 (dd, 1 H, J2,1 = 3.7, J2,3 = 10.6 Hz, H-2), 
5.54 (dd, 1 H, J3,4 = 3.3 Hz, H-3), 5.28 (d, 1 H, H-1), 5.06 (dd, 1 H, J3,4 = 9.3, J3,2 = 9.7 
Hz, H-3), 4.96 and 4.66 (each d, each 1 H, J = –11.9 Hz, 2-CH2Ph), 4.85 (dd, 1 H, J2,1 = 8.0 
Hz, H-2), 4.77 and 4.56 (each d, each 1 H, J = –12.4 Hz, 3-CH2Ph), 4.74 and 4.48 (each d, each 
1 H, J = –11.9 Hz, 6-CH2Ph), 4.72 (d, 1 H, J1,2 = 2.0 Hz, H-1),  4.71 and 4.65 (each d, each 1 H, J 
= –12.1 Hz, 2-CH2Ph), 4.67 and 4.50 (each d, each 1 H, J = –11.8 Hz, 4-CH2Ph), 4.67 (dd, 1 H, 
J4,5 = 1.0 Hz, H-4), 4.62 (d, 1 H, H-1), 4.37 and 4.25 (each d, each 1 H, J = –12.1 Hz, 6-
CH2Ph), 4.35 and 4.30 (each d, each 1 H, J = –11.8 Hz, 3-CH2Ph), 4.25 (d, 1 H, J1,2 = 0.5 Hz, 
H-1), 4.22 (dd, 1 H, J4,3 = 8.9, J4,5 = 9.6 Hz, H-4), 4.09 (dd, 1 H, J6a,5 = 1.6, J6a,6b = –12.9 
Hz, H-6a), 3.89 (dd, 1 H, J6a,5 = 1.9, J6a,6b = –11.7 Hz, H-6a), 3.86 (dd, 1 H,  J4,3 = 9.1, 
J4,5 = 9.5 Hz, H-4), 3.85 (dd, 1 H, J6b,5 = 1.4 Hz, H-6b), 3.83 (ddd, 1 H, H-5), 3.82 (dd 1 
H, J3,2 = 3.1 Hz, H-3), 3.81 (dd, 1 H, J6b,5 = 4.3 Hz, H-6b), 3.78 (dd, 1 H, J6a,5 = 4.6, J6a,6b = –
10.9 Hz, H-6a), 3.74 (dd, 1 H, J4,5 = 9.7 Hz, H-4), 3.72 (dd, 1 H, H-2), 3.69 (dd, 1 H, J6b,5 = 1.9 
Hz, H-6b), 3.66 (ddd, 1 H, H-5), 3.57 (dd, 1 H, J2,3 = 3.0 Hz, H-2), 3.42 (dd, 1 H, J6a,5 = 2.0, 
J6a,6b = –11.7 Hz, H-6a), 3.31 (s, 3 H, OCH3), 3.30 (dd, 1 H, J6b,5 = 4.2 Hz, H-6b), 3.23 (dd, 1 
H,  H-3), 3.18 (ddd, 1 H, H-5), 3.14 (ddd, 1 H, H-5), 2.10 (s, 3 H, 3-OCOCH3), 1.93 (s, 3 H, 
2-OCOCH3), 1.10 and 0.92 (each s, each 9 H, C(CH3)3). 
 
13
C NMR (150.9 MHz, CDCl3):  170.4 (3-OCOCH3), 169.5 (2-OCOCH3), 166.1 (2-
OCOPh), 165.8 (3-OCOPh), 139.3–126.9 (arom. C), 101.6 (C-1), 100.7 (C-1), 99.2 (C-1), 
98.0 (C-1), 82.2 (C-3), 78.4 (C-3), 75.8 (C-4), 75.4 (C-2), 75.3 (C-4, C-5), 74.6 (2-
OCH2Ph, C-5), 74.2 (C-4), 73.9 (C-2), 73.6 (4-OCH2Ph), 73.5 (6-OCH2Ph), 73.4 (6-
OCH2Ph), 73.1 (C-3), 72.8 (2-OCH2Ph), 72.4 (C-2, 3-OCH2Ph), 71.4 (C-5), 71.1 (C-4), 71.0 
(3-OCH2Ph, C-3), 68.9 (C-6), 68.8 (C-2), 68.6 (C-6), 68.3 (C-6), 67.0 (C-5), 66.8 ( C-
6), 54.8 (OCH3), 27.5 and 27.3 (C(CH3)3), 23.1 and 20.8 (C(CH3)3), 20.8 (3-OCOCH3), 20.7 
(2-OCOCH3). 
HRMS: m/z calcd. for C100H114O25SiNa [M + Na]
+
 1765.7316; found 1765.7266.  
 
 101 
Methyl 2,3-di-O-benzoyl--D-galactopyranosyl-(1→6)-2,3,4-tri-O-benzyl--D-
mannopyranosyl-(1→4)-2,3-di-O-acetyl-6-O-benzyl--D-glucopyranosyl-(1→4)-2,3,6-tri-O-
benzyl--D-mannopyranoside (22). Synthesized from 21 (50 mg, 0.03 mmol) according to the 
general procedure for removal of silyl protective groups to give the title compound as a colorless 
oil (31 mg, 68 %). TLC: Rf = 0.26 (hexane:EtOAc 1:2). []D = +20.8 (c 0.8, CHCl3). 
1
H NMR 
(600.13 MHz, CDCl3):  8.02–7.18 (m, 45 H, arom. H),  5.72 (dd, J2,1 = 3.8, J2,3 = 10.5 Hz, 
H-2),  5.71 (d, 1 H, H-1), 5.65 (dd, 1 H, J3,4 = 3.2 Hz, H-3), 5.12 (dd, 1 H, J3,4 = 9.5, J3,2 
= 9.8 Hz, H-3), 5.09 (dd, 1 H, J2,1 = 8.2 Hz, H-2), 4.81 and 4.51 (each d, each 1 H, J = –11.1 
Hz, 4-CH2Ph), 4.75 and 4.52 (each d, each 1 H, J = –11.9 Hz, 6-CH2Ph),  4.73 (d, 1 H, J1,2 = 2.0 
Hz, H-1), 4.73 and 4.56 (each d, each 1 H, J = –12.5 Hz, 3-CH2Ph), 4.71 (d, 1 H, H-1), 4.70 and 
4.47 (each d, each 1 H, J = –12.1 Hz, 2-CH2Ph), 4.69 and 4.65 (each d, each 1 H, J = –12.4 Hz, 
2-CH2Ph), 4.38 and 4.22 (each d, each 1 H, J = –12.1 Hz, 6-CH2Ph), 4.34 and 4.30 (each d, each 
1 H, J = –11.8 Hz, 3-CH2Ph), 4.29 (dd, 1 H, J4,5 = 1.2 Hz, H-4), 4.25 (s, 1 H, H-1), 4.21 
(dd, 1 H, J4,3 = 8.8, J4,5 = 9.8 Hz, H-4), 4.19 (dd, 1 H, J4,5 = 9.7 Hz, H-4), 4.10 (ddd, 1 H, J5,6b 
= 3.1, J5,6a = 6.3 Hz, H-5), 4.05 (dd, 1 H, J6a,5 = 1.7, J6a,6b = –12.5 Hz, H-6a), 3.89 (dd, 1 
H, J6a,6b = –12.4 Hz, H-6a), 3.83 (dd, 1 H, J3,2 = 3.2 Hz, H-3), 3.80 (dd, 1 H, J6a,5 = 4.6, J6a,6b 
= –11.1 Hz, H-6a), 3.71 (dd, 1 H, H-2), 3.70 (dd, 1 H, H-6b), 3.69 (dd, 1 H, J6b,5 = 1.8 Hz, H-
6b), 3.66 (ddd, 1 H, H-5), 3.64 (dd, 1 H, J4,3 = 9.1, J4,5 = 9.5 Hz, H-4), 3.62 (dd, 1 H, J6b,5 = 
6.1 Hz, H-6b), 3.55 (d, 1 H, J2,3 = 3.0 Hz, H-2), 3.38 (dd, 1 H, J6a,5 = 2.4, J6a,6b = –11.0 Hz, 
H-6a), 3.33 (dd, 1 H, J6b,5 = 2.9 Hz, H-6b), 3.32 (s, 3 H, OCH3), 3.31 (ddd, 1 H, H-5), 3.23 
(dd, 1 H, H-3), 3.19 (ddd, 1 H, H-5), 2.08 (s, 3 H, 3-OCOCH3), 2.00 (s, 3 H, 2-OCOCH3).  
13
C NMR (150.9 MHz, CDCl3):  170.9 (3-OCOCH3), 170.0 (2-OCOCH3), 166.0 (3-OCOPh), 
165.8 (2-OCOPh), 139.3–126.7 (arom. C), 101.0 (C-1, 1JC-1,H-1 = 155.8 Hz, C-1, 
1
JC-1,H-1 = 
162.1 Hz), 99.1 (C-1, 
1
JC-1,H-1 = 168.0 Hz), 97.6 (C-1, 
1
JC-1,H-1 = 173.5 Hz), 82.1 (C-3), 78.4 
(C-3), 76.5 (C-5), 75.7 (C-4), 74.8 (4-OCH2Ph), 74.3 (C-4, C-5), 73.9 (C-4), 73.6 (C-2, 2-
OCH2Ph, 6-OCH2Ph), 73.4 (6-OCH2Ph), 72.8 (C-3), 72.7 (2-OCH2Ph), 72.3 (C-2), 72.0 (3-
OCH2Ph), 71.3 (C-5, C-3), 71.1 (C-5), 71.0 (3-OCH2Ph), 69.8 (C-4), 69.3 (C-2), 69.0 
(C-6), 68.7 (C-6), 67.7 (C-6), 63.2 (C-6), 54.8 (OCH3), 20.9 (3-OCOCH3), 20.8 (2-
OCOCH3). 
 102 
HRMS: m/z calcd. for C92H98O25Na [M + Na]
+
 1625.6295; found 1625.6266.  
 
Methyl -D-galactopyranosyl-(1→6)-2,3,4-tri-O-benzyl--D-mannopyranosyl-(1→4)-6-O-
benzyl--D-glucopyranosyl-(1→4)-2,3,6-tri-O-benzyl--D-mannopyranoside. Synthesized 
from 22 (33 mg, 0.02 mmol) according to the general procedure for deacetylation to give the title 
compound as a white foam (26 mg, quant.). TLC: Rf = 0.38 (MeOH:DCM 1:10). 
1
H NMR 
(600.13 MHz, CD3OD + CDCl3):  7.38–7.18 (m, 35 H, arom. H), 4.89 (d, 1 H, J1,2 = 4.4 Hz, 
H-1), 4.88 and 4.60 (each d, each 1 H, J = –11.9 Hz, 2-CH2Ph), 4.78 and 4.59 (each d, each 1 
H, J = –11.7 Hz, 3-CH2Ph), 4.76 and 4.69 (each d, each 1 H, J = –12.2 Hz, 2-CH2Ph), 4.75 (d, 1 
H, J1,2 = 2.0 Hz, H-1), 4.73 and 4.60 (each d, each 1 H, J = –12.0 Hz, 6-CH2Ph), 4.69 and 4.66 
(each d, each 1 H, J = –12.2 Hz, 4-CH2Ph), 4.50 (d, 1 H, J1,2 = 7.8 Hz, H-1), 4.46 (s, 2 H, 3-
CH2Ph), 4.44 and 4.23 (each d, each 1 H, J = –12.1 Hz, 6-CH2Ph), 4.34 (d, 1 H, J1,2 = 0.7 Hz 
H-1), 4.28 (dd, 1 H, J4,3 = 8.8, J4,5 = 9.6 Hz, H-4), 4.01 (dd, 1 H, J6a,5 = 4.9, J6a,6b = –11.4 Hz, H-
6a), 3.95 (dd, 1 H, J4,5 = 1.2, J4,3 = 3.3 Hz, H-4), 3.91 (dd, 1 H, J6b,5 = 2.1 Hz, H-6b), 3.89 
(dd, 1 H, J3,2 = 3.3 Hz, H-3), 3.86 (dd, 1 H, J3,2 = 9.9 Hz, H-3), 3.81 (ddd, 1 H, H-5), 3.80 
(dd, 1 H, J6a,5 = 2.7, J6a,6b = –11.6 Hz, H-6a), 3.80 (ddd, 1 H, J5,6b = 5.5, J5,6a = 6.3 Hz, 
H-5), 3.77 (dd, 1 H, H-2), 3.75 (dd, 1 H, J6a,6b = –11.1 Hz, H-6a), 3.74 (dd, 1 H, H-6b), 
3.74 (dd, 1 H, J6b,5 = 8.2 Hz, H-6b), 3.74 (dd, 1 H, H-2), 3.68 (dd, 1 H, J4,3 = 9.2, J4,5 = 
9.8 Hz, H-4), 3.64 (dd, 1 H, J2,3 = 3.0 Hz, H-2), 3.52 (ddd, 1 H, H-5), 3.51 (dd, 1 H, J4,3 = 
8.5, J4,5 = 9.9 Hz, H-4), 3.48 (dd, 1 H, J3,2 = 9.4 Hz, H-3), 3.41 (dd, 1 H, H-3), 3.37 (dd, 1 H, 
J6a,5 = 2.2, J6a,6b = –11.1 Hz, H-6a), 3.35 (s, 3 H, OCH3), 3.29 (dd, 1 H, H-2), 3.29 (dd, 1 H, 
J6b,5 = 3.7 Hz, H-6b), 3.18 (ddd, 1 H, H-5).  
13
C NMR (150.9 MHz, CD3OD + CDCl3): 139.5–127.5 (arom. C), 103.6 (C-1), 102.4 (C-1), 
99.6 (C-1), 99.6 (C-1), 82.7 (C-3), 82.0 (C-4), 78.8 (C-3), 76.0 (C-4), 75.7 (C-3, C-2), 75.5 
(2-OCH2Ph), 75.1 (C-4), 74.7(2-OCH2Ph), 74.3 (C-2, C-5), 74.2 (C-5), 74.1 (C-2), 73.9 
(6-OCH2Ph), 73.7 (6-OCH2Ph), 73.2 (4-OCH2Ph), 72.6 (3-OCH2Ph), 72.4 (3-OCH2Ph), 71.8 
(C-5), 71.1 (C-5), 70.3 (C-4, C-3), 69.8 (C-2), 69.7 (C-6), 68.7 (C-6), 67.2 (C-6), 62.1 
(C-6), 55.1 (OCH3).  
HRMS: m/z calcd. for C74H86O21Na [M + Na]
+
 1333.5559; found 1333.5548. 
 
 103 
Methyl -D-galactopyranosyl-(1→6)--D-mannopyranosyl-(1→4)--D-glucopyranosyl-
(1→4)--D-mannopyranoside (2). Synthesized from Methyl -D-galactopyranosyl-(1→6)-
2,3,4-tri-O-benzyl--D-mannopyranosyl-(1→4)-6-O-benzyl--D-glucopyranosyl-(1→4)-2,3,6-tri-
O-benzyl--D-mannopyranoside (24 mg, 0.02 mmol) according to the general procedure for 
hydrogenolysis thereby providing 2 as a colorless oil (12 mg, quant.). []D = +31.8 (c 1.0, 
MeOH). 
1
H NMR (600.13 MHz, D2O, 35 C):  5.00 (d, 1 H, J1,2 = 3.9 Hz, H-1), 4.76 (d,1 
H, J1,2 = 1.8 Hz, H-1), 4.75 (d, 1 H, J1,2 = 0.9 Hz, H-1), 4.52 (d, 1 H, J1,2 = 8.0 Hz, H-1), 4.07 
(dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.99 (dd, 1 H, J4,3 = 1.3, J4,5 = 3.8 Hz, H-4), 3.98 (dd, 1 H, 
J2,3 = 3.4 Hz, H-2), 3.96 (dd, 1 H, J6a,5 = 6.7, J6a,6b = –10.6 Hz, H-6a), 3.95 (dd, 1 H, J6a,5 = 
2.7, J6a,6b = –12.6 Hz, H-6a), 3.95 (dd, 1 H, J5,6a = 3.0, J5,6b = 8.8 Hz, H-5), 3.95 (dd, 1 H, 
J3,2 = 10.2 Hz, H-3), 3.89 (dd, 1 H, J6a,5 = 2.2, J6a,6b = –12.5 Hz, H-6a), 3.86 (dd, 1 H, J3,4 = 
9.6 Hz, H-3), 3.85 (dd, 1 H, J6b,5 = 5.3 Hz, H-6b), 3.85 (dd, 1 H, J4,5 = 9.8 Hz, H-4), 3.81 (dd, 1 
H, H-2), 3.78 (dd, 1 H, J6b,5 = 2.1 Hz, H-6b), 3.74 (dd, 1 H, J6a,6b = –11.1 Hz, H-6a), 
3.74 (dd, 1 H, H-6b), 3.73 (dd, 1 H, J6b,5 = 5.1 Hz, H-6b), 3.73 (ddd, 1 H, H-5), 3.68 (dd, 1 H, 
J4,3 = 9.5, J4,5 = 9.8 Hz, H-4), 3.68 (dd, 1 H, J4,3 = 9.7, J4,5 = 9.9 Hz, H-4), 3.67 (dd, 1 H, 
J3,2 = 10.0 Hz, H-3), 3.65 (dd, 1 H, H-3), 3.62 (ddd, 1 H, H-5), 3.61 (ddd, 1 H, H-5), 3.40 (s, 
3 H, OCH3), 3.34 (dd, 1 H, H-2). 
13
C NMR (150.9 MHz, D2O, 35 C): 103.0 (C-1, 
1
JC-1,H-1 = 163.3 Hz), 101.2 (C-1, 
1
JC-1,H-1 = 
172.5 Hz), 100.8 (C-1, 1JC-1,H-1 = 159.4 Hz), 98.9 (C-1, 
1
JC-1,H-1 = 170.6 Hz), 79.6 (C-4), 
77.3 (C-4), 75.1 (C-5, C-5), 74.7 (C-3), 73.5 (C-2, C-3), 71.8 (C-5), 71.6 (C-3), 71.1 (C-
2), 70.1 (C-2), 70.0 (C-5), 69.9 (C-4, C-3), 69.1 (C-2), 67.2 (C-4), 66.8 (C-6), 61.8 (C-
6), 60.9 (C-6), 60.8 (C-6), 55.4 (OCH3).  
HRMS: m/z calcd. for C25H44O21Na [M + Na]
+
 703.2273; found 703.2273.  
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Episode 3: Synthesis of Glycoconjugates 
 
 
 
Glycoconjugate is a general term for a large group of structures containing a glycone 
permanently linked to another chemical species (some examples are shown above). There has 
always been much interest in the synthesis of these compounds and their mimics due to the wide 
occurrence of such compounds in nature and their biological applications. This chapter focuses 
on the synthesis of several biologically relevant classes of glycoconjugates including saponins, 
lignan glycosides and anthracyclines. In addition, some key guidelines for the NMR 
spectroscopic characterization of glycoconjugates will be provided. 
 
 
 
 
 
 
This chapter is based on the previously published papers: F. S. Ekholm, P. Eklund, R. Leino, “A 
Short Semi-Synthesis and Complete NMR-Spectroscopic Characterization of the Naturally 
Occurring Lignan Glycoside Matairesinol 4,4-di-O--D-glucoside”, Carbohydr. Res. 2010, 
345, 1963–1967; F. S. Ekholm, G. Schneider, J. Wölfling, R. Leino, “Synthesis of a Small 
Library of Estradiol-Based Glycosteroid Mimics Containing a Modified D-Ring”, Eur. J. 
Org. Chem. 2011, 1064–1077; F. S. Ekholm, G. Schneider, J. Wölfling, R. Leino, “An 
Approach to the Synthesis and Attachment of Scillabiose to Steroids”, Steroids 2011, 76, 
588–595; F. S. Ekholm, L. Lagerquist, R. Leino, “Stereo- and Regioselective Glycosylation of 
4-Deoxy--Rhodomycinone”, Carbohydr. Res. 2011, 346, 858–862. 
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1 Introduction 
Glycoconjugate is a general term encompassing many classes of compounds including 
glycoproteins, glycopeptides and glycolipids.
1
 More precisely, glycoconjugates consist of a 
glycone part permanently attached to an aglycone core. In this Episode, both the term 
glycoconjugate and the discussion will be limited mainly to aglycones consisting of lignans, 
tetracyclines and steroids.
2
 These classes of compounds are widely distributed and common in 
nature.
2,3
 In addition to their wide occurrence, many of the glycoconjugates isolated from plant 
and animal species possess interesting biological properties.
2,3,4
 Classical examples of such 
properties include the cytotoxic activities of anthracyclines and the physiological and 
pharmacological effects of cardenolides and saponins.
5
 The overall biological activity of these 
compounds are usually connected to the nature of the molecule as a whole (containing both the 
glycone and the aglycone).
6
 The isolation and synthesis of glycoconjugates (and mimics thereof) 
has always been an important topic in carbohydrate chemistry due to the biological significance 
of such compounds. The isolation of intact glycoconjugates from their natural sources is often 
difficult due to the small quantities of material present in the biological matrix and the unstable 
nature of the glycosides towards acidic extractions. Chemical synthesis is, therefore, usually the 
preferred choice for large scale preparation of glycoconjugates after the initial identification of a 
new glycoconjugate with biological potential. Accordingly, one of the main goals of this research 
field is the synthesis of complex compounds for biological evaluations and to simultaneously 
increase the understanding on their biological interactions, functions and properties.  
The synthesis of glycoconjugates can be achieved by two slightly different pathways. The first 
route to glycoconjugates, and a long-time provider of new chemical reactions, is total synthesis.
7
 
This approach offers several benefits as the construction of partially protected aglycones can be 
achieved from readily available starting materials. As a result, difficult glycosylation reactions 
may be performed at early stages in the synthetic route simultaneously eliminating the difficulties 
associated with regioselective glycosylations of unprotected aglycones. On the other hand, it is 
often expensive and time-consuming to perform the tedious synthetic transformations usually 
required for total synthesis of naturally occurring aglycones.  
The second route to glycoconjugates involves the regio- and stereoselective glycosylation of 
isolated aglycones (either partially protected or unprotected) in cases where large amounts of 
aglycone are accessible.
8
 If the actual aglycone can be isolated on large scale, such procedure is 
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often to be preferred over total synthesis routes despite that the aglycone can not be modified 
with similar freedom. There are many challenges associated with the glycosylation of aglycones. 
First, aglycones may contain several sites of glycosylation of which only a few might be 
glycosylated in the naturally occuring product. In addition, aglycones usually contain many other 
functional groups which may increase the steric hindrance near the glycosylation site. When 
combining steric hindrance with the low reactivity of secondary alcohols (often the glycosylation 
sites in aglycones), problems associated with the efficiency of glycosylation reactions may arise.  
In this Episode, methods for the glycosylation of aglycones are addressed and discussed, 
culminating in the synthesis of various glycoconjugates including glycosteroids, saponin mimics, 
lignan glycosides and glycosylated anthracyclines.
8a,9
 In addition, potential biological 
applications and some key-guidelines concerning the NMR spectroscopic characterization of 
these glycoconjugates will be presented.  
 
2 Results and Discussion 
2.1 Synthesis of Estradiol-Based Glycosteroid Mimics 
Glycosteroids are a class of naturally occurring compounds consisting of a lipophilic steroid part 
and a hydrophilic carbohydrate moiety. Recent advances in glycobiology have revealed that these 
glycoconjugates play important biological roles ranging from prevention of bacterial infections to 
manipulation of immune responses.
10
 In addition, it has been reported previously that amphiphilic 
glycosteroids may enhance the transport of polar molecules across cellular membranes.
1a
 Steroids 
are also known to be more active in certain areas of the human body, e.g., estradiol activities have 
been reported not only in the female reproductive system but also in locations ranging from the 
lungs and brain to the bones.
11 
Combining these two principles would potentially provide 
molecules capable of increasing the transport of polar molecules across membranes at partially 
selective locations in the body. Such molecules could also be considered as primitive delivery 
systems. In this thesis, the interest in glycosteroids is partially connected to these applications. 
The most important part of a delivery system would naturally be the steroid backbone. In this 
work, an estradiol based steroid mimic was selected as a suitable backbone structure. To diminish 
or remove the apparent side effects caused by estradiol itself, modifications to the steroid 
backbone were planned. It is well known that the hydroxyl group at C-3 is important for the 
pharmacological activity of steroids.
12
 In order to prevent these undesirable pharmacological 
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side-effects, this functionality should be permanently blocked when aiming at transport 
molecules. Glycosylation of this hydroxyl group cannot be considered as permanent protection 
since glycosides are generally cleaved under physiological conditions.  
 
 
Figure 1. Chemical structures of the steroid acceptors 1–3. 
 
The steroid acceptors 1–3 used in the present study were constructed from the common precursor 
16,17-seco-3-methoxyestra-1,3,5(10),16-tetraene-13α-carbaldehyde. This precursor can be 
prepared from estrone 3-methyl ether in four steps by Grob fragmentation, as the key 
transformation, as reported previously by Schneider and coworkers.
13
 Conveniently, this 
procedure allows the protection of the hydroxyl group at C-3 as a methyl ether during the early 
stages of the synthesis. Steroid acceptor 1 was synthesized from this precursor in almost 
quantitative yield by reduction with NaBH4 in ethanol.
14
 Compounds 2 and 3 can be synthesized 
as a separable mixture from the common precursor by metal-mediated allylation.
15
 Additional 
modifications to the steroid backbone were desirable in order to minimize the possible 
pharmacological side-effects. The D-ring of the steroid was chosen as the site for further 
modifications which is obvious when examining the structures of the steroid acceptors in Figure 
1. In several previous reports, large variations in the steroid D-ring were tolerated while retaining 
the biological role and mode of action of steroids.
16 
Consequently, in the present study, it was 
interesting to evaluate the effects of acyclic versus cyclic D-rings. In addition, the D-ring 
hydroxyl group in steroids 1–3 was subjected to further modifications by glycosylation. 
Modification by glycosylation should influence the solubility of these molecules and the overall 
selectivity of the system as also mentioned in the introduction. Glycosylation of steroids is 
challenging due to the low reactivity of secondary alcohols.
6
 As a result, several earlier reported 
procedures on steroid glycosylation suffer from moderate yields.
17
 In the present study, the 
methyl group (C-18) close to the glycosylation center increases the steric hindrance, thereby 
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making highly selective and efficient glycosylation reactions an even greater challenge. Of the 
steroid acceptors investigated here, compound 1 contains a primary hydroxyl group in contrast to 
the secondary hydroxyl groups in acceptors 2 and 3. It was accordingly selected as the model 
substrate for initial glycosylation screening (Figure 1). 
 
 
Figure 2. Chemical structures of the carbohydrate donors 4–10. 
 
Several glycosyl donors have been investigated earlier for glycosylation of steroids.
2b,6
 In light of 
our previous experience with thio-donors,
18
 these were selected as a starting point for the initial 
screening of glycosyl donors. Given that all the acceptors 1–3 contain alkene functionalities, the 
commonly employed NIS/TfOH promoter system was not feasible for activation of the thio-
donors.
19
 Instead, the attention was turned to the BSP/TTBP/Tf2O activation protocol developed 
by Crich and coworkers
20
 (utilized earlier at our laboratory as shown in Episode 1) for activation 
of glycosyl donors 4 and 5. In both cases, however, moderate yields (~50%) were observed. 
Furthermore, in glycosylation with 5, the selectivity was fairly low (β/α, 4:1). In addition to the 
moderate efficiency and poor selectivity of this protocol, the major drawback of this approach is 
the need for a four-fold molar excess of the promoter over the substrate. Consequently, the thio-
donors were abandoned and the search for a different glycosylation strategy was initiated.  
Another class of frequently utilized glycosyl donors are based on imidates, commonly 
trichloracetimidates (TCA).
21
 In several previous studies, acetylated TCA-donors have been used 
for the glycosylation of steroids.
6
 In Episode 1, BF3·OEt2 was found as the best promoter for 
TCA-donor in the glycosylation of cyclohexanol.
18b
 With steroids sharing the lipophilic features 
of cyclohexanol, this promoter was intitially tested in the glycosylation of 1 with donor 6. 
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Unfortunately, in the case of 1, the use of BF3·OEt2 resulted in decomposition of starting 
materials and failed to provide the desired target molecule. Next, trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) was tested as a promoter. TMSOTf has been successfully 
applied as a promoter in glycosylation reactions with imidate donors previously.
2b,6,22
 Under 
similar reaction conditions, with TMSOTf as a promoter, the glycosylation gave a mixture of 
three components which were isolated and identified by NMR spectroscopic analysis as the target 
compound (33%), the acetylated acceptor (33 %) and a mixture of partially deacetylated 
glycosteroids (33 %).
23
 In order to circumvent these problems and to retain the beneficial 
properties of neighboring group participation displayed by ester groups at C-2, the acetyl 
protecting groups were exchanged to the slightly bulkier benzoyl groups.  
 
 
Scheme 1. Reaction conditions: i) TMSOTf, corresponding acceptor (1–3), corresponding donor 
(4–10), –20 C, CH2Cl2, 1.5–2 h, 11 (91 %), 12 (90 %), 13 (92 %), 14 (88 %), 15 (not determined 
due to purification difficulties), 16 (77 %), 17 (not determined due to purification difficulties), 18 
(79 %); ii) NaOMe, MeOH/THF, 1:1, r.t., 3–20 h, 19 (90 %), 20 (quant.), 21 (88 %), 22 (quant.), 
23 (85 % over two steps), 24 (77 %), 25 (85 % over two steps), 26 (91 %).
24
 
 
Under unoptimized reaction conditions with 0.2 equiv. of TMSOTf as promoter in 
dichloromethane at –20 °C, the reaction between 1 and 7 proceeded in 91% yield. Applying 
similar reaction conditions to the sterically more demanding acceptor 3 did not result in any 
significant decrease in yield. In comparison to the activation strategy utilized with thio-donors (4 
equiv. of promoters), this glycosylation protocol is much more benign and more efficient. After 
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this successful first reaction, donors 8–10 were prepared according to slightly modified literature 
procedures (Figure 2).
25
 The glycosylation reactions were then performed by applying the same 
protocol as in the initial screening with the results summarized in Scheme 1. Interestingly, donors 
9 and 10 gave slightly lower yields than donors 7 and 8. This is most likely due to the less 
intrusive arrangement of the substituents at C-1 and C-2 which, in the case of 7 and 8, occupy an 
axial–axial relationship. Furthermore, glycosylation of the more sterically hindered acceptors 2 
and 3 with 9 and 10 resulted in lower yield, probably due to the equatorial 2-OBz group which 
apparently increases the steric bulk near the reacting center. Bearing only ester protective groups, 
the glycosteroids could easily be deprotected under Zemplén conditions with NaOMe in 
MeOH/THF.
26
 Tetrahydrofuran was required as co-solvent due to the amphiphilic character of 
the molecules in the deprotected state. All deprotections proceeded in good to excellent yields 
(77–99 %). Due to the amphiphilicity of the final products (Rf values 0.4–0.7 in MeOH/CH2Cl2, 
1:5), they were also amenable to purification by column chromatography thus enabling a simple 
method for removing the methyl benzoate formed during the final deprotection step. 
 
 
Scheme 2. Reaction conditions: i) Grubbs 2
nd
 generation catalyst (10 mol%),  reflux 6 h, then r.t. 
overnight, CH2Cl2, 27 (97 %), 28 (quant.), 29 (72 %), 30 (75 %); ii) NaOMe, MeOH/THF, 1:1, 
r.t., 3–20 h, 31 (98 %), 32 (quant.), 33 (82 %), 34 (90 %).27 
 
With the glycosteroids 12, 14, 16, and 18 each possessing two terminal double bonds at hand, 
their application in ring-closing olefin metathesis (RCM) was investigated next.
28
 RCM is an 
excellent method for creating medium-sized rings as exemplified by the large number of papers 
dealing with this subject.
29
 Since the reaction produces two molecules (substrate and ethylene) 
from one and is driven by an increase in entropy, the initial reactions were performed at room 
temperature using Grubbs 2
nd
 generation catalyst. At this temperature the reaction failed to yield 
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the desired product and, consequently, the mixture was refluxed in CH2Cl2 for six hours and 
allowed to stand overnight. These conditions proved successful and the products were isolated in 
up to 97% yields (Scheme 2). With the manno- and rhamnosylated steroids the yields were nearly 
quantitative, whereas in the case of gluco- and galactosteroids the yields were slightly lower 
(~77%). The difference in yields is possibly due to the equatorial benzoyl group at C-2 in the 
latter two substrates which increases the steric bulk near the reacting center. As a logical 
extension, an evaluation of the possibility for a RCM-glycosylation sequence was performed. 
Unfortunately, glycosylation of the more sterically hindered ring-closed products decreased the 
yield significantly and this approach was abandoned already during the early stages of this work. 
In addition, RCM reactions directly on the debenzoylated substrate would have been interesting 
to study. Such an approach would, however, require a non-conventional metathesis catalyst 
instead of the commercially available Grubbs catalyst and was therefore not investigated further 
in the present study. The ring-closed products were instead smoothly deprotected under 
conditions described previously thereby providing the glycosteroids 31–34.  
To summarize, several glycosyl donors were investigated for the glycosylation of steroids. In this 
work, benzoylated TCA-donors proved superior. The benzoylated TCA-donors prepared were, as 
shown above, utilized in the synthesis of a small library of amphiphilic glycosteroids. The 
amphiphilic character of the molecules depends on both the number of hydroxyl groups in the 
sugars and the acyclic vs. cyclic structure of the D-ring. As a logical next step, the procedures 
developed for the synthesis of glycosteroids in the current section were evaluated in the synthesis 
of more challenging targets. In the following sections, the glycosylation of several relevant 
aglycones are described based heavily on the procedures developed during this initial screening 
of glycosyl donors. 
 
2.2 Coupling of Scillabiose to Model Steroid 
Scillabiose (4-O-(-D-glucopyranosyl)--L-rhamnopyranoside) is a frequently occuring 
disaccharide glycone in natural steroids.
30 
In addition to the presence of scillabiose in steroids, a 
closely related glycon containing glucuronic acid instead of glucose has been found in molecules 
isolated from Acrosiphonia centralis, Ulva lactuca and Klebsiella.
31
 Two well known saponins 
bearing the scillabiose glycone (Figure 3) are hellebrin, a potent cytotoxic compound isolated 
from Helleborus niger, and transvaalin, a constituent of herbal medicines isolated from Urginea 
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sanguinea.
30a,30d,32
 In addition to the biological properties mentioned above, hellebrin displays T-
cell suppressive effects which can be applied in immunoregulation. Transvaalin in turn, has been 
utilized for the purification of blood, removal of abdominal pain and as abortifacient.
30d,32,33
 Due 
to the occurrence of scillabiose and closely related compounds in several naturally occurring 
biomolecules and pharmaceutically active species, we became interested in developing a 
synthetic route for the attachment of scillabiose to steroids. In general, a convergent route is 
usually preferred as it minimizes the amount of synthetic steps with the incorporated aglycone 
simultaneously decreasing the risk of altering sensitive functionalities in the aglycone.  
 
 
Figure 3. Natural products containing the scillabiose glycon: hellebrin (left) and transvaalin 
(right). 
 
Synthesis of saponins has received significant attention in recent years.
34 
As mentioned in the 
previous section, the utilization of benzoylated imidate donors in the glycosylation of steroids 
was superior in terms of efficiency and minimal waste generation.
9a,22
 Additional advantages of 
imidate donors are the simple and rapid methods applied for their preparation.
21a
 Therefore, they 
were also implemented in the current synthetic approach. While the synthesis of the methyl 
glycoside of scillabiose has been published earlier,
35
 glycosylations utilizing scillabiose based 
donors are scarce in the literature and, apparently, only one report concerning the subject has 
emerged to date.
36
 In that work, the thio donor utilized resulted in an : mixture of the product.  
Overall, in the synthesis of glycosylated biomolecules, minimization of the number of synthetic 
steps incorporating the aglycone is preferred. This is mainly to ensure that reactive centers in the 
aglycone moiety remain unaltered. Therefore, wherever possible, glycosylations by convergent 
routes are preferred over linear ones.
2a,37
 Furthermore, protective groups should essentially be 
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removable in one step and under mild conditions in order to avoid multiple deprotection 
sequences which may affect sensitive functional groups. Based on these requirements an 
approach for the preparation of a scillabiose glycosyl donor (containing protective groups 
removable in a single step) was deviced.  
 
 
Scheme 3. Synthesis of donors 38 and 39: i) 9 (see previous section), TMSOTf, CH2Cl2, 1.5–2 h, 
85%; ii) 80% AcOH, 80 C, 5 h, 96%; iii) BzCl, pyridine, 4 h, 89%; iv) 1. NBS, Acetone:H2O 
10:1, 1 h, 92%; 2. DBU, Cl3CCN, CH2Cl2, 0 C, 1.5 h, 77%. 
 
The synthesis of donors 38 and 39 is illustrated in Scheme 3. The present strategy was based on 
the preparation of a thiophenyl rhamnoside acceptor. The thiophenyl functionality has been 
shown to be stable under various reaction conditions and, furthermore, it can be selectively 
activated in the presence of other functionalities and under mild conditions, thereby making it an 
excellent anomeric protective group.
38 
In order to minimize the protective group manipulations 
needed,
 
the cis C-2 and C-3 hydroxyl groups were protected in one step
 
as an isopropylidene 
acetal.
39
 Conveniently, the hydroxyl group
 
at C-4 remains untouched thus providing acceptor 35. 
In
 
the previous synthesis by Bebault and Dutton, the formation of this isopropylidene acetal
 
was 
followed by an acetylation/deacetylation sequence at C-4.
35
 These two steps are, however, not 
necessary
 
for preparation of acceptor 35 as also shown in a more recent
 
study.
40 
In short, the 
synthesis of acceptor 35 commenced by
 
slightly modified literature procedures involving 
BF3·OEt2 promoted
 
glycosylation of peracetylated L-rhamnose with thiophenol,
41
 followed by 
deacetylation under Zemplén conditions
26
 and,
 
as the final step, formation of the 2,3-O-
isopropylidene acetal in
 
61% overall yield. Glycosylation of acceptor 35 with donor 9 (see page 
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111) using
 
TMSOTf as promoter provided the disaccharide 38 in 85% isolated
 
yield.
2a,9a,22
 While 
compound 38 could, in principle, be used
 
as a glycosyl donor, a similar donor was shown to yield 
a mixture of products with poor selectivity in previous work.
36
 In addition, removal of the 2,3-O-
isopropylidene acetal requires harsh conditions which may affect sensitive functionalities in 
biomolecules.
42
 Furthermore, in contrast to ester protective groups at C-2, the isopropylidene 
acetal does not enhance the α-selectivity in the glycosylation. For enhancing the beneficial 
properties, in particular neighboring group participation displayed by ester protective groups, the 
isopropylidene acetal was cleaved under acidic conditions (80 % AcOH) at 80 C providing 37 in 
96% yield. The newly formed hydroxyl groups were benzoylated thus providing thiodonor 38 in 
89% yield. As mentioned above, the best results in glycosidation of steroid alcohols were 
obtained by TMSOTf promoted activation of an imidate donor.
9a
 Consequently, in the present 
study, the scillabiose thiodonor was converted to an imidate donor. The thiophenyl group was 
activated with NBS, hydrolyzed,
43
 and the newly formed hemiacetal converted to the 
corresponding imidate with DBU and trichloroacetonitrile
21a 
thus providing donor 39 in 71% 
isolated yield over two steps as shown in Scheme 3. 
With donors 38 and 39 synthesized, the focus was shifted to the glycosylation study. 3-
Hydroxy-androst-5-en-17-one (40) was selected as a model substrate for the glycosylation 
reaction. This steroid carries identical stereochemistry (at C-3, C-8, C-9, C-13 and C-14) to the 
aglycones of transvaalin and hellebrin and was therefore considered to be a suitable model.
30a,30d 
In order to explore the suitability of TMSOTf-promoted glycosylation with imidate donors in the 
present study, the monosaccharide donors 8 and 9 (see page 111) were first evaluated. With both 
of these donors the glycosylations proceeded smoothly and the unprotected glycosteroids 44 and 
45 were after deprotection under Zemplén conditions
26 
isolated in high yields (77–89% over two 
steps). Next, the possibility of utilizing donor 38 in the glycosidation was explored. The use of 
this donor would be desirable as it shortens the reaction sequence by two steps. Due to the 
presence of an alkene functionality in steroid 40, the commonly employed activation procedure 
featuring NIS/TfOH was yet again avoided.
38
 Instead, activation of the thioglycoside using the 
methodology of Crich was employed (for a more detailed discussion see Episode 1).
44
 A 
moderate conversion (∼50%) was obtained by the use of this protocol. In order to evaluate and 
compare the reactivity of scillabiose donors 38 and 39, the imidate donor was tested next. When 
the glycosylation reaction was performed with donor 39, following the standard activation 
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protocol, saponin 43 could be isolated in 88% yield. One step debenzoylation under Zemplén 
conditions provided the deprotected glycosteroid 46 in 90% yield. THF was required as co-
solvent in the deprotection due to the amphiphilic nature of the deprotected molecule. Column 
purification of the final compound was once again possible and enabled a simple way of 
removing the methyl benzoate formed during the deprotection. 
 
 
Scheme 4. Glycosylation of model steroid 40: i) Donor 8, 9 or 39, TMSOTf, –20 C, 1.5–2 h, 
CH2Cl2, 41 (not determined due to purification difficulties), 42 (not determined due to 
purification difficulties), 43 (88 %); ii) NaOMe, MeOH:THF 1:1, 3–20 h, 44 (89 % over two 
steps), 45 (78 over two steps), 46 (90 %). 
 
To summarize, a viable approach to the synthesis and attachment of scillabiose to steroids was 
developed. This convergent approach may also be applied to the synthesis of other naturally 
occurring saponins sharing this glycone.
30,31
 Due to the potent cytotoxic activity of hellebrin the 
compounds prepared in this section were also screened for cytotoxic activity, being however, not 
toxic.
45
 After demonstrating the efficiency of benzoylated TCA-donors in the glycosylation of 
steroids, the study was continued by investigating their applicability to other aglycones of 
biological interest. In the next section, the applicability of the benzoylated TCA-donors for the 
regioselective glycosylation of the anthracycline 4-deoxy--rhodomycinone is described.  
 
2.3 Stereo- and Regioselective Glycosylation of 4-Deoxy--rhodomycinone 
Anthracyclines are compounds consisting of a sugar residue attached to a tetracyclic aglycone 
core. Anthracyclines, such as doxorubicin and daunorubicin (Figure 4), possess many 
biologically and clinically important properties and have found widespread use in the treatment 
of leukemia, breast carcinomas and other solid tumors.
46
 While bearing large potential, the 
undesired side-effects (such as myelosuppression, gastrointestinal disorders and cumulative 
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cardiotoxicity) have limited the applications of anthracyclines.
47 
In order to reduce the number of 
side effects associated with anthracyclines, a vast number of such compounds have been prepared 
simultaneously providing advances in glycosylation methodologies, isolation processes and 
medical properties.
48
 By these routes, both naturally occurring and synthetically modified 
anthracyclines have been produced.
49
 Suprisingly, several of the glycosylation methodologies 
developed suffer from poor selectivites, low efficiencies and long reaction times.
50
 Therefore, it 
was of interest to screen the imidate donors prepared earlier (see page 111) in the glycosylation 
of anthracyclines. It should be noted, that the ester protective groups at C-2 (in the donors 
described here) influence the stereoselectivities of the glycosylation reactions. In many of the 
earlier reports where poor selectivities were observed, 2-deoxy sugar derivatives of 
anthracyclines were targeted. Nevertheless, circumventing the stereoselectivity issues and 
generating a method with increased efficiency and shorter reaction time would still be appealing 
for the industrial production of similar and related pharmaceuticals. 
 
 
Figure 4. Chemical structures of the two well known anthracyclines doxorubicin and 
daunorubicin. 
 
4-Deoxy--rhodomycinone (47) was selected as a suitable model substrate for evaluation of 
benzoylated TCA-donors.
51
 4-Deoxy--rhodomycinone resembles rhodomycinone which is an 
intermediate in the biosynthetic pathway leading to doxorubicin.
52
 Suprisingly, imidate donors 
have not been applied to the glycosylation of tetracyclines as frequently as bromo-, chloro-, thio- 
and glycal donors.
50b,53 
Nevertheless, they have been applied extensively in the glycosylation of 
other biomolecules as also discussed in previous sections of this Episode.
2a,9a
 The regioselective 
glycosylation of 47 could, in principle, be considered challenging due to the presence of four free 
hydroxyl groups in the aglycone structure. It is, however, much less challenging since two of 
them are aromatic and one is sterically hindered by an alkyl group. In the present work, 
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benzoylated imidate donors were considered to be better than acetylated imidate donors due to 
the larger size of the benzoyl groups in comparison to acetyl groups. This could, potentially, 
enhance the regioselectivity of the glycosylation. As mentioned previously, the ester protective 
groups at C-2 in the donors increase the overall stereoselectivity of the glycosidation by 
neighboring group participation.
54 
In an initial experiment, TMSOTf and BF3OEt2 were screened 
as promoters. The weaker Lewis acid TMSOTf proved to be superior and was thus utilized as a 
promoter in the remaining experiments. Following the standard activation protocol by the inverse 
glycosylation approach using only 0.2 equivalents of TMSOTf as a promoter and 1.1 equivalents 
of donor 9 (Figure 2), 7-O-glucosylated 4-deoxy--rhodomycinone was isolated in 96 % yield. 
Intrigued by these initial results, imidate donors 7, 8, and 10 (Figure 2) were next evaluated in the 
glycosylation reaction. The reactions proceeded in 93–98 %  conversions (based on NMR) and 
the results are shown in Scheme 5. The products were simply filtered after the glycosylation 
reaction and utilized as such in the final deprotection step.  The regioselectivities of the products 
were easily determined from the HMBC correlation between H-7 and C-1. The 
stereoselectivities of the reactions were determined based on the H-1–H-2 coupling constants 
and compared to literature values.
55
 Deprotection under Zemplén conditions proceeded smoothly 
to give the desired compounds in high yields.
26
 It was noticed that upon addition of sodium 
methoxide the solution turned purple and upon neutralization back to red thus providing a simple 
way of monitoring the conditions in the final deprotection. Owing to the amphiphilic character of 
the deprotected molecules, the compounds could be purified by column chromatography thereby 
providing a simple method for removing the methyl benzoate formed as a side product in the 
final deprotection. 
Based on a literature survey, this is the first example of benzoylated imidate donors being applied 
to the glycosylation of anthracyclines and based on the successfully prepared set of 
anthracyclines presented here,
 
such donors may find further use in the glycosylations of similar 
compounds. Furthermore, the methodology described herein utilizes only 1.1 equiv. of donor and 
0.2 equiv. of promoter as compared to other procedures where 2–3 equiv. of both donor and 
promoter have been applied thus making it more environmentally benign compared with the 
earlier reported methods. 
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Scheme 5. i) 1. TMSOTf, –40 C, CH2Cl2, 2. corresponding donor, 2 h, 48 (96 %), 49 (not 
determined), 50 (not determined), 51 (not determined); ii) NaOMe, MeOH/THF, 1:1, r.t., 3–20 h, 
52 (97%), 53 (86 % over two steps), 54 (90 % over two steps), 55 (92 % over two steps). 
 
To summarize, benzoylated imidate donors were found to be suitable alternatives, in comparison 
with other carbohydrate donors, for glycosylation of anthracyclines. The method described herein 
and utilized in the presented synthesis of glycosylated anthracyclines should prove valuable to 
others working on similar compounds due to its high efficiency and operational simplicity. The 
synthesized compounds will in future work be screened for biological activity.  
With benzoylated TCA-donors performing well in the glycosylation of several of the above 
mentioned aglycones, it was desirable and logical to incorporate the use of these donors also in 
the synthesis of naturally occurring compounds, not only natural product mimics. The naturally 
occurring lignan glycoside MDG (matairesinol diglucoside) was chosen as suitable target and the 
semi-synthesis of this compound will be presented next. 
 
2.4 Semi-Synthesis of the Naturally Occurring Lignan Glycoside Matairesinol Diglucoside 
Lignans, defined as two cinnamic acid residues connected through a –-linkage,56 are a 
widespread class of natural products present in plants, trees, and fruits.
57
 Isolated lignans possess 
biologically interesting properties including antioxidative, antiestrogenic, and anticarcinogenic 
activities.
58
 Due to their wide occurrence and biological relevance these structures have also been 
the target of several total synthesis studies.
59
 The previous studies have, however, solely focused 
on the aglycones although many of the lignans exist in nature as glycosides. The neglectance of 
lignan glycosides may be due to the early isolation processes where strong acids were used for 
extraction. The acidic conditions resulted in the cleavage of glycosidic bonds and, therefore, only 
the deglycosylated aglycones were isolated.
60
 In recent years, advanced isolation processes have 
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been developed correlating with an increased number of reports on lignan glycosides.
61 
While the 
structures of many lignan glycosides isolated from natural sources have been elucidated, reports 
dealing with their synthesis are scarce.
62 
Surprisingly, lignan glycosides have not been prepared 
previously by semi-synthetic approaches. A synthetic route to these compounds is important for a 
number of reasons: 1) As mentioned previously, isolation of intact lignan glycosides from natural 
sources is difficult; 2) Natural sources seldom provide sufficient amounts of material for 
biological evaluation; and 3) By chemical synthesis a diversity of structural analogues may be 
prepared for exploration and comparison of the biological properties of both natural and 
unnatural lignans and lignan glycosides. 
In the present study, (8R,8R)-matairesinol 4,4-di-O--D-glucopyranoside (MDG) found in the 
stems of Trachelospermum asiaticum var. intermedium
63
 was selected as the target molecule to 
be prepared by semi-synthesis. A simple retrosynthetic analysis suggests the construction of this 
compound from glucose and hydroxymatairesinol (HMR) (Scheme 6). Such semi-synthetic 
approach is appealing with D-glucose being the most abundant biomolecule on earth, whereas 
(7R,8R,8R)/(7R,8R,8S)-hydroxymatairesinol (HMR) mixture, the major isomer being easily 
convertible to (R,R)-matairesinol (MR), is readily available on multi-ton scale from pulp mill side 
streams.
64
 As mentioned in the introductory part of this Episode, tedious total synthetic strategies 
should be avoided whenever the aglycone can be isolated on large scale from natural sources. 
Therefore, we set out to synthesize MDG by the route shown in Scheme 7. 
 
 
Scheme 6. Retrosynthetic analysis of matairesinol diglucoside. 
 
Phenolic compounds, such as the aglycon of 56, are often considered as difficult glycosylation 
targets due to the electron-withdrawing properties of the aromatic ring. Furthermore, steric 
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hindrance from other substituents on the aromatic ring contributes to the difficulties associated 
with aromatic O-glycosylation. It has been shown previously that electron-rich aromatic aglycons 
are preferably glycosylated under acidic conditions with anomeric acetates or 
trichloroacetimidates (TCA).
65 
Since the TCA-donors
66
 are in general more reactive than the 
anomeric acetates, they were selected as glycosyl donors also in the present study. In the 
literature, mainly acetylated TCA-donors have been utilized. In our hands, as also mentioned on 
page 112, the acetyl group at C-2 is occasionally activated and transferred to the acceptor 
molecule under the employed reaction conditions thereby decreasing the yield of the desired 
product. In glycosylation of steroids, these side reactions were avoided by replacing the acetyl 
groups with benzoyl groups simultaneously retaining the beneficial properties of neighboring 
group participation displayed by ester protective groups at C-2.   
The benzoylated glucose TCA-donor was prepared according to the methods decribed earlier. 
HMR on the other hand, is found in exceptionally large concentrations (>10 % of dry weight) in 
the knots of Norway spruce (Picea abies). In a typical isolation procedure the knots are dried, 
ground and extracted with acetone-water to obtain HMR.
64a, 64c
 For large scale isolation, the 
HMR–K-acetate adduct can be utilized as described by Freudenberg.67 Eklund, Sjöholm and 
coworkers have previously described the conversion of HMR to MR in nearly quantitative yield 
in one step by hydrogenation or metal hydride reduction.
68 
In the present study, the latter 
procedure was utilized for preparation of MR (57). 
 
 
Scheme 7. Reactions conditions for synthesis of MDG; i) 9 (see Figure 2, page 111), BF3OEt2, 
CH2Cl2, 0 C, 1.5–2 h, 69 %; ii) MeOH:THF:H2O:Et3N (5:6:1:2), 55 C, 100 h, 67 %.  
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With the starting materials at hand, the focus was shifted to the glycosylation reaction. Generally, 
TCA-donors can be activated by a catalytic amount of Lewis acid.
66
 In many cases, TMSOTf has 
been successfully applied as the promoter in glycosylation reactions and was accordingly 
screened also for the glycosylation of MR.
65,69
 Here, the use of TMSOTf as promoter resulted in 
an O/C-linked mixture of diglucosylated matairesinol in moderate conversion (50 %). Changing 
the reaction temperature (–50–0 C) or the amount of TMSOTf (0.2–1 equiv) did not improve the 
glycosylation selectivity and efficiency. The promoter was therefore switched to the stronger 
Lewis acid BF3OEt2 which has previously been used with success in similar reactions.
65,70
 With 
BF3OEt2 as the promoter, the reaction proceeded smoothly under unoptimized reaction 
conditions to give the desired compound in 69 % yield after purification by column 
chromatography. For deprotection of benzoyl and ester protective groups in general, NaOMe in 
MeOH (Zemplén conditions) is the most commonly employed procedure.
26
 In the present study, 
deprotection under these conditions gave a mixture of products probably due to presence of the 
lactone functionality or the slightly acidic -proton in the vicinity of this center. Accordingly, a 
milder deprotection method was desired. In the literature, Et3N has been utilized for sensitive 
substrates as a milder alternative in solvent mixtures containing MeOH:H2O:Et3N (5:1:1).
71
 An 
initial screening reaction at ambient temperature proved unsuccessful using this solvent 
combination. By adjusting the proportions of the mixture to MeOH:THF:H2O:Et3N (5:6:1:2) and 
heating the reaction mixture at 55 C for four days the conversion was found to be complete as 
indicated by TLC (MeOH:CH2Cl2 1:3, Rf = 0.26). After purification of the crude mixture by 
column chromatography, the product was isolated in 67 % yield. The specific rotation, measured 
here in MeOH ([]D –19.8), was in good agreement with the value reported by Nishibe and 
coworkers for the isolated native compound ([]D –24.0 in EtOH).
63 
 
Interestingly, the complete NMR spectroscopic characterization of MDG has not been reported 
previously. Furthermore, for various reasons, many of the aglycones are difficult to fully assign 
which is generally also visible in the literature as many of the individual signals in the 
1
H-NMR 
spectra are reported in regions without their respective coupling patterns. The next section will 
provide some basic guidelines to the complete characterization of the different classes of 
compounds discussed in this Episode.  
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2.5 NMR Spectroscopic Characterization of Glycoconjugates 
Accurate NMR data is important for a number of reasons. It is commonly utilized to ensure the 
identity of a synthetic or isolated compound but can also be used in the determination of three 
dimensional structures (as shown in Episode 1) and biological properties. The NMR 
spectroscopic characterization of glycoconjugates can be challenging. Therefore, this section is 
devoted to the NMR spectroscopic characterization of the compounds discussed in this Episode. 
The characterization flow will here be exemplified by the complete NMR spectroscopic 
characterization of glycosteroid 46 and lignan glycoside 56. All other compounds synthesized 
were characterized utilizing the same principles and techniques.  
 
Figure 6. Numbering of saponin 46 (left); and the starting points for the NMR spectroscopic 
characterization with red arrows (right). 
 
As shown in Figure 6, several signals were selected as starting points for the NMR spectroscopic 
characterization of glycosteroid 46. The glycone part was first characterized starting with the well 
separated anomeric protons of rhamnose (d at 4.82 ppm) and glucose (d at 4.58 ppm). Since some 
of the signals from these two sugars were overlapping in the 
1
H-NMR spectrum (especially the 
region between 3.90–3.65 ppm), the anomeric signals where targeted by selective excitation (400 
ms spinlock time) utilizing the 1D-TOCSY experiment.
72 
By use of this measurement, these two 
spin-systems could be easily separated thus providing a convenient way of identifying the signals 
corresponding to each sugar respectively. The 1D-TOCSY spectra are shown in Figure 7. By the 
use of COSY and HSQC (Figures 8 and 9), all signals from the glycone part could next be 
identified in both the 
1
H- and 
13
C-NMR spectra. 
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H-1
H-2
H-6H-3
H-4
H-5
H-1
H-2
H-5
H-4
H-3
H-6a
H-6b
 
Figure 7. 1D-TOCSY spectra of the different sugar residues in 46: from the top, Glcp, Rhap 
and the entire 
1
H-NMR spectrum.  
 
 
Figure 8. COSY spectrum (showing proton J-coupled to eachother) of compound 46. 
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Figure 9. HSQC spectrum (showing proton–carbon correlations) of compound 46. 
 
 
Figure 10. HMBC spectrum (showing proton–carbon correlations over multiple bonds) of 
compound 46. 
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Figure 11. Spectral simulation of the 2.52–0.85 ppm region of the 1H NMR spectrum of 46 using 
PERCH NMR software: simulated spectrum (above), observed spectrum (below). 
 
From the HMBC spectrum (Figure 10), the correlation between H-1 and C-3 (77.9 ppm) and H-3 
(3.44 ppm) and C-1 (99.6 ppm) was clearly visible thus providing a starting point for the 
characterization of the aglycone. By use of COSY, both of the H-2 and H-4 protons could be 
identified. The corresponding signals in the 
13
C-NMR spectra were easily determined by the use 
of HSQC. Next, the spectral characterization was continued from the well separated signals of H-
6 (ddd at 5.42 ppm), C-6 (122.4 ppm) and C-5 (141.9 ppm). From the HMBC correlation of C-5, 
H-19 (s at 1.06 ppm) and H-1eq (ddd at 1.91 ppm) could be identified. By use of HSQC the 
corresponding carbon signals were solved. From the COSY spectra the correlations between H-6 
and both of the H-7 protons were visible. Furthermore, the HMBC correlation between H-6 and 
C-10 was used to completely solve the A-ring of the steroid. The HMBC correlation of H-19–C-9 
and H-6–C-8 enabled the complete characterization of the B-ring. For solving the C- and D-rings, 
the carbonyl carbon of C-17 (223.8 ppm) and the methyl group connected to C-13 were chosen as 
starting points. From the HMBC correlations of C-17 both of the H-15 protons could be found. 
From the HMBC correlations of H-18 it was possible to identify C-12, C-13 and C-14. By use of 
COSY and HSQC the C- and D-rings could now be completely solved. While assignations of this 
type can be considered straightforward or routine, obtaining accurate coupling constants in these 
systems is extremely difficult. This is mainly due to the severe overlap of signals in the steroid 
region. As decribed in Episode 1, the complete assignation of a -1,2-linked mannotetraose by 
use of the NMR simulation software PERCH was performed in earlier work.
73
 Herein, this 
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program was utilized to completely assign the proton spectra of the compounds prepared, 
exemplified by the high field region of the 
1
H-NMR spectrum of 46 shown in Figure 11.  
 
Figure 12. Numbering of MDG (56) (left); and the starting points for the NMR spectroscopic 
characterization with red arrows (right). 
 
 
Figure 13. HMBC spectrum (showing proton–carbon correlations over multiple bonds) of 
compound 56. 
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The NMR spectroscopic data reported in the literature on the naturally occurring lignan glycoside 
MDG
63
 was not convincing. Therefore, the necessary NMR spectroscopic experiments were 
conducted with the synthesized structure 56. The NMR spectra of MDG were recorded at 20 C 
in order to shift the water signal which was otherwise overlapping with the anomeric protons. 
The 
13
C-NMR signal of C-9 (181.4 ppm) was selected as a starting point for the structural 
elucidation. The correlations between C-9–H-7a, C-9–H-7b, C-9–H-8, C-9–H-9a and C-9–H-
9b were clearly visible by HMBC (Figure 13). By use of COSY and HSQC both the 
1
H- and 
13
C-
NMR chemical shifts of these signals, as well as the signals for H-8 and C-8, could be 
determined. Assignation of the aromatic rings was based on the HMBC correlation between H-7a 
(2.62 ppm) and H-7b (2.53 ppm) to C-6 (122.2 ppm) and C-2 (114.0 ppm).  
 
H-1
H-2 H-5
H-4
H-3
H-6a H-6b
H-1
H-6a
H-6b
H-2
H-3
H-4
H-5
 
Figure 14. 1D-TOCSY spectra of the different sugar residues and the entire 
1
H-NMR spectrum 
of the carbohydrate region of 56. 
 
The remaining signals from the aromatic ring were then easily assigned by HMBC and a similar 
methodology was also applied for resolving the signals of the second aromatic ring. The positions 
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of the glucose moieties were determined by HMBC based on the correlation between C-4 (146.6 
ppm) and H-1 (4.87 ppm). While the assignation of these signals can be considered fairly 
straightforward, the assignation of the carbohydrate moieties of MDG turned out to be extremely 
difficult due to severe signal overlap. For resolving the carbohydrate part, 1D-TOCSY (TOtal 
Correlation SpectroscopY) was again utilized.
72
 The only separable signals were those from the 
anomeric protons (4.87 and 4.86 ppm) and even their separation was marginal as shown in Figure 
14. As a result, a narrow 1D-TOCSY excitation range was required. Here, such a range was 
achieved by prolonging the pulse and reducing the pulse power.  
While the 1D-TOCSY NMR spectra significantly enhanced the complete assignation, accurrate 
and reliable coupling constants could not be extracted from the spectral data alone. Therefore, the 
spectral simulation software PERCH was utilized to acquire accurate chemical shifts and 
coupling patterns for the individual signals.
73
  
As discussed above, utilization of basic NMR spectroscopic techniques (
1
H, 
13
C, 1D-TOCSY, 
COSY, HSQC, HMBC and NOESY) in combination with spectral simulations led to the 
complete assignation of all glycoconjugates synthesized in the present chapter. The most 
important experiments were in most cases high resolution HMBC and 1D-TOCSY which 
significantly simplified the characterization of the 
1
H- and 
13
C-NMR spectra. 
 
3 Conclusions 
To summarize, glycoconjugates are structures consisting of a carbohydrate moiety permanently 
linked to another chemical species. These structures are widely distributed in nature and often 
associated with various biological applications and functions. In this Episode, methods for the 
glycosylation of several different aglycones, including steroids, tetracyclines and lignans, were 
addressed and discussed. The initial screening of glycosyl donors revealed that benzoylated 
imidate donors are optimal for the glycosylation of aglycones. These donors were next applied to 
the synthesis of a limited library of glycosteroids. Evaluation of the synthesized molecules in 
pharmaceutical delivery systems has not been investigated yet.  
In the second part of the Episode, a method for the attachment of scillabiose to steroids was 
developed. Since the saponins synthesized resembled the structure of hellebrin (a potent cytotoxic 
compound) they were also tested in similar applications but were found to be inactive.
45 
 132 
In the third part, benzoylated TCA-donors were applied in the regioselective glycosylation of 4-
deoxy--rhodomycinone with excellent results. The environmentally benign approach utilized in 
the synthesis of these structures could be valuable for industrial synthesis of similar compounds 
due to the operational simplicity, short reaction time and minimal waste generation of the 
protocol. The deprotected anthracyclines will in future work be screened for cytotoxicity.  
In the last part dealing with synthesis of glycoconjugates, the naturally occurring lignan glycoside 
MDG was synthesized utilizing the cheap and renewable starting materials HMR and D-glucose. 
While not discussed in the present Episode, a few other lignan glycosides were also prepared to 
ensure the reliability of the methodology.
8a
 Both lignans and lignan glycosides are currently of 
interest in the food industry due to their wide occurrence and health promoting effects.  
In addition to the synthesis, some key-guidelines to solving NMR spectroscopic challenges 
associated with glycoconjugates were given and exemplified by the complete characterization of 
structures 46 and 56.   
 
4 Experimental Section 
Reaction solvents were dried and distilled prior to use when necessary. All reactions containing 
moisture- or air-sensitive reagents were carried out under argon atmosphere. The NMR spectra 
were recorded with Bruker Avance NMR spectrometer operating at 600.13 MHz (
1
H: 600.13 
MHz, 
13
C: 150.90 MHz). The probe temperature during the experiments was kept at 25 C unless 
indicated otherwise. All products were fully characterized by utilization of the following 1D-
techniques: 
1
H, 
13
C and TOCSY and the following 2D-techniques; DQF-COSY, NOESY, HSQC 
and HMBC by using pulse sequences provided by the manufacturer. Chemical shifts are 
expressed on the  scale (in ppm) using TMS (tetramethylsilane), residual chloroform or 
methanol as internal standards. Coupling constants are given in Hz and provided only once, when 
first encountered. Coupling patterns are given as s (singlet), d (doublet), t (triplet) etc. The 
following indexes are used to clarify between protons on the same carbon: eq = equatorial, ax = 
axial, t = trans and c = cis. The computational analysis of all compounds was achieved by 
utilization of the PERCH NMR software with starting values and spectral parameters obtained 
from the various NMR techniques used.
73
 HRMS were recorded using Bruker Micro Q-TOF with 
ESI (electrospray ionization) operated in positive mode. Optical rotations were measured at 23 
C, unless otherwise stated, with a Perkin Elmer polarimeter equipped with a Na-lamp (589 nm). 
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TLC was performed on aluminium sheets precoated with silica gel 60 F254 (Merck). Flash 
chromatography was carried out on silica gel 60 (0.040–0.060 mm, Merck). Spots were 
visualized by UV followed by charring with 1:4 H2SO4/MeOH and heating. 
 
4.1 General Experimental Procedures 
 
General procedure for glycosylation of steroids and tetracyclines. To a solution containing 
the corresponding acceptor (1 equiv) and pre-activated 4 Å MS in dry CH2Cl2 (1.6 ml/0.1 mmol 
substrate) was added TMSOTf (0.2 equiv.) at –20 C. The reaction mixture was stirred for 10 
minutes and the corresponding donor (1.3 equiv) dissolved in dry CH2Cl2 (1.7 ml/0.1 mmol 
substrate) was added dropwise to the solution. The resulting mixture was stirred for 1.5–2 h, 
brought to r.t., diluted with CH2Cl2 (20 ml) and washed with sat. NaHCO3-solution (20 ml). The 
organic phase was dried over Na2SO4, filtered and concentrated. The crude product was purified 
by column chromatography (hexane:EtOAc, 4:1) to give the corresponding protected 
glycoconjugate. 
 
General procedure for deprotection for steroids and anthracyclines. To a solution containing 
the protected glycosteroid (1 equiv) in dry MeOH or dry MeOH:THF mixture (2:1) (6.3 ml/0.1 
mmol substrate) was added NaOMe (2 equiv) and the resulting mixture was stirred for 3–20 h at 
r.t., neutralized with DOWEX 50 H
+
-form, filtered and concentrated. The crude product was 
purified by column chromatography (CH2Cl2→CH2Cl2:MeOH 5:1 for all compounds except 21, 
22, 32 which were purified with EtOAc) to give the deprotected glycoconjugate. 
 
General procedure for ring-closing metathesis. To a solution containing the corresponding 
glycosteroid bearing two terminal alkenes (1 equiv) in dry CH2Cl2 (1.7 ml/0.1 mmol substrate) 
was added Grubbs 2
nd
 generation catalyst (10 mol%) and the resulting mixture was refluxed for 6 
h at 40 C, brought to r.t., stirred overnight and concentrated. The crude product was purified by 
column chromatography (hexane:EtOAc, 4:1) to give the corresponding ring-closed glycosteroid. 
 
General procedure for removal of isopropylidene acetal. A solution containing the 
corresponding protected substrate (1 equiv.) in 80 % AcOH (17 ml/1 g) was stirred at 80 C for 5 
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h, brought to r.t. and concentrated. The crude product was purified by column chromatography 
with hexane-EtOAc 2:3 as eluent to give the deprotected substrate. 
 
General procedure for benzoylation of hydroxyl groups. The substrate bearing hydroxyl 
groups was dissolved in a mixture of pyridine (15 ml/1 g) and BzCl (7.5 ml/1 g) and allowed to 
stir until TLC indicated complete disappearance of starting material.  The reaction was quenched 
after 4 h with MeOH, concentrated, dissolved in CH2Cl2 (40 ml) and washed with water (2  20 
ml) and brine (20 ml). The organic phase was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash chromatography with hexane:EtOAc (1:0 
→ 4:1) as eluent to give the benzoylated compound.  
 
General procedure for converting thio-glycoside into an imidate donor. To a solution 
containing thioglycoside (1 equiv.) in acetone:H2O (10:1, 28 ml/ 1 g) was added NBS (1.5 equiv.) 
at 0 C. The reaction was brought to r.t. and stirring was continued for 1 h. This process was 
repeated twice after which TLC indicated the reaction to be complete. The reaction was quenched 
with sat. NaHCO3-solution (15 ml), diluted with CH2Cl2 (30 ml) and washed with brine (20 ml). 
The organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The crude 
product was purified by column chromatography with hexane:EtOAc 4:1 as eluent to give the 
corresponding hemiacetal.  The hemiacetal (1 equiv.) was dissolved in CH2Cl2 (20 ml/1 g) and 
DBU (0.1 equiv.) and Cl3CCN (2.4 equiv.) was added at 0 C. The reaction mixture was stirred 
for 1.5 h, brought to r.t., diluted with CH2Cl2 (30 ml) and washed with brine (20 ml). The organic 
phase was dried with anhydrous Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography with hexane:EtOAc:Et3N 3:1:0.01 as eluent to give the 
corresponding imidate donor. 
 
General procedure for glycosylation of lignans. To a solution containing lignan (1 equiv.), 
glycosyl donor (2.6 equiv.) and pre-activated 4 Å MS in dry CH2Cl2 (14 ml/1 g) was added 
BF3OEt2 (0.5 equiv.) at 0 C. The resulting mixture was stirred for 1.5–2 h, brought to r.t., 
diluted with CH2Cl2 (20 ml) and washed with sat. NaHCO3-solution (20 ml). The organic phase 
was dried over Na2SO4, filtered and concentrated. The crude product was purified by column 
chromatography (hexane:EtOAc, 1:1) to give the lignan glycoside. 
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General procedure for deprotection of lignan glycosides. The protected lignan glycoside (1 
equiv.) was dissolved in a mixture containing MeOH:THF:H2O:Et3N (5:6:1:2, 20 ml/1 g) and the 
solution was stirred at 55 C for 100 h and concentrated. The crude product was purified by 
column chromatography (MeOH:CH2Cl2 1:3) to give the deprotected lignan glycoside. 
 
4.2 Analytical Data on Selected Substrates
 
 
13,17-seco-13-methyl-1-(2,3,4,6-tetra-O-benzoyl--D-mannopyranosyloxy)-3-
methoxyestra-1,3,5(10),16-tetraene (11). Synthesized from 1 (51 mg, 0.17 mmol) and 7 (176 
mg, 0.24 mmol) according to the general procedure for glycosylation of steroids and tetracyclines 
providing 11 as a white foam (135 mg, 91 %). Rf = 0.65 (hexane:EtOAc 1:1); []D –11.3 (c 0.3, 
CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.12–7.25 (m, 20 H, arom. H), 7.26 (d, 1 H, J1,2 = 8.6 
Hz, H-1), 6.75 (dd, 1 H, J2,4 = 2.8 Hz, H-2), 6.64 (d, 1 H, H-4), 6.08 (dd, 1 H, J4,3 = 10.1, J4,5 = 
10.2 Hz, H-4), 5.93 (dddd, 1 H, J16,15a = 6.2, J16,15b = 6.4, J16,17c = 10.3, J16,17t = 17.2 Hz, H-16), 
5.92 (dd, 1 H, J3,2 = 3.4 Hz, H-3), 5.77 (dd, 1 H, J2,1 = 1.8 Hz, H-2), 5.10 (dddd, 1 H, J17t,17c 
= –1.4, J17t,15b = –1.6, J17t,15a = –1.9 Hz, H-17t), 5.09 (d, 1 H, H-1), 5.02 (dddd, 1 H, J17c,15a = –
1.6, J17c,15b = –1.9 Hz, H-17c), 4.71 (dd, 1 H, J6a,5 = 2.6, J6a,6b = –12.2 Hz, H-6a),  4.50 (dd, 1 
H, J6b,5 = 5.0 Hz, H-6b), 4.44 (ddd, 1 H, H-5), 3.78 (s, 3 H, 3-OCH3), 3.76 and 3.25 (each d, 
each 1 H, J = –9.4 Hz, H-1), 2.87 (ddd, 1 H, J6a,7eq = 2.7, J6a,7ax = 5.5, J6a,6b = –13.6 Hz, H-6a), 
2.85 (ddd, 1 H, J6b,7eq = 5.8, J6b,7ax = 12.4 Hz, H-6b), 2.36 (ddd, 1 H, J9,11eq = 3.4, J9,8 = 10.4, J9,11ax 
= 12.2 Hz, H-9), 2.35 (dddd, 1 H, J11eq,12eq = 2.9, J11eq,12ax = 3.8, J11eq,11ax = –12.7 Hz, H-11eq),  
2.32 (ddddd, 1 H, J15a,14 = 3.0, J15a,15b = –16.6 Hz, H-15a), 2.16 (dddd, 1 H, J7eq,8 = 2.5, J7eq,7ax = –
12.8 Hz, H-7eq), 2.08 (ddddd, 1 H, J15b,14 = 5.6 Hz, H-15b), 1.81 (ddd, 1 H, J12ax,12eq = –12.8, 
J12ax,11ax = 13.9 Hz, H-12ax), 1.76 (ddd, 1 H, J12eq,11ax = 3.3 Hz, H-12eq), 1.53 (ddd, 1 H, J14,8 = 
11.1 Hz, H-14), 1.46 (dddd, 1 H, H-11ax),  1.43 (dddd, 1 H, J8,7ax = 11.9 Hz, H-8), 1.38 (dddd, 1 
H, H-7ax), 0.91 (s, 3 H, H-18) ppm.    
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 165.5 (3-OCOPh, 4-OCOPh, 2-
OCOPh), 157.5 (C-3), 140.0 (C-16), 137.9 (C-5), 133.5–128.3 (arom. C), 132.7 (C-10), 126.6 (C-
1), 114.5 (C-17), 113.4 (C-4), 111.7 (C-2), 98.4 (C-1), 77.4 (C-1), 70.5 (C-2), 70.2 (C-3), 
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69.0 (C-5), 67.0 (C-4), 63.0 (C-6), 55.2 (3-OCH3), 44.6 (C-14), 43.3 (C-9), 41.6 (C-8), 38.2 
(C-13), 36.6 (C-12), 32.7 (C-15), 30.6 (C-6), 27.5 (C-7), 26.4 (C-11), 16.2 (C-18) ppm.  
HRMS: m/z calcd. for C54H54O11Na [M + Na]
+
 901.3564; found 901.3546.  
 
(1S)-13,17-seco-13-(but-3-en-1-(2,3,4,6-tetra-O-benzoyl--D-mannopyranosyloxy)-
1-yl)-3-methoxyestra-1,3,5(10),16-tetraene (12). Synthesized from 3 (87 mg, 0.255 mmol) and 
7 (265 mg, 0.358 mmol) according to the general procedure for glycosylation of steroids and 
tetracyclines providing 12 as a white foam (211 mg, 90 %). Rf = 0.83 (hexane:EtOAc 1:1); []D –
19.1 (c 0.5, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.10–7.25 (m, 20 H, arom. H), 7.26 (d, 1 
H, J1,2 = 8.6 Hz, H-1), 6.75 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.63 (d, 1 H, H-4), 6.18 (dd, 1 H, J4,5 = 
10.0, J4,3 = 10.2 Hz, H-4), 6.01 (dddd, 1 H, J16,15a = 6.4, J16,15b = 6.9, J16,17c = 10.2, J16,17t = 17.1 
Hz, H-16), 5.99 (dddd, 1 H, J3,2a = 5.7, J3,2b = 8.4, J3,4c = 10.1, J3,4t = 17.0 Hz, H-3),  5.92 (dd, 
1 H, J3,2 = 3.1 Hz, H-3), 5.81 (dd, 1 H, J2,1 = 1.9 Hz, H-2), 5.27 (dddd, 1 H, J4t,2b = –1.1, 
J4t,2a = –1.4, J4t,4c = –1.8 Hz, H-4t), 5.22 (d, 1 H, H-1), 5.16 (dddd, 1 H, J17t,17c = –1.4, J17t,15b = 
–1.6, J17t,15a = –2.1 Hz, H-17t), 5.14 (dddd, 1 H, J4c,2b = –0.7, J4c,2a = –1.3 Hz, H-4c), 5.02 
(dddd, 1 H, J17c,15b = –1.2, J17c,15a = –2.1 Hz, H-17c), 4.72 (dd, 1 H, J6a,5 = 2.5, J6a,6b = –12.1 
Hz, H-6a), 4.55 (ddd, 1 H, J5,6b = 3.6 Hz, H-5), 4.44 (dd, 1 H, H-6b), 3.81 (dd, 1 H, J1,2a = 
2.5, J1,2b = 8.2 Hz, H-1), 3.79 (s, 3 H, 3-OCH3), 2.85 (ddd, 1 H, J6a,7eq = 2.3, J6a,7ax = 7.4, J6a,6b = 
–12.3 Hz, H-6a), 2.85 (ddd, 1 H, J6b,7eq = 5.4, J6b,7ax = 9.6 Hz, H-6b), 2.59 (ddddd, 1 H, J15a,14 = 
2.8, J15a,15b = –16.4 Hz, H-15a), 2.55 (ddddd, 1 H, J2a,2b = –15.0 Hz, H-2a), 2.45 (ddddd, 1 H, H-
2b), 2.36 (dddd, 1 H, J11eq,9 = 3.3, J11eq,12ax = 3.3, J11eq,12eq = 4.7, J11eq,11ax = –13.0 Hz, H-11eq), 
2.32 (ddd, 1 H, J9,8 = 10.7, J9,11ax = 12.3 Hz, H-9),  2.27 (ddddd, 1 H, J15b,14 = 4.3 Hz, H-15b), 
2.25 (dddd, 1 H, J7eq,8 = 2.1, J7eq,7ax = –12.9 Hz, H-7eq), 1.86 (ddd, 1 H, J12ax,12eq = –11.4, J12ax,11ax 
= 13.9 Hz, H-12ax), 1.77 (ddd, 1 H, J12eq,11ax = 3.3 Hz, H-12eq), 1.61 (ddd, 1 H, J14,8 = 12.5 Hz, 
H-14),  1.51 (dddd, 1 H, J8,7ax = 11.1 Hz, H-8), 1.43 (dddd, 1 H, H-11ax), 1.34 (dddd, 1 H, H-
7ax), 0.99 (s, 3 H, H-18) ppm.   
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 165.5 (3-OCOPh, 4-OCOPh), 165.3 
(2-OCOPh), 157.5 (C-3), 139.2 (C-16), 138.0 (C-5), 136.3 (C-3), 133.4–128.3 (arom. C), 132.5 
(C-10), 126.6 (C-1), 118.2 (C-4), 115.3 (C-17), 113.4 (C-4), 111.7 (C-2), 98.7 (C-1), 87.7 (C-
1), 71.0 (C-2), 70.1 (C-3), 69.9 (C-5), 66.8 (C-4), 62.7 (C-6), 55.2 (3-OCH3), 43.6 (C-14), 
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43.4 (C-9), 42.1 (C-13), 41.3 (C-8), 35.6 (C-2), 33.6 (C-12), 33.0 (C-15), 30.5 (C-6), 27.7 (C-7), 
26.3 (C-11), 18.5 (C-18) ppm. 
HRMS: m/z calcd. for C57H58O11Na [M + Na]
+
 941.3877; found 941.3864.  
 
13,17-seco-13-methyl-1-(2,3,4-tri-O-benzoyl--L-rhamnopyranosyloxy)-3-
methoxyestra-1,3,5(10),16-tetraene (13). Synthesized from 1 (72 mg, 0.24 mmol) and 8 (208 
mg, 0.34 mmol) according to the glycosylation of steroids and tetracyclines 13 as a white foam 
(168 mg, 92 %). Rf = 0.75 (hexane:EtOAc 1:1); []D +96.7 (c 0.12, CHCl3). 
1
H NMR (600.13 
MHz, CDCl3):  8.13–7.23 (m, 15 H, arom. H), 7.26 (d, 1 H, J1,2 = 8.5 Hz, H-1), 6.74 (dd, 1 H, 
J2,4 = 2.8 Hz, H-2), 6.65 (d, 1 H, H-4), 5.94 (dddd, 1 H, J16,15a = 6.3, J16,15b = 6.9, J16,17c = 10.1, 
J16,17t = 17.1 Hz, H-16), 5.85 (dd, 1 H, J3,2 = 3.5, J3,4 = 10.1 Hz, H-3), 5.70 (dd, 1 H, J2,1 = 
1.8 Hz, H-2), 5.70 (dd, 1 H, J4,5 = 9.7 Hz, H-4),  5.08 (dddd, 1 H, J17t,17c = –1.6, J17t,15a = –1.7, 
J17t,15b = –1.8 Hz, H-17t), 5.00 (dddd, 1 H, J17c,15a = –1.5, J17c,15b = –1.5 Hz, H-17c), 4.97 (d, 1 H, 
H-1), 4.20 (dq, 1 H, J5,6 = 6.3 Hz, H-5), 3.78 (s, 3 H, 3-OCH3), 3.56 and 3.41 (each d, each 1 
H, J = –9.5 Hz, H-1), 2.88 (ddd, 1 H, J6a,7eq = 2.5, J6a,7ax = 5.0, J6a,6b = –17.3 Hz, H-6a), 2.86 (ddd, 
1 H, J6b,7eq = 5.9, J6b,7ax = 13.0 Hz, H-6b), 2.41 (ddd, 1 H, J9,11eq = 4.2, J9,11ax = 11.6, J9,8 = 11.9 Hz, 
H-9), 2.36 (dddd, 1 H, J11eq,12eq = 3.1, J11eq,12ax = 3.7, J11eq,11ax = –12.9 Hz, H-11eq), 2.31 (ddddd, 1 
H, J15b,14 = 3.7, J15b,15a = –15.6 Hz, H-15b), 2.19 (dddd, 1 H, J7eq,8 = 3.6, J7eq,7ax = –14.4 Hz, H-
7eq), 2.12 (ddddd, 1 H, J15a,14 = 4.6 Hz, H-15a), 1.90 (ddd, 1 H, J12ax,12eq = –13.1, J12ax,11ax = 13.7 
Hz, H-12ax), 1.70 (ddd, 1 H, J12eq,11ax = 3.3 Hz, H-12eq), 1.62 (ddd, 1 H, J14,8 = 11.0 Hz, H-14), 
1.49 (dddd, 1 H, H-11ax), 1.44 (dddd, 1 H, J8,7ax = 12.6 Hz, H-8), 1.42 (dddd, 1 H, H-7ax), 1.40 
(d, 3 H, H-6), 0.92 (s, 3 H, H-18) ppm.    
13
C NMR (150.9 MHz, CDCl3):  165.8 (4-OCOPh), 165.5 (2-OCOPh, 3-OCOPh), 157.5 (C-
3), 140.0 (C-16), 138.0 (C-5), 133.4–128.3 (arom. C), 132.9 (C-10), 126.4 (C-1), 114.4 (C-17), 
113.4 (C-4), 111.6 (C-2), 98.1 (C-1), 76.8 (C-1), 71.9 (C-4), 70.8 (C-2), 70.2 (C-3), 66.8 
(C-5), 55.2 (3-OCH3), 44.5 (C-14), 43.3 (C-9), 41.4 (C-8), 38.3 (C-13), 36.5 (C-12), 32.8 (C-
15), 30.5 (C-6), 27.5 (C-7), 26.3 (C-11), 17.7 (C-6), 16.6 (C-18) ppm.  
HRMS: m/z calcd. for C47H50O9Na [M + Na]
+
 781.3352; found 781.3336; m/z calcd. for 
C47H54O9N [M + NH4]
+
 776.3799; found 776.3777. 
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(1S)-13,17-seco-13-(but-3-en-1-(2,3,4-tri-O-benzoyl--L-rhamnopyranosyloxy)-1-yl)-
3-methoxyestra-1,3,5(10),16-tetraene (14). Synthesized from 3 (122 mg, 0.358 mmol) and 8 
(311 mg, 0.508 mmol) according to the general procedure for glycosylation of steroids and 
tetracyclines providing 14 as a white foam (251 mg, 88 %). Rf = 0.83 (hexane:EtOAc 1:1); []D 
+116.3 (c 0.16, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.10–7.22 (m, 15 H, arom. H), 7.26 
(d, 1 H, J1,2 = 8.5 Hz, H-1), 6.73 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.63 (d, 1 H, H-4), 6.07 (dddd, 1 H, 
J3,2a = 6.4, J3,2b = 7.2, J3,4c = 10.2, J3,4t = 17.1 Hz, H-3), 5.93 (dddd, 1 H, J16,15b = 5.5, J16,15a = 
7.5, J16,17c = 10.1, J16,17t = 16.8 Hz, H-16), 5.83 (dd, 1 H, J3,2 = 3.2, J3,4 = 10.1 Hz, H-3), 5.75 
(dd, 1 H, J2,1 = 1.8 Hz, H-2), 5.68 (dd, 1 H, J4,5 = 9.8 Hz, H-4), 5.15 (dddd, 1 H, J4t,2a = –
1.4, J4t,2b = –1.5, J4t,4c = –2.0 Hz, H-4t), 5.08 (dddd, 1 H, J4c,2b = –1.0, J4c,2a = –1.4, H-4c), 
5.06 (d, 1 H, H-1), 5.05(dddd, 1 H, J17t,17c = –1.4, J17t,15a = –1.8, J17t,15b = –2.1 Hz, H-17t), 4.85 
(dddd, 1 H, J17c,15a = –1.7, J17c,15b = –1.8 Hz, H-17c), 4.34 (dq, 1 H, J5,6 = 6.2 Hz, H-5), 3.78 (s, 
3 H, 3-OCH3), 3.69 (dd, 1 H, J1,2a = 2.8, J1,2b = 7.5 Hz, H-1), 2.88 (ddd, 1 H, J6a,7eq = 1.0, J6a,7ax 
= 5.0, J6a,6b = –16.5 Hz, H-6a), 2.85 (ddd, 1 H, J6b,7eq = 6.3, J6b,7ax = 13.8 Hz, H-6b), 2.55 (ddddd, 
1 H, J2a,2b = –15.7 Hz, H-2a), 2.48 (ddddd, 1 H, J15a,14 = 2.8, J15a,15b = –16.5 Hz, H-15a), 2.43 
(ddddd, 1 H, H-2b), 2.42 (ddd, 1 H, J11eq,9 = 3.6, J9,8 = 11.3, J9,11ax = 11.8 Hz, H-9), 2.36 (dddd, 1 
H, J11eq,12eq = 3.1, J11eq,12ax = 3.8, J11eq,11ax = –12.9 Hz, H-11eq), 2.19 (dddd, 1 H, J7eq,8 = 2.7, 
J7eq,7ax = –12.3 Hz, H-7eq),  2.13 (ddddd, 1 H, J15b,14 = 5.5 Hz, H-15b), 1.91 (ddd, 1 H, J12ax,12eq = 
–13.2, J12ax,11ax = 13.8 Hz, H-12ax), 1.73 (ddd, 1 H, J14,8 = 10.5 Hz, H-14), 1.63 (ddd, 1 H, 
J12eq,11ax = 3.8 Hz, H-12eq), 1.51 (dddd, 1 H, J7ax,8 = 10.8 Hz, H-7ax), 1.46 (dddd, 1 H, H-8), 1.42 
(dddd, 1 H, H-11ax), 1.35 (d, 1 H, H-6), 0.95 (s, 3 H, H-18) ppm.   
13
C NMR (150.9 MHz, CDCl3):  166.0 (4-OCOPh), 165.7 (3-OCOPh), 165.6 (2-OCOPh), 
157.6 (C-3), 140.0 (C-16), 138.2 (C-5), 137.5 (C-3), 133.5–128.4 (arom. C), 132.9 (C-10), 126.7 
(C-1), 116.2 (C-4), 115.1 (C-17), 113.5 (C-4), 111.8 (C-2), 100.1 (C-1), 88.7 (C-1), 72.1 (C-
4), 71.0 (C-2), 70.3 (C-3), 67.3 (C-5), 55.4 (3-OCH3), 43.7 (C-14), 43.2 (C-9), 42.7 (C-13), 
42.4 (C-8), 35.8 (C-2), 33.2 (C-15), 32.9 (C-12), 30.7 (C-6), 27.7 (C-7), 26.5 (C-11), 18.0 (C-
18), 17.8 (C-6) ppm. 
HRMS: m/z calcd. for C50H54O9Na [M + Na]
+
 821.3666; found 821.3644; m/z calcd. for 
C50H58O9N [M + NH4]
+
 816.4112; found 816.4092. 
 
 139 
(1S)-13,17-seco-13-(but-3-en-1-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyloxy)-1-
yl)-3-methoxyestra-1,3,5(10),16-tetraene (16). Synthesized from 3 (75 mg, 0.220 mmol) and 9 
(228 mg, 0.308 mmol) according to the general procedure for glycosylation of steroids and 
tetracyclines providing 16 as a white foam (153 mg, 77 %). Rf = 0.70 (hexane:EtOAc 1:1); []D 
+28.0 (c 0.2, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.06–7.15 (m, 20 H, arom. H), 7.00 (d, 
1 H, J1,2 = 8.7 Hz, H-1), 6.64 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.50 (d, 1 H, H-4), 6.06 (dddd, 1 H, 
J3,2a = 5.2, J3,2b = 8.4, J3,4c = 10.1, J3,4t = 17.0 Hz, H-3), 5.90 (dd, 1 H, J3,4 = 9.5, J3,2 = 9.9 
Hz, H-3), 5.86 (dddd, 1 H, J16,15b = 5.4, J16,15a = 7.4, J16,17c = 10.2, J16,17t = 17.1 Hz, H-16), 5.67 
(dd, 1 H, J4,5 = 9.9 Hz, H-4), 5.60 (dd, 1 H, J2,1 = 7.8 Hz, H-2), 5.13 (dddd, 1 H, J17c,15b = –
1.5, J17c,17t = –1.6, J17c,15a = –1.9 Hz, H-17c), 5.08 (dddd, 1 H, J17t,15a = –1.7, J17c,15b = –2.2 Hz, H-
17t), 4.96 (d, 1 H, H-1), 4.95 (dddd, 1 H, J4t,2a = –1.3, J4t,4c = –2.0, J4t,2b = –2.2 Hz, H-4t), 4.84 
(dddd, 1 H, J4c,2b = –1.3, J4c,2a = –1.3 Hz, H-4c), 4.68 (dd, 1 H, J6a,5 = 3.1, J6a,6b = –12.0 Hz, 
H-6a), 4.47 (dd, 1 H, J6b,5 = 5.2 Hz, H-6b), 4.08 (ddd, 1 H, H-5), 3.75 (s, 3 H, 3-OCH3), 3.63 
(dd, 1 H, J1,2a = 2.8, J1,2b = 7.4 Hz, H-1), 2.59 (ddd, 1 H, J6b,7eq = 6.0, J6b,7ax = 11.9, J6a,6b = –16.5 
Hz, H-6b), 2.51 (ddd, 1 H, J6a,7eq = 1.8, J6a,7ax = 5.4, H-6a), 2.41 (ddddd, 1 H, J2a,2b = –15.5 Hz, 
H-2a), 2.40 (ddddd, 1 H, H-2b), 2.22 (ddddd, 1 H, J15a,14 = 2.3, J15a,15b = –16.6 Hz, H-15a), 2.02 
(dddd, 1 H, J11eq,9 = 3.3, J11eq,12eq = 3.4, J11eq,12ax = 3.9, J11eq,11ax = –12.8 Hz, H-11eq), 1.87 (ddddd, 
1 H, J15b,14 = 6.1 Hz, H-15b), 1.75 (dddd, 1 H, J7eq,8 = 2.5, J7eq,7ax = –12.9 Hz, H-7eq), 1.60 (ddd, 1 
H, J12ax,12eq = –13.3, J12ax,11ax = 13.5 Hz, H-12ax), 1.48 (ddd, 1 H, J12eq,11ax = 3.2 Hz, H-12eq), 1.38 
(ddd, 1 H, J9,8 = 10.5, J9,11ax = 12.1 Hz, H-9), 1.33 (ddd, 1 H, J14,8 = 10.7 Hz, H-14), 1.13 (dddd, 1 
H, H-11ax), 1.11 (dddd, 1 H, J8,7ax = 11.8 Hz, H-8), 0.73 (s, 3 H, H-18), 0.44 (dddd, 1 H, H-7ax) 
ppm.                    
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 165.9 (3-OCOPh), 165.2 (4-OCOPh), 
165.0 (2-OCOPh), 157.1 (C-3), 140.4 (C-16), 137.7 (C-3), 137.5 (C-5), 133.4–128.3 (arom. C), 
132.4 (C-10), 126.6 (C-1), 115.0 (C-17, C-4), 113.0 (C-4), 111.3 (C-2), 101.7 (C-1), 84.9 (C-
1), 72.9 (C-3), 72.3 (C-2), 71.9 (C-5), 69.9 (C-4), 63.1 (C-6), 55.1 (3-OCH3), 42.6 (C-14), 
42.3 (C-13), 42.1 (C-8, C-9), 35.9 (C-2), 33.3 (C-15), 31.5 (C-12), 30.2 (C-6), 26.7 (C-7), 26.1 
(C-11), 17.3 (C-18) ppm. 
HRMS: m/z calcd. for C57H58O11Na [M + Na]
+
 941.3871; found 941.3866; m/z calcd. for 
C57H58O11K [M + K]
+
 957.3611; found 957.3595.  
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(1R)-13,17-seco-13-(but-3-en-1-(2,3,4,6-tetra-O-benzoyl--D-galactopyranosyloxy)-
1-yl)-3-methoxyestra-1,3,5(10),16-tetraene (18). Synthesized from 2 (81 mg, 0.237 mmol) and 
10 (246 mg, 0.330 mmol) according to the general procedure for glycosylation of steroids and 
tetracyclines providing 18 as a white foam (173 mg, 79 %). Rf = 0.18 (hexane:EtOAc 4:1); []D 
+69.3 (c 0.4, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.09–7.23 (m, 20 H, arom. H), 7.20 (d, 
1 H, J1,2 = 8.6 Hz, H-1), 6.72 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.61 (d, 1 H, H-4), 5.95 (dd, 1 H, J4,5 
= 1.1, J4,3 = 3.6 Hz, H-4), 5.88 (dddd, 1 H, J3,2a = 6.3, J3,2b = 8.0, J3,4c = 10.0, J3,4t = 17.4 Hz, 
H-3), 5.80 (dddd, 1 H, J16,15b = 6.1, J16,15a = 7.3, J16,17c = 10.0, J16,17t = 16.8 Hz, H-16), 5.76 (dd, 1 
H, J2,1 = 7.8, J2,3 = 10.4 Hz, H-2), 5.60 (dd, 1 H, H-3), 5.04 (d, 1 H, H-1),4.95 (dddd, 1 H, 
J4c,2b = –0.6, J4c,2a = –0.8, J4c,4t = –1.0 Hz, H-4c), 4.94 (dddd, 1 H, J4t,2b = –1.1, J4t,2a = –1.8 
Hz, H-4t), 4.94 (dddd, 1 H, J17t,15a = –0.8, J17t,17c = –1.6, J17t,15b = –2.3 Hz, H-17t), 4.91 (dddd, 1 
H, J17c,15a = –0.7, J17c,15b = –1.0 Hz, H-17c), 4.64 (dd, 1 H, J6a,5 = 7.0, J6a,6b = –11.4 Hz, H-6a),  
4.43 (dd, 1 H, J5,6b = 6.0 Hz, H-6b), 4.26 (ddd, 1 H, H-5), 3.91 (dd, 1 H, J1,2a = 2.3, J1,2b = 
8.7 Hz, H-1), 3.78 (s, 3 H, 3-OCH3), 2.82 (ddd, 1 H, J6a,7eq = 2.1, J6a,7ax = 7.6, J6a,6b = –12.1 Hz, 
H-6a), 2.82 (ddd, 1 H, J6b,7eq = 5.6, J6b,7ax = 9.5 Hz, H-6b), 2.41 (ddddd, 1 H, J2a,2b = –14.5 Hz, H-
2a), 2.21 (dddd, 1 H, J11eq,12eq = 2.4, J11eq,12ax = 4.0, J11eq,9 = 5.8 , J11eq,11ax = –13.4 Hz, H-11eq),  
2.20 (ddddd, 1 H, J15a,14 = 3.1, J15a,15b = –15.8 Hz, H-15a), 2.17 (ddd, 1 H, J9,11ax = 11.4, J9,8 = 11.5 
Hz, H-9), 2.14 (ddddd, 1 H, H-2b), 2.12 (dddd, 1 H, J7eq,8 = 2.2, J7eq,7ax = –12.2 Hz, H-7eq), 1.91 
(ddddd, 1 H, J15b,14 = 5.2 Hz, H-15b), 1.79 (ddd, 1 H, J12eq,11ax = 3.8, J12eq,12ax = –13.2 Hz, H-
12eq), 1.43 (dddd, 1 H, J8,14 = 9.8, J8,7ax = 11.5 Hz, H-8), 1.37 (dddd, 1 H, J11ax,12ax = 13.0 Hz, H-
11ax), 1.36 (ddd, 1 H, H-12ax), 1.29 (ddd, 1 H, H-14),  1.26 (dddd, 1 H, H-7ax), 1.06 (s, 3 H, H-
18) ppm.   
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 165.7 (3-OCOPh), 165.6 (4-OCOPh), 
165.1 (2-OCOPh), 157.4 (C-3), 139.9 (C-16), 137.9 (C-5), 136.6 (C-3), 133.5–128.3 (arom. C), 
132.8 (C-10), 126.5 (C-1), 116.7 (C-4), 114.6 (C-17), 113.4 (C-4), 111.6 (C-2), 100.3 (C-1), 
83.4 (C-1), 71.8 (C-3), 71.1 (C-5), 70.3 (C-2), 68.4 (C-4), 62.3 (C-6), 55.2 (3-OCH3), 45.5 
(C-14), 43.6 (C-9), 42.2 (C-8), 41.6 (C-13), 34.5 (C-2), 32.8 (C-15), 31.0 (C-12), 30.5 (C-6), 
27.7 (C-7), 25.9 (C-11), 17.6 (C-18) ppm. 
HRMS: m/z calcd. for C57H58O11Na [M + Na]
+
 941.3877; found 941.3872.  
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13,17-seco-13-methyl-1-(-D-mannopyranosyloxy)-3-methoxyestra-1,3,5(10),16-tetraene 
(19). Synthesized from 11 (128 mg, 0.145 mmol) according to the general procedure for 
deprotection of glycosteroids and anthracyclines providing 19 as a white solid (60 mg, 90 %).Rf = 
0.48 (MeOH:CH2Cl2 1:5); []D +115.6 (c 0.1, MeOH). 
1
H NMR (600.13 MHz, CD3OD):  7.17 
(d, 1 H, J1,2 = 8.6 Hz, H-1), 6.66 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.58 (d, 1 H, H-4), 5.90 (dddd, 1 H, 
J16,15a = 6.1, J16,15b = 7.1, J16,17c = 10.2, J16,17t = 17.1 Hz, H-16), 5.04 (dddd, 1 H, J17t,17c = –1.5, 
J17t,15b = –1.7, J17t,15a = –2.1 Hz, H-17t), 4.94 (dddd, 1 H, J17c,15b = –1.6, J17c,15a = –1.7 Hz, H-17c), 
4.72 (d, 1 H, J1,2 = 1.7 Hz, H-1), 3.84 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.82 (dd, 1 H, J6a,5 = 
2.4, J6a,6b = –11.6 Hz, H-6a), 3.73 (s, 3 H, 3-OCH3), 3.72 (dd, 1 H, J6b,5 = 5.5 Hz, H-6b), 
3.71 (dd, 1 H, J3,4 = 9.4 Hz, H-3), 3.71 and 3.11 (each d, each 1 H, J = –9.5 Hz, H-1), 3.63 
(dd, 1 H, J4,5 = 9.9 Hz, H-4), 3.57 (ddd, 1 H, H-5), 2.80 (ddd, 1 H, J6a,7eq = 2.3, J6a,7ax = 6.3, 
J6a,6b = –12.2 Hz, H-6a), 2.79 (ddd, 1 H, J6b,7eq = 5.9, J6b,7ax = 11.5 Hz, H-6b), 2.39 (ddddd, 1 H, 
J15a,14 = 3.2, J15a,15b = –16.2 Hz, H-15a), 2.28 (dddd, 1 H, J11eq,12eq = 3.0, J11eq,9 = 3.6, J11eq,12ax = 
3.9, J11eq,11ax = –13.1 Hz, H-11eq), 2.24 (ddd, 1 H, J9,8 = 10.6, J9,11ax = 12.1 Hz, H-9), 2.19 (dddd, 
1 H, J7eq,8 = 2.5, J7eq,7ax = –13.1 Hz, H-7eq), 2.08 (ddddd, 1 H, J15b,14 = 5.4 Hz, H-15b), 1.73 (ddd, 
1 H, J12ax,12eq = –13.2, J12ax,11ax = 13.9 Hz, H-12ax), 1.62 (ddd, 1 H, J12eq,11ax = 3.4 Hz, H-12eq), 
1.47 (ddd, 1 H, J14,8 = 11.2 Hz, H-14), 1.38 (dddd, 1 H, J8,7ax = 11.6 Hz, H-8), 1.37 (dddd, 1H, H-
11ax), 1.25 (dddd, 1 H, H-7ax), 0.88 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CD3OD):  158.9 (C-3), 141.4 (C-16), 138.9 (C-5), 133.8 (C-10), 127.4 
(C-1), 114.9 (C-17), 114.2 (C-4), 112.6 (C-2), 102.5 (C-1), 78.0 (C-1), 74.7 (C-5), 72.8 (C-
3), 72.2 (C-2), 68.5 (C-4), 62.9 (C-6), 55.5 (3-OCH3), 46.4 (C-14), 45.0 (C-9), 43.0 (C-8),  
39.3 (C-13), 37.9 (C-12), 33.9 (C-15), 31.5 (C-6), 28.9 (C-7), 27.7 (C-11), 17.0 (C-18) ppm. 
HRMS: m/z calcd. for C26H38O7Na [M + Na]
+
 485.2503; found 485.2503; m/z calcd. for 
C26H42O7N [M + NH4]
+
 480.2961; found 480.2952. 
 
(1S)-13,17-seco-13-(but-3-en-1-(-D-mannopyranosyloxy)-1-yl)-3-methoxyestra-
1,3,5(10),16-tetraene (20). Synthesized from 12 (59 mg, 0.064 mmol) according to the general 
procedure for deprotection of glycosteroids and anthracyclines providing 20 as a white solid (33 
mg, quant.). Rf = 0.52 (MeOH:CH2Cl2 1:5). []D +71.5 (c 0.2, MeOH).
1
H NMR (600.13 MHz, 
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CD3OD):  7.16 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.65 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.58 (d, 1 H, H-4), 
6.02 (dddd, 1 H, J16,15a = 6.3, J16,15b = 7.3, J16,17c = 10.2, J16,17t = 17.1 Hz, H-16), 5.95 (dddd, 1 H, 
J3,2a = 5.7, J3,2b = 8.3, J3,4c = 10.2, J3,4t = 17.1 Hz, H-3),  5.14 (dddd, 1 H, J4t,2a = –1.3, J4t,2b = 
–1.5, J4t,4c = –1.6 Hz, H-4t), 5.08 (dddd, 1 H, J4c,2b = –0.2, J4c,2a = –1.9, H-4c), 5.05 (dddd, 1 
H, J17t,17c = –1.4, J17t,15b = –1.6, J17t,15a = –2.1 Hz, H-17t), 4.95 (dddd, 1 H, J17c,15b = –1.4, J17c,15a = 
–1.9 Hz, H-17c), 4.89 (d, 1 H, J1,2 = 1.9 Hz, H-1), 3.93 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.78 
(dd, 1 H, J6b,5 = 4.2, J6b,6a = –14.0 Hz, H-6b), 3.77 (dd, 1 H, J6a,5 = 2.2, H-6a), 3.74 (dd, 1 
H, J4,5 = 9.7, J4,3 = 9.9 Hz, H-4), 3.72 (s, 3 H, 3-OCH3), 3.72 (dd, 1 H, J1,2a = 2.0, J1,2b = 7.9 
Hz, H-1), 3.71 (dd, 1 H, H-3), 3.71 (ddd, 1 H, H-5), 2.78 (ddd, 1 H, J6a,7eq = 1.9, J6a,7ax = 6.2, 
J6a,6b = –12.3 Hz, H-6a), 2.78 (ddd, 1 H, J6b,7eq = 6.2, J6b,7ax = 11.5 Hz, H-6b), 2.57 (ddddd, 1 H, 
J15a,14 = 3.7, J15a,15b = –16.0 Hz, H-15a), 2.55 (ddddd, 1 H, J2a,2b = –14.8 Hz, H-2a), 2.27 (ddddd, 
1 H, H-2b), 2.27 (dddd, 1 H, J11eq,12eq = 3.1, J11eq,9 = 3.7, J11eq,12ax = 3.9, J11eq,11ax = –13.2 Hz, H-
11eq), 2.24 (dddd, 1 H, J7eq,8 = 2.4, J7eq,7ax = –12.7 Hz, H-7eq), 2.20 (ddd, 1 H, J9,8 = 10.7, J9,11ax = 
12.1 Hz, H-9), 2.18 (ddddd, 1 H, J15b,14 = 4.8 Hz, H-15b), 1.77 (ddd, 1 H, J12ax,12eq = –13.2, 
J12ax,11ax = 13.8 Hz, H-12ax), 1.72 (ddd, 1 H, J14,8 = 10.9 Hz, H-14), 1.51 (ddd, 1 H, J12eq,11ax = 3.1 
Hz, H-12eq), 1.40 (dddd, 1 H, J8,7ax = 11.4 Hz, H-8), 1.32 (dddd, 1 H, H-11ax), 1.25 (dddd, 1 H, 
H-7ax), 0.93 (s, 3 H, H-18) ppm.   
13
C NMR (150.9 MHz, CD3OD):  158.9 (C-3), 141.3 (C-16), 139.0 (C-5), 138.7 (C-3), 133.7 
(C-10), 127.4 (C-1), 117.3 (C-4), 115.1 (C-17), 114.2 (C-4), 112.6 (C-2), 102.8 (C-1), 87.5 (C-
1), 75.2 (C-5), 72.7 (C-2, C-3), 68.1 (C-4), 62.5 (C-6), 55.5 (3-OCH3), 44.7 (C-9), 44.5 (C-
14), 43.2 (C-13), 43.1 (C-8), 37.0 (C-15), 34.8 (C-12), 34.4 (C-2), 31.5 (C-6), 28.9 (C-7), 27.6 
(C-11), 19.2 (C-18) ppm. 
HRMS: m/z calcd. for C29H42O7Na [M + Na]
+
 525.2828; found 525.2813; m/z calcd. for 
C29H46O7N [M + NH4]
+
 520.3274; found 520.3272. 
 
13,17-seco-13-methyl-1-(-L-rhamnopyranosyloxy)-3-methoxyestra-1,3,5(10),16-tetraene 
(21). Synthesized from 13 (164 mg, 0.216 mmol) according to the general procedure for 
deprotection of glycosteroids and anthracyclines providing 21 as a white solid (85 mg, 88 %). Rf 
= 0.21 (EtOAc); []D +13.8 (c 0.10, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  7.18 (d, 1 H, J1,2 
= 8.7 Hz, H-1), 6.70 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.60 (d, 1 H, H-4), 5.82 (dddd, 1 H, J16,15b = 
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6.5, J16,15a = 6.7, J16,17c = 10.2, J16,17t = 17.1 Hz, H-16), 4.99 (dddd, 1 H, J17t,17c = –1.5, J17t,15b = –
1.5, J17t,15a = –2.0 Hz, H-17t), 4.93 (dddd, 1 H, J17c,15b = –1.2, J17c,15a = –1.9 Hz, H-17c), 4.70 (d, 1 
H, J1,2 = 1.6 Hz, H-1), 3.94 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.79 (dd, 1 H, J3,4 = 9.3 Hz, H-
3), 3.76 (s, 3 H, 3-OCH3), 3.66 (dq, 1 H, J5,6 = 6.2, J5,4 = 9.4 Hz, H-5), 3.51 (dd, 1 H, H-4), 
3.37 and 3.24 (each d, each 1 H, J = –9.5 Hz, H-1), 2.82 (ddd, 1 H, J6a,7eq = 2.3, J6a,7ax = 5.2, J6a,6b 
= –17.1 Hz, H-6a), 2.80 (ddd, 1 H, J6b,7eq = 6.4, J6b,7ax = 12.2 Hz, H-6b), 2.25 (ddd, 1 H, J9,11eq = 
4.2, J9,11ax = 10.9, J9,8 = 12.0 Hz, H-9), 2.23 (dddd, 1 H, J11eq,12eq = 2.7, J11eq,12ax = 3.9, J11eq,11ax = –
11.8 Hz, H-11eq), 2.20 (ddddd, 1 H, J15a,14 = 5.1, J15a,15b= –15.8 Hz, H-15a), 2.12 (dddd, 1 H, 
J7eq,8 = 2.4, J7eq,7ax = –12.8 Hz, H-7eq), 2.00 (ddddd, 1 H, J15b,14 = 3.4 Hz, H-15a), 1.73 (ddd, 1 H, 
J12ax,12eq = –12.6, J12ax,11ax = 14.1 Hz, H-12ax), 1.49 (ddd, 1 H, J12eq,11ax = 3.4 Hz, H-12eq), 1.46 
(ddd, 1 H, J14,8 = 10.7 Hz, H-14), 1.39 (dddd, 1 H, H-11ax), 1.35 (dddd, 1 H, J8,7ax = 11.1 Hz, H-
8), 1.34 (d, 3 H, H-6), 1.29 (dddd, 1 H, H-7ax), 0.77 (s, 3 H, H-18) ppm.    
13
C NMR (150.9 MHz, CDCl3):  157.4 (C-3), 140.2 (C-16), 137.9 (C-5), 132.8 (C-10), 126.4 
(C-1), 114.1 (C-17), 113.4 (C-4), 111.6 (C-2), 99.9 (C-1), 75.8 (C-1), 73.0 (C-4), 72.1 (C-3), 
71.1 (C-2), 68.0 (C-5), 55.2 (3-OCH3), 44.2 (C-14), 43.4 (C-9), 41.3 (C-8), 38.1 (C-13), 36.5 
(C-12), 32.7 (C-15), 30.5 (C-6), 27.6 (C-7), 26.2 (C-11), 17.6 (C-6), 16.5 (C-18) ppm.  
HRMS: m/z calcd. for C26H38O6Na [M + Na]
+
 496.2566; found 496.2546.  
 
(1S)-13,17-seco-13-(but-3-en-1-(-L-rhamnopyranosyloxy)-1-yl)-3-methoxyestra-
1,3,5(10),16-tetraene (22). Synthesized from 14 (59 mg, 0.064 mmol) according to the general 
procedure for deprotection of glycosteroids and anthracyclines providing 22 as a white solid (33 
mg, quant.). Rf = 0.4 (EtOAc). []D +20.5 (c 0.07, CHCl3). 
1
H NMR (600.13 MHz, CHCl3):  
7.18 (d, 1 H, J1,2 = 8.7 Hz, H-1), 6.70 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.60 (d, 1 H, H-4), 6.00 (dddd, 
1 H, J3,2a = 6.7, J3,2b = 6.8, J3,4c = 10.2, J3,4t = 17.2 Hz, H-3), 5.83 (dddd, 1 H, J16,15b = 5.8, 
J16,15a = 7.0, J16,17c = 10.2, J16,17t = 17.0 Hz, H-16), 5.05 (dddd, 1 H, J4t,4c = –1.6, J4t,2a = –1.7, 
J4t,2b = –1.7 Hz, H-4t), 5.02 (dddd, 1 H, J17t,17c = –1.4, J17t,15a = –1.9, J17t,15b = –2.0 Hz, H-17t), 
5.00 (dddd, 1 H, J4c,2b = –1.1, J4c,2a = –1.9, H-4c), 4.98 (dddd, 1 H, J17c,15b = –1.7, J17c,15a = –1.7 
Hz, H-17c), 4.76 (d, 1 H, J1,2 = 1.7 Hz, H-1), 3.98 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.79 (dq, 1 
H, J5,6 = 6.2, J5,4 = 9.4 Hz, H-5), 3.76 (s, 3 H, 3-OCH3), 3.74 (dd, 1 H, J3,4 = 9.3 Hz, H-3), 
3.50 (dd, 1 H, J1,2a = 3.4, J1,2b = 6.7 Hz, H-1), 3.47 (dd, 1 H, H-4), 2.81 (ddd, 1 H, J6a,7eq = 1.5, 
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J6a,7ax = 5.4, J6a,6b = –13.9 Hz, H-6a), 2.80 (ddd, 1 H, J6b,7eq = 6.5, J6b,7ax = 12.3 Hz, H-6b), 2.45 
(ddddd, 1 H, J2a,2b = –15.4 Hz, H-2a), 2.35 (ddddd, 1 H, J15a,14 = 2.7, J15a,15b = –16.4 Hz, H-15a), 
2.28 (ddddd, 1 H, H-2b), 2.23 (dddd, 1 H, J11eq,12eq = 2.9, J11eq,9 = 3.7, J11eq,12ax = 3.9, J11eq,11ax = –
13.1 Hz, H-11eq), 2.21 (ddd, 1 H, J9,8 = 10.2, J9,11ax = 12.1 Hz, H-9), 2.13 (dddd, 1 H, J7eq,8 = 2.7, 
J7eq,7ax = –12.8 Hz, H-7eq), 1.99 (ddddd, 1 H, J15b,14 = 6.2 Hz, H-15b), 1.66 (ddd, 1 H, J12ax,12eq = –
12.8, J12ax,11ax = 14.1 Hz, H-12ax), 1.50 (ddd, 1 H, J12eq,11ax = 3.3 Hz, H-12eq), 1.50 (ddd, 1 H, 
J14,8 = 11.0 Hz, H-14), 1.37 (dddd, 1 H, J8,7ax = 12.3 Hz, H-8), 1.33 (dddd, 1 H, H-11ax), 1.29 
(dddd, 1 H, H-7ax), 1.27 (d, 3 H, H-6), 0.82 (s, 3 H, H-18) ppm.   
13
C NMR (150.9 MHz, CHCl3):  157.4 (C-3), 139.9 (C-16), 137.9 (C-5), 137.5 (C-3), 132.5 (C-
10), 126.6 (C-1), 115.7 (C-4), 114.8 (C-17), 113.3 (C-4), 111.7 (C-2), 102.2 (C-1), 87.9 (C-1), 
73.3 (C-4), 72.0 (C-3), 71.1 (C-2), 68.2 (C-5), 55.2 (3-OCH3), 43.7 (C-14), 43.1 (C-9), 42.5 
(C-13), 42.3 (C-8), 35.7 (C-2), 32.9 (C-15), 32.6 (C-12), 30.6 (C-6), 27.7 (C-7), 26.4 (C-11), 
17.4 (C-6), 17.3 (C-18) ppm. 
HRMS: m/z calcd. for C29H42O6Na [M + Na]
+
 509.2879; found 509.2855. 
 
13,17-seco-13-methyl-1-(-D-glucopyranosyloxy)-3-methoxyestra-1,3,5(10),16-tetraene 
(23). Synthesized from 1 (44 mg, 0.146 mmol) and 9 (152 mg, 0.205 mmol) according to the 
general procedure for glycosylation of steroids and tetracyclines providing an impure mixture 
(126 mg, 97 %). The deprotection step was performed according to the general procedure for 
deprotection of glycosteroids and anthracyclines starting with the mixture (85 mg, 0.096 mmol) 
and providing 23 as a white solid (39 mg, 88 %). Rf = 0.62 (MeOH:CH2Cl2 1:5); []D +29.4 (c 
2.5, MeOH). 
1
H NMR (600.13 MHz, CD3OD):  7.16 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.65 (dd, 1 H, 
J2,4 = 2.7 Hz, H-2), 6.57 (d, 1 H, H-4), 5.97 (dddd, 1 H, J16,15a = 6.3, J16,15b = 7.2, J16,17c = 10.3, 
J16,17t = 17.1 Hz, H-16), 5.04 (dddd, 1 H, J17t,17c = –1.5, J17t,15b = –2.0, J17t,15a = –2.2 Hz, H-17t), 
4.92 (dddd, 1 H, J17c,15b = –1.6, J17c,15a = –1.8 Hz, H-17c), 4.24 (d, 1 H, J1,2 = 7.8 Hz, H-1), 3.88 
(dd, 1 H, J6a,5 = 2.2, J6a,6b = –12.0 Hz, H-6a), 3.72 (s, 3 H, 3-OCH3), 3.70 and 3.40 (each d, 
each 1 H, J = –9.6 Hz, H-1), 3.69 (dd, 1 H, J6b,5 = 5.6 Hz, H-6b), 3.36 (dd, 1 H, J3,4 = 9.0, 
J3,2 = 9.2 Hz, H-3), 3.30 (dd, 1 H, J4,5 = 9.6 Hz, H-4), 3.26 (ddd, 1 H, H-5), 3.22 (dd, 1 H, 
H-2), 2.78 (ddd, 1 H, J6a,7eq = 1.9, J6a,7ax = 6.1, J6a,6b = –11.9 Hz, H-6a), 2.78 (ddd, 1 H, J6b,7eq = 
6.6, J6b,7ax = 11.5 Hz, H-6b), 2.35 (ddddd, 1 H, J15a,14 = 3.3, J15a,15b = –16.0 Hz, H-15a), 2.26 
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(dddd, 1 H, J11eq,12eq = 3.8, J11eq,9 = 3.8, J11eq,12ax = 3.9, J11eq,11ax = –13.3 Hz, H-11eq), 2.25 (ddd, 1 
H, J9,8 = 10.7, J9,11ax = 12.0 Hz, H-9), 2.19 (dddd, 1 H, J7eq,8 = 2.2, J7eq,7ax = –13.0 Hz, H-7eq), 
2.05 (ddddd, 1 H, J15b,14 = 5.6 Hz, H-15b), 1.85 (ddd, 1 H, J12ax,11ax = 13.3, J12ax,12eq = –13.6 Hz, 
H-12ax), 1.63 (ddd, 1 H, J14,8 = 11.5 Hz, H-14), 1.60 (ddd, 1 H, J12eq,11ax = 3.4 Hz, H-12eq), 1.36 
(dddd, 1 H, J8,7ax = 11.2 Hz, H-8), 1.35 (dddd, 1H, H-11ax), 1.25 (dddd, 1 H, H-7ax), 0.84 (s, 3 
H, H-18) ppm. 
13
C NMR (150.9 MHz, CD3OD):  158.9 (C-3), 142.0 (C-16), 139.0 (C-5), 134.0 (C-10), 127.4 
(C-1), 114.6 (C-17), 114.3 (C-4), 112.6 (C-2), 104.9 (C-1), 78.9 (C-1), 78.2 (C-3), 77.9 (C-
5), 75.3 (C-2), 71.7 (C-4), 62.8 (C-6), 55.5 (3-OCH3), 45.4 (C-14), 44.9 (C-9), 43.2 (C-8),  
39.5 (C-13), 37.6 (C-12), 34.2 (C-15), 31.5 (C-6), 28.9 (C-7), 27.7 (C-11), 17.0 (C-18) ppm. 
HRMS: m/z calcd. for C26H38O7Na [M + Na]
+
 485.2515; found 485.2500.  
 
(1S)-13,17-seco-13-(but-3-en-1-(-D-glucopyranosyloxy)-1-yl)-3-methoxyestra-
1,3,5(10),16-tetraene (24). Synthesized from 15 (60 mg, 0.065 mmol) according to the general 
procedure for deprotection glycosteroids and anthracyclines providing 24 as a white solid (25 mg, 
77 %). Rf = 0.43 (MeOH:CH2Cl2 1:5). []D +24.0 (c 1.67, MeOH).
1
H NMR (600.13 MHz, 
CD3OD):  7.17 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.65 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.57 (d, 1 H, H-4), 
6.18 (dddd, 1 H, J3,2b = 6.2, J3,2a = 7.6, J3,4c = 10.1, J3,4t = 17.2 Hz, H-3), 6.05 (dddd, 1 H, 
J16,15b = 6.1, J16,15a = 6.5, J16,17c = 10.2, J16,17t = 17.2 Hz, H-16), 5.09 (dddd, 1 H, J17t,17c = –1.6, 
J17t,15b = –1.8, J17t,15a = –2.1 Hz, H-17t), 5.00 (dddd, 1 H, J4t,2b = –1.4, J4t,2a = –1.5, J4t,4c = –2.3 
Hz, H-4t), 4.98 (dddd, 1 H, J17c,15b = –1.4, J17c,15a = –2.1 Hz, H-17c), 4.93 (dddd, 1 H, J4c,2b = –
0.9, J4c,2a = –1.2, H-4c), 4.41 (d, 1 H, J1,2 = 8.0 Hz, H-1), 3.85 (dd, 1 H, J6a,5 = 2.5, J6a,6b = 
–11.7 Hz, H-6a), 3.72 (s, 3 H, 3-OCH3), 3.69 (dd, 1 H, J1,2a = 3.7, J1,2b = 6.5 Hz, H-1), 3.68 
(dd, 1 H, J6b,5 = 5.6, H-6b), 3.33 (dd, 1 H, J3,4 = 9.3, J3,2 = 9.5 Hz, H-3), 3.30 (dd, 1 H, 
J4,5 = 9.1, Hz, H-4), 3.22 (dd, 1 H, H-2), 3.20 (ddd, 1 H, H-5), 2.78 (ddd, 1 H, J6a,7eq = 1.8, 
J6a,7ax = 5.9, J6a,6b = –13.2 Hz, H-6a), 2.77 (ddd, 1 H, J6b,7eq = 6.3, J6b,7ax = 11.5 Hz, H-6b), 2.47 
(ddddd, 1 H, J15a,14 = 2.1, J15a,15b = –16.7 Hz, H-15a), 2.46 (ddddd, 1 H, J20a,20b = –14.6 Hz, H-2a), 
2.40 (ddddd, 1 H, H-2b), 2.29 (ddd, 1 H, J9,11eq = 3.5, J9,8 = 11.2, J9,11ax = 11.5 Hz, H-9), 2.27 
(dddd, 1 H, J11eq,12eq = 3.5, J11eq,12ax = 3.8, J11eq,11ax = –12.7 Hz, H-11eq), 2.18 (dddd, 1 H, J7eq,8 = 
2.5, J7eq,7ax = –12.6 Hz, H-7eq), 2.05 (ddddd, 1 H, J15b,14 = 6.2 Hz, H-15b), 2.02 (ddd, 1 H, J14,8 = 
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10.6 Hz, H-14), 1.96 (ddd, 1 H, J12ax,12eq = –13.3, J12ax,11ax = 13.4 Hz, H-12ax), 1.55 (ddd, 1 H, 
J12eq,11ax = 3.3 Hz, H-12eq), 1.36 (dddd, 1 H, J8,7ax = 11.1 Hz, H-8), 1.30 (dddd, 1 H, H-7ax), 1.29 
(dddd, 1 H, H-11ax), 0.87 (s, 3 H, H-18) ppm.   
13
C NMR (150.9 MHz, CD3OD):  158.9 (C-3), 142.0 (C-16), 140.2 (C-3), 139.0 (C-5), 134.0 
(C-10), 127.6 (C-1), 115.2 (C-17), 114.8 (C-4), 114.2 (C-4), 112.6 (C-2), 105.2 (C-1), 86.0 (C-
1), 78.3 (C-3), 77.6 (C-5), 75.8 (C-2), 71.9 (C-4), 63.0 (C-6), 55.5 (3-OCH3), 44.2 (C-9, C-
8), 43.6 (C-13), 43.3 (C-14), 42.9 (C-13), 37.3 (C-2), 34.5 (C-15), 33.2 (C-12), 31.7 (C-6), 29.1 
(C-7), 27.9 (C-11), 18.2 (C-18) ppm. 
HRMS: m/z calcd. for C29H42O7Na [M + Na]
+
 525.2828; found 525.2821. 
 
13,17-seco-13-methyl-1-(-D-galactopyranosyloxy)-3-methoxyestra-1,3,5(10),16-tetraene 
(25). Synthesized from 1 (19 mg, 0.063 mmol) and 10 (65 mg, 0.088 mmol) according to the 
general procedure for glycosylation of steroids and tetracyclines. A pure product was, however, 
not obtained and thus the deprotection step was carried out according to the general procedure for 
deprotection of glycosteroids and anthracyclines providing 25 as a white solid (30 mg, 85 % over 
two steps). Rf = 0.58 (MeOH:CH2Cl2 1:5); []D +38.0 (c 0.87, MeOH). 
1
H NMR (600.13 MHz, 
CD3OD):  7.17 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.66 (dd, 1 H, J2,4 = 2.6 Hz, H-2), 6.58 (d, 1 H, H-4), 
5.98 (dddd, 1 H, J16,15a = 6.0, J16,15b = 7.4, J16,17c = 10.2, J16,17t = 17.1 Hz, H-16), 5.03 (dddd, 1 H, 
J17t,17c = –1.2, J17t,15b = –1.5, J17t,15a = –2.3 Hz, H-17t), 4.91 (dddd, 1 H, J17c,15b = –1.5, J17c,15a = –
1.9 Hz, H-17c), 4.19 (d, 1 H, J1,2 = 7.7 Hz, H-1), 3.63 (dd, 1 H, J4,5 = 1.3, J4,3 = 3.5  Hz, H-
4), 3.79 (dd, 1 H, J6a,5 = 6.0, J6a,6b = –11.6 Hz, H-6a), 3.73 (dd, 1 H, J6b,5 = 4.8 Hz, H-6b), 
3.73 (s, 3 H, 3-OCH3), 3.69 and 3.42 (each d, each 1 H, J = –9.5 Hz, H-1), 3.55 (dd, 1 H, J2,3 = 
9.8 Hz, H-2),  3.49 (ddd, 1 H, H-5), 3.46 (dd, 1 H, H-3), 2.79 (ddd, 1 H, J6a,7eq = 1.8, J6a,7ax = 
5.6, J6a,6b = –11.5 Hz, H-6a), 2.79 (ddd, 1 H, J6b,7eq = 6.5, J6b,7ax = 12.1 Hz, H-6b), 2.35 (ddddd, 1 
H, J15a,14 = 3.4, J15a,15b = –16.0 Hz, H-15a), 2.27 (dddd, 1 H, J11eq,12eq = 3.3, J11eq,9 = 3.7, J11eq,12ax = 
3.9, J11eq,11ax = –13.0 Hz, H-11eq), 2.26 (ddd, 1 H, J9,8 = 10.9, J9,11ax = 11.9 Hz, H-9), 2.21 (dddd, 
1 H, J7eq,8 = 2.3, J7eq,7ax = –13.0 Hz, H-7eq), 2.06 (ddddd, 1 H, J15b,14 = 5.2 Hz, H-15b), 1.87 (ddd, 
1 H, J12ax,12eq = –13.3, J12ax,11ax = 13.7 Hz, H-12ax), 1.65 (ddd, 1 H, J14,8 = 11.3 Hz, H-14), 1.60 
(ddd, 1 H, J12eq,11ax = 3.4 Hz, H-12eq), 1.37 (dddd, 1 H, J8,7ax = 10.8 Hz, H-8), 1.36 (dddd, 1H, H-
11ax), 1.27 (dddd, 1 H, H-7ax), 0.84 (s, 3 H, H-18) ppm. 
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13
C NMR (150.9 MHz, CD3OD):  158.9 (C-3), 142.1 (C-16), 139.0 (C-5), 134.0 (C-10), 127.4 
(C-1), 114.5 (C-17), 114.3 (C-4), 112.6 (C-2), 105.5 (C-1), 78.9 (C-1), 76.6 (C-5), 75.1 (C-
3), 72.7 (C-2), 70.4 (C-4), 62.5 (C-6), 55.5 (3-OCH3), 45.3 (C-14), 44.9 (C-9), 43.2 (C-8),  
39.5 (C-13), 37.7 (C-12), 34.2 (C-15), 31.6 (C-6), 29.0 (C-7), 27.8 (C-11), 17.1 (C-18) ppm. 
HRMS: m/z calcd. for C26H38O7Na [M + Na]
+
 485.2515; found 485.2497.  
 
(1R)-13,17-seco-13-(but-3-en-1-(-D-galactopyranosyloxy)-1-yl)-3-methoxyestra-
1,3,5(10),16-tetraene (26). Synthesized from 18 (40 mg, 0.044 mmol) according to the general 
procedure for deprotection of glycosteroids and anthracyclines providing 26 as a colorless oil (20 
mg, 91 %). Rf = 0.66 (MeOH:CH2Cl2 1:5). []D +41.8 (c 1.3, MeOH).
1
H NMR (600.13 MHz, 
CD3OD):  7.16 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.65 (dd, 1 H, J2,4 = 2.5 Hz, H-2), 6.57 (d, 1 H, H-4), 
6.17 (dddd, 1 H, J3,2b = 7.0, J3,2a = 7.1, J3,4c = 10.2, J3,4t = 17.0 Hz, H-3), 5.90 (dddd, 1 H, 
J16,15b = 6.3, J16,15a = 7.0, J16,17c = 10.1, J16,17t = 17.0 Hz, H-16), 5.09 (dddd, 1 H, J4t,2a = –1.5, 
J4t,2b = –1.5, J4t,4c = –2.1 Hz, H-4t), 5.03 (dddd, 1 H, J17t,15b = –1.7, J17t,17c = –1.8, J17t,15a = –1.8 
Hz, H-17t), 5.00 (dddd, 1 H, J4c,2b = –0.9, J4c,2a = –0.9, H-4c), 4.96 (dddd, 1 H, J17c,15b = –1.6, 
J17c,15a = –1.6 Hz, H-17c), 4.42 (d, 1 H, J1,2 = 7.6 Hz, H-1), 3.91 (dd, 1 H, J1,2a = 2.8, J1,2b = 
8.2 Hz, H-1), 3.83 (dd, 1 H, J4,5 = 1.1, J4,3 = 3.5 Hz, H-4), 3.74 (dd, 1 H, J6a,5 = 6.6, J6a,6b 
= –11.1 Hz, H-6a), 3.72 (s, 3 H, 3-OCH3), 3.71 (dd, 1 H, J6b, 5 = 5.8 Hz, H-6b), 3.50 (dd, 1 H, 
J2,3 = 9.7 Hz, H-2), 3.45 (dd, 1 H, H-3), 3.41 (ddd, 1 H, H-5), 2.80 (ddd, 1 H, J6a,7eq = 2.6, 
J6a,7ax = 5.2, J6a,6b = –13.9 Hz, H-6a), 2.78 (ddd, 1 H, J6b,7eq = 6.3, J6b,7ax = 11.5 Hz, H-6b), 2.51 
(ddddd, 1 H, J2a,2b = –14.7 Hz, H-2a), 2.41 (ddddd, 1 H, H-2b), 2.34 (ddddd, 1 H, J15a,14 = 2.7, 
J15a,15b = –16.2 Hz, H-15a), 2.23 (dddd, 1 H, J11eq,12eq = 3.1, J11eq,12ax = 3.8, J11eq,9 = 4.6, J11eq,11ax = 
–12.8 Hz, H-11eq), 2.19 (ddd, 1 H, J9,8 = 10.6, J9,11ax = 14.7 Hz, H-9), 2.18 (dddd, 1 H, J7eq,8 = 
2.4, J7eq,7ax = –15.4 Hz, H-7eq), 2.00 (ddddd, 1 H, J15b,14 = 5.0 Hz, H-15b), 1.82 (ddd, 1 H, 
J12eq,11ax = 3.4, J12eq,12ax = –13.4 Hz, H-12eq), 1.57 (ddd, 1 H, J12ax,11ax = 13.0 Hz, H-12ax), 1.41 
(dddd, 1 H, J8,14 = 11.0, J8,7ax = 11.7 Hz, H-8), 1.40 (ddd, 1 H, H-14), 1.30 (dddd, 1 H, H-11ax), 
1.26 (dddd, 1 H, H-7ax), 1.04 (s, 3 H, H-18) ppm.   
13
C NMR (150.9 MHz, CD3OD):  158.9 (C-3), 141.5 (C-16), 139.1 (C-3), 138.9 (C-5), 133.9 
(C-10), 127.4 (C-1), 116.5 (C-4), 115.0 (C-17), 114.3 (C-4), 112.6 (C-2), 104.1 (C-1), 84.8 (C-
1), 76.4 (C-5), 75.2 (C-3), 73.2 (C-2), 70.2 (C-4), 62.3 (C-6), 55.5 (3-OCH3), 46.7 (C-14), 
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45.0 (C-9), 43.9 (C-8), 42.9 (C-13), 35.9 (C-2), 34.0 (C-15), 32.6 (C-12), 31.5 (C-6), 29.1 (C-7), 
27.4 (C-11), 18.6 (C-18) ppm. 
HRMS: m/z calcd. for C29H42O7Na [M + Na]
+
 525.2828; found 525.2828.  
 
3-Methoxy-D-dihomo-estra-17b-(2,3,4,6-tetra-O-benzoyl--D-mannopyranosyloxy)-
1,3,5(10),16-tetraene (27). Synthesized from 12 (132 mg, 0.143 mmol) according to the general 
procedure for ring-closing metathesis providing 27 as a yellowish foam (124 mg, 97 %). Rf = 
0.33 (hexane:EtOAc 4:1); []D –30.0 (c 0.15, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.12–
7.26 (m, 20 H, arom. H), 7.16 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.73 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.65 
(d, 1 H, H-4), 6.08 (dd, 1 H, J4,5 = 10.1, J4,3 = 10.2 Hz, H-4), 5.91 (dddd, 1 H, J16,17a2 = –1.9, 
J16,15b = 4.2, J16,15a = 8.5, J16,17 = 10.0 Hz, H-16), 5.91 (dd, 1 H, J3,2 = 3.2 Hz, H-3), 5.63 (dddd, 1 
H, J17,17a1 = 3.1, J17,15a = –5.8, J17,17a2 = 7.5 Hz, H-17), 5.59 (dd, 1 H, J2,1 = 1.6 Hz, H-2), 4.75 
(dd, 1 H, J6a,5 = 2.2, J6a,6b = –12.0 Hz, H-6a), 4.61 (ddd, 1 H, J5,6b = 5.6 Hz, H-5), 4.49 (dd, 1 
H, H-6b), 3.78 (s, 3 H, 3-OCH3), 3.45 (dd, 1 H, J17b,17a2 = 2.1, J17b,17a1 = 10.2 Hz, H-17b), 2.84 
(ddd, 1 H, J6a,7eq = 2.9, J6a,7ax = 4.1, J6a,6b = –15.4 Hz, H-6a), 2.83 (ddd, 1 H, J6b,7eq = 7.3, J6b,7ax = 
12.3 Hz, H-6b), 2.68 (dddd, 1 H, J17a1,15b = 2.5, J17a1,17a2 = –15.8 Hz, H-17a1), 2.33 (dddd, 1 H, H-
17a2), 2.26 (dddd, 1 H, J11eq,12ax = 3.2, J11eq,9 = 3.7, J11eq,12eq = 3.7, J11eq,11ax = –13.7 Hz, H-11eq), 
2.25 (ddd, 1 H, J12eq,11ax = 3.3, J12eq,12ax = –12.1 Hz, H-12eq), 2.25 (dddd, 1 H, J15a,14 = 1.0, J15a,15b 
= –16.0 Hz, H-15a), 2.21 (dddd, 1 H, J7eq,8 = 2.5, J7eq,7ax = –13.8 Hz, H-7eq), 2.10 (ddd, 1 H, J9,8 = 
11.0, J9,11ax = 11.7 Hz, H-9), 2.09 (dddd, 1 H, J15b,14 = 10.4, H-15b),  1.53 (dddd, 1 H, J11ax,12ax = 
13.8 Hz, H-11ax), 1.42 (ddd, 1 H, H-12ax), 1.26 (dddd, 1 H, J7ax,8 = 9.0 Hz, H-7ax), 1.25 (dddd, 1 
H, J8,14 = 9.0 Hz, H-8), 1.22 (ddd, 1 H, H-14), 1.18 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 166.0 (4-OCOPh), 165.6 (3-OCOPh, 2-
OCOPh), 157.5 (C-3), 138.1 (C-5), 134.6 (C-16), 133.5–128.3 (arom. C), 133.2 (C-10), 126.1 (C-
1), 125.8 (C-17), 113.2 (C-4), 111.4 (C-2), 95.2 (C-1), 85.1 (C-17b), 71.7 (C-2), 70.2 (C-5), 
70.1 (C-3), 67.0 (C-4), 63.4 (C-6), 55.2 (3-OCH3), 49.0 (C-14), 43.1 (C-9), 42.7 (C-13), 39.3 
(C-8), 38.5 (C-12), 30.2 (C-6), 28.1 (C-17a), 27.8 (C-7), 26.1 (C-11), 25.9 (C-15), 12.8 (C-18) 
ppm.   
HRMS: m/z calcd. for C55H54O11Na [M + Na]
+
 913.3564; found 913.3550. 
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3-methoxy-D-dihomo-estra-17b-(2,3,4-tri-O-benzoyl--L-rhamnopyranosyloxy)-
1,3,5(10),16-tetraene (28). Synthesized from 14 (164 mg, 0.205 mmol) according to the general 
procedure for ring-closing metathesis providing 28 as a white foam (159 mg, quant.). Rf = 0.29 
(hexane:EtOAc 4:1); []D +76.3 (c 0.15, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.13–7.23 
(m, 15 H, arom. H), 7.24 (d, 1 H, J1,2 = 8.4 Hz, H-1), 6.74 (dd, 1 H, J2,4 = 2.6 Hz, H-2), 6.64 (d, 1 
H, H-4), 5.91 (dddd, 1 H, J16,17a1 = –1.9, J16,15b = 4.4, J16,15a = 8.2, J16,17 = 10.5 Hz, H-16), 5.83 
(dd, 1 H, J3,2 = 3.5, J3,4 = 10.0 Hz, H-3), 5.72 (dd, 1 H, J4,5 = 10.0 Hz, H-4), 5.68 (dd, 1 H, J2,1 
= 1.6 Hz, H-2), 5.63 (dddd, 1 H, J17,17a1 = 3.0, J17,15b = –4.7, J17,17a2 = 7.7 Hz, H-17), 5.12 (d, 1 H, 
H-1), 4.33 (dq, 1 H, J5,6 = 6.3 Hz, H-5), 3.77 (s, 3 H, 3-OCH3), 3.35 (dd, 1 H, J17b,17a2 = 2.7, 
J17b,17a1 = 10.6 Hz, H-17b), 2.86 (ddd, 1 H, J6a,7eq = 3.5, J6a,7ax = 5.0, J6a,6b = –16.1 Hz, H-6a), 2.83 
(ddd, 1 H, J6b,7eq = 6.6, J6b,7ax = 12.1 Hz, H-6b), 2.77 (dddddd, 1 H, J17a1,15a = 0.9, J17a1,15b = 5.3, 
J17a1,17a2 = –15.6 Hz, H-17a1), 2.47 (ddd, 1 H, H-17a2), 2.37 (dddd, 1 H, J11eq,12eq = 3.0, J11eq,12ax = 
3.8, J11eq,9 = 4.2, J11eq,11ax = –13.1 Hz, H-11eq), 2.29 (ddd, 1 H, J9,8 = 8.8, J9,11ax = 12.9 Hz, H-9), 
2.27 (ddd, 1 H, J12eq,11ax = 3.4, J12eq,12ax = –13.0 Hz, H-12eq), 2.28 (ddd, 1 H, J15a,14 = 1.0, J15a,15b = 
–16.0 Hz, H-15a), 2.23 (dddd, 1 H, J7eq,8 = 1.8, J7eq,7ax = –12.7 Hz, H-7eq), 2.08 (ddddd, 1 H, 
J15b,14 = 5.6 Hz, H-15b), 1.54 (dddd, 1 H, J11ax,12ax = 13.2 Hz, H-11ax), 1.47 (ddd, 1 H, H-12ax), 
1.37 (d, 1 H, H-6), 1.32 (dddd, 1 H, J7ax,8 = 14.1 Hz, H-7ax), 1.28 (dddd, 1 H, J8,14 = 12.3 Hz, H-
8), 1.26 (ddd, 1 H, H-14), 1.16 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CDCl3):  165.8 (4-OCOPh), 165.7 (2-OCOPh), 165.6 (3-OCOPh), 
157.5 (C-3), 138.1 (C-5), 134.0 (C-16), 134.0–128.3 (arom. C), 133.2 (C-10), 126.1 (C-1, C-17), 
113.3 (C-4), 111.4 (C-2), 100.2 (C-1), 90.6 (C-17b), 71.9 (C-4), 71.1 (C-2), 70.2 (C-3), 67.1 
(C-5), 55.2 (3-OCH3), 48.8 (C-14), 43.4 (C-9), 43.2 (C-13), 39.6 (C-8), 37.9 (C-12), 31.5 (C-
17a), 30.3 (C-6), 27.9 (C-7), 26.3 (C-15), 26.0 (C-11), 17.6 (C-6), 12.7 (C-18) ppm.   
HRMS: m/z calcd. for C48H50O9Na [M + Na]
+
 793.3353; found 793.3331; m/z calcd. for 
C48H54O9N [M + NH4]
+
 788.3799; found 788.3768. 
 
3-Methoxy-D-dihomo-estra-17b-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyloxy)-
1,3,5(10),16-tetraene (29). Synthesized from 16 (98 mg, 0.107 mmol) according to the general 
procedure for ring-closing metathesis providing 29 as a white foam (69 mg, 72 %). Rf = 0.29 
(hexane:EtOAc 4:1); []D +8.5 (c 0.15, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.05–7.28 
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(m, 20 H, arom. H), 6.87 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.67 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.58 (d, 1 
H, H-4), 5.92 (dd, 1 H, J3,4 = 9.5, J3,2 = 9.9 Hz, H-3), 5.79 (dddd, 1 H, J16,17a1 = –2.5, J16,15b = 
4.5, J16,15a = 8.9, J16,17 = 9.9 Hz, H-16), 5.61 (t, 1 H, J4,5 = 9.9 Hz, H-4), 5.59 (dd, 1 H, J2,1 = 7.9 
Hz, H-2), 5.31 (dddd, 1 H, J17,15b = –2.6, J17,17a1 = 3.8, J17,17a2 = 8.4 Hz, H-17), 4.92 (d, 1 H, H-
1), 4.66 (dd, 1 H, J6a,5 = 3.1, J6a,6b = –12.0 Hz, H-6a), 4.50 (dd, 1 H, J6b,5 = –6.5 Hz, H-6b), 
4.16 (ddd, 1 H, H-5), 3.75 (s, 3 H, 3-OCH3), 3.63 (dd, 1 H, J17b,17a2 = 2.8, J17b,17a1 = 11.1 Hz, H-
17b), 2.78 (ddd, 1 H, J6a,7eq = 3.3, J6a,7ax = 5.7, J6a,6b = –16.9 Hz, H-6a), 2.74 (ddd, 1 H, J6b,7eq = 
6.2, J6b,7ax = 10.9 Hz, H-6b), 2.67 (ddddd, 1 H, J17a1,15b = 2.5, J17a1,17a2 = –15.7 Hz, H-17a1), 2.56 
(ddd, 1 H, H-17a2), 2.13 (dddd, 1 H, J7eq,8 = 3.2, J7eq,7ax = –13.2 Hz, H-7eq), 2.13 (ddd, 1 H, J15a,14 
= 0.1, J15a,15b = –15.7 Hz, H-15a), 2.02 (ddd, 1 H, J9,11eq = 4.1, J9,8 = 10.6, J9,11ax = 11.5 Hz, H-9), 
1.91 (ddddd, 1 H, J15b,14 = 10.1 Hz, H-15b), 1.90 (ddd, 1 H, J12eq,11eq = 3.3, J12eq,11ax = 3.3, J12ax,12eq 
= –13.4 Hz, H-12eq), 1.50 (dddd, 1 H, J11eq,12ax = 4.0, J11eq,11ax = –13.9 Hz, H-11eq), 1.22 (dddd, 1 
H, J7a,8 = 10.5 Hz, H-7ax), 1.06 (ddd, 1 H, J14,8 = 11.1 Hz, H-14), 1.06 (dddd, 1 H, H-8), 1.05 
(ddd, 1 H, J12ax,11ax = 13.3 Hz, H-12ax), 0.90 (dddd, 1 H, H-11ax), 0.82 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 165.9 (3-OCOPh), 165.3 (4-OCOPh), 
165.1 (2-OCOPh), 157.5 (C-3), 138.1 (C-5), 133.8 (C-16), 133.5–128.3 (arom. C), 133.3 (C-10), 
126.8 (C-17), 125.7 (C-1), 113.1 (C-4), 111.4 (C-2), 103.6 (C-1), 90.5 (C-17b), 72.9 (C-3), 72.2 
(C-2), 72.1 (C-5), 70.1 (C-4), 63.4 (C-6), 55.2 (3-OCH3), 48.8 (C-14), 43.5 (C-13), 43.0 (C-9), 
39.4 (C-8), 37.8 (C-12), 31.9 (C-17a), 30.2 (C-6), 27.9 (C-7), 25.9 (C-15), 25.0 (C-11), 12.0 (C-
18) ppm. 
HRMS: m/z calcd. for C55H54O11Na [M + Na]
+
 913.3558; found 913.3545; m/z calcd. for 
C55H54O11K [M + K]
+
 929.3298; found 929.3284.  
 
3-Methoxy-D-dihomo-estra-17b-(2,3,4,6-tetra-O-benzoyl--D-galactopyranosyloxy)-
1,3,5(10),16-tetraene (30). Synthesized from 18 (89 mg, 0.097 mmol) according to the general 
procedure for ring-closing metathesis providing 30 as a colorless oil (65 mg, 75 %). Rf = 0.33 
(Hexane:EtOAc 4:1); []D +32.2 (c 0.27, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.11–7.20 
(m, 20 H, arom. H), 7.21 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.72 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.62 (d, 1 
H, H-4), 5.99 (dd, 1 H, J4,5 = 1.2, J4,3 = 3.6 Hz, H-4), 5.79 (dd, 1 H, J2,1 = 7.9, J2,3 = 10.4 Hz, 
H-2), 5.64 (dd, 1 H, H-3), 5.50 (dddd, 1 H, J16,17a2 = –1.3, J16,15b = 2.3, J16,15a = 8.0, J16,17 = 10.8 
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Hz, H-16), 5.31 (dddd, 1 H, J17,15a = –2.5, J17,17a1 = 5.2, J17,17a2 = 5.8 Hz, H-17), 4.81 (d, 1 H, H-
1), 4.68 (dd, 1 H, J6a,5 = 6.8, J6a,6b = –11.3 Hz, H-6a), 4.43 (dd, 1 H, J6b,5 = –6.6 Hz, H-6b), 
4.29 (ddd, 1 H, H-5), 3.77 (s, 3 H, 3-OCH3), 3.63 (dd, 1 H, J17b,17a2 = 1.6, J17b,17a1 = 8.5 Hz, H-
17b), 2.80 (ddd, 1 H, J6a,7eq = 3.6, J6a,7ax = 5.7, J6a,6b = –11.3 Hz, H-6a), 2.77 (ddd, 1 H, J6b,7eq = 
6.2, J6b,7ax = 12.4 Hz, H-6b), 2.40 (dddd, 1 H, J17a1,15b = 3.4, J17a1,17a2 = –17.9 Hz, H-17a1), 2.27 
(dddd, 1 H, J11eq,12eq = 2.9, J11eq,12ax = 3.9, J11eq,9 = 4.0, J11eq,11ax = –13.0 Hz, H-11eq), 2.23 (ddd, 1 
H, J9,8 = 10.5, J9,11ax = 12.4 Hz, H-9), 2.17 (dddd, 1 H, H-17a2), 2.15 (dddd, 1 H, J15a,14 = 0.2, 
J15a,15b = –17.5 Hz, H-15a), 2.03 (dddd, 1 H, J7eq,8 = 2.8, J7eq,7ax = –12.2 Hz, H-7eq), 1.83 (ddd, 1 
H, J12ax,11ax = 13.8, J12ax,12eq = –13.3 Hz, H-12ax), 1.79 (dddd, 1 H, H-15b), 1.82 (ddd, 1 H, 
J12eq,11ax = 3.7 Hz, H-12eq), 1.53 (ddd, 1 H, J14,8 = 11.1 Hz, H-14), 1.47 (dddd, 1 H, H-11ax), 1.22 
(dddd, 1 H, J8,7a = 10.4 Hz, H-8), 1.15 (dddd, 1 H, H-7ax), 0.97 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CDCl3):  166.0 (6-OCOPh), 165.7 (4-OCOPh), 165.6 (3-OCOPh), 
165.1 (2-OCOPh), 157.4 (C-3), 138.1 (C-5), 133.6 (C-10), 133.5–128.3 (arom. C), 132.3 (C-16), 
126.5 (C-1), 125.8 (C-17), 113.2 (C-4), 111.4 (C-2), 99.3 (C-1), 84.7 (C-17b), 71.8 (C-3), 71.3 
(C-5), 69.9 (C-2), 68.3 (C-4), 62.0 (C-6), 55.2 (3-OCH3), 44.0 (C-14), 43.3 (C-9), 40.7 (C-13), 
39.0 (C-8), 33.2 (C-12), 30.2 (C-6), 27.8 (C-17a), 27.1 (C-7), 26.3 (C-15), 26.0 (C-11), 17.0 (C-
18) ppm. 
HRMS: m/z calcd. for C55H54O11Na [M + Na]
+
 913.3564; found 913.3552; m/z calcd. for 
C55H54O11K [M + K]
+
 929.3303; found 929.3301.  
 
3-Methoxy-D-dihomo-estra-17b-(-D-mannopyranosyloxy)-1,3,5(10),16-tetraene (31). 
Synthesized from 27 (119 mg, 0.134 mmol) according to the general procedure for deprotection 
of glycosteroids and anthracyclines providing 31 as a white solid (53 mg, 98 %). Rf = 0.52 
(MeOH:CH2Cl2 1:5). 
1
H NMR (600.13 MHz, CD3OD):  7.17 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.68 
(dd, 1 H, J2,4 = 2.6 Hz, H-2), 6.60 (d, 1 H, H-4), 5.89 (dddd, 1 H, J16,17a2 = –2.1, J16,15b = 4.2, 
J16,15a = 8.3, J16,17 = 9.8 Hz, H-16), 5.60 (dddd, 1 H, J17,15a = –2.7, J17,17a1 = 5.1, J17,17a2 = 7.7 Hz, 
H-17), 4.87 (d, 1 H, J1,2 = 1.6 Hz, H-1), 3.83 (dd, 1 H, J6a,5 = 2.4, J6a,6b = –12.0 Hz, H-6a), 
3.75 (dd, 1 H, J6b,5 = 5.1 Hz, H-6b), 3.75 (s, 3 H, 3-OCH3), 3.74 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 
3.73 (ddd, 1 H, J5,4 = 9.8 Hz, H-5), 3.72 (dd, 1 H, J3,4 = 9.4 Hz, H-3), 3.68 (dd, 1 H, H-4), 3.37 
(dd, 1 H, J17b,17a2 = 1.9, J17b,17a1 = 9.9 Hz, H-17b), 2.83 (ddd, 1 H, J6a,7eq = 3.1, J6a,7ax = 5.6, J6a,6b = 
–16.4 Hz, H-6a), 2.80 (ddd, 1 H, J6b,7eq = 6.0, J6b,7ax = 11.7 Hz, H-6b), 2.53 (dddd, 1 H, J17a1,15b = 
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2.8, J17a1,17a2 = –15.7 Hz, H-17a1), 2.30 (dddd, 1 H, J11eq,12eq = 2.8, J11eq,12ax = 3.5, J11eq,9 = 3.6, 
J11eq,11ax = –15.1 Hz, H-11eq), 2.28 (dddd, 1 H, H-17a2), 2.23 (dddd, 1 H, J15a,14 = 1.3, J15a,15b = –
15.5 Hz, H-15a), 2.12 (dddd, 1 H, J7eq,8 = 2.7, J7eq,7ax = –13.3 Hz, H-7eq), 2.06 (ddd, 1 H, J15a,14 = 
10.5Hz, H-15b), 1.45 (dddd, 1 H, J11ax,12ax = 13.8 Hz, H-11ax), 1.43 (ddd, 1 H, H-12ax), 1.30 
(ddd, 1 H, J14,8 = 10.3 Hz, H-14), 1.27 (dddd, 1 H, J7ax,8 = 9.7 Hz, H-7ax),  1.22 (dddd, 1 H, H-8), 
1.05 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CD3OD):  158.7 (C-3), 138.9 (C-5), 135.3 (C-16), 134.3 (C-10), 126.8 
(C-17), 126.7 (C-1), 113.9 (C-4), 112.3 (C-2), 98.2 (C-1), 83.7 (C-17b), 75.2 (C-2), 72.8 (C-5), 
72.5 (C-3), 68.2 (C-4), 62.7 (C-6), 55.5 (3-OCH3), 50.2 (C-14), 44.4 (C-9), 43.6 (C-13), 40.6 
(C-8), 39.6 (C-12), 31.1 (C-6), 28.8 (C-7), 28.2 (C-17a), 27.0 (C-11), 26.7 (C-15), 13.3 (C-18) 
ppm. 
HRMS: m/z calcd. for C27H38O7Na [M + Na]
+
 498.2515; found 498.2504; m/z calcd. for 
C27H38O7K [M + K]
+
 513.2255; found 513.2238.  
 
3-Methoxy-D-dihomo-estra-17b-(-L-rhamnopyranosyloxy)-1,3,5(10),16-tetraene (32). 
Synthesized from 28 (155 mg, 0.200 mmol) according to the general procedure for deprotection 
of glycosteroids and anthracyclines providing 32 as a white solid (71 mg, quant.). Rf = 0.17 
(EtOAc); []D –32.5 (c 0.08, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  7.15 (d, 1 H, J1,2 = 8.6 
Hz, H-1), 6.68 (dd, 1 H, J2,4 = 2.4 Hz, H-2), 6.61 (d, 1 H, H-4), 5.83 (dddd, 1 H, J16,17a1 = –2.1, 
J16,15b = 4.3, J16,15a = 8.3, J16,17 = 10.4 Hz, H-16), 5.58 (dddd, 1 H, J17,17a1 = 2.6, J17,15b = –4.4, 
J17,17a2 = 7.7 Hz, H-17), 4.84 (d, 1 H, J1,2 = 1.6 Hz, H-1), 4.00 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 
3.81 (dq, 1 H, J5,6 = 6.3, J5,4 = 9.0 Hz, H-5), 3.78 (dd, 1 H, J3,4 = 9.6 Hz, H-3), 3.75 (s, 3 H, 3-
OCH3), 3.52 (dd, 1 H, H-4), 3.21 (dd, 1 H, J17b,17a2 = 3.0, J17b,17a1 = 10.4 Hz, H-17b), 2.81 (ddd, 1 
H, J6a,7eq = 4.5, J6a,7ax = 5.6, J6a,6b = –16.4 Hz, H-6a), 2.78 (ddd, 1 H, J6b,7eq = 6.5, J6b,7ax = 12.8 Hz, 
H-6b), 2.60 (ddddd, 1 H, J17a1,17a2 = –15.3 Hz, H-17a1), 2.38 (ddd, 1 H, H-17a2), 2.22 (dddd, 1 H, 
J11eq,12ax = 3.2, J11eq,12eq = 4.3, J11eq,9 = 4.3, J11eq,11ax = –12.6 Hz, H-11eq), 2.21 (ddd, 1 H, J9,8 = 8.7, 
J9,11ax = 14.0 Hz, H-9), 2.19 (ddd, 1 H, J15a,14 = 1.0, J15a,15b = –15.6 Hz, H-15a), 2.16 (dddd, 1 H, 
J7eq,8 = 1.8, J7eq,7ax = –11.7 Hz, H-7eq), 2.00 (ddd, 1 H, J12eq,11ax = 3.8, J12eq,12ax = –12.9 Hz, H-
12eq), 1.95 (ddddd, 1 H, J15b,14 = 8.5, H-15b), 1.43 (dddd, 1 H, J11ax,12ax = 11.3 Hz, H-11ax), 1.34 
(d, 1 H, H-6), 1.32 (ddd, 1 H, H-12ax), 1.26 (dddd, 1 H, J7ax,8 = 11.3 Hz, H-7ax), 1.18 (ddd, 1 H, 
J14,8 = 10.0 Hz, H-14), 1.18 (dddd, 1 H, H-8), 0.96 (s, 3 H, H-18) ppm.   
 153 
13
C NMR (150.9 MHz, CDCl3):  157.5 (C-3), 138.1 (C-5), 133.6 (C-16), 133.3 (C-10), 126.3 
(C-17), 125.9 (C-1), 113.2 (C-4), 111.4 (C-2), 102.8 (C-1), 89.8 (C-17b), 73.1 (C-4), 72.0 (C-
3), 71.2 (C-2), 68.4 (C-5), 55.2 (3-OCH3), 48.8 (C-14), 43.4 (C-13), 43.2 (C-9), 39.6 (C-8), 
38.1 (C-12), 31.4 (C-17a), 30.2 (C-6), 27.9 (C-7), 26.2 (C-15), 25.9 (C-11), 17.5 (C-6), 12.6 (C-
18) ppm.   
HRMS: m/z calcd. for C27H38O6Na [M + Na]
+
 481.2566; found 481.2552. 
 
3-Methoxy-D-dihomo-estra-17b-(-D-glucopyranosyloxy)-1,3,5(10),16-tetraene (33). 
Synthesized from 29 (66 mg, 0.075 mmol) according to the general procedure for deprotection of 
glycosteroids and anthracyclines providing 33as a white solid (29 mg, 82 %). Rf = 0.66 
(MeOH:CH2Cl2 1:5). 
1
H NMR (600.13 MHz, CD3OD):  
1
H NMR (600.13 MHz, CD3OD):  
7.15 (d, 1 H, J1,2 = 8.6 Hz, H-1), 6.66 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.59 (d, 1 H, H-4), 5.84 (dddd, 
1 H, J16,17a1 = –4.6, J16,15b = 2.8, J16,15a = 8.7, J16,17 = 10.3 Hz, H-16), 5.66 (dddd, 1 H, J17,17a1 = 2.2, 
J17,15b = –4.5, J17,17a2 = 8.6 Hz, H-17), 4.36 (d, 1 H, J1,2 = 7.7 Hz, H-1), 3.85 (dd, 1 H, J6a,5 = 2.4, 
J6a,6b = –11.8 Hz, H-6a), 3.73 (s, 3 H, 3-OCH3), 3.69 (dd, 1 H, J6b,5 = 5.5 Hz, H-6b), 3.34 (dd, 1 
H, J3,4 = 8.5, J3,2 = 9.5 Hz, H-3), 3.30 (dd, 1 H, J4,5 = 10.0, H-4), 3.25 (dd, 1 H, J17b,17a2 = 2.7, 
J17b,17a1 = 11.0 Hz, H-17b), 3.25 (ddd, 1 H, H-5), 3.20 (dd, 1 H, Hz, H-2), 2.82 (ddd, 1 H, J6a,7eq 
= 2.1, J6a,7ax = 5.8, J6a,6b = –16.2 Hz, H-6a), 2.78 (ddd, 1 H, J6b,7eq = 5.6, J6b,7ax = 11.3 Hz, H-6b), 
2.63 (ddddd, 1 H, J17a1,15b = 2.3, J17a1,17a2 = –15.4 Hz, H-17a1), 2.59 (ddd, 1 H, H-17a2), 2.50 
(ddd, 1 H, J12eq,11eq = 2.6, J12eq,11ax = 4.3, J12eq,12ax = –13.7 Hz, H-12eq), 2.25 (dddd, 1 H, J11eq,12ax = 
3.6, J11eq,9 = 3.7, J11eq,11ax = –12.8 Hz, H-11eq), 2.22 (dddd, 1 H, J7eq,8 = 3.2, J7eq,7ax = –13.0 Hz, H-
7eq), 2.22 (ddd, 1 H, J9,8 = 11.6, J9,11ax = 12.5 Hz, H-9), 2.21 (ddd, 1 H, J15a,14 = 0.6, J15a,15b = –
15.7 Hz, H-15a), 2.03 (ddddd, 1 H, J15a,14 = 10.2 Hz, H-15b), 1.38 (dddd, 1 H, J11ax,12ax = 12.5 Hz,  
H-11ax), 1.33 (ddd, 1 H, H-12ax), 1.27 (dddd, 1 H, J7ax,8 = 9.6 Hz, H-7ax), 1.16 (ddd, 1 H, J14,8 = 
10.9 Hz, H-14), 1.16 (dddd, 1 H, H-8), 1.06 (s, 3 H, H-18) ppm.              
13
C NMR (150.9 MHz, CDCl3):  159.0 (C-3), 139.1(C-5), 134.7(C-16), 134.6 (-10), 128.6 (C-
17), 126.8 (C-1), 114.1 (C-4), 112.4 (C-2), 106.7 (C-1), 89.9 (C-17b), 78.3 (C-3), 77.7 (C-5), 
75.9 (C-2), 71.7 (C-4), 62.8 (C-6), 55.5 (3-OCH3), 50.5 (C-14), 44.9 (C-13), 44.7 (C-9), 39.0 
(C-8), 33.2 (C-17a), 31.3 (C-6), 29.3 (C-7), 29.3 (C-7), 27.0 (C-11, C-15), 12.7 (C-18) ppm. 
HRMS: m/z calcd. for C27H38O7Na [M + Na]
+
 497.2515; found 497.2500. 
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3-Methoxy-D-dihomo-estra-17b-(-D-galactopyranosyloxy)-1,3,5(10),16-tetraene (34). 
Synthesized from 30 (63 mg, 0.071 mmol) according to the general procedure for deprotection of 
glycosteroids and anthracyclines providing 34 as a white solid (27 mg, 90 %). Rf = 0.33 
(hexane:EtOAc 4:1); []D +27.0 (c 0.10, MeOH). 
1
H NMR (600.13 MHz, CD3OD):  7.16 (d, 1 
H, J1,2 = 8.6 Hz, H-1), 6.66 (dd, 1 H, J2,4 = 2.7 Hz, H-2), 6.58 (d, 1 H, H-4), 5.73 (dddd, 1 H, 
J16,17a2 = –1.3, J16,15b = 2.9, J16,15a = 7.9, J16,17 = 10.8 Hz, H-16), 5.59 (dddd, 1 H, J17,15b = –3.1, 
J17,17a1 = 3.8, J17,17a2 = 6.6 Hz, H-17), 4.21 (d, 1 H, J1,2 = 7.7 Hz, H-1), 3.85 (dd, 1 H, J4,5 = 1.0, 
J4,3 = 3.4 Hz, H-4), 3.75 (dd, 1 H, J6a,5 = 6.1, J6a,6b = –11.2 Hz, H-6a), 3.73 (s, 3 H, 3-OCH3), 
3.72 (dd, 1 H, J6b,5 = –6.4 Hz, H-6b), 3.64 (dd, 1 H, J17b,17a2 = 1.6, J17b,17a1 = 9.1 Hz, H-17b), 3.50 
(dd, 1 H, J2,3 = 9.7 Hz, H-2), 3.47 (dd, 1 H, H-3), 3.46 (ddd, 1 H, H-5),   2.81 (ddd, 1 H, J6a,7eq 
= 4.6, J6a,7ax = 5.0, J6a,6b = –16.3 Hz, H-6a), 2.78 (ddd, 1 H, J6b,7eq = 5.7, J6b,7ax = 13.1Hz, H-6b), 
2.61 (dddd, 1 H, J17a1,15b = 3.1, J17a1,17a2 = –17.1 Hz, H-17a1), 2.31 (ddd, 1 H, J15a,14 = 1.1, J15a,15b 
= –16.5 Hz, H-15a), 2.29 (dddd, 1 H, J11eq,12eq = 3.4, J11eq,9 = 3.7, J11eq,12ax = 3.8, J11eq,11ax = –12.8 
Hz, H-11eq), 2.26 (ddddd, 1 H, J17a1,15b = 2.3 Hz, H-17a2), 2.22 (ddd, 1 H, J9,8 = 10.1, J9,11ax = 
12.1 Hz, H-9), 2.17 (dddd, 1 H, J7eq,8 = 2.9, J7eq,7ax = –12.8 Hz, H-7eq), 1.96 (ddddd, 1 H, H-15b), 
1.86 (ddd, 1 H, J12ax,11ax = 13.5, J12ax,12eq = –13.5 Hz, H-12ax), 1.68 (ddd, 1 H, J12eq,11ax = 3.5 Hz, 
H-12eq), 1.66 (ddd, 1 H, J14,8 = 12.0 Hz, H-14), 1.44 (dddd, 1 H, H-11ax), 1.26 (dddd, 1 H, J8,7a = 
9.6 Hz, H-8), 1.22 (dddd, 1 H, H-7ax), 1.04 (s, 3 H, H-18) ppm.   
13
C NMR (150.9 MHz, CDCl3):  159.0 (C-3), 139.0 (C-5), 134.6 (C-10), 133.0 (C-16), 128.2 
(C-17), 127.0 (C-1), 114.1 (C-4), 112.5 (C-2), 103.1 (C-1), 86.2 (C-17b), 76.5 (C-5), 75.2 (C-
3), 72.6 (C-2), 70.3 (C-4), 62.3 (C-6), 55.6 (3-OCH3), 46.5 (C-14), 45.1 (C-9), 41.7 (C-13), 
40.6 (C-8), 34.0 (C-12), 31.3 (C-6), 29.5 (C-17a), 28.6 (C-7), 27.4 (C-11), 27.3 (C-15), 17.7 (C-
18) ppm. 
HRMS: m/z calcd. for C27H38O7Na [M + Na]
+
 497.2515; found 497.2510. 
 
Phenyl 2,3-O-isopropylidene-4-O-(2,3,4,6-tetra-O-benzoyl--D-glycopyranosyl)-1-thio--
L-rhamnopyranoside (36). Synthesized from 35 (91 mg, 0.3 mmol) and 9 (295 mg, 0.4 mmol) 
according to the general procedure for glycosylation of steroids and tetracyclines providing 36 as 
a white foam (290 mg, 85 %). Rf = 0.41 (hexane:EtOAc 2:1); []D –73.3 (c 0.2, CHCl3). 
1
H NMR 
 155 
(600.13 MHz, CDCl3):  8.04–7.23 (m, 20 H, arom. H), 5.94 (dd, 1 H, J3,4 = 9.5, J3,2 = 9.8 Hz, 
H-3), 5.66 (dd, 1 H, J4,5 = 10.0 Hz, H-4), 5.66 (d, 1 H, J1,2 = 0.9 Hz, H-1), 5.52 (dd, 1 H, J2,1 = 
8.0 Hz, H-2), 5.34 (d, 1 H, H-1), 4.66 (dd, 1 H, J6a,5 = 3.1, J6a,6b = –12.1 Hz, H-6a), 4.48 (dd, 
1 H, J6b,5 = 5.7 Hz, H-6b), 4.20 (dd, 1 H, J2,3 = 5.6 Hz, H-2), 4.15 (ddd, 1 H, H-5), 4.04 (dq, 
J5,6 = 6.2, J5,4 = 10.0 Hz, H-5), 4.03 (dd, 1 H, J3,4 = 7.5 Hz, H-3), 3.67 (dd, 1 H, H-4), 1.48 and 
1.26 (each s, each 3 H, O2C(CH3)2), 1.22 (d, 3 H, H-6) ppm.   
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 165.8 (3-OCOPh), 165.3 (2-OCOPh, 4-
OCOPh), 133.5–127.7 (arom. C), 109.5 (O2C(CH3)2), 100.5 (C-1), 83.6 (C-1), 81.0 (C-4), 77.7 
(C-3), 76.6 (C-2), 73.1 (C-3), 72.3 (C-5), 72.1 (C.2), 69.9 (C-4), 65.5 (C-5), 63.2 (C-6), 27.9 
and 26.3 (O2C(CH3)2), 17.3 (C-6) ppm.   
HRMS: m/z calcd. for C49H46O13SNa [M + Na]
+
 897.2557; found 897.2554.  
 
Phenyl 4-O-(2,3,4,6-tetra-O-benzoyl--D-glycopyranosyl)-1-thio--L-rhamnopyranoside 
(37). Synthesized from 36 (300 mg, 0.34 mmol) according to the general procedure for removal 
of isopropylidene acetal to give 37 as a colorless oil (210 mg, 95 %). Rf = 0.28 (hexane:EtOAc 
1:1); []D –125.0 (c 0.1, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.04–7.20 (m, 20 H, arom. 
H), 5.95 (dd, 1 H, J3,4 = 9.5, J3,2 = 9.8 Hz, H-3), 5.69 (dd, 1 H, J4,5 = 9.9 Hz, H-4), 5.56 (dd, 1 
H, J2,1 = 7.9 Hz, H-2), 5.42 (d, 1 H, J1,2 = 1.4 Hz, H-1), 5.29 (d, 1 H, H-1), 4.70 (dd, 1 H, J6a,5 
= 3.1, J6a,6b = –12.1 Hz, H-6a), 4.46 (dd, 1 H, J6b,5 = 5.3 Hz, H-6b), 4.18 (ddd, 1 H, H-5), 4.18 
(dq, J5,6 = 6.2, J5,4 = 9.6 Hz, H-5), 4.06 (dd, 1 H, J2,3 = 3.4 Hz, H-2), 3.81 (dd, 1 H, J3,4 = 9.3 Hz, 
H-3), 3.74 (dd, 1 H, H-4), 1.26 (d, 3 H, H-6) ppm. 
13
C NMR (150.9 MHz, CDCl3):  166.2 (6-OCOPh), 165.9 (3-OCOPh), 165.4 (4-OCOPh), 
165.3 (2-OCOPh), 133.9–127.5 (arom. C), 101.0 (C-1), 87.3 (C-1), 81.4 (C-4), 73.1 (C-3), 72.6 
(C-2), 72.4 (C.2), 72.3 (C-5), 71.4 (C-3), 69.7 (C-4), 67.5 (C-5), 62.9 (C-6), 17.5 (C-6) ppm.   
HRMS: m/z calcd. for C46H42O13SNa [M + Na]
+
 857.2544; found 857.2215.  
 
Phenyl 2,3-di-O-benzoyl-4-O-(2,3,4,6-tetra-O-benzoyl--D-glycopyranosyl)-1-thio--L-
rhamnopyranoside (38).  Synthesized from 37 (207 mg, 0.25 mmol) according to the general 
procedure for benzoylation of hydroxyl groups to give 38 as a slightly yellowish foam (230 mg, 
89 %). Rf = 0.60 (hexane:EtOAc 1:1); []D –35.0 (c 0.2, CHCl3). 
1
H NMR (600.13 MHz, CDCl3): 
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 8.07–7.05 (m, 30 H, arom. H), 5.84 (dd, 1 H, J2,1 = 1.7, J2,3 = 3.3 Hz, H-2), 5.80 (dd, 1 H, J3,4 
= 9.6, J3,2 = 9.9 Hz, H-3), 5.67 (dd, 1 H, J4,5 = 9.9 Hz, H-4), 5.55 (dd, 1 H, J2,1 = 7.9 Hz, H-
2), 5.55 (d, 1 H, H-1), 5.55 (dd, 1 H, J3,4 = 9.7 Hz, H-3), 5.15 (d, 1 H, H-1), 4.80 (dd, 1 H, J6a,5 
= 3.2, J6a,6b = –12.1 Hz, H-6a), 4.48 (dd, 1 H, J6b,5 = 5.3 Hz, H-6b), 4.48 (dq, J5,6 = 6.2, J5,4 = 
9.4 Hz, H-5), 4.25 (ddd, 1 H, H-5), 4.14 (dd, 1 H, H-4), 1.48 (d, 3 H, H-6) ppm. 
13
C NMR (150.9 MHz, CDCl3):  166.1 (6-OCOPh), 165.7 (3-OCOPh), 165.2 (4-OCOPh), 
165.1 (2-OCOPh, 2-OCOPh), 164.8 (3-OCOPh), 137.8–125.3 (arom. C), 101.3 (C-1), 85.7 (C-
1), 77.6 (C-4), 72.8 (C-3), 72.5 (C-3), 72.0 (C-5, C-2), 71.8 (C-2), 69-7 (C-4), 68.5 (C-5), 62.9 
(C-6), 17.9 (C-6) ppm. 
HRMS: m/z calcd. for C60H50O15SNa [M + Na]
+
 1065.2768; found 1065.2763. 
 
2,3-Di-O-benzoyl-4-O-(2,3,4,6-tetra-O-benzoyl--D-glycopyranosyl)--L-rhamnopyranose 
trichloroacetimidate (39). Synthesized from 38 (157 mg, 0.15 mmol) according to the general 
procedure for converting thio-glycoside into an imidate donor to give 2,3-di-O-benzoyl-4-O-
(2,3,4,6-tetra-O-benzoyl--D-glycopyranosyl)--L-rhamnopyranose as a white foam (131 mg, 
92 %). The synthesis was continued from 2,3-di-O-benzoyl-4-O-(2,3,4,6-tetra-O-benzoyl--D-
glycopyranosyl)--L-rhamnopyranose (97 mg, 0.10 mmol) according to the general procedure for 
converting thio-glycoside into an imidate donor to give the title compound as a white foam (86 
mg, 77 %). Rf = 0.64 (hexane:EtOAc 1:1); []D +25.2 (c 0.2, CHCl3). 
1
H NMR (600.13 MHz, 
CDCl3):  8.71 (s, 1 H, OCNHCCl3), 8.06–7.05 (m, 30 H, arom. H), 6.33 (d, 1 H, J1,2 = 2.0 Hz, 
H-1), 5.76 (dd, 1 H,  J2,3 = 3.4 Hz, H-2), 5.75 (dd, 1 H, J3,4 = 9.5, J3,2 = 9.9 Hz, H-3), 5.62 (dd, 
1 H, J4,5 = 9.9 Hz, H-4), 5.52 (dd, 1 H, J3,4 = 9.6 Hz, H-3), 5.49 (dd, 1 H, J2,1 = 7.9 Hz, H-2), 
5.12 (d, 1 H, H-1), 4.78 (dd, 1 H, J6a,5 = 3.2, J6a,6b = –12.0 Hz, H-6a), 4.45 (dd, 1 H, J6b,5 = 
5.4 Hz, H-6b), 4.21 (ddd, 1 H, H-5), 4.18 (dq, J5,6 = 6.2, J5,4 = 9.6 Hz, H-5), 4.12 (dd, 1 H, H-4), 
1.49 (d, 3 H, H-6) ppm. 
HRMS: m/z calcd. for C56H46O16Cl3Na [M + Na]
+
 1116.1780; found 1116.1755. 
 
3-(2,3-di-O-benzoyl-4-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)--L-
rhamnopyranosyloxy)-androst-5-en-17-one (43). Synthesized from 40 (17 mg, 0.06 mmol) and 
39 (82 mg, 0.07 mmol) according to the general procedure for glycosylation of steroids and 
 157 
tetracyclines providing 43 as a white foam (82 mg, 88 %). Rf = 0.48 (hexane:EtOAc 1:1); []D 
+15.0 (c 0.2, CHCl3). 
1
H NMR (600.13 MHz, CDCl3):  8.06–7.07 (m, 30 H, arom. H), 5.74 (dd, 
1 H, J3,4 = 9.7, J3,2 = 9.8 Hz, H-3), 5.63 (dd, 1 H, J4,5 = 9.9 Hz, H-4), 5.49 (dd, 1 H, J3,2 = 
3.4, J3,4 = 9.7 Hz, H-3), 5.49 (dd, 1 H, J2,1 = 1.5 Hz, H-2), 5.49 (dd, 1 H, J2,1 = 7.9 Hz, H-2), 
5.34 (ddd, 1 H, J6,4ax = –1.8, J6,7ax = 2.1, J6,7eq = 5.2 Hz, H-6), 5.08 (d, 1 H, H-1), 5.01 (d, 1 H, 
H-1), 4.78 (dd, 1 H, J6a,5 = 3.3, J6a,6b = –12.0 Hz, H-6a), 4.46 (dd, 1 H, J6b,5 = 5.3 Hz, H-
6b), 4.21 (ddd, 1 H, H-5), 4.06 (dq, J5,6 = 6.2, J5,4 = 9.5 Hz, H-5), 3.49 (dddd, 1 H, J3,2eq = 
4.5, J3,4eq = 4.8, J3,4ax = 11.3, J3,2ax = 11.5 Hz, H-3), 2.46 (ddd, 1 H, J16eq,15eq = 1.0, J16eq,15ax = 8.9, 
J16eq,16ax = –19.3 Hz, H-16eq), 2.35 (ddd, 1 H, J4eq,2ax = –2.3, J4eq,4ax = –13.3 Hz, H-4eq), 2.27 
(dddddd, 1 H, J4ax,2eq = –1.1, J4ax,7eq = 2.7, J4ax,7ax = 3.3 Hz, H-4ax), 2.10 (dddd, 1 H, J7eq,8 = 5.0, 
J7eq,7ax = –16.8 Hz, H-7eq), 2.08 (ddd, 1 H, J16ax,15eq = 8.9, J16ax,15ax = 9.3 Hz, H-16ax), 1.94 
(dddd, 1 H, J15eq,14 = 5.7, J15eq,15ax = –12.4 Hz, H-15eq), 1.93 (dddd, 1 H, J2eq,1ax = 3.9, J2eq,2ax = –
12.2 Hz, H-2eq), 1.88 (ddd, 1 H, J1eq,2eq = 3.3, J1eq,2ax = 3.7, J1eq,1ax = –13.8 Hz, H-1eq), 1.86 (ddd, 
1 H, J12eq,11eq = 2.7, J12eq,11ax = 4.3, J12eq,12ax = –13.1 Hz, H-12eq), 1.69 (dddd, J11eq,12ax = 4.1, 
J11eq,9 = 4.5, J11eq,11ax = –13.8 Hz, H-11eq), 1.67 (ddddd, 1 H, J2ax,1ax = 13.4 Hz, H-2ax), 1.66 
(dddd, 1 H, J8,7ax = 10.2, J8,14 = 10.8, J8,9 = 11.0 Hz, H-8), 1.62 (dddd, 1 H, H-7ax), 1.54 (dddd, 1 
H, J15ax,14 = 12.9 Hz, H-15ax), 1.50 (dddd, 1 H, J11ax,9 = 11.0, J11ax,12ax = 13.4 Hz, H-11ax), 1.42 
(d, 1 H, H-6), 1.29 (ddd, 1 H, H-12ax), 1.28 (ddd, 1 H, H-14), 1.08 (ddd, 1 H, H-1ax), 1.05 (s, 3 
H, H-19), 1.00 (ddd, 1 H, H-9), 0.89 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CDCl3):  221.2 (C-17), 166.1 (6-OCOPh), 165.7 (3-OCOPh), 165.4 
(2-OCOPh), 165.2 (4-OCOPh, 2-OCOPh), 164.8 (3-OCOPh), 140.7 (C-5), 133.5–128.1 
(arom. C), 121.1 (C-6), 101.4 (C-1), 95.9 (C-1), 77.9 (C-3), 77.8 (C-4), 72.8 (C-3), 72.3 (C-
3), 71.9 (C-5), 71.8 (C-2), 71.2 (C-2), 69.8 (C-4), 67.0 (C-5), 63.0 (C-6), 51.8 (C-14), 50.2 
(C-9), 47.6 (C-13), 38.5 (C-4), 37.2 (C-1), 36.9 (C-10), 35.9 (C-16), 31.5 (C-8), 31.4 (C-12), 30.8 
(C-7), 29.3 (C-2), 21.9 (C-15), 20.3 (C-11), 19.4 (C-19), 18.0 (C-6), 13.5 (C-18) ppm. 
HRMS: m/z calcd. for C73H72O17Na [M + Na]
+
 1243.4667; found 1243.4642. 
 
3-(-L-rhamnopyranosyloxy)-androst-5-en-17-one (44). Synthesized from 40 (32 mg, 0.12 
mmol) and 8 (100 mg, 0.16 mmol) according to the general procedure for glycosylation of 
steroids and tetracyclines, however a pure product was not obtained and thus the deprotection 
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step was done according to the general procedure for deprotection of glycosteroids and 
anthracyclines providing 10 as a white solid (40 mg, 89 % over two steps). Rf = 0.23 (EtOAc). 
1
H 
NMR (600.13 MHz, CD3OD and CDCl3):  5.39 (ddd, 1 H, J6,4ax = –1.9, J6,7ax = 2.0, J6,7eq = 5.2 
Hz, H-6), 4.88 (d, 1 H, J1,2 = 1.7 Hz, H-1), 3.82 (dd, 1 H, J2,3 = 3.4 Hz, H-2), 3.71 (dd, 1 H, 
J3,4 = 9.4 Hz, H-3), 3.69 (dq, 1 H, J5,6 = 6.2, J5,4 = 9.5 Hz, H-5), 3.50 (dddd, 1 H, J3,2eq = 4.4, 
J3,4eq = 4.8, J3,2ax = 11.4, J3,4ax = 11.4 Hz, H-3), 3.39 (dd, 1 H, H-4), 2.48 (ddd, 1 H, J16eq,15eq = 
0.4, J16eq,15ax = 8.8, J16eq,16ax = –19.5 Hz, H-16eq), 2.38 (ddd, 1 H, J4eq,2ax = –2.1, J4eq,4ax = –13.1 
Hz, H-4eq), 2.20 (ddddd, 1 H, J4ax,7ax = 3.2, J4ax,7eq = 3.2 Hz, H-4ax), 2.13 (dddd, 1 H, J7eq,8 = 5.4, 
J7eq,7ax = –17.4 Hz, H-7eq), 2.11 (ddd, 1 H, J16ax,15eq = 8.9, J16ax,15ax = 9.3 Hz, H-16ax), 1.98 
(dddd, 1 H, J15eq,14 = 5.8, J15eq,15ax = –12.5 Hz, H-15eq), 1.88 (ddd, 1 H, J1eq,2eq = 3.3, J1eq,2ax = 3.7, 
J1eq,1ax = –13.5 Hz, H-1eq), 1.87 (ddd, 1 H, J2eq,1ax = 3.8, J2eq,2ax = –12.6 Hz, H-2eq), 1.84 (ddd, 1 
H, J12eq,11eq = 2.8, J12eq,11ax = 4.3, J12eq,12ax = –13.5 Hz, H-12eq), 1.70 (dddd, J11eq,12ax = 4.2, J11eq,9 
= 5.3, J11eq,11ax = –13.7 Hz, H-11eq), 1.69 (dddd, 1 H, J8,7ax = 10.3, J8,9 = 10.9, J8,14 = 11.2 Hz, H-
8), 1.68 (ddd, 1 H, H-7ax), 1.59 (ddddd, 1 H, J2ax,1ax = 14.0 Hz, H-2ax), 1.58 (dddd, 1 H, J15ax,14 = 
12.7 Hz, H-15ax), 1.51 (dddd, 1 H, J11ax,9 = 12.3, J11ax,12ax = 13.8 Hz, H-11ax), 1.32 (ddd, 1 H, H-
14), 1.28 (d, 1 H, H-6), 1.29 (ddd, 1 H, H-12ax), 1.11 (ddd, 1 H, H-1ax), 1.05 (s, 3 H, H-19), 
1.03 (ddd, 1 H, H-9), 0.91 (s, 3 H, H-18) ppm.             
13
C NMR (150.9 MHz, CD3OD and CDCl3):  222.8 (C-17), 140.4 (C-5), 121.0 (C-6), 97.9 (C-
1), 76.2 (C-3), 72.8 (C-4), 71.2 (C-3), 72.1 (C-2), 68.1 (C-5), 51.6 (C-14), 50.1 (C-9), 47.6 (C-
13), 38.2 (C-4), 37.1 (C-1), 36.7 (C-10), 35.7 (C-16), 31.3 (C-8), 31.2 (C-12), 30.6 (C-7), 29.1 
(C-2), 21.7 (C-15), 20.1 (C-11), 19.1 (C-19), 17.1 (C-6), 12.3 (C-18) ppm. 
HRMS: m/z calcd. for C25H38O6Na [M + Na]
+
 457.2566; found 457.2549.  
 
3-(-D-glucopyranosyloxy)-androst-5-en-17-one (45). Synthesized from 40 (37 mg, 0.13 
mmol) and 9 (133 mg, 0.18 mmol) according to the general procedure for glycosylation of 
steroids and tetracyclines, however a pure product was not obtained and thus the deprotection 
step was done according to the general procedure for deprotection of glycosteroids and 
anthracyclines providing 45 as a white powder (41 mg, 78 % over two steps). Rf = 0.60 
(MeOH:CH2Cl2 1:5). 
1
H NMR (600.13 MHz, CD3OD and CDCl3):  5.42 (ddd, 1 H, J6,4ax = –1.6, 
J6,7ax = 2.5, J6,7eq = 5.3 Hz, H-6), 4.40 (d, 1 H, J1,2 = 7.8 Hz, H-1), 3.86 (dd, 1 H, J6a,5 = 2.6, 
 159 
J6a,6b = –11.9 Hz, H-6a), 3.71 (dd, 1 H, J6b,5 = 5.5 Hz, H-6b), 3.62 (dddd, 1 H, J3,2eq = 4.4, J3,4eq 
= 4.7, J3,4ax = 11.3, J3,2ax = 11.6 Hz, H-3), 3.40 (dd, 1 H, J3,4 = 8.9, J3,2 = 9.3 Hz, H-3), 3.35 (dd, 
1 H, J4,5 = 9.8 Hz, H-4), 3.29 (ddd, 1 H, H-5), 3.21 (dd, 1 H, H-2), 2.48 (ddd, 1 H, J16eq,15eq = 
1.1, J16eq,15ax = 8.9, J16eq,16ax = –19.6 Hz, H-16eq), 2.46 (ddd, 1 H, J4eq,2ax = –2.4, J4eq,4ax = –13.2 
Hz, H-4eq), 2.30 (dddddd, 1 H, J4ax,2eq = –2.4, J4ax,7ax = 2.6, J4ax,7eq = 2.7 Hz, H-4ax), 2.14 (dddd, 
1 H, J7eq,8 = 5.0, J7eq,7ax = –17.3 Hz, H-7eq), 2.11 (ddd, 1 H, J16ax,15eq = 8.9, J16ax,15ax = 9.4 Hz, H-
16ax), 1.99 (dddd, 1 H, J15eq,14 = 5.9, J15eq,15ax = –12.4 Hz, H-15eq), 1.96 (ddddd, J2eq,1eq = 2.4, 
J2eq,1ax = 3.8, J2eq,2ax = –12.9 Hz, H-2eq), 1.90 (ddd, 1 H, J1eq,2ax = 3.6, J1eq,1ax = –13.4 Hz, H-1eq), 
1.82 (ddd, 1H, J12eq,11eq = 2.6, J12eq,11ax = 4.2, J12eq,12ax = –12.8 Hz, H-12eq), 1.71 (dddd, 1 H, J8,7ax 
= 10.9, J8,14 = 10.9, J8,9 = 11.1 Hz, H-8), 1.70 (dddd, J11eq,12ax = 4.1, J11eq,9 = 4.8, J11eq,11ax = –13.9 
Hz, H-11eq), 1.68 (dddd, 1 H, H-7ax), 1.64 (ddddd, 1 H, J2ax,1ax = 13.9 Hz, H-2ax), 1.60 (dddd, 1 
H, J15ax,14 = 12.8 Hz, H-15ax), 1.53 (dddd, 1 H, J11ax,12ax = 12.5, J11ax,9 = 13.0 Hz, H-11ax), 1.34 
(ddd, 1 H, H-14), 1.29 (ddd, 1 H, H-12ax), 1.11 (ddd, 1 H, H-1ax), 1.07 (s, 3 H, H-19), 1.03 (ddd, 
1 H, H-9), 0.91 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CD3OD and CDCl3):  222.4 (C-17), 140.2 (C-5), 120.5 (C-6), 100.7 (C-
1), 78.1 (C-3), 76.1 (C-3), 75.8 (C-5), 73.1 (C-2), 69.8 (C-4), 61.1 (C-6), 51.2 (C-14), 49.8 
(C-9), 47.1 (C-13), 38.0 (C-4), 36.7 (C-1), 36.2 (C-10), 35.2 (C-16), 30.9 (C-8), 30.8 (C-12), 30.2 
(C-7), 28.9 (C-2), 21.2 (C-15), 19.7 (C-11), 18.4 (C-19), 12.6 (C-18) ppm. 
HRMS: m/z calcd. for C25H38O7Na [M + Na]
+
 473.2515; found 473.2513. 
 
3-(4-(-D-glucopyranosyl)--L-rhamnopyranosyloxy)-androst-5-en-17-one (46). 
Synthesized from 43 (55 mg, 0.05 mmol) according to the general procedure for deprotection of 
steroids and anthracyclines providing 46 as a white solid (24 mg, 90 %). Rf = 0.35 
(MeOH:CH2Cl2 1:5); []D –32.1 (c 1.0, MeOH). 
1
H NMR (600.13 MHz, CD3OD):  5.42 (ddd, 1 
H, J6,4ax = –1.8, J6,7ax = 2.2, J6,7eq = 5.2 Hz, H-6), 4.82 (d, 1 H, J1,2 = 1.8 Hz, H-1), 4.58 (d, 1 H, 
J1,2 = 7.8 Hz, H-1), 3.87 (dd, 1 H, J3,2 = 3.3, J3,4 = 9.7 Hz, H-3), 4.84 (dd, 1 H, J6a,5 = 2.4, 
J6a,6b = –11.9 Hz, H-6a), 3.77 (dd, 1 H, H-2), 3.70 (dq, J5,6 = 6.4, J5,4 = 9.5 Hz, H-5), 3.69 
(dd, 1 H, J6b,5 = 5.3 Hz, H-6b), 3.60 (dd, 1 H, H-4), 3.44 (dddd, 1 H, J3,2eq = 4.4, J3,4eq = 4.7, 
J3,2ax = 11.2, J3,4ax = 11.6 Hz, H-3), 3.36 (dd, 1 H, J3,2 = 9.2, J3,4 = 9.6 Hz, H-3), 3.30 (dd, 1 
H, J4,5 = 9.0 Hz, H-4), 3.26 (ddd, 1 H, H-5), 3.21 (dd, 1 H, H-2), 2.45 (ddd, 1 H, J16eq,15eq = 
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0.4, J16eq,15ax = 8.9, J16eq,16ax = –19.5 Hz, H-16eq), 2.38 (ddd, 1 H, J4eq,2ax = –2.3, J4eq,4ax = –13.1 
Hz, H-4eq), 2.19 (dddddd, 1 H, J4ax,2eq = –2.2, ,  J4ax,7eq = 2.9, J4ax,7ax = 3.2 Hz, H-4ax), 2.13 
(dddd, 1 H, J7eq,8 = 4.7, J7eq,7ax = –16.6 Hz, H-7eq), 2.08 (ddd, 1 H, J16ax,15eq = 9.0, J16ax,15ax = 9.4 
Hz, H-16ax), 1.97 (dddd, 1 H, J15eq,14 = 5.8, J15eq,15ax = –12.5 Hz, H-15eq), 1.91 (ddd, 1 H, J1eq,2eq 
= 3.4, J1eq,2ax = 3.8, J1eq,1ax = –13.4 Hz, H-1eq), 1.85 (dddd, 1 H, J2eq,1ax = 3.8, J2eq,2ax = –12.7 Hz, 
H-2eq), 1.79 (ddd, 1 H, J12eq,11eq = 2.6, J12eq,11ax = 4.2, J12eq,12ax = –12.7 Hz, H-12eq), 1.70 (dddd, 
1 H, J8,7ax = 10.5, J8,14 = 11.1, J8,9 = 11.2 Hz, H-8), 1.70 (dddd, J11eq,12ax = 4.3, J11eq,9 = 5.0, 
J11eq,11ax = –13.4 Hz, H-11eq), 1.68 (dddd, 1 H, H-7ax), 1.59 (dddd, 1 H, J15ax,14 = 12.7 Hz, H-
15ax), 1.58 (ddddd, 1 H, J2ax,1ax = 13.9 Hz, H-2ax), 1.54 (dddd, 1 H, J11ax,9 = 12.6, J11ax,12ax = 13.5 
Hz, H-11ax), 1.34 (ddd, 1 H, H-14), 1.31 (d, 1 H, H-6), 1.27 (ddd, 1 H, H-12ax), 1.11 (ddd, 1 H, 
H-1ax), 1.06 (s, 3 H, H-19), 1.04 (ddd, 1 H, H-9), 0.89 (s, 3 H, H-18) ppm. 
13
C NMR (150.9 MHz, CD3OD):  223.8 (C-17), 141.9 (C-5), 122.4 (C-6), 105.7 (C-1), 99.6 
(C-1), 83.6 (C-4), 78.2 (C-3), 78.0 (C-5), 77.9 (C-3), 76.1 (C-2), 72.6 (C-2), 72.4 (C-3), 
71.5 (C-4), 68.5 (C-5), 62.7 (C-6), 53.0 (C-14), 51.8 (C-9), 48.8 (C-13), 39.5 (C-4), 38.5 (C-
1), 38.0 (C-10), 36.7 (C-16), 32.8 (C-8), 32.7 (C-12), 31.9 (C-7), 30.6 (C-2), 22.8 (C-15), 21.5 
(C-11), 19.8 (C-19), 18.1 (C-6), 13.9 (C-18) ppm.  
HRMS: m/z calcd. for C31H48O11Na [M + Na]
+
 619.3094; found 619.3080. 
 
7-O-(2,3,4,6-tetra-O-benzoyl--D-glucopyranosyl)-4-deoxy--rhodomycinone (48). 
Synthesized from 47 (29 mg, 0.07 mmol) and 9 (57 mg, 0.077 mmol) according to the general 
procedure for glycosylation of steroids and tetracyclines providing 48 as a red solid (67 mg, 96 
%). Rf = 0.96 ( MeOH:CH2Cl2 1:10); 
1
H NMR (600.13 MHz, CDCl3):  13.41 (s, 1 H, 6-OH), 
13.18 (s, 1 H, 11-OH), 8.296.90 (m, 24 H, arom. H), 6.02 (dd, 1 H, J3,4 = 9.5, J3,2 = 10.0 Hz, 
H-3), 5.72 (dd, 1 H, J4,5 = 10.0 Hz, H-4), 5.56 (d, 1 H, J1,2 = 8.0 Hz, H-1), 5.45 (dd, 1 H, H-
2), 5.34 (dd, 1 H, J7,8a = 1.8, J7,8b = 4.2 Hz, H-7), 4.76 (dd, 1 H, J6a,5 = 3.1, J6a,6b = 12.1 Hz, H-
6a), 4.58 (dd, 1 H, J6b,5 = 5.0 Hz, H-6b), 4.32 (d, 1 H, J10,8a = 1.2 Hz, H-10), 4.30 (ddd, 1 H, 
H-5), 3.67 (s, 3 H, 10-COOCH3), 2.55 (ddd, 1 H, J8a,8b = 15.0 Hz, H-8a), 2.20 (dd, 1 H, H-8b), 
1.73 (dq, 1 H, J13a,14 = 7.3, J13a,13b = 13.9 Hz, H-13a), 1.45 (dq, 1 H, J13b,14 = 7.3 Hz, H-13b), 
1.10 (dd, 1 H, H-14). 
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13
C NMR (150.90 MHz, CDCl3):  186.7 (C-5), 186.2 (C-12), 171.7 (10-COOCH3), 166.3 (6-
OCOPh), 165.8 (3-OCOPh), 165.3 (4-OCOPh), 165.2 (2-OCOPh), 156.3 (C-6), 156.1 (C-11), 
135.2128.1 (arom. C), 111.7 (C-11a), 111.2 (C-5a), 103.1 (C-1), 72.5 (C-5), 72.4 (C-3), 72.1 
(C-2), 71.8 (C-7), 70.8 (C-9), 69.8 (C-4), 63.0 (C-6), 52.4 (10-COOCH3), 51.4 (C-10), 34.7 (C-
8), 32.8 (C-13), 6.8 (C-14). 
HRMS: m/z calcd. for C56H46O17Na1 [M+Na]
+
 1013.2633; found 1013.2668. 
 
7-O-(2,3,4,6-tetra-O-benzoyl--D-mannopyranosyl)-4-deoxy--rhodomycinone (49). 
Synthesized from 47 (31 mg, 0.074 mmol) and 7 (61 mg, 0.081 mmol) according to the general 
procedure for glycosylation of steroids and anthracyclines providing 49 as an orange solid 
(containing 10 % of hydrolyzed donor) (107 mg). Rf = 0.58 (hexane:EtOAc 1:1) . 
1
H NMR 
(600.13 MHz, CDCl3):  13.80 (s, 1 H, 6-OH), 13.40 (s, 1 H, 11-OH), 8.407.21 (m, 24 H, arom. 
H), 6.23 (dd, 1 H, J4,3 = 10.1, J4,5 = 10.2 Hz, H-4), 5.82 (dd, 1 H, J3,2 = 3.2 Hz, H-3), 5.64 (d, 
1 H, J1,2 = 1.9 Hz, H-1), 5.64 (dd, 1 H, J7,8a = 1.7, J7,8b = 3.9 Hz, H-7), 5.61 (dd, 1 H, H-2), 4.96 
(ddd, 1 H, J5,6a = 2.5, J5,6b = 3.6 Hz, H-5), 4.83 (dd, 1 H, J6a,6b = 12.2 Hz, H-6a), 4.58 (dd, 1 
H, H-6b), 4.48 (d, 1 H, J10,8a = 1.1 Hz, H-10), 3.74 (s, 3 H, 10-COOCH3), 2.53 (ddd, 1 H, J8a,8b 
= 15.4 Hz, H-8a), 2.20 (dd, 1 H, H-8b), 1.86 (dq, 1 H, J13a,14 = 7.3, J13a,13b = 13.9 Hz, H-13a), 
1.57 (dq, 1 H, J13b,14 = 7.3 Hz, H-13b), 1.21 (dd, 1 H, H-14). 
13
C NMR (150.90 MHz, CDCl3):  187.1 (C-5), 187.0 (C-12), 171.7 (10-COOCH3), 166.4 (6-
OCOPh), 165.7 (2-OCOPh), 165.6 (4-OCOPh, 3-OCOPh), 157.0 (C-6), 156.3 (C-11), 
136.4129.1 (arom. C), 112.5 (C-11a), 111.9 (C-5a), 95.1 (C-1), 71.1 (C-2), 71.0 (C-9), 70.2 
(C-5), 70.0 (C-3), 67.7 (C-7), 66.6 (C-4), 62.9 (C-6), 52.6 (10-COOCH3), 52.1 (C-10), 32.7 (C-
13), 29.8 (C-8), 6.9 (C-14). 
HRMS: m/z calcd. for C56H46O17Na1 [M+Na]
+
 1013.2633; found 1013.2626. 
 
7-O-(2,3,4,6-tetra-O-benzoyl--L-rhamnopyranosyl)-4-deoxy--rhodomycinone (50). 
Synthesized from 47 (25 mg, 0.06 mmol) and 8 (41 mg, 0.067 mmol) according to the general 
procedure for glycosylation of steroids and tetracyclines providing 50 as a orange solid 
(containing 10 % of hydrolyzed donor) (68 mg). Rf = 0.74 (hexane:EtOAc 1:1) . 
1
H NMR (600.13 
MHz, CDCl3):  13.53 (s, 1 H, 6-OH), 13.37 (s, 1 H, 11-OH), 8.367.17 (m, 19 H, arom. H), 5.82 
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(dd, 1 H, J2,1 = 1.9, J2,3 = 3.4 Hz, H-2), 5.73 (dd, 1 H, J4,5 = 9.8, J4,3 = 10.1 Hz, H-4), 5.65 (d, 
1 H, H-1), 5.64 (dd, 1 H, H-3), 5.40 (dd, 1 H, J7,8a = 1.7, J7,8b = 4.4 Hz, H-7), 4.45 (dq, 1 H, J5,6 
= 6.2 Hz, H-5), 4.40 (d, 1 H, J10,8a = 1.2 Hz, H-10), 3.75 (s, 3 H, 10-COOCH3), 2.50 (ddd, 1 H, 
J8a,8b = 15.0 Hz, H-8a), 2.36 (dd, 1 H, H-8b), 1.92 (dq, 1 H, J13a,14 = 7.3, J13a,13b = 14.0 Hz, H-
13a), 1.54 (dq, 1 H, J13b,14 = 7.3 Hz, H-13b), 1.45 (d, 1 H, H-6), 1.20 (dd, 1 H, H-14). 
13
C NMR (150.90 MHz, CDCl3):  187.1 (C-12), 186.7 (C-5), 171.5 (10-COOCH3), 165.9 (4-
OCOPh), 165.4 (2-OCOPh, 3-OCOPh), 156.8 (C-6), 156.1 (C-11), 134.6127.2 (arom. C), 
112.3 (C-11a), 111.9 (C-5a), 101.5 (C-1), 72.8 (C-7), 71.6 (C-4), 71.1 (C-9), 70.6 (C-2), 70.0 
(C-3), 68.1 (C-5), 52.6 (10-COOCH3), 52.0 (C-10), 33.8 (C-8), 32.4 (C-13), 17.7 (C-6), 6.9 (C-
14).   
HRMS: m/z calcd. for C49H42O15Na1 [M+Na]
+
 893.2421; found 893.2400. 
 
7-O-(2,3,4,6-tetra-O-benzoyl--D-galactopyranosyl)-4-deoxy--rhodomycinone (51). 
Synthesized from 47 (41 mg, 0.10 mmol) and 10 (82 mg, 0.11 mmol) according to the general 
procedure for glycosylation of steroids and tetracyclines providing 51 as a red solid (containing 
10 % hydrolyzed donor) (136 mg). Rf = 0.94 (MeOH:CH2Cl2 1:10); 
1
H NMR (600.13 MHz, 
CDCl3):  13.42 (s, 1 H, 6-OH), 13.20 (s, 1 H, 11-OH), 8.326.90 (m, 24 H, arom. H), 6.06 (dd, 
1 H, J4,5 = 1.4, J4,3 = 3.5 Hz, H-4), 5.77 (dd, 1 H, J3,2 = 10.5 Hz, H-3), 5.68 (dd, 1 H, J2,1 = 
8.0 Hz, H-2), 5.55 (d, 1 H, H-1), 5.39 (dd, 1 H, J7,8a = 1.8, J7,8b = 4.2 Hz, H-7), 4.78 (dd, 1 H, 
J6a,5 = 6.5, J6a,6b = 11.2 Hz, H-6a), 4.50 (ddd, 1 H, J5,6b = 6.6 Hz, H-5), 4.49 (dd, 1 H, H-6b), 
4.37 (d, J10,8a = 1.2 Hz, 1 H, H-10), 3.69 (s, 3 H, 10-COOCH3), 2.61 (ddd, 1 H, J8a,8b = 14.9 Hz, 
H-8a), 2.26 (dd, 1 H, H-8b), 1.75 (dq, 1 H, J13a,14 = 7.3, J13a,13b = 14.0 Hz, H-13a), 1.55 (dq, 1 H, 
J13b,14 = 7.4 Hz, H-13b), 1.20 (dd, 1 H, H-14). 
13
C NMR (150.90 MHz, CDCl3):  186.5 (C-5), 186.0 (C-12), 171.5 (10-COOCH3), 166.0 (6-
OCOPh), 165.6 (4-OCOPh), 165.4 (3-OCOPh), 165.1 (2-OCOPh), 156.1 (C-6), 155.9 (C-11), 
135.2126.6 (arom. C), 111.5 (C-11a), 111.0 (C-5a), 103.3 (C-1), 71.7 (C-7), 71.6 (C-5), 71.0 
(C-9), 70.7 (C-3), 69.8 (C-2), 68.1 (C-4), 62.0 (C-6), 52.3 (10-COOCH3), 51.0 (C-10), 34.8 (C-
8), 32.9 (C-13), 6.7 (C-14). 
HRMS: m/z calcd. for 1013.2633; found 1013.2564. 
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7-O-(-D-glucopyranosyl)-4-deoxy--rhodomycinone (52). Synthesized from 48 (91 mg, 0.09 
mmol) according to the general procedure for deprotection of glycosteroids and anthracyclines 
providing 52 as a red solid (51 mg, 97 %). Rf = 0.14 (MeOH:CH2Cl2 1:10). 
1
H NMR (600.13 
MHz, CD3OD+CDCl3):  8.207.75 (m, 4 H, arom. H), 5.29 (dd, 1 H, J7,8a = 1.7, J7,8b = 4.5 Hz, 
H-7), 4.91 (d, 1 H, J1,2 = 7.8 Hz, H-1), 4.24 (d, 1 H, J10,8a = 1.2 Hz, H-10), 3.93 (dd, 1 H, J6a,5 
= 2.2, J6a,6b = 11.8 Hz, H-6a), 3.79 (dd, 1 H, J6b,5 = 5.1 Hz, H-6b), 3.70 (s, 3 H, 10-
COOCH3), 3.47 (dd, 1 H, J3,4 = 8.9, J3,2 = 9.3 Hz, H-3), 3.43 (ddd, 1 H, J5,4 = 9.8 Hz, H-5),  
3.39 (dd, 1 H, H-4), 3.22 (dd, 1 H, H-2), 2.66 (ddd, 1 H, J8a,8b = 15.1 Hz, H-8a), 2.22 (dd, 1 H, 
H-8b), 1.71 (dq, 1 H, J13a,14 = 7.3, J13a,13b = 14.0 Hz, H-13a), 1.57 (dq, 1 H, J13b,14 = 7.3 Hz, H-
13b), 1.15 (dd, 1 H, H-14). 
13
C NMR (150.90 MHz, CD3OD+CDCl3):  188.1 (C-5), 187.9 (C-12), 172.8 (10-COOCH3), 
157.8 (C-6), 156.8 (C-11), 137.6127.9 (arom. C), 112.9 (C-11a), 112.6 (C-5a), 106.2 (C-1), 
78.1 (C-5), 77.7 (C-3), 75.5 (C-2), 72.3 (C-7), 71.9 (C-9), 71.3 (C-4), 62.5 (C-6), 52.8 (10-
COOCH3), 52.0 (C-10), 36.2 (C-8), 34.1 (C-13), 7.2 (C-14). 
HRMS: m/z calcd. for C28H30O13Na1 [M+Na]
+
 597.1584; found 597.1588. 
 
7-O-(-D-mannopyranosyl)-4-deoxy--rhodomycinone (53). Synthesized from 49 (107 mg 
(containing impurites), 0.1 mmol) according to the general procedure for deprotection of 
glycosteroids and anthracyclines providing 53 as a red solid (37 mg, 86 % (over two steps)). Rf = 
0.16 (MeOH:CH2Cl2 1:10) . 
1
H NMR (600.13 MHz, CD3OD+CDCl3):  8.377.85 (m, 4 H, 
arom. H), 5.53 (dd, 1 H, J7,8a = 1.8, J7,8b = 3.9 Hz, H-7), 5.28 (d, 1 H, J1,2 = 1.7 Hz, H-1), 4.34 
(d, 1 H, J10,8a = 1.1 Hz, H-10), 4.14 (ddd, 1 H, J5,6a = 2.9, J5,6b = 3.3, J5,4 = 10.0 Hz, H-5), 
3.94 (dd, 1 H, J6a,6b = 12.1 Hz, H-6a), 3.93 (dd, 1 H, H-6b), 3.82 (dd, 1 H, J4,3 = 9.5, Hz, H-
4), 3.81 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.72 (s, 3 H, 10-COOCH3), 3.68 (dd, 1 H, H-3), 2.48 
(ddd, 1 H, J8a,8b = 15.3 Hz, H-8a), 2.07 (dd, 1 H, H-8b), 1.79 (dq, 1 H, J13a,14 = 7.3, J13a,13b = 
14.1 Hz, H-13a), 1.54 (dq, 1 H, J13b,14 = 7.3 Hz, H-13b), 1.15 (dd, 1 H, H-14).         
13
C NMR (150.90 MHz, CD3OD+CDCl3):  186.7 (C-5), 186.4 (C-12), 171.3 (10-COOCH3), 
156.1 (C-6), 155.3 (C-11), 135.1126.6 (arom. C), 111.8 (C-11a), 111.3 (C-5a), 97.0 (C-1), 73.4 
(C-5), 70.8 (C-3), 70.7 (C-2), 70.5 (C-9), 66.3 (C-4), 65.3 (C-7), 60.9 (C-6), 51.9 (10-
COOCH3), 51.6 (C-10), 32.2 (C-13), 29.1 (C-8), 6.0 (C-14). 
 164 
HRMS: m/z calcd. for C28H30O13Na1 [M+Na]
+
 597.1584; found 597.1588. 
 
7-O-(L-rhamnopyranosyl)-4-deoxy--rhodomycinone (54). Synthesized from 50 (65 mg 
(containing impurites), 0.074 mmol) according to the general procedure for deprotection 
glycosteroids and anthracyclines providing 54 as a red solid (30 mg, 90 % over two steps). Rf = 
0.45 (EtOAc) . 
1
H NMR (600.13 MHz, CD3OD+CDCl3):  8.307.82 (m, 4 H, arom. H), 5.38 (d, 
1 H, J1,2 = 1.9 Hz, H-1), 5.25 (dd, 1 H, J7,8a = 1.7, J7,8b = 4.5 Hz, H-7), 4.26 (d, 1 H, J10,8a = 1.3 
Hz, H-10), 3.95 (dd, 1 H, J2,3 = 3.3 Hz, H-2), 3.88 (dq, 1 H, J5,6 = 6.2, J5,4 = 9.5 Hz, H-5), 
3.73 (s, 3 H, 10-COOCH3), 3.55 (dd, 1 H, J3,4 = 9.5 Hz, H-3), 3.48 (dd, 1 H, H-4), 2.40 (ddd, 1 
H, J8a,8b = 15.0 Hz, H-8a), 2.16 (dd, 1 H, H-8b), 1.84 (dq, 1 H, J13a,14 = 7.3, J13a,13b = 14.0 Hz, 
H-13a), 1.50 (dq, 1 H, J13b,14 = 7.3 Hz, H-13b), 1.38 (d, 1 H, H-6), 1.15 (dd, 1 H, H-14).    
13
C NMR (150.90 MHz, CD3OD+CDCl3):  186.5 (C-5), 186.4 (C-12), 171.3 (10-COOCH3), 
156.2 (C-6), 155.4 (C-11), 134.9126.6 (arom. C), 111.4 (C-11a), 111.2 (C-5a), 104.1 (C-1), 
72.2 (C-4), 71.4 (C-7), 70.8 (C-3), 70.6 (C-9), 70.3 (C-2), 69.3 (C-5), 51.9 (10-COOCH3), 51.4 
(C-10), 33.6 (C-8), 32.0 (C-13), 16.7 (C-6), 6.1 (C-14).   
HRMS: m/z calcd. for C28H30O12Na1 [M+Na]
+
 581.1635; found 581.1624. 
 
7-O-(-D-galactopyranosyl)-4-deoxy--rhodomycinone (55). Synthesized from 51 (136 mg, 0.1 
mmol) according to the general procedure for deprotection of glycosteroids and anthracyclines 
providing 55 as a red solid (54 mg, 92% yield over two steps). Rf = 0.17 (MeOH:CH2Cl2 1:10). 
1
H NMR (600.13 MHz, CD3OD+CDCl3):  8.337.86 (m, 4 H, arom. H), 5.30 (dd, 1 H, J7,8a = 
1.9, J7,8b = 4.3 Hz, H-7), 4.83 (d, 1 H, J1,2 = 7.7 Hz, H-1), 4.28 (s, 1 H, H-10), 3.94 (dd, 1 H, 
J4,5 = 1.4, J4,3 = 3.2 Hz, H-4),  3.85 (dd, 1 H, J6a-5 = 5.8, J6a-6b = 11.7 Hz, H-6a), 3.84 (dd, 1 
H, J6b-5 = 6.3 Hz, H-6b), 3.72 (s, 3 H, 10-COOCH3), 3.67 (ddd, 1 H, H-5), 3.62 (dd, 1 H, J3,2 = 
9.5 Hz, H-3), 3.56 (dd, 1 H, H-2), 2.69 (ddd, 1 H, J8a,8b = 15.0 Hz, H-8a), 2.21 (dd, 1 H, H-8b), 
1.75 (dq, 1 H, J13a,14 = 7.1, J13a,13b = 14.0 Hz, H-13a), 1.53 (dq, 1 H, J13b,14 = 7.6 Hz, H-13b), 
1.14 (dd, 1 H, H-14). 
13
C NMR (150.90 MHz, CD3OD+CDCl3):  186.5 (C-5, C-12), 171.3 (10-COOCH3), 156.1 (C-
6), 155.3 (C-11), 134.6126.5 (arom. C), 111.4 (C-11a), 111.2 (C-5a), 105.1 (C-1), 74.8 (C-5), 
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72.8 (C-3), 71.4 (C-7), 71.1 (C-2), 70.1 (C-9), 68.2 (C-4), 60.6 (C-6), 51.7 (10-COOCH3), 50.3 
(C-10), 34.0 (C-8), 32.5 (C-13), 5.9 (C-14). 
HRMS: m/z calcd. for C28H30O13Na1 [M+Na]
+
 597.1584; found 597.1577. 
 
(8R,8R)-Matairesinol 4,4-di-O--D-glucopyranoside (56). Synthesized from 58 (73 mg, 0.048 
mmol) according to the general procedure on the deprotection of lignan glycosides and providing 
the title compound as a white foam (22 mg, 67 %). Rf = 0.26 (MeOH:CH2Cl2 1:3); []D
30
 –19.8 
(c 1.00, MeOH). 
1
H NMR (600.13 MHz, CD3OD, 20 C):  7.03 (d, 1 H, J5,6 = 8.2 Hz, H-5), 
7.00 (d, 1 H, J5,6 = 8.2 Hz, H-5), 6.72 (d, 1 H, J2,6 = 2.0 Hz, H-2), 6.62 (d, 1 H, J2,6 = 2.0 Hz, H-
2), 6.61 (dd, 1 H, H-6), 6.55 (dd, 1 H, H-6), 4.87 (d, 1 H, J1,2 = 7.8 Hz, H-1), 4.86 (d, 1 H, 
J1,2 = 7.7 Hz, H-1), 4.26 (dd, 1 H, J9a,8 = 7.4, J9a,9b = –9.1 Hz, H-9a), 3.99 (dd, 1 H, J9b,8 = 6.9 
Hz, H-9b), 3.87 (dd, 1 H, J6a,5 = 2.3, J6a,6b = –12.1 Hz, H-6a), 3.86 (dd, 1 H, J6a,5 = 2.2, 
J6a,6b = –12.0 Hz, H-6a), 3.78 and 3.77 (each s, each 3 H, 3-OCH3 and 3-OCH3), 3.68 (dd, 1 
H, J6b,5 = 5.6 Hz, H-6b), 3.68 (dd, 1 H, J6b,5 = 5.7 Hz, H-6b), 3.50 (dd, 1 H, J2,3 = 9.4 Hz, 
H-2), 3.50 (dd, 1 H, J2,3 = 9.4 Hz, H-2), 3.48 (dd, 1 H, J3,4 = 9.0 Hz, H-3), 3.48 (dd, 1 
H, J3,4 = 9.1 Hz, H-3), 3.43 (ddd, 1 H, J5,4 = 9.9 Hz, H-5), 3.42 (ddd, 1 H, J5,4 = 9.8 Hz, 
H-5), 3.40 (dd, 1 H, H-4), 3.39 (dd, 1 H, H-4), 2.92 (dd, 1 H, J7a,8 = 4.9, J7a,7b = –13.9 Hz, 
H-7a), 2.92 (dd, 1 H, J7b,8 = 8.2 Hz, H-7b), 2.67 (ddd, 1 H, J8,8 = 7.4 Hz, H-8), 2.62 (dd, 1 H, 
J7a,8 = 7.4, J7a,7b = –13.8 Hz, H-7a), 2.53 (dd, 1 H, J7b,8 = 7.9 Hz, H-7b), 2.52 (ddddd, 1 H, H-8) 
ppm.  
13
C NMR (150.9 MHz, CD3OD, 20 C):  181.4 (C-9), 150.5 (C-3, C-3), 146.8 (C-4), 146.6 (C-
4), 134.6 (C-1), 134.1 (C-1), 122.9 (C-6), 122.2 (C-6), 117.7 (C-5), 117.6 (C-5), 114.5 (C-2), 
114.0 (C-2), 102.8 (C-1, C-1), 78.1 (C-5, C-5), 77.8 (C-3, C-3), 74.9 (C-2, C-2), 73.0 
(C-9), 71.4 and 71.3 (C-4, C-4), 62.5 (C-6, C-6), 56.6 (3-OCH3,3-OCH3), 47.7 (C-8), 42.3 
(C-8), 39.1 (C-7), 35.6 (C-7) ppm. 
HRMS: m/z calcd. for C32H42O16Na [M+Na]
+
 705.2371; found 705.2331. 
 
(8R,8R)-Matairesinol 4,4-di-2,3,4,6-tetra-O-benzoyl--D-glucopyranoside (58). Synthesized 
from 57 (28 mg, 0.079 mmol) and 9 (152 mg, 2.6 equiv.) according to the general procedure for 
glycosylation of lignans to give the title compound as a white solid (83 mg, 69 %). Rf = 0.17 
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(hexane:EtOAc 1:1); []D
23
 +0.0 (c 0.15, CHCl3). 
1
H NMR (600.13 MHz, CDCl3, 25 C):  
8.01–7.27 (m, 40 H, arom. H), 7.13 (d, 1 H, J5,6 = 8.1 Hz, H-5), 7.08 (d, 1 H, J5,6 = 8.1 Hz, H-5), 
6.55 (d, 1 H, J2,6 = 2.0 Hz, H-2), 6.49 (dd, 1 H, H-6), 6.30 (d, 1 H, J2,6 = 2.0 Hz, H-2), 6.29 (dd, 
1 H, H-6), 6.00 (dd, 1 H, J3,4 = 9.5, J3,2 = 9.7 Hz, H-3), 5.99 (dd, 1 H, J3,4 = 9.5, J3,2 = 
9.7 Hz, H-3), 5.79 (dd, 1 H, J2,1 = 7.8 Hz, H-2), 5.79 (dd, 1 H, J2,1 = 7.8 Hz, H-2), 5.74 
(dd, 1 H, J4,5 = 9.9 Hz, H-4), 5.73 (dd, 1 H, J4,5 = 9.9 Hz, H-4), 5.22 (d, 1 H, H-1), 5.20 
(d, 1 H, H-1), 4.65 (dd, 1 H, J6a,5 = 3.2, J6a,6b = –12.1 Hz, H-6a), 4.64 (dd, 1 H, J6a,5 = 
3.1, J6a,6b = –12.1 Hz, H-6a), 4.54 (dd, 1 H, J6b,5 = 5.9 Hz, H-6b), 4.52 (dd, 1 H, J6b,5 = 
5.9 Hz, H-6b), 4.23 (ddd, 1 H, H-5), 4.22 (ddd, 1 H, H-5), 4.00 (dd, 1 H, J9a,8 = 7.4, J9a,9b = –
9.2 Hz, H-9a), 3.75 (dd, 1 H, J9b,8 = 7.8 Hz, H-9b), 3.30 (s, 3 H, 3-OCH3), 3.27 (s, 3 H, 3-OCH3), 
2.91 (dd, 1 H, J7a,8 = 5.1, J7a,7b = –14.1 Hz, H-7a), 2.81 (dd, 1 H, J7b,8 = 7.3 Hz, H-7b), 2.50 
(dd, 1 H, J7a,8 = 6.2, J7a,7b = –14.1 Hz, H-7a), 2.48 (ddd, 1 H, J8,8 = 7.8 Hz, H-8), 2.36 (ddddd, 1 
H, J8,7b = 9.0 Hz, H-8), 2.35 (dd, 1 H, H-7b) ppm. 
13
C NMR (150.9 MHz, CDCl3, 25 C):  178.3 (C-9), 166.0 (6-OCOPh, 6-OCOPh), 165.8 
(3-OCOPh, 3-OCOPh), 165.2 (2-OCOPh, 2-OCOPh), 165.1 (4-OCOPh, 4-OCOPh), 
150.9 (C-3, C-3), 145.0 (C-4), 144.9 (C-4), 134.5 (C-1, C-1), 133.5–128.3 (arom. C), 121.1 (C-
6), 121.0 (C-5), 120.8 (C-5), 120.3 (C-6), 113.2 (C-2), 112.7 (C-2), 101.6 (C-1), 101.5 (C-
1), 72.6 (C-3, C-3), 72.4 (C-5, C-5), 71.7 (C-2, C-2), 71.0 (C-9), 69.7 (C-4, C-4), 
63.1 (C-6, C-6), 55.4 (3-OCH3,3-OCH3), 46.4 (C-8), 41.0 (C-8), 38.3 (C-7), 34.7 (C-7) ppm. 
HRMS: m/z calcd. for C88H74O24Na [M+Na]
+
 1537.4468; found 1537.4425. 
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Summary and Conclusions 
Carbohydrates are one of the major classes of biomolecules found in nature. In the biological 
introduction of this thesis, several relevant areas where carbohydrates are utilized today were 
highlighted. Special focus was placed on the use of carbohydrates as biomarkers (e.g., in the 
ABO-bloodsystem) and in immunological applications (e.g., carbohydrate based vaccines) 
although carbohydrates are widely applied also in many other areas. Due to the biological 
importance of carbohydrates, the limited amount of complex carbohydrates available in nature 
and the problems associated with their isolation, the synthesis of such compounds is important in 
order to provide pure oligosaccharides or conjugates thereof (devoid of biological 
contaminations) for biological evaluations. In the introduction to carbohydrate chemistry, 
structural and conformational properties of monosaccharides were described. Furthermore, a brief 
introduction to the reactivities of individual monosaccharides and the basics of oligosaccharide 
synthesis were provided. With these prerequisites, a short journey through several areas related to 
carbohydrate synthesis was started.  
In Episode 1, synthesis of β-(1→2)-linked mannopyranosides and various analogues was 
described. The synthesis culminated in the preparation of a β-(1→2)-linked mannotetraose, a 
cyclohexyl capped trisaccharide mimic and several 1,1- or 2,2-linked divalent mannosides 
(Figure 1). For preparation of divalent oligosaccharides, the Nobel prize winning procedures of 
Robert Grubbs featuring cross coupling metathesis with ruthenium based catalysts was utilized. 
In the β-selective mannosylations, the protocol originally developed by David Crich was applied. 
In the synthesis of the tetrasaccharide, however, the protocol was further modified and a 
convergent approach was found to be more suitable than the previously reported linear ones. 
Although much elegant work has undoubtedly been done in the field of -linked mannosylations 
by talented scientists, it is the personal view of this author that there is still need for a more 
benign glycosylation methodology. This view is based on the facts concerning the reduced 
efficiency in the synthesis of larger oligosaccharides in the protocol developed by Bundle and the 
amounts of waste (4.3 equivalents of promoters/donor) formed when utilizing the protocol 
developed by Crich.  
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Figure 1. Chemical structures of some of the synthesized compounds from Episode 1. 
 
In addition to the synthesis of molecules for biological screening of their immunostimulatory 
effects, the three dimensional structure of β-(1→2)-linked oligomannosides was investigated in 
detail by the use of NMR spectroscopic techniques, spectral simulation and molecular modeling. 
By these methods the first fully characterized 
1
H- and 
13
C-NMR spectra for the β-(1→2)-linked 
mannotetraose found in the cell wall of C. albicans could be reported (Figure 2).  
 
 
Figure 2. Spectral simulation of the 
1
H-NMR spectrum of β-(1→2)-linked mannotetraose in 
MeOD (5.2–3.1 ppm region) with the PERCH NMR software: simulated spectrum (above), 
observed spectrum (below). 
 
In Episode 2, the synthesis of a repeating trisaccharide unit and a less abundant tetrasaccharide 
fragment found in the galactoglucomannan-polysaccharide isolated from Picea abies was 
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decribed (Figure 3). The synthetic strategy was built around the selective ring-opening of 
benzylidene acetals in order to achieve acceptors for subsequent glycosylation reactions. Several 
procedures for the partial reduction of benzylidenes and α-selective galactosylations were 
screened before optimal reaction conditions were found. The chemical shifts of the synthesized 
compounds were compared to literature chemical shifts reported for the galactoglucomannan 
polysaccharide. While some deviances were obvious, most signals were found to be in good 
correlation with the values reported for the polymer. In addition, several chemical shifts not 
reported for the polysaccharide were found for the small molecular models and can be used as 
reference values when interpreting spectra of GGM in the future. In addition to these studies, 
small molecular models were synthesized in order to investigate whether the acetyl group “leap” 
from O-2/O-3 directly to O-6 would be possible as suggested previously in the literature for 
AcGGM. Based on our initial findings, such a leap is not possible for mannosides existing in the 
4
C1-conformation which is the preferred low energy conformation of naturally existing 
mannopyranoses. As mentioned in Episode 2, the studies related to this project is currently on-
going and the synthesis of the second trisaccharide repeating unit of the GGM-backbone is 
currently under planning along with some additional experiments related to the acetyl-group 
“leap”. 
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Figure 3. The proposed chemical structure for GGM, the synthesis of the blue and blue-red 
fragments was discussed in Episode 2. 
 
In Episode 3, methods for the glycosylation of different types of aglycones were investigated. An 
initial screening of glycosyl donors revealed benzoylated imidate donors to be most suitable for 
the glycosylation of steroid aglycones.  
In the first part of the Episode, benzoylated imidate donors were applied to the synthesis of a 
small library of glycosteroids with excellent efficiencies. These molecules were synthesized in 
order to evaluate their potential applications in drug delivery purposes. Biological screening 
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events of the glycosteroid backbones containing permanently attached active pharmaceuticals 
have, however, not been conducted yet. These are potential applications of the molecules which 
may be explored in the future.  
 
 
Figure 4. Chemical structures of some selected substrates from Episode 3. 
 
In the second part of Episode 3, a high yielding route for the coupling of the naturally occuring 
glycon scillabiose to steroids was developed. The synthesis was based on a convergent approach 
which minimized the synthetic steps with the incorporated aglycone in order to assure that 
sensitive functionalities remain unaltered in this moiety. The coupling of scillabiose was 
exemplified with the synthesis of a saponin resembling the structure of the naturally occuring 
cytotoxic compound hellebrin. In future work, it would be interesting to apply the procedure 
developed in Episode 3 to the synthesis of one of the naturally occuring saponins containing this 
glycone. 
In the third part of Episode 3, benzoylated TCA-donors were further applied in the regioselective 
glycosylation of 4-deoxy--rhodomycinone. The environmentally benign approach, utilized in the 
synthesis of these structures could be valuable for industrial synthesis of similar compounds due 
to the operational simplicity, short reaction time and minimal waste generation of the protocol. 
The synthesized compounds resemble the structures of existing anticancer drugs and will in 
future work be screened in similar applications.  
In the last part of Episode 3, a convenient semi-synthetic approach for the synthesis of MDG was 
developed starting from the two readily available starting materials HMR and D-glucose. This 
was, to our knowledge, one of the first synthetic protocols for the glycosylation of lignans and the 
first semi-synthesis reported for MDG. In the future, MDG will be screened for biological 
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activity and the glycoyslation protocol, developed in the synthesis of MDG, extended to the 
synthesis of other naturally occuring lignan glycosides. 
To conclude, a wide range of carbohydrate donors, activation protocols and protective groups 
were screened in this work. The synthetic protocols utilized in the different reaction sequences 
for glycosylation reaction, insertion and cleavage of protective group etc. can be found in the 
experimental sections of each Episode. Altogether, several of the commonly employed 
carbohydrate donors, such as thio- and imidate donors, sugar halides and peracetylated sugars, 
and protective groups, such as acetyl, benzoyl, allyl, propargyl, benzyl, methyl, 
tertbutyldimethylsilyl, benzylidene, isopropylidene, ditertbutylsilylene, 2,3-dimethoxybutan-2,3-
diyl etc., were utilized at one point or another during the synthetic pathways. In addition, both 
simple 1,2-trans glycosides and difficult 1,2-cis glycosides were synthesized during the work 
described in Episodes 1–3. Apart from the synthesis of target compounds, much effort was 
invested in the accurate characterization of the molecules by the use of a wide range of one- and 
two-dimensional NMR techniques in combination with spectral simulation and even molecular 
modeling. As a result, some basic guidelines to the characterization of oligosaccharides and 
several different classes of glycoconjugates are reported in each of the three Episodes. Taken 
together, this thesis is written for researchers starting their work in carbohydrate chemistry and 
contains the crucial basics for both the synthetic and NMR spectroscopic knowledge needed to 
succeed. 
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Epilogue and Future Perspectives 
 
While the basic strategies developed in the 1970s in carbohydrate synthesis are still widely 
utilized today, new technological and methodological improvements such as automated solution- 
and solid-phase synthetic protocols have emerged in recent times. These improvements enable 
the rapid synthesis of oligosaccharides, simultaneously extending the knowledge on their 
biological roles and sparking new interest in the fields of carbohydrate research. As a result, the 
field of carbohydrate science is flourishing now more than ever and achieving the reputation that 
it deserves. It will be of topical interest to follow the scientific breakthroughs that undoubtedly lie 
ahead in the near future. 
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